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Abstract 
Glucocorticoids (GCs) remain the mainstay therapeutic choice for the treatment of inflammation, 
and exert their potent anti-inflammatory effects via the glucocorticoid receptor (GRα). However, 
the chronic use of GCs, in addition to generating undesirable side-effects (e.g. hyperglycemia), 
results in homologous down-regulation of the GRα. This reduction in GRα protein levels has been 
coupled to a decrease in GC-responsiveness, in a number of psychological and pathological 
conditions, which may culminate in GC-acquired resistance, a major concern for chronic GC users. 
The current study investigated whether ligand-induced down-regulation of the GRα is influenced by 
the dimerization state of the receptor by transfecting human wild type GRα (hGRwt) or a 
dimerization deficient GRα mutant (hGRdim) into COS-1 cells. In addition, Compound A (CpdA), 
which abrogates GR dimerization, was used to mimic the effect of the hGRdim in HepG2 cells 
containing endogenous GRα. Furthermore, the ability of an endogenous mutant, mGRdim, to 
undergo ligand-induced receptor turnover was compared to that of the wild-type GRα, mGRwt, in 
MEF-mGRdim and MEF-mGRwt cells, respectively. Whole-cell-binding and Western blotting 
revealed that the hGRwt, but not the hGRdim, underwent homologous down-regulation following 
dexamethasone (Dex), a potent synthetic GC, and cortisol (F), an endogenous GC, treatment. In 
contrast, ligand-induced down-regulation of GRα was abolished by CpdA treatment or the use of 
hGRdim, suggesting a novel role for GRα dimerization in mediating receptor turnover. These 
findings from the COS-1 cells were supported by results from the HepG2 cells, and, in part, by 
results from the MEF cells. Moreover, the dimerization state of the GRα influenced the post-
translational processing of the receptor, impacting its degradation via the proteasome. Specifically, 
‘loss’ of GRα dimerization via CpdA treatment or the use of the dimerization deficient GRα mutant, 
restricted hyper-phosphorylation at Ser404, which has been coupled to increased GRα degradation, 
as well as restricted the interaction of GRα with the E3 ligase, FBXW7α, thus hampering receptor 
turnover. Lastly, a model to mimic acquired GC resistance was established and tested. Results from 
these experiments demonstrated that prolonged GC treatment of mGRwt (i.e. ‘gain’ of GRα 
dimerization) leads to molecular GC resistance (i.e. GILZ) and clinical GC resistance (FKBP51), 
whilst maintaining the up-regulation of a metabolic gene (i.e. TAT). In contrast, ‘loss’ of GRα 
dimerization partially restricts acquired resistance, at a molecular and clinical level, whilst 
displaying an improved side-effect profile in terms of restricting the expression of a metabolic gene 
(i.e. TAT). These results expand our understanding of factors that contribute to GC-resistance and 
may be exploited clinically. 
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Opsomming 
Glukokortikoïede (GK's) bly die staatmaker terapeutiese keuse vir die behandeling van inflammasie 
en oefen hul kragtige anti-inflammatoriese effekte uit via die glukokortikoïede reseptor (GRα). Die 
chroniese gebruik van GK's, benewens die ontwikkeling van ongewenste newe-effekte (bv. 
hiperglisemie), lei ook ter tot homoloë afregulering van die GRα. Hierdie afname in GRα 
proteïenvlakke word gekoppel aan 'n afname in GK-responsiwiteit, in 'n aantal sielkundige en 
patologiese toestande, wat kan lei tot GK-verworwe weerstand, 'n groot kommer vir chroniese GK-
gebruikers. Die huidige studie ondersoek of ligand-geïnduseerde afregulering van die GRα 
beïnvloed word deur die dimerisasietoestand van die reseptor deur menslike wilde tipe GRα 
(hGRwt) of 'n dimerisasie-defektiewe GRα-mutant (hGRdim) in COS-1-selle te transfekteer. 
Daarbenewens is Compound A (CpdA), wat GR-dimerisasie ophef, gebruik om die effek van die 
hGRdim in HepG2-selle wat endogene GRα bevat, na te boots. Verder is die vermoë van 'n 
endogene mutant, mGRdim, om ligand-geïnduseerde reseptoromset te ondergaan, vergelyk met dié 
van die wild-tipe GRα, mGRwt, onderskeidelik in MEF-mGRdim en MEF-mGRwt-selle. Heel-sel-
binding Western klad het aangetoon dat die hGRwt, maar nie die hGRdim nie, homoloë 
afregulering ondersogaan na behandeling met deksametason (Dex), 'n kragtige sintetiese GK, en 
kortisol (F), 'n endogene GK. In teenstelling hiermee is ligand-geïnduseerde afregulering van GRα 
afgeskaf deur CpdA-behandeling of die gebruik van hGRdim, wat 'n splinternuwe rol vir GRa-
dimerisasie in die bemiddeling van reseptoromset voorstel. Hierdie bevindings van die COS-1-selle 
is ondersteun deur die resultate van die HepG2-selle, en gedeeltelik deur die resultate van die MEF-
selle. Verder het die dimeriseringstoestand van die GRα die post-translasie-modifisering van die 
reseptor beïnvloed, wat afbraak deur die proteasoom beïnvloed het. Spesifiek, 'verlies' aan GRα-
dimerisasie via CpdA-behandeling of die gebruik van die dimerisasie-defektiewe GRα-mutant, het 
hiperfosforilering by Ser404, wat gekoppel is aan verhoogde GRα-afbraak, sowel as die interaksie 
van GRα met die E3-ligase, FBXW7α, beperk wat dus die reseptoromset belemmer het. Laastens is 
'n model om verworwe GK-weerstand na te boots daargestel en getoets. Resultate van hierdie 
eksperimente het getoon dat langdurige GK behandeling van mGRwt (dws 'wins van GRα 
dimerisasie) lei tot molekulêre GK weerstand (dws GILZ) en kliniese GK weerstand (dws 
FKBP51), terwyl die opregulering van 'n metaboliese geen (dws TAT ) behoue bly. In teenstelling 
hiermee verminder 'verlies' van GRα-dimerisasie die verworwe weerstand, op molekulêre en 
kliniese vlak, terwyl 'n verbeterde newe-effekprofiel vertoon word in terme van die beperking van 
die uitdrukking van 'n metaboliese geen (dws TAT). Hierdie resultate brei ons begrip uit van faktore 
wat bydra tot GK-weerstand en kan klinies ontgin word. 
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Chapter 1:   
Introduction 
1.1. Introduction 
‘Life is like riding a bicycle. To keep your balance, you must keep moving’ Albert Einstein1 
In 2014, the World Health Organization (WHO) reported that 43% of deaths reported in South 
Africa were due to non-communicable diseases (NCDs)
2
. Furthermore, an alarming 89% and 88% 
of deaths in the United Kingdom and United States, respectively, were as a result of NCDs
3
. NCDs, 
a collective term for a range of medical conditions, are classified as diseases that are non-infectious 
and non-transmissible from patient to patient, with the four main NCDs being cardiovascular 
disease, cancer, chronic respiratory disease and diabetes
2,3
.  
The progression of many of these NCDs is driven by chronic inflammation and they are often 
classified as inflammatory-linked or auto-immune. Chronic inflammation represents a profound 
prolonged increase in systemic inflammatory processes, which disrupts the system’s homeostasis 
and which may ultimately result in an inability of the system to adapt and thus a ‘point of no 
return’2,3. The pathological manifestations associated with inflammatory diseases embody this 
‘point of no return’. Unlike chronic inflammation, acute inflammation, a brief inflammatory 
response, serves as a protective mechanism allowing for the organism to cope with temporary 
threats and for homeostasis of the biological system to be restored
4
. In terms of the magnitude of the 
inflammatory response, chronic inflammation is considered to be a low-level of inflammation, with 
subtle local and systemic signs
5
 (Fig. 1.1). In contrast, acute inflammation is characterised by a 
greater inflammatory response with prominent symptoms such as swelling, redness, pain and heat
5
 
(Fig. 1.1).  
The inflammatory response, which culminates in either chronic or acute inflammation, is intricately 
linked to the stress response. Thus, the inflammatory response activates the stress response and 
perturbing the stress response, via a stressor, may disrupt the balance of the inflammatory 
response
4–6
. The interrelatedness of these two responses or systems may be eloquently described by 
a ‘bidirectional interaction’4–6 (Fig. 1.1). Broadly speaking, acute stress is a normal response to 
everyday life
4
. It often occurs following an unpredictable threat, such as an injury, and is associated 
with the fight-or-flight response. Activation of the stress response by an acute stressor results in the 
synthesis and secretion of physiological mediators, some of whose fundamental role is to suppress 
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inflammation, also termed immunosuppression
4–6
 (Fig. 1.1). Moreover, the acute stress response is 
short-lived and once the threat or challenge has been removed the stress-response is able to return to 
baseline or adapt to the stress
4
 (Fig. 1.1). Whilst acute stress responses are understood as adaptive 
reactions to overcome challenges and restore homeostasis, chronic stress, as a result of the repeated 
exposure to a physical or psychological stressor for a prolonged period of time, is often associated 
with enhanced inflammation and in most cases causes irreversible damage
4,6–8
 (Fig. 1.1). More 
specifically, chronic stress permanently alters endocrine-autonomic-immune signalling pathways, at 
both a central and peripheral level leading to inflammatory dis-inhibition and disease promotion
4–
7,9,10
 (Fig. 1.1). 
Figure 1.1: A ‘bidirectional interaction’ exists between the stress response and inflammation. The stress response 
is activated by stressors, which may be acute or chronic. Activation of the stress response stimulates signalling 
pathways to produce physiological mediators, which may act directly on the inflammatory response. In terms of acute 
stress, these physiological mediators function to reduce inflammation through immunosuppression, allowing for the 
biological system to adapt to the stressor and homeostasis to be restored. In contrast, repeated chronic stress, leads to 
continual activation of signalling pathways associated with the stress response. In turn, an excess in physiological 
mediators can have permissive or stimulatory effects on the inflammatory response, ultimately enhancing inflammation. 
It is this, prolonged chronic inflammation that has pathological consequences and in many cases drives the progression 
of a number of NCDs.  
Central to the stress-response is the hypothalamic-pituitary-adrenal (HPA) axis, which functions to 
maintain homeostasis by modulating the inflammatory response and other systems within the body, 
including the metabolic, cardiovascular and reproductive systems
11,12
. In order to mediate the 
regulation of multiple cellular processes within these systems, the finely-tuned HPA-axis 
coordinates the synthesis and secretion of glucocorticoids (GCs) into the periphery
4
. Broadly 
speaking, upon activation, in an ultradian/circadian manner or in response to internal or external 
threats, such as infection, pain, or stress
13–16
, the hypothalamus secretes corticotrophin-releasing 
hormone (CRH), which directly acts on the anterior pituitary gland, stimulating the release of 
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adrenocorticotropic hormone (ACTH)
15,17
 (Fig. 1.2). ACTH then stimulates the release, into the 
blood stream, of endogenous GCs, such as cortisol (F), from the adrenal cortex, where they are 
synthesised
15,18
 (Fig. 1.2). Once in the blood these lipophilic molecules are transported to their 
target tissues and cells, bound to carrier proteins such as corticosteroid-binding globulin (CBG), 
where they then bind to their cognate receptor, the glucocorticoid receptor alpha isoform (GRα)19–
22
. 
Figure 1.2: The HPA axis regulates the synthesis and secretion of GCs following activation by the circadian rhythm or 
stress. Figure from Oakley et al.
15
 where CRH refers to corticotrophin releasing hormone, and ACTH refers to 
adrenocorticotropic hormone. Activation by these hormones of the anterior pituitary and adrenal gland, respectively, is 
represented by the green arrows. Conversely, the red lines indicate the inhibitory negative feedback loops of the GCs, 
via the GRα, onto the hypothalamus and anterior pituitary gland. 
Stress-induced changes in HPA-axis signalling may result in the disruption of the homeostatic 
activity of the stress response, and an overall increase in the concentration of circulating GCs
4,5
. 
This altered HPA axis signalling has a multitude of effects, disrupting homeostasis at both the 
central and peripheral level and directly impacting the inflammatory response, and subsequently the 
degree of inflammation within the system
4–7,9,10
 (Fig. 1.1). However, depending on the magnitude of 
the stressor and the length of time of exposure to a particular stressor, the system may or may not be 
able to adapt. To introduce the central and peripheral effects of altered HPA-axis signalling and the 
ability of the system to reassert homeostasis, a figure adapted from Romero et al.
23
, which describes 
the Reactive Scope Model (Fig. 1.3), is used as framework. 
Firstly, central homeostasis of the stress system via the HPA-axis is predominantly maintained via 
negative feedback of endogenous GCs, via the GRα, on the hypothalamus and anterior-pituitary 
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gland (Fig. 1.2). Under ultradian/circadian signalling these negative feedback loops function to 
ensure optimal HPA-axis signalling and to maintain the endogenous concentration of GCs within 
the range of predictive homeostasis
23
 (Fig. 1.3). Acute stress such as from infection, pain or injury, 
stimulates HPA-axis activity leading to an increase in the concentration of circulating endogenous 
GCs
4,7,23
. This increase in the GC concentration represents an adaptive reaction of the stress 
response employed to overcome challenges, in this case the acute stressor. The adjustment the 
system needs to make, in this case to the HPA-axis activity, in order to respond to unpredictable 
perturbations (e.g. acute stress) is referred to as reactive homeostasis
23
 (Fig. 1.3). In the case of 
acute stress, it provides elasticity for the system to react and adapt to the stress-induced increase in 
HPA-axis activity and the subsequent increase GC concentration
24
. As the system makes these 
necessary adjustments it undergoes ‘wear and tear’ through maintaining GC concentrations within 
this reactive homeostasis range
23. This ‘wear and tear’ may be described by the term allostatic load 
and refers to the cost incurred by the system to maintain stability through change (i.e. maintaining 
the GC concentration within the reactive homeostasis range)
23,24
 (Fig. 1.3).  
The concept of allostatic load can be thought of in terms of one of Albert Einstein’s quotes: ‘‘Life is 
like riding a bicycle. To keep your balance, you must keep moving’, which suggests that 
maintaining homeostasis of a system (life), requires continual adaption (peddling of opposing left 
and right legs) whilst expending energy (energy required to generate force on peddles). 
Furthermore, as with a tiring cyclist, this allostatic load will eventually drive a gradual decrease in 
the ability of the system to cope and ultimately reduce the threshold between reactive homeostasis 
and homeostatic overload, which may result in homeostatic failure
23
 (Fig. 1.3). The latter is a 
consequence of sustained ‘wear and tear’ or a cumulative allostatic load and is often the result of 
repeated/prolonged stress activation, known as chronic stress.  
Chronic stress encourages prolonged stress-induced changes in HPA-axis activity resulting in HPA 
axis hyper-activity
25–27
. Consequently, this leads to a prolonged surge in the concentrations of 
circulating endogenous GCs
4
. These elevated endogenous GC concentrations are driven above the 
reactive homeostasis range into a pathological range referred to as homeostatic overload
23
 (Fig. 
1.3). Unlike short-term acute stress, these prolonged stimulatory effects induced by chronic stress 
on the HPA axis, and significantly higher GC concentrations, in many cases, lead to pathological 
consequences. In addition to chronic stress, the therapeutic use of exogenous GCs, for the treatment 
of inflammation, may also promote an increase in the concentration of circulating GCs into the 
homeostatic overload range
10
 (Fig. 1.3). This GC excess may result in adverse side-effects, such as 
hyperglycaemia, through a GC-mediated increase in the expression of metabolic enzymes and the 
unnecessary excess mobilization of glucose. In the case of both chronic stress and prolonged 
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exogenous GC treatment, the dysregulation of the HPA axis is further compounded by deficient 
GRα-mediated negative feedback loops, which are unable to contest the homeostatic overload, in 
terms of GC concentration, leading to an insufficiency in HPA-axis suppression
15
 (Fig. 1.2 and 1.3). 
One of the proposed reasons for defective negative regulation of the HPA axis is the peripheral 
effects induced by prolonged GC excess. An example, and central theme to this study, is ligand-
induced GRα down-regulation in peripheral tissues and cells28. 
 
Figure 1.3: The homeostatic activity of the stress system may be described using an adapted version of the 
Reactive Scope Model by Romero et al.
23
. Under basal conditions, optimal homeostatic activity of the stress-system 
occurs (dashed green line). Moreover, GCs are synthesised and secreted in a pulsatile manner following 
circadian/ultradian activation, resulting in slight changes in the GC concentration, which may be described as predictive 
homeostasis (thick grey line). Acute stress stimulates HPA-axis activity and drives an increase in the GC concentration 
to above the predictive homeostasis range (thick grey line). Subsequently, this perturbation encourages an adaption by 
the stress response, termed reactive homeostasis, which functions to counteract the stressor. In the case of chronic, 
prolonged stress, the stress system becomes hyperactive, driving a severe increase in GC concentration, which the 
system cannot counteract, and causing homeostatic overload. It is in this range where pathological consequences 
develop and disease progression ensues. 
The GC/GRα signalling pathway functions, in peripheral tissues and cells, to directly increase the 
expression of anti-inflammatory genes and decrease the expression of pro-inflammatory genes (Fig. 
1.4). It is these two mechanisms, termed GC-mediated transactivation and transrepression, 
respectively, which collectively allow for the classification of GCs as powerful immunosuppressive 
physiological mediators, serving to counteract inflammation, and allowing for peripheral 
homeostasis to be maintained during optimal HPA axis signalling
29
.  
1. Specifically, GCs (e.g. endogenous GC, F) secreted by the adrenal gland (Fig. 1.2) are 
transported in the blood to tissue- or cell-specific sites, where they bind to their cognate 
receptor, the GRα15.  
2. This binding results in a consequent change in the receptor conformation and the 
dissociation of the bound inhibitory protein complex (including the heat shock proteins)
15
.  
3. Subsequently, this conformational change facilitates receptor dimerization and then 
translocation of the GC-GRα complex from the cellular cytoplasm into the nucleus15,30.  
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4. Once in the nucleus, the GC-bound GRα acts as a ligand-activated transcription factor to 
positively (i.e. transactivation) and negatively (i.e. transrepression) regulate the expression 
of a large cohort of GC-responsive genes
15
.  
5. Following the modulation of GC-responsive gene expression, the GC-GRα complex is 
exported to the cytoplasm
15
.  
6. Once exported it is targeted for degradation by the proteasome15.  
 
 
Figure 1.4: The GC/GRα signalling pathway. (1) GCs are transported in the blood to target tissues or cells where they 
diffuse across cell membranes into the cytoplasm and bind to the GRα. (2) Binding of GCs initiates a conformational 
change in the GRα and dissociation of an inhibitory protein complex. (3) The GC-GRα complex either dimerizes or 
remains as a monomer and translocates to the nucleus. (4) The GC-GRα complex binds to glucocorticoid response 
elements (GREs) or other transcription factor response elements (e.g. NFκB-RE) to regulate the expression of GC-
responsive genes. (5) Following transactivation or transrepression the GC-GRα complex is exported to the cytoplasm 
where it is targeted for degradation by post-translational modifications (e.g. phosphorylation and ubiquitination), via (6) 
the proteasome. 
Under basal or acute stress conditions, degradation of the GRα, induced down-stream of ligand-
binding, serves to protect the cell from continual GC/GRα signalling and maintains GC function 
within the normal reactive scope
23
 (Fig. 1.3). In contrast, prolonged exposure to excess GCs, as a 
result of chronic stress or exogenous GC administration, not only alters the central homeostasis of 
the HPA-axis, but promotes enhanced GRα protein down-regulation in peripheral cells and 
tissues
31–37
. In this case, receptor levels are significantly reduced, which results in a disintegration 
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of the negative feedback loop of GCs on the HPA axis and drives GC concentrations above the 
reactive homeostasis range and into homeostatic overload
23
 (Fig. 1.3). Furthermore, due to the fact 
that GCs serve as endogenous anti-inflammatory molecules to combat inflammation, significant 
reductions in the GRα, through which they mediate their effects, have severe implications. In 
addition, pharmacologically, a significant reduction in GRα expression has been linked to a 
concomitant reduction in GC response and this decrease in GC sensitivity poses potential problems 
for the use of GCs as anti-inflammatory drugs
38–43
. Moreover, in some cases it leads to partial or 
complete acquired resistance to GC treatment and the subsequent deterioration of clinical control 
when treating a variety of auto-immune and inflammation-associated diseases (e.g. asthma and 
haematological cancers)
15,44,45
. Studies have demonstrated that one of the ways in which the GC 
response may be maintained over time is through restoration of GRα expression, which may 
ultimately reverse acquired resistance to GC treatment
46–48
. One of the ways this has been achieved 
is through the use of Ginsenoside Rh1, which ameliorates the ligand-induced down-regulation of 
the GRα protein and reverses resistance, thereby ultimately restoring homeostasis at a cellular 
level
49
. 
CompoundA (CpdA) or 2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride, is a 
synthetic analogue of a phenyl aziridine precursor that occurs in the shrub Salsola tuberculatiformis 
Botsch
50. Prolonged treatment with CpdA does not mediate wild type GRα down-regulation37,51,52. 
This finding is in stark contrast to Dexamethasone (Dex), a potent GRα agonist used 
pharmacologically, shown by Visser et al.
52
 to result in a significant reduction in wild type GRα 
protein and mRNA expression over time, which supported the findings of several other studies in 
which Dex was used
31–37
. Furthermore, CpdA has a non-steroidal structure and is known to have a 
dissociative behaviour when it comes to GC/GRα signalling, which allows for its classification as a 
selective glucocorticoid receptor modifier (SGRM)
37,52
. Essentially, this dissociative behaviour 
refers to CpdA’s ability to negatively down-regulate pro-inflammatory genes, mediating its well 
documented potent anti-inflammatory potential, without positively up-regulating genes often 
associated with adverse side-effects of GCs
36,53–55
. More specifically CpdA efficiently mediates 
transrepression, but not transactivation, via the GRα. It is thought that the dissociative behaviour of 
CpdA may be as a result of its ability to prevent the formation of GRα dimers, for which Robertson 
et al.
56
 along with others
53
 provided a strong case by revealing that the dimerization abrogating 
capabilities of CpdA differed from the dimerization promoting capabilities of Dex. Taken together, 
these characteristics of CpdA sparked interest in a possible link between GRα dimerization and 
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GRα turnover, which in the current study is initially further investigated using a human 
dimerization deficient
1
 mutant GRα, hGRdim57. 
The dimerization deficient mutant, hGRdim, was created by introducing a single amino acid 
exchange, of an alanine for a threonine at amino acid position 458, in the dimerization loop (D-
loop) of the wild type human GRα57, thus producing a mutant with a single disrupted dimerization 
interface. The D-loop is located within the second zinc finger, found within the DNA-binding 
domain of the hGRα, which is involved in mediating receptor/DNA interactions57. Based on 
previous findings, in which dimerization is inhibited through this D-loop amino acid exchange in 
another steroid receptor, the androgen receptor (AR)
58
, it was widely accepted that the same 
mutation would prevent dimerization of the GRα. Classically, it is thought that GRα dimerization is 
a requirement for direct DNA-binding of the receptor to a glucocorticoid response element (GRE) 
and thus the reported reduced affinity of hGRdim for the GRE initially provided evidence
59
 for is 
inability to successfully form GRα dimers. However, there is conflicting evidence surrounding the 
inability of hGRdim to dimerize
56,60
. Despite this, hGRdim is still the most widely characterised and 
utilized dimerization deficient GRα mutant56,59 and, in the current study, will be used to substantiate 
the effects that a CpdA-induced ‘loss2’ of wild type GRα dimerization has on receptor turnover.  
Thus, the current study hypothesizes that there is an association between ligand-induced GRα 
dimerization and ligand-induced down-regulation of the GRα protein.  
To prove or disprove this hypothesis, the following questions were asked: 
1. Is receptor dimerization a requirement for ligand-induced receptor turnover?  
2. Mechanistically, how does the inability of the GRα to dimerize prevent ligand-induced 
down-regulation? 
3. Following prolonged GC treatment do changes in GRα protein expression mediate 
downstream effects, through the modulation of GC-responsive gene expression? 
In order to address the above questions the following aims were established, which are reflected in 
the results chapters 4, 5 and 6, respectively: 
- Chapter 4: Investigate the role of ligand-induced receptor dimerization in mediating GRα 
protein turnover through the treatment of endogenous human GRα or transiently transfected 
wild-type (hGRwt) and dimerization-deficient mutant GRα (hGRdim) with dimerization 
                                                 
1Deficient is defined by the Cambridge Dictionary as “not having enough of” and thus we will use this term as such 
throughout the thesis to describe an impaired, but not totally disrupted, dimerization ability. 
2
 Loss is defined by the Cambridge Dictionary as “the fact you no longer have something or have less of something” 
and thus we have used the word to mean “less of” rather than “total loss” throughout the thesis. 
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promoting GCs, both endogenous (F) and synthetic (Dex), and a dimerization abrogating 
GC (CpdA). 
- Chapter 5: Determine how the inability of GRα to dimerize impedes molecular 
mechanisms involved in ligand-induced GRα protein down-regulation, via proteasomal 
degradation, with specific reference to post-translational modifications such as 
phosphorylation and ubiquitination. 
- Chapter 6: Explore how changes in the expression of both GRα mRNA and protein, due to 
a ‘loss’ or ‘gain’ of receptor dimerization, modulates the mRNA expression of a subset of 
GC-responsive genes, by establishing a model to mimic a continuum of acquired resistance 
to GC treatment. 
In addition to the results chapters outlined above and the current chapter, Chapter 1, which 
highlighted the importance of homeostasis and provided background on the HPA-axis and more 
specifically, the GC/GRα signalling pathway, while furthermore describing results from previous 
studies, which provided a platform to launch this study, this thesis consists of 3 additional chapters, 
namely Chapter 2, 3 and 7. Chapter 2, a review article written for publication, aims to enlighten 
the reader about the broad spectrum of GC resistance, both congenital and acquired, while honing in 
on the idea of acquired GC resistance as a continuum and discussing factors which may affect this 
continuum of resistance. Important to note, is that some repetition of Chapter 1 is unavoidable as 
these concepts will be included in the manuscript for publication. Chapter 3, details the material 
and methods used in the current study, while Chapter 7 discusses the findings of the current study. 
Here, an in depth analysis of all the results in the current study is presented by contextualizing the 
findings in terms of the current literature, stating the limitations of this study and providing future 
perspectives.  
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Chapter 2:  
“Acquired GC resistance”: reviewing the 
importance of glucocorticoid receptor 
expression. 
2.1. Introduction  
In 2014, the World Health Organization (WHO) reported that 43% of deaths reported in 
South Africa were due to non-communicable diseases (NCDs), with the four main NCDs 
being cardiovascular disease, cancer, chronic respiratory disease and diabetes
1,2
. Furthermore, 
an alarming 89% and 88% of deaths in the United Kingdom and United States, respectively, 
were as a result of NCDs
2
. The progression of many NCDs and psychological/pathological 
conditions are driven by chronic, persistent inflammation
1–3
. Unlike acute inflammation, 
which serves as a protective mechanism allowing for homeostasis to be returned following a 
temporary threat, chronic inflammation represents a prolonged increase in the systemic 
inflammatory process, which continuously disrupts the system’s homeostasis, ultimately 
resulting in an inability of the system to adapt
3,4
. This sustained disruption in the homeostasis 
of the system, has a knock on effect, modulating a number of essential systemic signalling 
pathways, such as the hypothalamic-pituitary-adrenal (HPA) axis, which is central to the 
stress response
4
. Due to the interrelatedness of the stress and inflammatory response, chronic 
persistent inflammation, can be considered both a cause and a consequence of a prolonged 
disruption of the central HPA axis signalling pathway’s homeostasis, which in turn has many 
peripheral effects, one of these being an increase in circulating glucocorticoids (GCs)
3,5–8
.  
Endogenous GCs are physiological mediators synthesised and regulated by the HPA-axis and 
secreted in an ultradian/circadian manner or in response to internal or external threats, such as 
infection, pain, or stress
9–12
. GCs function within the body to regulate inflammation and 
maintain internal homeostasis of the biological system
3,5–7,9,13,14
. To this day, exogenous GCs, 
designed to mimic the biological anti-inflammatory action of endogenous GCs, remain the 
mainstay therapeutic choice for the treatment of chronic inflammation as a result of disease 
and/or psychological or physical stress
14–16
. Currently one of the most widely prescribed 
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drugs in the world with an estimated 1.2% of the population of the United States of America 
(USA) using GCs
17,18
. Whilst often efficient in curbing damaging inflammation it is believed 
that approximately 30% of all patients who require pharmacological GC treatment, 
experience a degree of damaging GC insensitivity
19
. Specifically, 4-10% of asthma patients, 
30% of rheumatoid arthritis patients, almost all chronic obstructive pulmonary disease 
(COPD) and sepsis patients
20
 and 10-30% of untreated acute lymphoblastic leukaemia (ALL) 
patients
21
 experience varying degrees of GC insensitivity. 
Due to this stochastic response to GCs, within disease groups
22–24
 compounded by inter-
individual and intra-individual variation in patient GC sensitivity as well as tissue-specific 
intra-individual GC–responsiveness among organs, tissues, cells and even within the same 
cell
19,25
, research is now focused on developing diagnostic tools for determining GC 
sensitivity prior to treatment so that GCs may be used selectively in personalized therapeutic 
regimes
19,26
. This will likely assist in limiting the generation of adverse side-effects and 
prevent the development of further GC insensitivity
27–30
. 
This review revisits and highlights the importance of the glucocorticoid receptor alpha 
isoform (GRα), the receptor to which GCs bind and which mediate their biological effects, in 
GC sensitivity, specifically in terms of an acquired resistance to GC treatment. Primary focus 
is given to disease- or treatment associated reductions in receptor levels, which drive the 
development of GC insensitivity, as well as the molecular mechanisms involved in mediating 
receptor turnover at both the mRNA and protein level. Furthermore, methods to restore GRα 
protein expression and improve GC sensitivity are briefly detailed. To conclude, we propose 
the notion that the role of the conformation of the liganded receptor is somewhat undervalued 
and overlooked when considering ways in which GC resistance may be curbed, suggesting 
that this fundamental aspect of GC/GRα signalling requires further investigation and that the 
link between liganded-GRα conformation and receptor turnover should be considered as it 
may have implications in acquired GC resistance. 
2.2. GC resistance  
GCs, both endogenous and exogenous, mediate their biological effects via their ubiquitously 
expressed cognate receptor, GRα17,31. Briefly, the synthesis and secretion of GCs into the 
blood stream is tightly regulated by the HPA-axis
17
. Once in the bloodstream, delivery of 
these GCs to various tissues and cells as well as the activity and bioavailability of these small 
lipophilic molecules is further governed by transport proteins, cortisol-binding globulin 
Stellenbosch University  https://scholar.sun.ac.za
 19 
 
(CBG) and albumin
17
. Upon reaching the cell, GCs diffuse across the cell membrane and bind 
the intracellular GRα17. Upon binding, the GRα undergoes a conformational change driving 
the dissociation of an inhibitory multi-protein complex consisting of, amongst others, Heat-
shock protein 90 (Hsp90) and FK506 binding protein 51/52 (FKBP51/52), allowing for 
subsequent translocation of the GRα to the nucleus of the cell32. It is here where the GC-
bound GRα mediates its biological effects via various mechanisms of transrepression or 
transactivation of a wide range of GC-responsive genes. Generally speaking, it is thought that 
the GC-mediated transrepression of pro-inflammatory genes is what provides the 
indispensable potent anti-inflammatory potential of GCs
32
. As specific details of the GC/GRα 
signalling pathway are not the focus of this paper, comprehensive reviews by Desmet et al.
32
, 
Ratman et al.
33
, Vandevyver et al.
34
 and Weikum et al.
35
 are recommended. 
Central to the ability of GCs to combat inflammation (i.e. patient sensitivity to GC treatment) 
is the requirement for a significant amount of functional GRα through which they may 
mediate their effects
36–38
, which we term the GRα ‘functional pool’. Importantly, there are a 
multitude of factors which can regulate the ‘functional pool’ of GRα, either at the level of the 
activity of the receptor and/or at the level of the amount (i.e. expression) of the GRα, thus 
ultimately contributing to GC resistance. In short, disruptions in GRα function are known to 
modulate the subcellular localization, ligand binding, and transactivation ability of the 
receptor
25
, and are regulated by, amongst others, increases in additional GR isoforms (GRβ 
and GRγ) due to alternative splicing events, inactivating GRα mutations, the inflammatory 
cytokine profile of the cellular microenvironment and mutations/polymorphisms in the ERK 
pathway, as eloquently reviewed by Nicolaides et al.
4
, Oakley et al.
11,14,39
, Merkulov et al.
40
 
and Patel et al.
41
. However, rather than altered GRα activity, the focal point of this review is 
‘reviewing the importance of GRα expression’ with regards to GC resistance.  
GC resistance is highly complex and multi-faceted and has been extensively identified and 
studied in health and disease
42
. Broadly speaking, GC resistance may be divided into two 
major groups: generalized or acquired GC resistance
4,42
. Importantly generalized GC 
resistance is also referred to as systemic or primary resistance, whilst acquired GC resistance 
is also known as localized or secondary resistance. However, in this review we will only 
make use of the terms generalized and acquired GC resistance. Essentially, these two groups 
of GC resistance are distinctively different in terms of their occurrence within a biological 
system with the latter form affecting distinct tissues and/or cells and not present throughout 
the organism (or patient)
42
. However, with that said, central to both of these two types of GC 
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resistance is dysfunction of the GRα ‘functional pool’. In the next section we provide a short 
synopsis of generalized GC resistance whilst honing in on acquired GC resistance and the 
importance of GRα mRNA and protein expression in the development of this acquired GC 
insensitivity. 
2.2.1. Generalized GC resistance  
In terms of generalized GC resistance, two severe hereditary/familial conditions, termed 
Primary Generalised Glucocorticoid Sensitivity (PGGS) and Primary Generalized 
Glucocorticoid Resistance (PGGR), also at times referred to as Chrousos Syndrome and 
characterized by rare hereditary pathological point mutations of the GR gene
25
 and others 
(e.g. ER22/23EK polymorphism)
42
, represent the extremities of GC responsiveness (i.e. 
hypersensitivity and hyposensitivity). These inactivating mutations lead to perturbations in 
the GR ‘functional pool’ by mainly altering receptor function (e.g. reduced transactivational 
capabilities, DNA-binding, ligand-binding affinity and abnormal nuclear translocation) but in 
some cases also GRα mRNA and/or protein expression4,25,42,43. The effect of these mutations 
is considered generalized as it occurs throughout the biological system (i.e. in every cell)
4,42
. 
In addition to these hereditary mutations, a number of acquired gene polymorphisms in the 
GR gene and additional genes (e.g. ER22/23EK polymorphism) are known to lead to GRα 
deregulation at the level of GRα activity, however these should not be confused with acquired 
GC resistance, addressed in the next section, as these acquired gene mutations still elicit a 
generalized effect, as in the case of the hereditary mutations
42
. With this generalized form of 
GC resistance falling beyond the scope of the current review, we advise reviews by Quax et 
al.
42
, Vandevyver et al.
44
, Nicolaides et al.
4,25
,  Charmandari et al.
45
 and Beck et al.
43
. 
2.2.2. Acquired GC resistance  
Unlike generalized GC resistance, localized, acquired GC resistance is often restricted to a 
specific tissue or cell type (i.e. immune cells), rendering these peripheral tissues/cells 
insensitive to circulating GCs (endogenous and/or exogenous) over time
26,27,42
. Moreover, 
this form of GC resistance is significantly more common in the general population and has 
been linked to a number of psychological and pathological conditions/diseases (Table 1). An 
apt description for this form of GC resistance is a “consequence of a pathophysiological 
process”17, however, what this description excludes is the development of acquired GC 
resistance following prolonged GC treatment (Table 2). Acquired GC resistance has been 
identified and defined in a number of diseases/conditions and often develops after a period of 
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acceptable GC response (i.e. at the start of the therapeutic regime), posing a significant 
challenge for the clinical use of GCs
27,42
. 
2.2.3. Current diagnostic approaches for determining GC resistance  
GC resistant patients often require higher GC doses for prolonged periods of time in order to 
efficiently combat chronic inflammation in a number of psychological and physical 
conditions, which likely leads to the generation of adverse side-effects (e.g. osteoporosis and 
hyperglycemia) and may compound GC insensitivity
37
. With this in mind it is of utmost 
importance for practitioners to be able to evaluate the GC-responsiveness of individualized 
patients before devising a therapeutic regime; this will allow for GCs to be used selectively 
and permit personalized GC treatment, depending on patient sensitivity, resulting in the 
optimal therapeutic outcome of GC treatment
19
. Currently, a range of endocrine and 
biochemical methods are employed to determine GC insensitivity in patients or in vitro, 
respectively, however, at present no single, standardized method for determining patient 
sensitivity to GC treatment exists
19
.  
In terms of systemic or generalized GC resistance, patients display clinical heterogeneity 
ranging from asymptomatic to mild and severe symptoms (e.g. hypertension, hirsutism, 
hyperandrogenism, fatigue and hypokalemia), eloquently reviewed by Nicolaides et al.
25
. 
Thus, initially, an in depth analysis into the family and personal history of the patient must be 
conducted in order to detect any history of clinical manifestations of GC resistance
4,25
. 
Thereafter, concentrations of the endogenous GC, cortisol (F), should be monitored using 
protocols such as the cortisol awakening rise/response (CAR)
46
 or the 24-hour urinary free 
cortisol (UFC)
25
, as examples. Following which, a dexamethasone (Dex) suppression test 
(DST) or the more recent Dex/CRH suppression test is conducted to test the responsiveness 
of the central HPA axis, which is regulated by a GC-mediated negative feedback loop
26,42
. 
Lastly, specific gene sequencing to detect possible mutations in the GR gene can be used to 
confirm the diagnosis of generalized GC resistance in a patient
4,25
. 
Localized or tissue-specific resistance is more difficult to diagnose than systemic or 
generalized resistance, which generally displays a ‘clinical picture’ of GC resistance4,25. In 
general, patients are mostly asymptomatic and thus a range of in depth biochemical 
diagnostic approaches are required to determine the GC-responsiveness of specific tissue 
and/or cells
19,26,47
.  
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Examples of these include:  
1. Investigating GC-mediated inhibition of cell proliferation using various assays such as 
the BrdU incorporation lymphocyte steroid sensitivity assay (BLISS)
19
, a specific 
prognostic model measured by the Lille score
48
, chemiluminescence and flow 
cytometry
49
. 
2. Measuring the responsiveness of GC mediated genes (e.g. interleukin 8 (IL-8), 
interleukin 17 (IL-17), matrix metalloproteinase-1 (MMP) or dual specificity protein 
phosphatase 1 (DUSP-1))
50–52
 
3. The analysis of GRα function (e.g. ligand binding and nuclear translocation) 
4. Lastly, and importantly for the current review, the mRNA and protein expression of 
the GRα receptor. 
A wealth of data has been collected demonstrating differences in GRα mRNA and/or protein 
expression between steroid responders and non-responders in both normal versus disease 
states, as well as within disease states ‘with’ or ‘without’ GC therapy (Table 1 and 2). 
However, an increasing demand for more sensitive and specific GC response tests remains, to 
be able to quantify/identify individual patient GC insensitivity thus avoiding unnecessary 
high-doses of GCs and the afore mentioned consequences
27
. 
2.3. GRα expression in health and disease  
In many, but certainly not all stress-related, psychological and pathological conditions, 
reductions in the expression (i.e. mRNA and/or protein) of GRα have been noted, relative to 
‘normal’ or healthy patients40,42 (Table 2.1). These disease-associated reductions, of up to 
80%, in the GRα ‘functional pool’ often produce GC-resistant forms within disease groups, 
which are exceptionally challenging to manage clinically
40,42,53
. In addition to the disease-
associated reductions in receptor mRNA and/or protein expression (i.e. generally mediated 
via endogenous GCs), treatment (i.e. with exogenous synthetic GCs) associated reductions in 
the GRα ‘functional pool’ are well documented (Table 2.2). Important to note is that it is 
often difficult to distinguish between ligand-induced GRα down-regulation as a pathological 
consequence of disease progression and exogenous treatment induced receptor turnover, as 
with some patients withholding GC treatment would not be ethical
54
. Furthermore, many 
diseased GC resistant patients require higher GC doses for longer periods of time to elicit 
sufficient anti-inflammatory effects, which generally has been shown to compound the 
development of GC resistance, through further reducing the GRα ‘functional pool’, which is 
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neatly demonstrated by Andreae et al.
55
. In this section, ligand-induced reductions in GRα 
expression at the mRNA or protein level, which are driven by stress or pathological or 
psychological conditions (Table 2.1) and/or by exogenous GC use as therapeutics (Table 2.2), 
are specifically reviewed. 
2.3.1. Disease-associated reductions in GRα expression  
2.3.1.1. Stress  
There is a wealth of evidence implicating environmental effects such as physical, 
psychological or pre/post-natal stress, in the development of acquired GC resistance through 
modulation of GRα mRNA and/or protein expression, which has implications for the 
treatment of a number of stress-related disorders and potentially a number of chronic 
psychological or pathological conditions
56
. Importantly, the modulation of GRα levels, 
induced by various stressors, is fundamentally dependent on the duration of the stressor, the 
environment in which the stress occurs, and lastly the individual’s sensitivity to stress57–63. 
Generally speaking, stress leads to significant increases in circulating endogenous GCs, 
which subsequently modulates GRα expression in peripheral tissues or cells64. Moreover, 
stress-induced, GC-mediated GRα down-regulation is tissue-specific57–62. Whilst it is thought 
to be an adaptive mechanism employed by the cell to protect against the damaging effects of 
unrelenting stress, this reduction in GRα expression and GC response poses major challenges 
for the therapeutic use of GCs
64
. In the next section we provide examples of these stress-
induced effects on GRα mRNA and protein expression, honing in on cases where receptor 
expression is reduced (Table 2.1).  
2.3.1.1.1. Pre/post-natal stress 
Early life stress (ELS), which includes pre- and post-natal stress, may alter HPA axis 
signalling (reviewed by Van Bodegom et al.
65
), which has prolonged consequences on GRα 
mRNA and/or protein expression, GC sensitivity and susceptibility to psychological 
conditions (i.e. depression) in adulthood, in rodents and humans
66–75
. A number of studies, 
which investigate post- and pre-natal stress (i.e. using maternal separation (MS) and 
preconception paternal stress (PPS) as ELS stressors) have demonstrated the downstream 
effects of ELS on GRα mRNA and/or protein expression76–81.  
Firstly, in terms of post-natal stress in humans, a convincing amount of evidence exists 
associating the effects of childhood trauma (i.e. physical abuse or adoption) with the 
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methylation status of the GRα promoter82–84, however, only a handful of human studies, on 
receptor mRNA expression have been conducted
71–73
. Specifically, in adult suicide 
completers, with a history of severe childhood abuse, GRα mRNA expression in drastically 
reduced in hippocampal regions of the brain, relative to controls
71,72
. Moreover, this reduction 
in receptor mRNA expression was thought to be a consequence of childhood abuse mediated 
alterations in the HPA signalling pathway, and consequent increases in circulating GCs
71,72
. 
Additionally a study by Perroud et al.
73
, demonstrated pre-natal (i.e. rather than post-natal) 
stress in humans, such as maternal stress, led to transgenerational transmission of the 
maternal stress to offspring, in the form of biological alterations in HPA signalling, from a 
cohort of women who were exposed to the Tutsi genocide during pregnancy. Interestingly, 
rather than increases in GC concentrations, mothers and their children had reduced levels of 
the circulating endogenous GC, F, despite displaying significant reductions in GRα mRNA 
expression
73
, suggesting that a direct link between an increase in GC concentration and 
reductions in receptor expression, should always be made with caution. 
In terms of rodent post-natal stress models, a recent study by Woo et al.
76
 demonstrated a 
decrease in GRα mRNA expression in rats as a direct consequence of MS as infants. This was 
supported by additional studies in which reductions in receptor mRNA expression in the 
frontal cortex and hippocampus of adult and adolescent rodents was noted, following ELS in 
the form of infant MS
75,77
. Additionally, MS has been shown to decrease GRα mRNA 
expression in the dorsal medial prefrontal cortex and amygdala in rats
70,78
, which is likely to 
have implications in lifelong maladaptive behaviour.  
Similarly to post-natal stress, pre-natal stress in rodents, both maternal and paternal, is known 
to drive changes in GRα mRNA and/or protein expression in offspring79,80. More specifically, 
in offspring of PPS rats (i.e. paternally stressed pups) a decrease in receptor mRNA 
expression in the hippocampi of these pups was documented relative to non-paternally 
stressed pups, with the pups displaying an increase in anxiety-like behaviour
79
. Additionally, 
in a study by Mueller et al.
80
, maternal stress was shown to increase the endogenous GC, 
corticosterone, in mice and reduce GRα protein expression in the dentate gyrus of offspring. 
This is supported by Bingham et al.
74
 where exogenous prenatal corticosterone exposure, 
used to mimic the prenatal stress-induced increase in circulating endogenous GCs, reduced 
receptor protein expression in the medial prefrontal cortex, hypothalamus and hippocampus 
of adult offspring. Lastly, a recent study by Lan et al.
81
 demonstrated that pre-natal stress 
leads to reductions in GRα protein expression in the limbic region in foetuses. 
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2.3.1.1.2. Physical or psychological stress: 
A large number of studies in rodent models, using various methods of inducing stress, have 
also demonstrated stress-induced reductions in both GRα mRNA and protein expression, in 
various tissues and/or cells, relative to non-stressed control groups (Table 2.1). Specifically, 
in terms of GRα mRNA, earlier studies by Paskitti et al.85 and Karandrea et al.63 
demonstrated that restraint stress led to significant reductions in receptor mRNA expression 
in brain regions (i.e. dentate gyrus, hippocampus and hypothalamus) of rats. In support of 
these findings are more recent studies, which have confirmed stress-induced GRα mRNA 
down-regulation in rats
76,86–90
. Interestingly, results from a study by Witzmann et al.
86
 
showed that prolonged restraint and psychological stress induced increases in the circulating 
endogenous GC (i.e. corticosterone) in adult rats resulted in a decrease in GRα mRNA 
expression in peripheral leucocytes, however. In another study where forced swim stress 
(FSS) was used as the stressor, reduced receptor mRNA expression in the dentate gyrus of 
rats, was noted, and thought to be mediated by the stress-induced increase in endogenous 
GCs
64
. Additionally, Jung et al.
87
 demonstrated that repeat social defeat (RSD) led to 
decreased GRα mRNA expression in splenic macrophages, which was later correlated to 
diminished GC sensitivity in these cells. More recently, Makhathini et al.
88
 noted that 
significant increases in corticosterone levels resulted in a consequent decrease in GRα mRNA 
expression in the hippocampi of rats, following repetitive restraint stress (RRS). In terms of 
GRα protein expression, exposure to repeated water-immersion and restraint stress (WIRS) 
increased GCs and decreased receptor protein expression in oligodendrocytes in the corpus 
callosum of rats, relative to non-stressed controls
89
. Moreover, restraint stress led to GRα 
protein reductions in the prefrontal cortex
90
 and hippocampi
76
 of rats and was thought to be 
GC-mediated. Additionally, in RSD a reduction in GRα protein led to diminished GC 
sensitivity
91
.  
A fairly well accepted notion is that certain chronic physical, psychological and/or pre-/post-
natal stressors can, in addition to encouraging the development of GC resistance, significantly 
increase susceptibility to severe psychological or pathological conditions
92,93
. An example in 
support of this notion is a recent study by Han et al.
92
 where stress-induced hypercortisolemia 
mediated a decrease in the GRα protein expression of hippocampi and the hypothalamus of 
mice, which subsequently increased their susceptibility to psychological disorders (e.g. 
depression), relative to control and resilient mice. Another example is provided by Li et al.
93
, 
where psychosocial stress, in the form of social disruption, reduced GRα mRNA and protein 
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expression in the lung tissues of asthmatic mice (i.e. in a murine model of allergic asthma), 
thereby decreasing GC sensitivity and driving asthma exacerbation, relative to the control 
asthmatic group not exposed to psychosocial stress. 
In conclusion, this section provided examples of a range of stress-related studies with 
indisputable evidence for the importance of GRα expression in mediating GC sensitivity and 
briefly highlights GC-mediated down-regulation as one of the likely mechanisms in which 
severe, prolonged stress may drive the progression of a range of psychological, pathological 
and auto-immune or inflammatory-linked disorders, further explored in the next section
56,94
.  
2.3.1.2. Psychological conditions: 
In many psychological disorders, including depression and schizophrenia, phenotypic overlap 
exists with patients displaying common symptoms such as flat affect, anhedonia and other 
negative symptoms
95
. Similarly, a large cohort of patients, but not all
96,97
, suffering from 
psychological disorders/conditions display consistent biological findings
98–103
, namely an in 
increase in inflammation and hyperactivity of the HPA, which drives hypercortisolemia (i.e. 
an increase in circulating endogenous GC, F) with consequences for GRα expression, either 
at the mRNA and/or protein level, in peripheral tissues
104
. Whilst it must be noted that vast 
heterogeneity in GRα expression exists in patients with psychological conditions103–105, the 
current review focuses on conditions/disorders which have been specifically linked to 
decreases in GRα mRNA and/or protein expression (Table 2.1). Specifically, a number of 
studies have demonstrated a reduction in GRα mRNA expression in patients suffering from 
major depression (MD) in various tissues of the brain including the hippocampus, prefrontal, 
temporal and entorhinal cortex, as well as in peripheral blood mononuclear cells 
(PBMCs)
95,106,107
. Moreover, these reductions in receptor mRNA expression were also noted 
for patients with schizophrenia and bipolar disorder
95
. In addition, a number of studies have 
provided evidence regarding patients suffering from post-traumatic stress disorder (PTSD) 
having reduced GRα mRNA expression, relative to healthy controls, in peripheral cells such 
as lymphocytes and PBMCs
108–111
. Interestingly, this reduction in receptor expression in 
peripheral PBMCs was found to be cumulative in PTSD patients with an increased trauma 
burden
111
. Furthermore, in patients suffering from generalized-anxiety disorder (GAD), a 
negative correlation was made between circulating GC concentrations and GRα mRNA 
expression, which was subsequently shown to result in diminished GC sensitivity
53
. Taken 
together, these studies highlight the importance of receptor expression in the pathophysiology 
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of various psychological disorders by providing examples of cases in which reduced GRα 
expression is noted, with implication in GC resistance. For more information on GC 
resistance in stress-induced psychopathologies, a review by Merkulov et al.
40
, is 
recommended.  
2.3.1.3. Pathological conditions 
2.3.1.3.1. Auto-immune or inflammatory-linked conditions 
It would appear that the existing literature detailing the disease-associated effects on GRα 
expression in a number of auto-immune and inflammatory conditions is somewhat 
contradictory, with differential effects on GRα mRNA and/or protein expression noted, 
relative to their normal or healthy counterparts. In addition, it seems considerably more 
difficult to tease apart whether modulations in receptor expression are a pathological 
consequence of the auto-immune disease (i.e. as in the case of many psychological disorders, 
often stress related) or as a result of prolonged GC treatment, which many of these patients 
require. Nevertheless, in this section we have highlighted cases in which reduced GRα 
mRNA and/or protein expression is noted in auto-immune or inflammatory-linked conditions, 
attempting to limit it to cases in which patients were not receiving treatment (Table 2.1).  
Firstly, in atopic dermatitis (AD), a condition linked to inflammation of the skin, significant 
reductions in GRα mRNA expression in systemic cells (i.e. PBMCs) of AD sufferers, relative 
to healthy controls, have been reported by Inui et al
112
. Moreover, in the same study, 
reductions in receptor expression were correlated to an increase in resistance to both topical 
GC treatment and the systemic administration of a potent GC
112
. To our knowledge, it would 
seem that this is the only study in which GRα mRNA expression and GC response have been 
comprehensively studied in AD
112
. The importance of GRα mRNA expression in the auto-
immune disease systemic lupus erythematous (SLE), also commonly referred to as lupus, for 
which inflammation of the skin predominantly on the face is a common symptom, has also 
been documented and is reviewed by Bazso et al.
113
 with disease-associated reductions in 
GRα mRNA expression reported by more than one study114–117. Specifically, a reduction in 
receptor mRNA expression has been reported in PBMCs
114–116
. Additionally, a study by Guan 
et al.
117
 demonstrated that GRα mRNA expression was higher in sensitive patients before 
receiving GC treatment, suggesting that reductions in receptor mRNA expression, in this 
case, were likely to be disease-associated. In addition, in peripheral tissues and cells (i.e. 
leucocytes) of patients suffering from a resistant form of another auto-immune disease, 
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namely inflammatory bowel disease (IBD), the disease-associated effects on GRα mRNA 
expression were either absent (i.e. no change in receptor mRNA expression)
118
 or led to 
reductions in receptor mRNA expression
119
, relative to healthy controls. Thus this may 
suggest that GRα expression is not the primary determinant for GC sensitivity in IBD, 
reviewed by Creed et al.
120
, however, a partial role for receptor mRNA and/or protein 
expression may exist. Lastly, in adult immune thrombocytopenia (ITP), a condition driven by 
an auto-immune response, reduced GRα mRNA and protein expression was correlated with 
GC resistance
121
. 
In terms of asthma, the majority of patients demonstrate a good therapeutic response to GC 
therapy, however, there are two known forms of asthma which are steroid resistant (i.e. Type 
I and II), reviewed in Luhadia et al.
122
, which have been linked to defects in GRα function 
and expression
123–125
. Type 1 has an increased GRβ/GRα cellular ratio, due to low GRα 
protein expression compounded by an increase in the GR isoform, GRβ, and has been linked 
to GC resistance
126
, whilst Type II is linked to disease-associated reduction in only GRα 
protein expression, relative to normal controls (i.e. non-asthmatic patients)
127
. With that said, 
it must be highlighted that an increase in GRα mRNA expression has also been detected in 
the PBMCs of asthmatic patients relative to healthy controls
128
. These studies suggest that the 
amount of GRα present in peripheral tissues/cells, be it in part, plays some role in the 
responsiveness of asthma patients to therapeutic GCs (e.g. inhaled corticosteroids), which 
function to reduce asthmatic exacerbations and restrict symptoms associated with this 
inflammatory-based lung disease
122
. In another lung condition, COPD, studies have 
demonstrated reductions in GRα mRNA129 and protein expression130 in the lung tissue of 
COPD patients, relative to the lung tissue from healthy controls, which has been linked to GC 
resistance. Moreover, Hodge et al.
131
 showed that lymphocyte senescence in COPD patients 
is due to a decrease in GRα expression and that this loss is associated with an increase in 
disease severity.  
In the two most common forms of arthritis, osteoarthritis and rheumatoid arthritis (RA), 
contradictory results have been documented for disease-associated effects on GRα 
expression. Interestingly, one study found that GRα mRNA expression decreases in RA 
patients receiving GC treatment but increases in untreated RA patients
132
 with another study 
showing a slight decrease in GRα protein expression in steroid-resistant RA133. This is 
consistent with a decrease in GRα protein expression in the lymphocytes of RA patients, 
however, this decrease was not correlated to diminished GC sensitivity
134
. In contrast, in 
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osteoarthritic (OA) human articular chondrocytes the reductions in both GRα protein and 
mRNA expression noted, relative to healthy controls, did result in reduced GC-
responsiveness
135
.  
Lastly, in a rodent model, T-cells obtained from mice with experimental autoimmune 
encephalomyelitis (EAE), have reduced GRα mRNA expression, which was linked to 
diminished GC sensitivity in terms of GC-resistant apoptosis
136
. 
In summary, it is clear that reductions in GRα mRNA and/protein expression are noted in a 
number of auto-immune diseases or inflammatory-linked conditions, which, in many cases, 
results in GC resistant forms of these diseases (e.g. GC resistant ITP, asthma and COPD). 
This diminished GC sensitivity, in a number of these conditions, poses a significant 
therapeutic challenge for the use of GCs in the treatment of these conditions. 
2.3.1.3.2. Cancer  
GCs are a primary therapeutic choice in cancer for either their pro-apoptotic effects or their 
use as an adjuvant therapy, in combination with chemotherapeutic agents, to reduce 
symptoms such as inflammation, allergic reactions, pain and nausea, which may also be 
caused by the tumour itself
137
. However, both the type of cancer cell as well as the GRα 
content of certain cancer cells is thought to play a significant role in mediating the response 
to GC treatment
137
. It is fairly well documented that high GRα expression is associated with a 
good response to GC treatment in lung cancer
137–142
. On the other hand, drastic reductions in 
GRα mRNA and/or protein expression, thought to be a pathological consequence of the 
tumorigenic process, in part, may lead to GC insensitivity. Specifically, a number of authors 
have detailed that a reduction in receptor expression negatively correlated to GC response
137–
142
; here we provide a number of examples in which this correlation holds true (Table 2.1). In 
ALL, the leading cause of cancer related deaths in the children, reduced GRα protein 
expression has been associated with GC resistant forms of ALL
143–147
. In addition in multiple 
myeloma (MM), reductions in receptor mRNA, and in some cases protein expression
148,149
, 
have been noted, leading to diminished GC sensitivity in terms of GC-mediated 
transactivation and apoptosis, rendering some MM cell lines GC resistant
150–152
. Furthermore, 
a number of lung cancers (i.e. small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC)) contain very little GRα content, both at the mRNA and protein level, and also 
display reduced GC sensitivity in terms of apoptosis
138–142
. Similarly,  Nesset et al.
153
 also 
demonstrated significant reductions in GRα mRNA expression in breast cancer tissues 
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relative to normal breast tissue, which supported an earlier study by Lien et al.
154
, where up 
to a 50% reduction in receptor mRNA expression in breast cancer tissues, was observed. 
Finally, in an early study by Vanderbilt et al.
155
, differences in GRα mRNA and protein 
expression were shown to differentially modulate the GC response in a rat hepatoma cell line. 
In summary, these studies provide a strong case for the requirement of an adequate GRα 
‘functional pool’ to mediate the indispensable pro-apoptotic and symptom-reducing effects of 
GCs in a number of malignancies.  
2.3.1.3.3. Infection and other conditions 
Additional cases of disease-associated reductions in GRα mRNA and/or protein expression 
have been documented in conditions such as sepsis, nephrotic syndrome (NS), keloid disease 
and stroke
156–160
. Specifically, in septic patients reductions in receptor mRNA or protein 
expression, relative to healthy controls, was noted in neutrophils
157
 and T-cells
156
, 
respectively. Moreover, these reductions in receptor expression were negatively correlated to 
GC-responsive gene expression
157
, an indication of an altered GC sensitivity. Although these 
studies on sepsis provide evidence for a link between disease-severity and the expression of 
GRα it must be noted that reports of this association are highly variable and thus for an in 
depth review on GRα expression and sepsis pathology a review by Dendoncker et al.17, is 
recommended. In terms of NS in children, the GRα protein expression was assessed before 
exogenous GC treatment in two patient groups, namely steroid-sensitive (SSNS) and those 
who had initial steroid resistance (SRNS)
158
. Patients who were considered resistant before 
the start of GC therapy were reported to have reductions in GRα protein expression in 
PBMCs, which Hammad et al.
158
 postulated may be one of the pathophysiological 
mechanisms of acquired GC resistance in these children.  As with NS, patients with a skin 
condition known as keloid disease can be separated into two groups, namely non-responders 
(nRPs) or responders (RPs)
159
. Before receiving GC therapy the nRPs were shown to have 
reduced GRα expression at both the mRNA and protein level in tissue isolated from keloid 
scars, which was associated with decreased GC sensitivity following treatment
159
. Lastly, in 
an in vitro model for hypoxia (used to mimic stroke events), murine brain micro-vascular 
endothelial cells were exposed to O2/glucose deprivation that resulted in significant 
reductions in GRα protein expression relative to normoxic (i.e. normal) cells, which was 
proposed to be the cause of a decrease in subsequent GC sensitivty
160
. 
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To summarize, it is clear that disease-associated reductions in the GRα mRNA and/or protein 
expression are apparent in pathological conditions, including those that disrupt the function 
of vital organs, such as the kidneys and heart, as well as the skin. Moreover, these reductions 
in receptor expression are often associated with GC insensitivity. 
2.3.2. Treatment-associated reductions in GRα expression mediated by exogenous 
GCs 
Cases in which reductions in the GRα ‘functional pool’ as a pathological consequence of the 
progression of the disease/condition relative to healthy controls are often associated with 
increasing concentrations of endogenous GCs (i.e. F or corticosterone). However, the effects 
of treatment with exogenous GCs (e.g. Dex, triamcinolone acetonide (TA), hydrocortisone 
and various prednisolone-based steroids, budesonide and fluticasone propionate), used as 
mainstay therapeutics to combat inflammation in many of these diseases/conditions, on GRα 
expression have not yet been addressed and are reviewed in this section, with a focus on 
comparing receptor expression ‘with GC treatment’ to ‘without GC treatment’. Important to 
note is that it is often difficult to discriminate between disease- and treatment induced 
reductions in receptor expression due to an inability to withhold treatment from patients with 
chronic inflammatory disorders
54
. Nonetheless, using cellular models containing endogenous 
or transiently transfected GRα, a number of studies have demonstrated dose- and time- 
dependent effects of exogenous GCs (i.e. with GC treatment) on GRα mRNA and protein 
turnover, relative to untreated cells (i.e. without GC treatment), additionally, these studies 
have been supported by various ex vivo and in vivo experiments in which the effects of 
prolonged, chronic exogenous GC treatment on receptor expression were investigated. In 
Table 2.2, we provide examples of, specifically, reductions in GRα expression as a result of 
exogenous GC treatment. 
Specifically, an early study by Rosewicz et al.
161
 demonstrated dose- and time dependent 
reductions (to approximately 50% relative to control in GRα mRNA expression by the 
synthetic GC, Dex, in human IM-9 lymphocytes and rat pancreatic acinar (AR42J) cells. This 
finding was supported by other studies, which confirmed the ability of various concentrations 
of Dex (10
-10
 to 10
-6
M) to mediate receptor turnover at the mRNA level, and additionally, at 
the level of protein expression, in hepatoma tissue culture cells (HTC), HeLa and COS-1 cells 
at a specific time point (i.e. 24 hours
162
) or over a treatment period of up to 72 hours
162–169
. 
Hoeck et al.
167
 also detected a Dex-induced decrease of GRα expression at both the level of 
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mRNA and protein in NIH 3T3 cells with up to a 75% and 80% reduction in receptor mRNA 
and protein expression, respectively. Moreover, pulse-chase experiments, in the same study, 
revealed a decrease in GRα half-life from 8 hours to 3 hours following hormone treatment. 
Furthermore, another study using Chinese Hamster ovary-derived (CHO) cells stably 
transfected with GRα (MG/hGR) showed a rapid Dex-mediated (5 nM) time-dependent 
reduction GRα protein expression to 50% of control, within 5 hours of treatment169. 
Moreover, even after 4 weeks of Dex treatment this decrease in receptor protein persisted and 
reached a maximal reduction in receptor protein levels of 70%
169
. In terms of GRα mRNA 
expression, a 50% reduction, relative to control, was noted within 2 hours of treatment that 
was then followed by a rise in receptor mRNA expression and subsequent decline after 12 
hours treatment with Dex
169. It was postulated that this ‘biphasic pattern’ observed at the 
GRα mRNA level may be due to the involvement of ligand-induced transcriptional, post-
transcriptional and translation mechanisms in mediating receptor mRNA expression, which 
was not reflected at the protein level
169
. Interestingly, a study by our own research group 
revealed a Dex-mediated decrease in GRα protein expression, but not mRNA, in mouse 
BWTG3 cells after 24 hours treatment, relative to an untreated control
170
. This is supported 
by Kleinschnitz et al.
160
, where no change in GRα expression was noted, however, a 
reduction in GRα protein to 39% was noted following Dex treatment, relative to the untreated 
control, in an in vitro model, namely the immortalized mouse brain capillary endothelial 
(cEND) cell line. In a recent study by Ramamoorthy et al.
171
 a 50 to 90% decrease in 
specifically nascent GRα mRNA was observed after Dex treatment in two human cell lines, 
namely the U2-0S and A459 cells. In line with this finding is an observed Dex-induced 
down-regulation of total GRα mRNA expression in human respiratory epithelial cells 
(BEAS-2B, A549, and primary nasal epithelial cells) 
172
 and HeLa cells
173
, where in the latter 
cell line a reduction to 57% of the control was observed, following prolonged treatment with 
Dex. Moreover, in a study using normal human liver (HL7702) cells, chronic Dex treatment 
down-regulated GRα expression at both the mRNA and protein level174. These studies have 
detailed reductions in GRα expression at both the mRNA and protein level but did not 
address the relevance of these Dex-mediated reductions in receptor expression in terms of GC 
sensitivity. A study by Dekelbab et al.
175
, however, suggests that GC sensitivity is 
compromised following chronic Dex treatment (i.e. over 72 hours), which results in GRα 
down-regulation in L6 muscle cells. Moreover, this study demonstrated rapid reductions in 
GRα protein expression following a mere 1 hour of treatment, however, no effect was noted 
at the level of GC-mediated transactivation at this early time point
175
. Conversely, in a study 
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by Gossye et al.
52
 the significant reductions in GRα protein, following Dex treatment over 24 
hours, were directly correlated to diminished GC sensitivity in fibroblast-like synoviocytes 
(FLS) cells. This was supported by a study by Li et al.
51
 that showed that prolonged Dex 
treatment (32 hours) resulted in reductions of GRα mRNA and protein in RAW 264.7 cells, 
which directly impacted the expression of GC-responsive genes. Sun et al.
176
 also 
demonstrated significant reductions in the GRα protein expression of PBMCs, following 18 
hours of Dex treatment, which resulted in a decrease in GC sensitivity, measured via GC-
mediated apoptosis, highlighting the negative implications of long-term GC therapy in the 
development of GC resistance. Lastly, in a study in which prolonged Dex treatment of HeLa 
cells for 2 years led to a reduction in GRα mRNA and protein expression to below detectable 
levels, receptor overexpression by transfection of a GRα plasmid following the period of 
prolonged Dex treatment, was unable to restore GC sensitivity in this system
177
. 
A number of studies using ex vivo and in vivo models mirror results of Dex-mediated 
reductions in receptor expression obtained in cell lines, outlined above. In a variety of mouse 
tissues (liver, kidney, lung and heart) and rat liver tissue, prolonged treatment with Dex (up to 
8 days) led to significant reductions in GRα mRNA and protein expression51,52,54,163,171,178–180, 
which in some cases was associated with diminished GC senisitivity
51,52
. In another ex vivo 
rodent study, using cultured mouse podocytes, both short- (i.e. 1 hour) and long-term (i.e. 5 
days) treatment with various concentrations of Dex (1, 10 and 100μM), administered to 
mimic constant oral vs. pulse intravenous GC treatments, led to reductions in GRα protein, 
but not mRNA, expression, which altered podocyte GC-responsive gene expression
180
. 
Additionally, in an in vivo study, chronic Dex administration for 3 days resulted in reductions 
in GRα protein expression in rat hippocampal neurons179. More evidence of the ability of 
prolonged Dex treatment (i.e. 7, 14, 21 and 28 days) to reduce receptor mRNA and protein 
expression in the frontal cortex and hippocampus of male mice is seen in an article by Hu et 
al.
178
. Moreover, in a human study in which Dex was administered in a therapeutic regime, of 
a total of four doses (4 mg per oral dose) every 6 hours, steady reductions in GRα protein 
expression in normal lymphocytes was observed, with the lowest levels in receptor protein 
expression detected 30 hours post-treatment
54
.  
In addition to the use of the synthetic GC, Dex, a number of studies, summarized in Table 
2.2, have demonstrated the effects of the prolonged use of other exogenous GCs (such as, 
TA, hydrocortisone, various prednisolone based GCs, fluticasone propionate and budesonide) 
on GRα mRNA and/or protein expression. Specifically, in an in vitro study conducted in a 
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murine fibroblast-like cell line (i.e. L929 cells), treatment with TA (1μM over 96 hours) 
decreased GRα mRNA and protein expression181. Furthermore, an in vivo study demonstrated 
a reduction in GRα protein expression in the livers of rats treated with hydrocortisone (5 
mg/100g body weight) intraperitoneally for 6 hours, relative to rats that did not receive 
hormone treatment
182
. In addition, treatment with prednisolone in human-derived HeLa cells, 
containing endogenous GRα, led to the suppression of receptor mRNA expression to 67% of 
the untreated control (100%)
173
. Consistent with this result, is GC-mediated reductions in 
GRα mRNA expression noted in vivo, in liver tissues, following exogenous 
methylprednisolone treatment
183
. Additionally, in an in vivo human asthmatic model, which 
investigated the effects of high doses of methyl-prednisolone (i.e. 120mg/ day for 10 days) on 
receptor expression in human blood monocytes, noteworthy reductions in GRα mRNA 
expression, relative to untreated asthmatic patients, was shown
184
. Furthermore, a study 
addressing reductions in GRα expression in steroid-treated renal transplant patients, relative 
to non-treated patients, established that high doses of various methyl-prednisolone based 
therapeutics caused a 50% reduction in GRα protein expression in lymphocyte 
subpopulations, whilst prolonged low-dose therapy caused only an 11% reduction
185
. 
Consistent with the disease-associated effects on GRα expression, reported in Table 2.1, 
Andreae et al.
55
 detailed reductions in receptor protein expression in PBMCs of patients with 
auto-immune disease ‘without treatment’, relative to healthy controls, additionally reporting 
even lower GRα protein expression in patients receiving GC treatment. Specifically, both 
low-dose oral GC treatment (i.e. 0.01–0.3 mg/kg orally) and high-dose intravenous pulse 
therapy (10–15 mg/kg) resulted in significant reductions in receptor protein expression, 
however, a more drastic reduction was observed following the high dose regimen
55
, 
suggesting a dose-dependent effect of GC therapy on GRα expression, also reported by 
Sanden et al.
186
. Although another study did not find the same disease-associated effects of 
asthma on GRα protein expression, a similar reduction in receptor expression was observed 
in asthmatic children treated with a short course of prednisolone therapy, relative to asthmatic 
children who did not receive GC treatment
187
. In support of this finding is a study where 
systemic GRα protein expression (i.e. in PBMCs) in patients with IBD not receiving 
prednisolone therapy, was not significantly different to normal controls, however, 
corticosteroid-treated IBD patients displayed lower receptor expression, relative to normal 
controls and patients without treatment
188
. In a recent study, GRα mRNA expression was 
investigated in PBMCs as a biomarker of GC resistance in Vogt-Koyanagi-Harada (VKH) 
disease, an inflammatory-disease that affects the eye
189
. A portion of these patients are GC 
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resistant, however, they do not display reduced GRα expression relative to the GC sensitive 
patients, before receiving treatment
189
. With that said, following treatment with prednisolone 
a 0.7-fold decrease in GRα mRNA expression was noted in resistant patients, which was 
absent in the sensitive patients. This reduction in receptor expression was correlated to 
clinical predictive factors of GC resistance for this disease, including tinnitus, fundus 
pigmentation and chronic disease. Lastly, local treatment of healthy individuals with two 
additional GCs, fluticasone propionate or budesonide, resulted in a significant, dose-
dependent reduction in GRα mRNA expression in nasal mucosal biopsy specimens190. 
Briefly, to summarize this section on GRα expression in health and disease, it is evident that 
many inflammatory-driven and auto-immune diseases drive reductions in receptor 
expression, as a pathological consequence of disease progression often associated with an 
increase in endogenous GCs. Moreover these disease-associated alterations in the GRα 
‘functional pool’ may lead to the development of an acquired resistance to GC treatment. 
Additionally, in a number of cases, the use of exogenous GCs as therapeutics, to curb 
inflammation and partially retard the advancement of these psychological and pathological 
conditions, led to further reductions in GRα expression, which may ultimately hasten the 
development of acquired GC resistance, currently a major threat in the pharmaceutical 
industry. With the incidence of these conditions increasing and the burden of resistance to 
GC treatment mounting, it is of utmost importance to fully understand the molecular 
mechanisms involved in ligand-induced GRα down-regulation. To date, a number of GC-
mediated molecular mechanisms which regulate the GRα ‘functional pool’ have been 
identified and are reviewed in the following section. 
2.3.3. GC-mediated molecular mechanisms involved in reducing GRα expression 
The wealth of data demonstrating disease- and/or treatment associated reductions in GRα 
expression underscores the physiological importance of fine-tuning GRα expression and 
encourages an urgency to comprehensively elucidate the multiple molecular mechanisms, 
employed by the cell, to tightly regulate the expression or ‘functional pool’ of this 
receptor
44,64
. 
The regulation of the GRα ‘functional pool’ may be described using a simple ‘push’ versus 
‘pull’ mechanism  where, when in a dynamic state of equilibrium and unperturbed, the 
synthesis of GRα is roughly equivalent to receptor turnover, and GRα expression occurs at a 
constant rate. Important to note is that the ‘push’, used by the current review, is governed by 
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two processes namely transcription and translation and whilst the ‘pull’ is defined by 
proteasomal-degradation (Fig. 2.1), specifically via the ubiquitin-proteasome pathway (UPS). 
Important to note is that the UPS generally regulates the degradation of intracellular proteins, 
whilst the lysosomal degradation pathway primarily degrades extracellular proteins and some 
cell surface proteins
191
. One can assume that perturbations in the balance or dynamic state of 
GRα regulation (i.e. ‘push’ is balanced by the ‘pull’) will most likely be due to alterations in 
GRα mRNA and/or protein expression. One of the ways in which the harmony of this 
dynamic state may be perturbed is via an increase in circulating endogenous
64
 (i.e. disease-
associated) or exogenous (prolonged, chronic use of therapeutics) GCs, which subsequently 
induces GC-mediated or ligand-induced (terms used interchangeably) GRα down-regulation.  
 
Figure 2.1: Specific regulation of the GRα protein ‘functional pool’, described by a simple ‘push’ vs. 
‘pull’ mechanism. 
Ligand-induced regulation of GRα expression is far from being straightforward but rather 
involves multiple layers of regulation at the epigenetic, transcriptional, post-transcriptional 
and post-translational levels
14,42
. Moreover, at each ‘level’ of GRα regulation multiple 
molecular mechanisms are involved, which function in a highly specific manner to stabilize 
or, importantly for the current review, destabilize the receptor, thus contributing to the 
complexity of the finely-tuned GC/GRα signalling pathway and potentially advancing 
acquired GC resistance. In this section, we review the molecular mechanisms specifically 
known to reduce GRα mRNA and protein expression as a direct result of ligand-binding 
(summarized in Table 2.2). However, it must be noted, that various indirect or ligand-
independent mechanisms
4,14,42,44
 (e.g. pro-inflammatory cytokines and the tissue-specific 
expression of additional GR isoforms as a result of alternative splicing) are also known to 
regulate GRα expression. For details on these ligand-independent mechanisms of GRα 
regulation, reviews by Vandevyver et al.
44
 and Quax et al.
42
 are recommended.  
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2.3.3.1. GRα mRNA regulation 
2.3.3.1.1. Epigenetic regulation 
In terms of epigenetic regulation of GRα expression, DNA methylation192 of the GRα 
(NCR31) promoter
31
 has been identified as one of the major mechanisms involved in disease-
associated acquired GC resistance
53,64,71,72,77,79,80,140,153,193
, across species, and is often 
positively-correlated with an increase in circulating GC concentrations
64
.  In contrast to the 
positive-correlation with GC concentration, a ligand-induced increase in DNA methylation of 
the GRα promoter is generally negatively-correlated with GRα mRNA expression in both 
humans and mice, which is summarized in Table 2.3.  
Generally speaking, extensive evidence exists implicating an increase in NCR31 DNA 
methylation in a consequent decrease in GRα mRNA expression77 and possibly a 
corresponding reduction in GRα protein expression79. A specific exonic sequence in the rat 
GRα gene was identified as a region that underwent substantial DNA methylation, following 
stressful events
192
. Specifically, increased DNA methylation at the exon 17 promoter, within 
the GRα gene, was shown to mediate a reduction in receptor mRNA expression in Wistar 
rats
77
. Similarly, a study by Niknazar et al.
79
 demonstrated a GC-mediated increase in the 
methylation status of the same exon (i.e. exon 17,) in the GRα gene, which led to a decrease in 
the GRα mRNA expression, in adult male and female Wistar rats. Additionally, a GC-
mediated increase in the methylation of exon 17 in the mouse GRα promoter region (−578 to 
−490 base pairs), resulted in a reduction in GRα protein expression80. Lastly, following acute 
stress, an increase in DNA methylation at the exon 17 promoter was observed, as well as an 
up to 75% reduction in GRα mRNA expression in dentate gyrus neurons of male Wistar 
rats
64
.  
In support of these findings from the rat studies, are a number of human studies in which 
DNA methylation of the GRα gene, specifically at exon1F, exon 1B, exon1H and exon 1C in 
humans, has been shown to result in reduced GRα mRNA expression53,71,72,140,153. 
Specifically, Mc Gowan et al.
72
 noted an increase in DNA methylation of the exon 1F 
promoter in the GRα gene and consequent reductions in GRα mRNA expression, in the 
hippocampal regions of victims with a history of abuse. Similarly, a recent study by Wang et 
al.
53
 detailed an increase in F in patients with GAD that resulted in DNA methylation of the 
exon 1F promoter in the GRα gene, which led to reductions in receptor mRNA expression as 
well as diminished GC sensitivity. Additionally, Nesset et al.
153
 investigated DNA 
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methylation of the GRα gene in breast cancer tissue, relative to normal tissue, and found an 
increase in the methylation status of the exon 1B promoter, which correlated with a decrease 
in GRα mRNA expression in the cancerous tissue. Furthermore, Kay et al.140 demonstrated 
an increase in DNA methylation at another site in the promoter, exon 1C, where a 6% increase 
in GRα methylation, significantly reduced receptor protein expression by up to 50%. Lastly, 
changes in the methylation status of the exon 1C and exon 1H promoter of the GRα gene, have 
been shown to modulate GRα mRNA expression in the hippocampi of suicide completers71. 
It must be noted that in some peripheral tissues and cells, a decrease in the differential 
methylation of the GRα promoter and a corresponding decrease in GRα mRNA expression 
has also been observed as reviewed by Tyrkra et al.
97
. However, although this finding 
highlights a level of complexity surrounding regulation of the GRα gene by DNA 
methylation, the effect is currently not well documented and requires further investigation. 
Nonetheless, although some ambiguity remains surrounding the emerging association 
between ligand-induced GRα gene methylation and receptor expression, what is clear is that 
in a broad number of psychological and pathological conditions this epigenetic mechanism is 
likely to contribute, to a certain degree, to the development of tissue-specific resistance to GC 
treatment as a result of GC-mediated reductions in the GRα mRNA expression.  
2.3.3.1.2. Transcriptional regulation 
It is well documented that in addition to GC-mediated transrepression of pro-inflammatory 
genes (i.e. IL-6), mainly via an indirect tethering mechanism
194
, GRα can also inhibit GC-
responsive gene expression by directly binding to a negative glucocorticoid response element 
(nGRE) in the promoter
195
. Recently, in support of earlier studies by Burnstein et al.
162,196,197
, 
which postulated that the GRα gene contained sequences sufficient for ligand-induced GRα 
mRNA down-regulation, a study by Ramamoorthy et al.
171
 successfully identified the 
presence of an nGRE in the GRα promoter. Subsequently, the ability of the receptor to 
regulate its own expression by binding to this nGRE present in the NCR31 promoter, 
following GC treatment, was demonstrated
171
. Furthermore, inhibition of transcription 
initiation of the GRα gene was shown to be the primary mechanism of this GC-mediated 
auto-regulatory loop, resulting in GC-mediated reductions in nascent GRα mRNA expression 
by up to 90% in some cells (e.g. A459 lung carcinoma cells)
171
. Specifically, following 
binding of the receptor to the intragenic response element, this process is mediated by a long-
range interaction between the GC-bound GRα at an nGRE present in exon 6 and a NCOR1 
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repression complex, which is assembled at the transcription start site of the gene
171
. 
Additionally, the ability of the GRα to regulate its own transcription in a GC-dependent 
manner, was found to be neither species nor tissue-specific, and was consistent across human, 
rat and mouse cell lines, as well as in mouse tissues
171
. Whilst this paper
171
 convincingly 
demonstrates the GC-mediated auto-regulatory loop occurring via an nGRE in the GRα gene 
promoter, it appears to be the only paper to do so. In terms of acquired/disease-associated 
glucocorticoid resistance, this constitutive repression of the GRα gene, via the GC-mediated 
auto-regulatory feedback loop, is likely to be compounded by disease-associated increases in 
circulating endogenous GCs and chronic, prolonged therapeutic GC regimes
171
. Thus it 
would be of interest to ascertain the biological activity of other GCs, such as selective 
glucocorticoid receptor modifiers (SGRMs) via this GRα nGRE.  
2.3.3.1.3. Post-transcriptional regulation 
Unlike transcriptional regulation of the GRα gene that leads to modulations in nascent 
receptor mRNA expression, post-transcriptional regulation involves the destabilization of 
mature receptor mRNA, via the presence of adenylate uridylate (AU)-rich elements present in 
the 3’-untranslated region (UTR) of the GRα mRNA, which may ultimately affect receptor 
protein expression, presenting another level of regulation for fine-tuning GRα 
expression
27,44,198,199
. One of the ways in which this can occur is through the regulatory role 
of micro-RNAs (miRNAs), a family of small non-coding RNAs, which bind to AU-rich 
regions in the UTR of target mRNAs. Unlike small interference RNAs (siRNAs), which 
function to degrade mRNA transcripts, miRNAs primarily prevent efficient translation of 
mRNA transcripts, however, can also induce degradation of these transcripts
200–203
.  
The ability of miRNAs to regulate GRα mRNA expression has been shown to be mediated by 
circulating GCs, both as a result of disease-associated or stress-induced increases in 
endogenous GC concentrations, as well as by treatment with exogenous GCs, with 
implications in acquired resistance to GCs
144,150,156,204–207
 (Table 2.3). To date, a number of 
miRNAs have been identified and shown to target GRα mRNA transcripts across a number of 
species (i.e. rodents and humans)
44
. A review by Vandevyver et al.
44
 discussed the majority, 
but not all
87
, of the miRNA target sites in the human GRα mRNA transcript and is 
recommended for an overview of these sites.  
In terms of GRα mRNA expression, a study by Riester et al.205 experimentally confirmed that 
four miRNAs, namely miR-96, miR-101a, miR-142-3p and miR-433, are able to reduce the 
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receptor mRNA expression by up to 40% in mice. Recently, RSD has been shown to increase 
the expression of two additional miRNAs, namely miR-29b and miR-340-5p, which was 
inversely correlated to GRα mRNA expression in splenic macrophages, of mice87. 
Additionally, a recent study demonstrated that FSS resulted in the increase of miR‐124a, in a 
time-dependent manner, which was associated with a reduction in GRα mRNA expression, in 
male Wistar rats
64
. 
Important to reiterate is that miRNAs act on GRα mRNA, primarily blocking translation, and 
thus this is considered mRNA regulation, however, the effects may only be reflected at the 
level of the receptor protein as demonstrated by a study in which restraint stress in rats, led to 
an increase in the expression of the ubiquitously expressed miR-18, which subsequently lead 
to a decrease in GRα protein but not mRNA expression, in the paraventricular nucleus of 
these rats
206
. This finding is supported by that of Vreugdenhill et al.
207
 where miR-18 reduced 
GRα protein expression by almost 40% in rat neuroscreen cells (NS1). Furthermore, Shimizu 
et al.
89
 revealed that a stress-induced increase in miR-124a led to a significant reduction in 
GRα protein expression in the corpus callosum of mice.  
Furthermore, in humans, a GC-mediated increase in miR-124 and consequent decrease in 
GRα mRNA and protein expression has also been demonstrated in ALL cells204 and in T-
cells of sepsis patients
156
. An investigation by Tessel et al.
150
 detailed the effects of the less 
commonly studied miR-130b on GRα protein expression. Specifically, overexpression of 
miR-130b led to significant decreases in GRα protein expression, however, unexpectedly, 
knockdown of this miR-130b did not alter GRα protein expression, in human MM cell 
lines
150
. Moreover, although these experiments were conducted in the presence of Dex, it is 
not clear whether GC’s directly mediate the expression of miR-130b150. Lastly, an increase in 
miR-142-3p expression has been noted in GC-resistant ALL patients
144
. Furthermore, this 
miRNA has been shown to target GRα mRNA resulting in a decrease in receptor protein 
expression
144
. Unfortunately, in many of these studies, it is unclear whether the up to 80% 
increase in miRNA expression
87
 is directly mediated via a disease-associated or stress-
induced increase in circulating GC concentrations, however, one could postulate that a 
positive correlation exists between the two (i.e. an increase in GC concentrations and an up-
regulation of miRNA expression). 
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2.3.3.2. GRα protein regulation 
2.3.3.2.1. Post-translational regulation 
In addition to GC-mediated GRα mRNA regulation, the receptor is also subjected to GC-
mediated protein regulation in the form of post-translational modifications (PTMs) (i.e. 
phosphorylation, ubiquitination and sumoylation)
11,16,44,208–213
. The nature and degree of these 
PTMs modulates both GRα function and expression, impacting GC-responsiveness in 
selective tissues and in some cases may contribute to an acquired GC resistance 
11,16,44,165,166,208–215
. For the sake of this review we will hone in on the PTMs which directly 
assist in GRα protein turnover, via the proteasome, in a GC-dependent manner, and thus for 
an overview of the effects of PTMs on GRα function we encourage additional comprehensive 
reviews
11,16,44,208–213
. 
With reference to GRα, the most widely studied and first PTM identified was 
phosphorylation
44
. Since the initial discovery, a number of GRα phosphorylation sites have 
been identified (Fig. 2.2). Although basal phosphorylation may occur in a ligand-independent 
manner
214,215
, hyper-phosphorylation at several of these sites is GC-mediated
214,215
 and is 
known to modulate GRα function (e.g. receptor ligand- and DNA-binding affinity, 
subcellular localisation, co-regulator interaction and gene regulation) as well as expression
44
. 
Moreover, various kinases (e.g. p38, ERK, JNK, CDKs and GSK3β) responsible for the 
specific phosphorylation of these sites, have been described
44
.  
 
Figure 2.2: Post-translational modification sites of human GRα with focus pertaining to phosphorylation, 
ubiquitination and sumoylation, adapted from Vandevyver et al.
44. The human GRα protein consists of 777 
amino acids (i.e. 1 to 777) and undergoes PTMS at numerous sites. Moreover, many of these PTM sites are 
contained within the N-terminal domain (NTD) (i.e. amino acids 1 to 421) of the receptor, with two present in 
close proximity of the DNA-binding domain (DBD) (i.e. amino acids 421 to 486). Specifically; phosphorylation 
(P) occurs at serine (e.g. S211, S226 and S404) residues, whilst ubiquitination (U) and sumoylation (S) occurs at 
lysine residues (i.e. K419 and K277, K293 and K703, respectively). Unlike the others, the K703 sumoylation 
site occurs within the ligand-binding domain (LBD) of the receptor (i.e. amino acids 526 to 777). Moreover, 
PTMs at these sites are known to modulate GRα function (white) or protein expression (red) and in some cases 
affect both receptor function and protein expression (pink).  
Studies have demonstrated that GC-mediated GRα phosphorylation mediates receptor protein 
turnover, leading to reductions in GRα protein expression, and thus it is likely that the 
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phosphorylation status of GRα plays an important role in the effectiveness of GC treatments 
or overall GC sensitivity
214,215
.  A study by Webster et al.
216
demonstrated that multiple point 
mutations (i.e. at more than one site at a time such as Serine 212 to alanine, Serine 220 to 
alanine and Serine 234 to alanine) in the mouse GRα protein led to a loss of ligand-induced 
GRα protein turnover. Additionally, Avenant et al.215, detailed the ability of GC-mediated 
hyper-phosphorylation at Ser211 and Ser226 to alter GRα half-life, in COS-1 cells transiently 
transfected with human GRα, using a panel of 12 ligands. Moreover, respectable correlations 
between ligand-selective phosphorylation and ligand-selective receptor turnover were made 
with potent synthetic GCs (i.e. Dex) inducing the greatest extent of receptor phosphorylation 
and thus considerably more GRα protein turnover215. In another study by Galliher-Beckley et 
al.
214
, a wealth of evidence was provided to support the notion that Dex-induced hyper-
phosphorylation mediated by GSK3β (i.e. the kinase responsible for phosphorylation at 
Ser404 for the human GRα and Ser412 for mouse GRα) at one of the more recently 
discovered phosphorylation sites, Ser404, enhances receptor turnover of the human GRα. 
Specifically, a mutant incapable of being phosphorylated a Ser404 and inhibition of 
phosphorylation at this site using a GSK3β, the kinase responsible for phosphorylation at 
Ser404, kinase inhibitor (BIO) confirmed that restricting Dex-induced Ser404 hyper-
phosphorylation of GRα resulted in an increase in receptor protein stability214. Whilst 
considerable evidence exists for the effects of GRα phosphorylation on receptor function (i.e. 
nuclear translocation and transcriptional activity), reviewed by Anbalagan et al.
208
, 
Ramamoorthy et al.
217
 and Vandevyver et al.
44
, to our knowledge, it is only these few 
papers
214–216
, which directly demonstrate the ability of phosphorylation at Ser211, Ser226, 
Ser404 in human GRα214,215 and at multiple sites (Ser212, Ser220 and Ser234) of the mouse 
GRα216, to impact receptor turnover. 
GRα protein receptor turnover is proteasome-dependent and before successful delivery to the 
catalytic proteasome, the receptor requires tagging with a second PTM, namely 
ubiquitination, which occurs following phosphorylation
165,166
. It was postulated that the 
inability of the GRα phospho-deficient mutants with mutations at multiple sites (i.e. Ser212, 
Ser220 and Ser234 of the mouse GRα216,218) to undergo degradation via the proteasome is 
due to inefficient phosphorylation-dependent ubiquitination, however, a lack of GRα 
ubiquitination was not demonstrated experimentally with these mutants. To date, only a 
single ubiquitination site for GRα has been identified and occurs within the PEST 
degradation motif at lysine 426 (K426) in mice and lysine 419 (K419) in humans. Mutations 
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at these specific residues restore GRα protein expression by restricting receptor protein 
turnover via the proteasome
165,166
. A number of studies have demonstrated that that GC-
mediated GRα protein turnover occurs via the proteasome, specifically, through the use of 
proteasome inhibitors (e.g. MG132, bortezomib, beta-lactone, and epoxomicin) GC-mediated 
down-regulation of the rodent and human GRα protein, was inhibited8,160,165,166,219–224. 
However,  unlike ubiquitination of  some of the other nuclear receptors
225
, such as the 
estrogen (ER)
226
 and mineralocorticoid (MR)
227
, GRα ubiquitination is not as widely studied 
and only a handful of papers exist demonstrating GC-mediated GRα 
ubiquitination
165,166,219,228
. Moreover, the notion that ubiquitination of GRα increases 
following GC treatment, seems to be controversial, with one paper demonstrating Dex-
mediated increase in GRα ubiquitination228 and another research group noting a Dex-induced 
reduction, rather than an increase, in GRα ubiquitination in the presence of a MG1328,166. It 
appears that the study of GC-mediated ubiquitination of GRα has, to some degree, been 
avoided, likely due to the difficulty of detection, however, it seems necessary for further 
research to be conducted in this specific area of GC/GRα signalling. The use of highly 
specific and sensitive assays, such as a Proximity-Ligation Assay (PLA), may provide more 
insight into GRα ubiquitination. Nevertheless, GRα ubiquitination and the ubiquitin-
proteasome pathway/system have been shown to function cooperatively to control receptor 
degradation rates, ultimately contributing to the stringent regulation of overall GRα 
levels
165,166
. 
In addition to phosphorylation and ubiquitination a third PTM has been shown to regulate 
GRα function208,210,229–232 (i.e. inhibiting the transcriptional activity of the receptor) and, less 
frequently, promote receptor protein degradation in a GC-dependent manner
210
. Similarly to 
ubiquitination, sumoylation is a dynamic, reversible process, which involves a multi-step, 
enzyme-catalysed reaction to mediate the covalent attachment of the SUMO protein to the 
protein of interest (i.e.GRα)233. Interestingly, unlike ubiquitin, there are a number of SUMO 
proteins, namely SUMO-1, SUMO-2/3. It is specifically the addition of SUMO-1, which is 
thought to drive GC-mediated protein turnover
210
. Le Drean et al.
210
 demonstrated that 
overexpression of SUMO-1 aids Dex-mediated receptor down-regulation, additionally 
implicating the proteasome in this degradation of the GRα protein, however, this paper does 
not detail at which site (i.e. lysine residue) this sumoylation occurs. To our knowledge, this is 
the only paper to describe the potential of sumoylation to regulate GRα protein expression.  
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Lastly, it is important to note there are a number of additional PTMS which the GRα protein 
is known to undergo, including acetylation, nitrosylation and oxidation, however, these are 
thought to modulate GRα function and, as of yet, no evidence exists for their ability to affect 
receptor protein stability, the focus of the current review. For this reason, reviews by Zhou et 
al.
211
, Duma et al.
16
, Nicolaides et al.
213
, Vandevyver et al.
44
, Anbalagan et al.
208
, Weikum et 
al.
35
, Kadmiel et al.
212
 are recommended for more information on how these additional PTMs 
impact GRα activity. 
2.3.3.3. Enzymes of the UPS that mediate GRα protein turnover 
Importantly, proteasomal degradation of the substrate (i.e. GRα) requires rounds of 
ubiquitination, mediated by various enzymes of the UPS (Fig. 2.3), to form a poly-ubiquitin 
chain, which is then recognized by the proteasome resulting in substrate degradation. There 
are number of enzymes that form part of the UPS, which interact with the GRα protein (Fig. 
2.3). These interactions are either ligand-independent or ligand-dependent, and function to 
regulate the expression or ‘functional pool’ of the receptor by mediating its turnover via the 
ubiquitin-dependent proteasomal degradation pathway
165,166
. As regulators of GRα expression 
these co-regulator/GRα interactions have implications in GC sensitivity and thus we briefly 
review some examples. Importantly, GRα interacts with a wide range of additional co-factors 
proteins, however, many of these other interactions are associated with mediating GRα 
function rather than expression and will not be discussed
14,234–241
.  
 
Figure 2.3: The ubiquitination of a substrate requires multiple rounds of a multi-step enzyme process 
before being targeted to the proteasome.  1. Ubiquitin (U) is activated by an activating enzyme (E1) in an 
energy (ATP) dependent manner. 2. The activated U molecule is then transferred to E2, a conjugating enzyme. 
3. E3 binds the substrate and the E2 and the transfer of the activated U molecule from E2 to the substrate occurs. 
4. This is repeated, until a poly-ubiquitinated chain is formed and the ubiquitinated substrate is then actively (i.e. 
ATP-dependent) delivered to the proteasome. 5. The catalytically active proteasome recognizes and degrades 
the substrate to produce inactive protein fragments.  
The binding of two enzymes associated with the UPS, namely the inactive E2 conjugating 
enzyme, tumour susceptibility gene 101 (TSG101)
242
 or the E3 ligase, carboxy-terminus of 
heat shock protein 70-interacting protein
243
 (CHIP), to the GRα protein does not require prior 
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ligand binding. Moreover, whilst binding of CHIP to GRα is unaffected by GC treatment219, 
the formation of the TSG101/GRα complex only occurs in the absence of ligand-binding (i.e. 
to the unliganded GRα)244. Specifically, TSG101 binds to the N-terminal region of the hypo-
phosphorylated unliganded receptor, both of which (i.e. unliganded GRα and TSG101) are 
located in the cytoplasm, and prevents protein turnover of the unliganded GRα, by acting as a 
dominant negative regulator of ubiquitination due to its catalytically inactive 
characteristic
244,245
. Knockdown experiments in which TSG101 was targeted, demonstrated 
an increase in the protein instability of the hypo-phosphorylated form of GRα, thus 
suggesting a role for TSG101 in protecting the unliganded GRα from receptor turnover244. 
Interestingly a mutant receptor, incapable of even undergoing basal phosphorylation (i.e. as is 
the case with unliganded GRα), namely GR(S203A/S211A), showed enhanced interaction 
with TSG101
244
, which demonstrates that the association of GRα with TSG101 is dependent 
on the GRα phosphorylation status. Unlike TSG101, CHIP appears to not be dependent on 
the phosphorylation status of GRα, but rather associates with the receptor regardless of the 
presence of ligands, and thus the phosphorylation status, however, its presence in the cell is 
vital for GC-mediated GRα protein turnover219. Interestingly, overexpression of CHIP in 
HT22 cells, where steady-state receptor levels were unaffected by prolonged hormone 
treatment, is able to restore GC-mediated down-regulation of the GRα protein via the 
ubiquitin-dependent proteasome degradation pathway, confirming a role for this E3 ligase in 
mediating receptor turnover and altering GRα expression219. 
Another interesting UPS enzyme, in terms of GC-mediated receptor turnover is F-box/WD 
repeat-containing protein 7 (FBXW7α), an E3 ubiquitin ligase which requires the presence of 
a CDC4 phosphodegron motif
246
 in the substrate. Furthermore, this catalytically active E3 
ligase requires preceding substrate phosphorylation, at this motif (i.e. the CDC4 
phosphodegron motif of the GRα), in order to mediate phosphorylation-dependent 
ubiquitination and subsequent proteasomal degradation via the proteasome
247
. Specifically, 
FBXW7α binding to GRα is primarily dependent on GSK3β-mediated phosphorylation at 
Ser404
214
, which then targets the GRα for ubiquitination and proteasomal degradation248. To 
demonstrate this Malyukova et al.
248
 demonstrated an increase in GRα protein expression 
following the inactivation of FBXW7α, via mutations, as well as noting that a GRα 
phosphorylation mutant (S404A) was incapable of GC-mediated ubiquitination, which 
partially restricted its degradation via the proteasome. From this evidence, it is clear that 
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FBXW7 activity and expression has implications for GC sensitivity by regulating GC-
mediated reductions in the GRα ‘functional pool’.  
Ubiquitin-Conjugating Enzyme (UbcH7), an E2 ligase, is a known co-regulator of steroid 
hormone receptors
249
 and, in terms of GRα, is known to directly interact with the C-terminus 
of the receptor with this interaction enhanced in the presence of the synthetic GC, Dex
250
. 
Moreover, UbcH7 has been shown to modulate GRα activity and, more importantly 
expression, by targeting the receptor protein for GC-mediated proteasome degradation
250
. 
Immunofluorescence studies have elucidated that UbcH7 is predominantly co-localized with 
liganded-GRα in the cell’s nucleus allowing for the interaction between these two proteins to 
take place, however, some UbcH7 expression in the cytoplasm does exist
250
. In a study by 
Garside et al.
250
, over-expression of a dominant negative form of UbcH7 preserved GRα 
expression, through increasing the stability of the receptor and restricting GC-mediated 
protein turnover, via the proteasome, which confirmed UbcH7 as a key regulator of GRα 
protein expression and supported a role for UbcH7 in mediating GC sensitivity
250
.  
Lastly, another recognized UPS enzyme involved in the regulation of GRα protein expression 
is the E3 ligase, murine double minute 2 (i.e. Mdm2 or Hdm2, the human homologue
251
). 
Unlike the other the other enzymes, Mdm2 relies on the presence of p53 to form a trimeric 
complex with GRα to mediate receptor protein turnover, both in the presence and absence of 
hormone, via the ubiquitin-dependent proteasomal pathway
236
. More specifically, the 
interaction of GRα and p53251 requires the ligase activity of Mdm2222 or Hdm2228 for the 
successful ubiquitination and turnover of the GRα protein. A study by Sengupta et al.228 
demonstrated that treatment of human umbilical endothelial cells with Dex enhanced GC-
mediated ubiquitination of GRα in the presence of all three proteins (i.e. GRα, p53 and 
Hdm2). Furthermore, disruption of the interaction of p53 with Hdm2 prevented Dex-induced 
ubiquitination of GRα and p53228. Of interest is another study by Kinyamu et al.222 where 
treatment with estrogen (i.e. the classical ligand for the ER) mediated GRα protein turnover, 
moreover, this study found that p53 and Mdm2 were interdependent and the presence of both 
these proteins was required for estrogen-mediated ER protein down-regulation, via the 
proteasomal degradation pathway
222
. 
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2.4. Restoring GRα expression and revisiting the relevance of receptor 
conformation:  
Combining all the evidence presented in this review, it is clear that significant reductions in 
GRα expression, both at the mRNA and protein level, whether disease-associated (Table 2.1), 
treatment-associated (Table 2.2) or both (i.e. disease-associated reductions compounded by 
exogenous GC use) are implicated in acquired GC resistance. Specifically, stress-induced 
(i.e. physical and psychological) reductions in the GRα ‘functional pool’, in many cases, 
results in altered behavioural effects (i.e. cognitive dysfunction and anxiety-like behaviour), 
which may, over time, drive the development of a number of psychological conditions (i.e. 
major depression, schizophrenia and bipolar disorder) and promote acquired GC resistance. 
Furthermore, reductions in the GRα ‘functional pool’ associated with the progression of 
pathological conditions (i.e. auto-immune of inflammatory-linked conditions, cancer and 
sepsis) encourage a wide range of GC-resistant forms of these conditions (i.e. GC resistant 
asthma, ITP and COPD) (Table 2.1). With the increasing incidence of these psychological 
and pathological conditions and the advancing threat of acquired GC resistance, a dire need 
for the development of novel GC therapeutics to combat chronic inflammation without 
eliciting GC resistance, exists. 
In order to develop novel GC therapeutics to restrict the development of acquired GC 
resistance, it is of utmost importance to fully elucidate the complex nature of GC/GRα 
signalling, with focus pertaining to the molecular mechanisms involved in promoting GRα 
turnover. In recent years, a number of molecular mechanisms (i.e. DNA methylation, mRNA 
regulation and post-translational modifications) involved in reducing GRα expression have 
been uncovered. Moreover, strategies to restore receptor expression and maintain the GRα 
‘functional pool’, through exploiting these molecular mechanisms, through combinatorial 
treatments with compounds (i.e. bortezomib (BZ)) have been explored and in some cases 
utilized in a clinical setting
51,89,160,223,252,253
.  
Ligand-induced GRα down-regulation can be prevented through the use of proteasome 
inhibitors, such as MG132, used in tissue culture cells, and BZ, used clinically
252,253
. 
Moreover, the use of BZ, a Food and Drug Administration (FDA) approved therapeutic
254
, 
has been shown to restore GC sensitivity through preventing receptor turnover
160,223
. 
Specifically, in a model of hypoxic blood brain barrier (BBB) damage, O2/glucose 
deprivation drives significant reductions (i.e. approximately 80% reduction) in GRα protein 
Stellenbosch University  https://scholar.sun.ac.za
 48 
 
expression, however, treatment with BZ restores receptor expression to approximately 90% 
in the absence of Dex and 50%, in the presence of Dex, relative to the control (100%). 
Importantly, this increase in GRα protein expression was directly correlated to an increase in 
GC sensitivity, in this model
160
, and mice that were treated with BZ in combination with Dex, 
several hours after a stroke was induced, showed a reduction in the development of brain 
edema, which Dex alone could not restrict, likely due to the reductions in the GRα protein 
expression induced by O2/glucose deprivation and compounded by Dex treatment
160
. 
Additionally, a study by Lesovaya et al.
223
 demonstrated the ability of BZ to increase the 
anticancer activities of GCs, by resulting in the accumulation GRα protein expression through 
proteasomal inhibition. Whist these studies provide support for proteasome inhibitors in 
restoring GC sensitivity by blocking receptor turnover, one must keep in mind that, the 
proteasome and UPS as a whole is fundamental for the finely tuned regulation of ubiquitous 
proteins
255
 and thus, one of the major limitations of using proteasome inhibitors, in the 
clinical setting, is the specific targeting of these inhibitors to prevent the degradation of 
particular proteins (i.e. GRα). 
In another study by Shimizu et al.
89
, stress induced significant down-regulation (i.e. over 
30%) of GRα protein expression, relative to non-stressed controls (100%), was noted. 
Interestingly, treatment of stressed mice with a compound called Yokukansan (YKS), a 
Japanese herbal medicine for the treatment of psychiatric and psychological symptoms
256,257
, 
was able to normalize GRα protein expression, counteracting the stress-induced receptor 
turnover by approximately 20%
89
. Moreover, this study was able to elucidate the mechanism 
of action of how YKS prevented GRα protein turnover89. Specifically, YKS led to significant 
reductions, almost 50%, in the expression of miR-124, a miRNA known to target GRα 
mRNA preventing its translation to GRα protein. These results suggests that the ability of 
YKS to restore receptor expression occurs at the post-transcriptional level, specifically 
through targeting of miR-124
89
. To our knowledge, this is one of the few studies to 
successfully determine the molecular underpinnings of a compound’s ability, in combination 
with GCs, to prevent reductions in the GRα ‘functional pool’. 
Another compound, namely Ginsenoside Rh1
51
 (one of the major active compounds of 
Ginseng, a highly valued herb, specifically in Asia
258
) has been shown to restore GRα 
expression, however, the exact molecular mechanisms involved in the mechanism of action 
of this compound in restricting receptor turnover, is not entirely understood. Specifically, Li 
et al.
51
 demonstrated that co-treatment of RAW 264.7 cells with Dex and Ginsenoside Rh1, 
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prevented reductions in GRα mRNA expression, relative to Dex treatment alone, thus 
potentiating Dex’s anti-inflammatory potential, specifically in prolonged treatments. In 
addition Ginsenoside Rh1 was able to restrict Dex-induced GRα protein turnover (i.e. to 34% 
of control) and partially restore GRα protein expression to 66% of the control51. Whilst in this 
study, the ability of Ginsenoside Rh1 was found to require mRNA transcription and new 
protein synthesis, suggesting its ability to transcriptionally and post-transcriptionally regulate 
GRα expression, the exact molecular mechanism of how this compound mediated regulation 
at these levels, remains to be elucidated.  
Generally, studies have focused on restoring the GRα ‘functional pool’ through preventing or 
restricting ligand-induced (i.e. endogenous or exogenous GCs) receptor turnover, at the 
mRNA and protein level. However, could one approach this from a different angle? 
Specifically is the development of a ligand, which binds to the GRα and selectively 
modulates the receptor conformation to allow for a maintained anti-inflammatory potential 
but reduced receptor turnover, viable? An idea that supports this notion, is that of ‘biased 
ligands’ by Lutrell et al.259 in G-protein coupled receptor signalling (GPCR). It is well 
documented that ligand binding to a receptor initiates a conformational change in the receptor 
that dictates the down-stream effects, however, Lutrell et al.
259
 makes the argument that 
through the use of ‘biased’ ligands one may be able to selectively modulate the 
‘conformational ensemble’, thus driving the ‘conformational equilibrium’ towards a 
particular state. In terms of GC/GRα signalling, the idea of selectively encouraging a specific 
GRα conformation to maintain the beneficial anti-inflammatory effects of GCs (via 
transrepression) whilst reducing the risk of generating side-effects (via transactivation), has 
previously been demonstrated through the development of dissociated GCs or SGRMs. 
Moreover, a recent review by De Bosscher et al.
194
 proposed a concept called the 
SEDIGRAM concept, further explored in Chapter 7, which essentially refines the idea of 
SGRMs by proposing that ligands able to drive monomeric GRα conformation may be more 
beneficial in prolonged treatment regimens for the treatment of chronic inflammation, due to 
their ability to transrepress pro-inflammatory genes without up-regulating metabolic genes 
associated with GC-mediated GRα transactivation, which have been linked to side effects. 
However, what was not addressed in this review, are the ligand-selective effects of GRα 
conformation on receptor turnover, with implications in acquired GC resistance. It is this 
notion, with focus pertaining to the dimerization state of GRα (i.e. dimer versus monomer), 
which forms the central theme of the current study. 
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2.5. Conclusions 
To conclude, acquired GC resistance, due to reductions in the GRα ‘functional pool’, is an 
ever increasing therapeutic challenge for the pharmaceutical industry and occurs ubiquitously 
throughout a number of psychological and pathological conditions. In recent years a number 
of the molecular mechanisms which underpin these GC-mediated reductions in the GRα 
‘functional pool’ have been elucidated, with attempts to counteract GC-mediated receptor 
turnover being made through combinatorial treatment of GCs with other compounds which 
disrupt transcriptional, post-transcriptional and post-translation GRα regulation. Whilst in 
some cases these strategies have proved fruitful, they are not without limitations (i.e. 
preventing all protein degradation). Thus, we believe the idea of ‘biased ligands’ and the 
overlooked and possibly undervalued importance of GRα conformation, with particular 
reference to the receptor’s dimerization state, requires investigation, specifically in terms of 
the ability of the ligand-induced dimerization state of the receptor to influence its turnover. 
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Table 2.1: Disease-associated reductions in GRα expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Peripheral blood mononuclear cells (PBMCs), b No change in GRα expression (mRNA or protein) (N.C), c Not detected (N.D)  
Type of 
condition 
(general) 
Broad 
category of 
disease 
condition 
Species Specific stress/condition/disease Tissue/cells 
GRα 
mRNA 
expression 
GRα 
protein 
expression 
Implications for GC sensitivity References 
Stress 
Pre/post-natal 
stress 
Humans 
Pre-natal stress 
Childhood adversity/abuse leading to adult 
suicide 
a PBMCs 
Hippocampus 
Reduced b N.C c N.D 71–73 
Rodents 
Early Life Stress (ELS) 
(i.e. maternal separation (MS) and 
preconception paternal stress (PPS)) 
Hippocampus, amygdala, 
limbic regions of brain dentate 
gyrus 
Reduced Reduced 
Cognitive dysfunction, altered 
behavioural affects, increase in 
anxiety-like behaviour, anhedonia 
74–81 
Physical or 
psychological 
stress 
Rodents 
Restraint stress, psychological stress, forced 
swim stress (FSS), 
repeated social defeat (RSD), 
repetitive restrain stress (RSS), 
water-immersion and restraint stress 
(WIRS) 
Hippocampus, amygdala, 
hypothalamus,  cerebellum, 
splenic macrophages, 
splenocytes, peripheral 
leucocytes, oligodendrocytes 
of corpus callosum, prefrontal 
cortex, lung tissues 
Reduced Reduced 
More susceptible to psychological 
disorders, asthma exacerbations, 
diminished GC sensitivity 
63,64,76,85–93 
Psychological 
condition 
Psychological 
conditions 
Humans 
Major depression (MD), Schizophrenia, 
Bipolar disorder 
Post-traumatic stress disorder (PTSD) 
General anxiety disorder (GAD) 
Hippocampus, prefrontal-, 
temporal- and entorhinal 
cortex, PBMCs, lymphocytes 
Reduced N.D 
Diminished GC sensitivity 
Treatment-resistant depression 
53,95,106–111 
Pathological 
conditions 
Auto-immune 
or 
inflammatory 
linked 
conditions 
Human 
Atopic Dermatitis (AD) PBMCs Reduced N.D 
GC resistant to topical treatment and 
systemic administration of potent 
corticosteroid 
112 
Systemic lupus erythematosus (SLE) PBMCs Reduced N.D Diminished GC sensitivity 115–117 
Inflammatory bowel disease (IBD) PBMCs Reduced N.C Impaired GC response 119 
Adult immune thrombocytopenia (ITP) PBMCs Reduced Reduced GC resistant ITP 121 
Asthma 
PBMCs, cells from skin 
biopsies of patients 
N.D Reduced GC resistant asthma 126,127 
Chronic obstructive pulmonary disease 
(COPD) 
PBMCs, lymphocytes, lung 
tissue 
Reduced Reduced GC resistant COPD 129–131,260 
Arthritis Chondrocytes and lymphocytes Reduced Reduced Steroid resistant arthritis 133–135 
Rodents Experimental encephalomyelitis (EAE) T cells Reduced Reduced GC-resistant apoptosis 136 
Cancer 
Human 
Acute Lymphoblastic Leukaemia (ALL) 
Multiple myeloma (MM) 
Small-cell Lung Cancer (SCLC), Non-small 
cell lung cancer (NSCLC), Breast cancer 
B-lineage leukaemia, 
T-ALL resistant, lymphoblasts, 
T-leukemic,  Multiple 
myeloma, human carcinoma, 
lung adenocarcinoma cells, 
breast tissue 
Reduced Reduced 
GC resistant ALL 
GC resistant MM and diminished  
GC sensitivity (transactivation and 
GC-mediated apoptosis) 
GC resistant SCLC 
21,138–154 
Rodents Liver cancer HTC cells Reduced Reduced Reduced sensitivity to Dex 155 
Infection and 
other 
conditions 
Human 
Sepsis Neutrophils and T-cells Reduced Reduced Diminished GC sensitivity 156,157 
Idiopathic nephrotic syndrome (NS) PBMCs NC Reduced 
Steroid resistant Nephrotic 
syndrome (SRNS) 
158 
Keloid disease Keloid tissue Reduced Reduced Diminished GC sensitivity 159 
Rodents Stroke 
mouse brain capillary 
endothelial cells (cEND) 
N.C Reduced Diminished GC sensitivity 160 
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Table 2.2: Treatment-associated reductions in GRα expression mediated by exogenous GCs 
Exogenous GC 
in vitro/ex 
vivo/in vivo 
Treatment conditions 
Cells/tissues 
GRα mRNA 
expression 
GRα protein 
expression 
Implications in GC sensitivity References 
Concentration Time 
Dex 
a in vitro 
Various Dex doses 
(10-10 to 10-6M) 
Generally up to 
72 hours with 
one study 
continuing 
treatment for up 
to 4 weeks and 
one for up to 2 
years 
Human IM-9 lymphocytes 
and rat pancreatic acinar (AR42J) cells 
Hepatoma tissue culture (HTC), HeLa, COS-1, cells 
NIH 3T3 cells, 
Chinese Hamster ovary-derived (CHO) cells, 
BWTG3 cells 
Mouse brain capillary endothelial (cEND) cells, 
U2-0S and A459, 
Human respiratory epithelial cells (BEAS-2B) 
Normal human liver (HL7702) cells L6 muscle cells, 
Fibroblast-like synoviocytes (FLS), 
RAW264.7 cells 
Peripheral blood mononuclear cells (PBMCs) 
Reduced Reduced 
Not all papers determined 
implications in GC sensitivity 
but the ones that did, 
demonstrated diminished GC 
sensitivity 
51,52,160–177 
b ex vivo) or c 
in vivo 
5μM, 20μg or 1mg/kg - 5mg/kg 
body weight 
Up to 48 hours, 
3 to 28 days 
Variety of mice and rat tissues 
(liver, kidney, lung and heart), 
Culture mouse podocytes 
Rat hippocampal neurons 
Mice frontal cortex and hippocampus tissue 
Human lymphocytes 
Reduced Reduced 
Not all papers determined 
implications in GC sensitivity 
but the ones that did, 
demonstrated diminished GC 
sensitivity 
51,52,54,163,171,172,178–180 
Triamcinolone 
acetonide (TA) 
in vitro 1μM Up to 96 hours 
L929 cells 
(a fibroblast-like cell line) 
Reduced Reduced d N.D 181 
Hydrocortisone in vivo 
Intraperitoneally 5 mg/100g 
body weight 
6 hours Liver tissue N.D Reduced Altered GC sensitivity 182 
Various prednisolone-
based steroids 
in vitro 10-5M 0 to 24 hours HeLa Reduced N.D N.D 173 
in vivo 
120mg/kg 
e Low-dose and 1 x mega dose; 
0.01–0.3 mg/kg orally or 10–15 
mg/kg f i.v. pulse therapy ; 
1mg/kg body weight 
10 days 
e Daily (oral) or 
3 doses; 
4-6 weeks (i.v) 
Liver tissue 
Human blood monocytes 
Lymphocyte subpopulations 
PBMCs 
Reduced Reduced 
Diminished GC sensitivity 
GC resistance based on clinical 
predictive factors for GC 
resistance (i.e.. fundus 
depigmentation and chronic 
disease in g VKH) 
55,183–189 
Fluticasone propionate 
(FP) and budesonide 
(BUD) 
in vivo 
Up to 400 μg/day of FP or 800 
μg/day of BUD was 
administered intranasally, given 
as a morning and evening dose 
Up to 2 weeks Nasal mucosa biopsy Reduced N.D N.D 190 
a in vitro: GC treatment of transiently, stably transfected or endogenous GRα in tissue culture cells. b ex vivo: GC treatment of endogenous GRα in cells/tissues derived directly from animals in a tissue culture assay. c in vivo: Subjects (rodents or patients) treated 
with GCs with cells/tissues retrieved and assayed (i.e. GC treatment does not occur in tissue culture). d Not detected (N.D). e See Berki et al.185 for details. f Intravenous therapy (i.v).g Vogt-Koyanagi-Harada (VKH) disease189.  
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Table 2.3: GC-mediated molecular mechanisms involved in reducing GRα expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 a Negative glucocorticoid response element (nGRE), b Not detected (N.D), c Not applicable (N.A) as effects exerted on GRα protein 
Level of regulation Molecular mechanism Species 
GRα mRNA 
expression 
GRα protein 
expression 
Reference 
Epigenetic  
DNA methylation of GRα gene 
 
 Rodents: exon 17 
 
 Humans: exon 1F, exon 1C,exon 1B, exon 1H 
Rodent Reduced Reduced 64,77,79,80 
Human Reduced Reduced 71,72,140,153 
Transcriptional 
GRα gene regulation via a nGRE 
 
 present in exon 6 
Human Reduced b N.D 164,171,197 
Post-transcriptional 
miRNA 
 
 Rodents:  miR-96, miR-101a, miR-142-3p, miR-433, 
miR-29b, miR-340-5p, miR-18 and miR-124a 
 
 Humans:  miR-124, miR-130b and miR-142-3p 
Rodent Reduced Reduced 64,87,89,205–207 
Human Reduced Reduced 144,150,156,204 
Post-translational 
Phosphorylation  
 
 Rodents:  
o c multiple mouse mutations  
(Ser212, Ser220 and Ser234) 
o hyper-phosphorylation at Ser412 
 
 Humans: hyper-phosphorylation at Ser211, Ser226 and 
Ser404 
 
Mouse N.A Decreased 214,216 
Human N.A Decreased 214,215 
Ubiquitination  
 
 Rodents: K426  
 
 Humans: K419 
 
Proteasome degradation (i.e. use of proteasome inhibitors) 
 
 Rodents: MG132 or bortezomib (BZ) 
 
 Humans: MG132 or BZ 
 
Human N.A Decreased 166,220–224 
Mouse N.A Decreased 8,160,165,166,219 
Sumoylation 
 
 Specific site unknown 
Human N.A Decreased 210 
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Chapter 3:  
Materials and methods 
3.1. General 
3.1.1. Test Compounds 
The test compounds, also referred to as ligands, used in this study, included a potent synthetic 
GRα agonist, Dex (11β,16α)-9-fluoro-11,17,21–trihydroxy-16-methylpregna-1,4-diene-3,20-
dione), and endogenous GC, F (11β,17α,21-trihydroxypregn-4-ene-3,20-dione-17-
hydroxycorticosterone), which were purchased from Sigma Aldrich (South Africa). 
Additionally, and a non-steroidal dissociative GC, CpdA (2-(4-acetoxyphenyl)-2-chloro-N-
ethylethylammonium chloride) was synthesized as previously described
1
 or purchased from 
Enzo Life Sciences (South Africa). All stock solutions were prepared in ethanol to a final 
concentration of 1 M and stored at -20⁰C. 
3.1.2. Plasmids  
Throughout this study the focus was on the hGRwt and hGRdim GRα plasmids, however, a 
number of mutation-specific and species-specific GRα plasmids were also investigated. In 
addition, an ubiquitin construct containing a HA-tag was utilized for the investigation of GRα 
ubiquitination. Lastly, the current study also made use of two GRα plasmids, which each 
contained a green-fluorescent protein tag (GFP), namely GFP-hGRwt and GFP-hGRdim. 
Details of all plasmids, their sources and references are to be found in Table 3.1. 
3.1.3. Cell culture and transfections  
Cell lines that were used in this study, included an African Green monkey kidney epithelial 
cell line (COS-1 cells), a human hepatoma derived cell line (HepG2 cells) and two mouse 
embryonic fibroblast cell lines (MEF-mGRwt and MEF-mGRdim)
2
. The COS-1 cells were 
purchased from American Type Culture Collection (USA) whilst the HepG2 and MEF cells 
were kind gifts from Barbara Burkhart (NIEHS, Research Triangle Park, USA) and Jan 
Tuckerman (University of Ulm, Germany), respectively.  
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The COS-1 cells were used to investigate the behaviour of the transiently transfected hGRwt 
and hGRdim plasmids because COS-1 cells are known to have little or no endogenous GRα. 
The HepG2 cell line was used to study the behaviour of endogenous human GRα and thus did 
not require transient transfections. The MEF cell lines, isolated from GR
wt
 and GR
dim
 mice as 
previously described
2
, allowed for comparison of the dimerization deficient mouse GRα 
(MEF-mGRdim) and wild type GRα (MEF-mGRwt) in an endogenous setting. 
3.1.3.1. Maintenance of cell lines 
All cell lines were maintained in high glucose (4.5 g/ml) Dulbecco’s modified Eagle’s 
medium (DMEM) (Sigma Aldrich, South Africa) supplemented with 10% fetal calf serum 
(FCS) (Merck, South Africa), 1.5 g/L sodium bicarbonate, 0.11 g/L sodium pyruvate and 100 
IU/ml penicillin and 100 µg/ml streptomycin (1% Pen/Strep) (Sigma-Aldrich, South Africa). 
For the HepG2 cells, additional L-glutamine was added to a final concentration of 2 mM. The 
four cell lines were maintained at a temperature of 37⁰C, 90% humidity and 5% CO2 in T75 
tissue culture flasks (Lasec, South Africa). All call lines were tested for mycoplasma and 
found to be negative. 
3.1.3.2. Transfections and cell culture during experiments 
Cells were seeded into tissue culture plates in supplemented DMEM, and all experiments 
were conducted on cells with a passage number between 1 and 35.  
Approximately 24 hours later, once COS-1 cells had reached 60-70% confluency, specific 
plasmids (Table 3.1) were transiently transfected using either FuGENE 6 or XtremeGENE 
HP Fugene transfection reagents (1 µg DNA: 2 µl FuGENE) as described by manufacturer 
(Roche, Germany) (Table 3.2). For transfections, double the amount of the hGRdim plasmid 
(ng/µl) was transfected in relation to that of the hGRwt, because of hGRdim’s lower 
expression efficiency. Due to the fact that endogenous GRα levels were analysed in HepG2 
and MEF cells, they did not require GRα plasmid transfection.  
During experiments COS-1 cells were induced with compounds (see details in figure legends) 
in unsupplemented DMEM, whilst HepG2 and MEF cells were induced in DMEM 
supplemented with 1% Pen/Strep and 10% charcoal-stripped FCS, due to the fact that these 
cells did not grow well in unsupplemented medium unlike the COS-1 cells, which was either 
purchased from Merck (South Africa) or stripped using a dextran coated charcoal (DCC)-
based stripping buffer. 
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3.1.3.3. Stripping of FCS using DCC-based stripping buffer 
The DCC-based stripping buffer contained activated charcoal and dextran from Leuconostoc 
species. (100:1 w/w ratio) purchased from Sigma Aldrich (South Africa), which was 
dissolved in a solution containing 0.25 M sucrose, 1.5 mM MgCl2 and 10 mM HEPES. The 
solution was placed overnight on a stirrer at 4°C overnight. The next day the stripping buffer 
was pelleted by centrifugation at 500 x g for 10 minutes at room temperature, in 50 ml tubes. 
The supernatant was then discarded and 50 ml of FCS was added to the pelleted charcoal. 
The tubes were then placed on a shaker overnight at 4°C to ensure sufficient mixing. The 
next day the 50 ml tubes were centrifuged at 2000 x g for 30 minutes, to pellet the charcoal. 
Following centrifugation, the supernatant (i.e. the steroid-stripped FCS) was collected and 
subsequently filter sterilized using a VacuCap® 90 PF filter unit (PALL Scientific, South 
Africa), aliquoted and stored at -20°C until used. 
3.2. Determining GRα protein concentration and analysing ligand-induced GRα 
protein down-regulation 
Throughout this study two different techniques, namely Western blotting (using various 
antibodies Table 3.3) and competitive whole cell GRα-binding were employed to determine 
the cellular GRα protein expression levels in the three cell lines (COS-1, HepG2 and MEF 
cells), both in the absence and presence of test compounds and/or inhibitors cycloheximide 
(CHX) and MG132 (Table 3.4). In the case of the Western blotting, GRα protein expression 
was normalised to a loading control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in 
order to ensure equal protein loading between treatment conditions. Additionally, for a more 
quantitative analysis on GRα protein expression whole cell GRα-binding was used to 
calculate the amount of receptor in terms of fmol/mg protein. 
3.2.1. Western blotting 
After appropriate seeding, transfections and treatments (see figure legends and Table 3.2), 
cells were washed once with ice-cold phosphate buffered saline (PBS) and harvested in 
sodium dodecyl sulphate (SDS) bromo-phenol blue reducing buffer (100 mM Tris-HCl pH 
6.8, 5% (w/v) SDS, 20% (v/v) glycerol, 2% (v/v) β-mercaptoethanol and 0.1% (w/v) 
bromophenol blue). Once lysates were prepared they were boiled for 10 minutes at 95⁰C, 
separated on 7.5% or 10% Mini-Protean TGX precast gels (BioRad, South Africa) using the 
BioRad MiniProtean gel system and power pack (BioRad, South Africa). The PageRuler 
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Prestained Protein Ladder (#26616, Thermo Scientific, USA) was also loaded to determine if 
the protein of interest was the correct size. Following protein separation in the gels, the 
proteins were then transferred to a Hybond-ECL nitrocellulose membrane (AEC Amersham, 
South Africa). Once transferred, membranes were blocked for 1 hour in 10 % milk powder or 
5% bovine serum albumin (BSA) purchased from Sigma (South Africa). Membranes were 
then washed once with 1 x Tris-buffered saline Tween (TBS-T) and probed with primary 
antibodies (Table 3.3) overnight at 4⁰C or at room temperature for 1 hour. Blots were then 
washed 1 x 15 minutes with TBS-T, 1 x 5 minutes with TBS-T and 1 x 5 minutes with Tris-
buffered saline (TBS) and then incubated with secondary antibodies (Table 3.3), for 1 hour. 
Subsequently the blots were immersed in either Pierce or BioRad ECL Western blotting 
detection agents (Thermo Scientific (USA) and BioRad (South Africa), respectively, for five 
minutes, and exposed to FUJI Medical X-Ray Film (Africa X-ray Industrial and Medical 
(AXIM, South Africa) or alternatively, bands were visualized using the chemiluminesence 
setting on the MyECL Imager (Thermo Scientific, USA). For protein normalisation, GAPDH 
as a loading control was probed (see figure legends and Table 3.3) and UNSCANIT or the 
MyECL Image analysis Version 2.0 software used to calculate the intensity of the bands. 
Results were expressed as the intensity of the band for the protein of interest normalized to 
the band for the loading control protein. In each experiment, compound treated samples were 
expressed, as a percentage, relative to the solvent (EtOH), unless otherwise stated (see figure 
legends), which was set at 100%.   
3.2.2. Whole cell GRα-binding  
In addition to Western blotting, the ligand-induced effects on GRα protein expression were 
also investigated using whole cell GRα-binding. For this a whole cell GRα binding 
experiment was conducted at each time point to determine GRα protein expression. For 
whole cell binding the optimal incubation time for binding equilibrium to be reached, needs 
to be determined. This has previously been determined for the COS-1 cells
3
 but not for the 
MEF cells. Thus, in the current study a whole cell binding experiment was conducted to 
determine the time to equilibrium in the MEF cells. Lastly, in both the COS-1 cells and the 
MEF cells (MEF-mGRwt and MEF-mGRdim) a homologous competitive binding 
experiment, with Dex, were conducted. This allowed for the ligand binding (Kd) affinity of 
Dex for the GRα, in these cells, to be determined as well as the cellular GRα concentration 
(fmol/mg protein). 
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3.2.2.1. Determining time to equilibrium in MEF cells  
MEF-mGRwt cells were seeded (Table 3.2) and 24 hours later were cells steroid starved in 
charcoal-stripped FCS with 1.5 g/L sodium bicarbonate, 0.11 g/L sodium pyruvate and 1% 
Pen/Strep (Sigma-Aldrich, South Africa), for an additional day. Following steroid starvation 
cells were incubated with 20 nM [
3
H]-Dex (with a specific activity of 77 Ci/mmol, purchased 
from AEC Amersham) (total binding) or 20 nM [
3
H]-Dex and an excess of unlabelled Dex 
(10 µM) (non-specific binding) for 0, 2 or 4 hours at 37⁰C and 5% CO2. After incubation, 
cells were placed on ice and washed 3 times with ice-cold 0.2% PBS-BSA, for 15 minutes 
per wash, to remove unbound ligand, and then washed quickly (another three times) with ice-
cold PBS to remove albumin. Cells were then lysed with 100μl passive lysis buffer (0.2% 
(v/v) Triton, 10% (v/v) glycerol, 2.8% (v/v) Tris-phosphate-ethylenediaminetetraacetic acid 
(EDTA) and 1.44 nM at room temperature and allowed to go through a freeze-thaw cycle. 
Thawed lysates (100 µl/well) were added to 1ml of scintillation fluid/well (Thermo 
Scientific, USA) and the counts per minute (cpm) were determined using a scintillation 
counter (Beckman LS 6500 Beta-Scintillation counter). Specific binding (cpm) was 
calculated by subtracting the non-specific binding from total binding (total binding - non-
specific binding = specific binding) and plotted, against time. One-phase exponential 
association curves were fitted to the data to determine an incubation time required to reach 
equilibrium in the MEF-mGRwt cells. This was then applied to the MEF-mGRdim cells.   
3.2.2.2. Determining GRα protein expression (cpm/mg protein) following a time course 
of ligand-induction, in COS-1 cells  
Cells, COS-1, were seeded, transfected (hGRwt and hGRdim) and treated with ligands for 
various lengths of time (see figure legends and Table 3.2). Following, which cells were 
washed 3 times, for 15 minutes each,  with pre-warmed  PBS supplemented with BSA, to a 
final concentrations of 0.2% (BSA-PBS) (to remove bound and free ligand). Subsequently, 
cells were quickly washed 3 times with pre-warmed PBS to remove the BSA. To determine 
the GRα expression following different lengths of ligand treatments, a whole cell GRα 
binding experiment was done for each time point. These whole cell binding experiments were 
performed as previously described
4
 with the following changes; unsupplemented DMEM 
containing 20 nM [
3
H]-Dex (with a specific activity of 68 Ci/mmol) in the absence (total 
binding) or presence (non-specific binding) of 10
 μM unlabelled Dex, was added to wells 
(500 μl/well) and incubated at 37ºC for 4 hours. After incubation cells were placed on ice and 
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washed three times with ice-cold 0.2% BSA-PBS for 15 minutes, to remove unbound ligand, 
followed by three washes with ice-cold PBS to remove BSA. Cells were then lysed, 
underwent a freeze-thaw cycle and cpms determined using a scintillation counter. Total 
protein concentration was determined using the Bradford method
5
, which was used to 
normalize results (cpm/mg protein) and specific binding was then calculated. Specific 
binding of lysates from solvent (EtOH) treated cells was set at 100% (dotted line) for each 
time point and % specific binding of lysates from compound treated cells were then 
determined relative to solvent (EtOH), at each time point, and plotted. All experiments were 
tested for ligand depletion and counting efficiency (CE), which was less than 10% and 
approximately 43%, respectively. 
3.2.2.3. Homologous competitive binding to determine ligand affinity (Kd) and Bmax  
For this experiment, cells were seeded, transfected (save the MEF cells) and steroid starved in 
charcoal-stripped FCS, 24 hours prior to the homologous competitive whole cell binding 
experiment (see figure legends and Table 3.2). This homologous binding experiment can only 
be conducted when the labelled ligand and the competing unlabelled ligand are chemically 
identical and allows for the determination of receptor number and affinity. To do this, cells 
were incubated in unsupplemented DMEM (500 μl/well) with either 20 nM [3H]-Dex or 40 
nM [
3
H]-Dex (specific activity of 77 Ci/mmol) containing solvent (EtOH) or increasing 
concentrations of unlabelled Dex (10
-11
 to 10
-5μM) at 37ºC for 4 hours. Following incubation, 
cells were washed, lysed, underwent a freeze-thaw cycle and cpms determined using a 
scintillation counter. Total protein concentration was determined using the Bradford method
5
,  
which was used to normalize total binding results (cpm/mg protein), which were then plotted 
against increasing concentrations of unlabelled Dex (logM). The data was then fit with a 
global-fitting one-site homologous non-linear regression curve
6
, which then provided one 
shared value for the binding affinity (logKd), the maximum binding of ligand to receptors 
(Bmax) and the measure of non-specific binding (NSB) from all sets of data. These values 
were then used to calculate the total cellular GRα concentration in terms of fmol/mg protein, 
in the next section. 
3.2.2.4. Calculating the total cellular GRα concentration (fmol/mg) protein  
Using the Bmax values (cpm/mg protein) derived from the homologous competitive binding 
experiments in combination with the reported CE (%) and the specific activity of the labelled 
[
3
H]-Dex (77 Ci/mmol), as well as the amount of disintegrations per minute (dpms), which is 
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2.22 x 10
12 in one Curie (Ci), one can calculate the GRα concentration of cells (fmol/mg 
protein), using the equation below: 
                 
     
                     
      (1) 
A step-by-step breakdown of this equation with the units for each value is now described. 
Firstly, the units for Equation 1 are as follows: 
                 
                 
                     
      (1) 
Next, the maximal binding (Bmax) with units of cpms/mg protein was converted to dpms/mg 
protein using Equation 2 and the experimentally determined counting efficiency (CE). 
                 
                  
  
 (2) 
Or rather 
                                     (2) 
Therefore, substituting Equation 2 into Equation 3 we now have the following, where the 
units for (CE) cancel each other out: 
                 
                  
                  
      (3) 
These units then cancel out to provide Equation 4: 
                                     (4) 
To get fmol/mg protein from mmol/mg protein we divide by a factor 10
12
, which then 
provides the GRα concentration of the cell in fmol/mg protein. 
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3.3. Investigating the interactions of GRα and components of the ubiquitin-
proteasome system (UPS), with reference to the localisation of these 
interactions. 
To further dissect ligand-induced down-regulation of the GRα protein at the proteasome level 
a number of additional techniques were used.  Firstly, to evaluate phosphorylation of the GRα 
protein, Western blotting (as described in 3.2.1) was conducted with an antibody specific for 
the GRα phosphorylated at serine 404 (Table 3.3). Additionally, the role of inhibiting 
phosphorylation at this site, using BIO (a GSK3β inhibitor) (Table 3.4) was also investigated 
with Western blotting. Subsequently, to investigate GRα ubiquitination and the interaction of 
GRα with certain UPS enzymes a small-interference RNA (siRNA) knockdown experiment 
and a number of co-immunoprecipitation’s (Co-IP) were conducted. Lastly, to further 
investigate the nature of these interactions, with selective components of the UPS, as well as 
the specific subcellular localisation of these interactions, immunofluorescence and a 
proximity-ligation assay was utilized.  
3.3.1. siRNA transfection  
The next day, after cells were seeded (Table 3.2), cells were transfected using HiPerfect 
Transfection reagent (Qiagen, Germany) with (8 μl: 40 nM siRNA) non-silencing control 
(NSC) (40 nM ) or a siTSG101 cocktail (40 nM), consisting of a mix of four siTSG101 
RNAs (Table 3.5) (Qiagen, Germany) in Opti-MEM® Reduced Serum Medium with 
GlutaMAX™ Supplement (Thermo Scientific, USA). The transfection mix was added 
directly to the cells, after a single wash with pre-warmed PBS, and incubated for 4 hours at 
37⁰C. After incubation, 500µls of complete medium (DMEM with 5% FCS and 1% 
Pen/Strep) was added to the cells and incubated overnight at 37⁰C. The next day, cells were 
transfected with either the hGRwt or hGRdim plasmids using the FuGENE or XtremeGENE 
HP transfection reagent (Table 3.2) and incubated for an additional 24 hours. Following 
treatment with compounds (see figure legends), cells were lysed in 100 µl of SDS bromo-
phenol blue reducing buffer and subjected to Western blotting using GAPDH as a loading 
control (Table 3.3). 
3.3.2. Co-IP  
For Co-IP, once cells had been seeded, transfected (Table 3.1 and 3.2) and treated with 
compounds (see figure legends), they were washed three times with 10 ml of ice-cold PBS 
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and then lysed in 500 µl of RIPA Buffer (#R2078, Sigma Aldrich, South Africa) 
supplemented with a Complete Mini Protease Inhibitor Tablet (Roche, Germany). The dishes 
were placed at -20 ⁰C overnight. Following a freeze and thaw cycle, cells were harvested and 
centrifuged at 16000 x g for 5 minutes. The supernatant was collected and the pellet 
discarded. For inputs, 9 µl of the supernatant per condition was set aside and 3 µl of 5 x SDS-
BB buffer added. Protein A/G PLUS-Agarose beads (#sc-2003, Santa Cruz Biotechnology, 
Germany) were pre-blocked using the following protocol; beads were centrifuged at 1500 x g 
for 5 minutes at 4⁰C and washed with 1 ml IP dilution buffer (0.01% SDS, 20 mM Tris pH 8, 
1.1% Triton-X-100, 167 mM NaCl, 1.2 mM EDTA, 1 x protease inhibitor tablet and made up 
to 10 ml with H2O) and centrifuged again at 1500 x g for 5 minutes at 4⁰C. Following 
centrifugation, 1 ml IP dilution buffer was added to 500 µl of beads along with 100 µg of 
Salmon Sperm DNA (11 mg/ml stock) (Thermos Scientific, USA) and rotated on a rotating 
wheel for 1 hour at 4⁰C. Subsequently, beads were centrifuged at 1500 x g for 5 minutes at 
4⁰C and approximately 500 µl of beads were re-suspended in 500 µl IP buffer to produce a 
50% slurry, which was kept at 4⁰C. Following pre-blocking of the beads, the sample 
supernatant was pre-cleaned with 15 μl of 50% slurry and rotated for 1 hour to minimize non-
specific binding to the beads. Once pre-cleaned, samples were centrifuged at 5500 x g for 1 
minute and the supernatant collected to which the specific antibody (Table 3.3) was added.  
The supernatant, with antibody (Table 3.3), was placed at 4⁰C to rotate overnight.  After 
incubation with antibody, 20 µl of pre-blocked 50% bead slurry was added to the supernatant, 
incubated at 4⁰C on a rotating wheel for 45 minutes and then precipitated at 5500 x g for 1 
minute. The supernatant was then aspirated and the beads washed 6 times with wash buffer 1 
(WB1) (0.1% SDS, 1% Triton x100, 2 mM EDTA, 20 mM Tris pH8 and 500 mM NaCl). 
After the last wash, the supernatant was aspirated and 25 µl of 2 x SDS bromo-phenol blue 
reducing buffer was added to the beads, which was then boiled at 95 ⁰C for ten minutes, to 
elute the immunoprecipitated proteins. Inputs and immunoprecipitation samples were 
centrifuged at 14 000 rpm for 5 minutes and the supernatants were subjected to Western 
blotting using antibodies (Table 3.3). 
3.3.3. Investigating the direct interaction GRα and UPS components with reference to 
subcellular localisation  
As detailed in Table 3.2, cells were seeded, transfected, re-plated where necessary (see figure 
legends) and treated. Subsequently, cells were washed three times with ice-cold PBS, fixed 
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and permeabilized. To do this, cells were incubated (at 37°C) with a 1:1 ratio of 4% 
paraformaldehyde and unsupplemented DMEM, for ten minutes. Following incubation, cells 
were washed 3 times with warm PBS for 5 minutes at a time and then incubated (at 37°C) 
with 4% paraformaldehyde (300 μl/well in an 8 well chamber) for another 10minutes. Once 
this incubation was completed, cells were washed again with warm PBS (3 times) for 5 
minutes at a time, which completed the fixing. Once fixed, cells were permeabilized with 
0.02% Triton-X for 6 minutes (300 μl/well in an 8 well chamber) at room temperature. Once 
permeabilized, cells underwent final washes (3 times with warm PBS for 5 minutes at a time) 
and then stored in PBS (300 μl/well in an 8 well chamber) at 4°C, ready for 
immunofluorescence or proximity-ligation assay (PLA). 
3.3.3.1. Subcellular localisation of GRα and UPS components using 
Immunofluorescence 
After permeabilization, cells were blocked with 5% PBS-BSA (300 µl/well) for 1 hour at 
room temperature. Cells were then washed 3 times with 1.5% PBS-BSA (300 µl/well) for 5 
minutes per wash and incubated with primary antibody, diluted in 5% PBS-BSA (100 
µl/well), for 1 hour at room temperature. Subsequently, cells were washed 3 times with 1.5% 
PBS-BSA (300 µl/well) for 5 minutes at a time and incubated with Alexa Fluor secondary 
antibodies (Table 3), diluted in 5% PBS-BSA (100 µl/well), for 1 hour at room temperature. 
Following incubation with primary and Alexa secondary antibodies (Table 3.3), cells were 
washed 3 times with PBS. For nuclei visualisation a stock solution of 10mg/ml Hoechst 
33258 stain (Sigma Aldrich, South Africa) was diluted (1:1000) in distilled water and 300 
µl/well added to the cells, which were then incubated for 5 minutes at room temperature. 
Finally, cells were washed 3 times with ice-cold PBS (300 µl/well) and stored in PBS at -
20⁰C until imaged using the LSM780 confocal microscope (Zeiss, Germany).  
3.3.3.2. Image acquisition and analysis  
The LSM780 confocal microscope with ELRYA PS1 super-resolution platform (Zeiss, 
Germany) was used for image acquisition. The microscope is equipped with a GaAsP 
detector, for signal collection. The settings for the signal detection for each experiment are 
detailed below: 
Immunofluorescence 
- Alexa488 (from 490 to 552 nm) 
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- Alexa594 (from 611 to 733 nm) 
- DAPI (from 410 to 473 nm) 
PLA (only) with untagged GRα plasmids: 
- Duolink amplification signal (from 611 to 733 nm) 
- DAPI (from 414 to 522 nm) 
PLA and GFP-tagged GRα plasmids: 
- Duolink amplification signal (from 611 to 733 nm) 
- GFP (from 499 to 561 nm) 
- DAPI (from 414 to 522 nm) 
The 405nm, 488 nm and 561 nm lasers, with their appropriate beam splitters (MB405 and 
MBS488/561) where used for exciting of the three respective fluorophores. Additionally, a 
LCI “Plan-Apochromat” 63x/1.4 Oil DIC objective was used. Moreover, the laser power and 
detection gains were optimised to prevent ‘bleedthrough’ and the image resolution was set at 
1024 x1024. Z-stacks were acquired and presented as maximum intensity projections. 
Lastly, the specific methods of quantification for the subcellular localisation, co-localisation 
and interaction, using PLA, of GRα and the selective UPS components are detailed in 
Chapter 5. 
3.3.3.3. Co-localisation of GRα and UPS components  
Confocal images acquired following immunofluorescence were used to determine the co-
localization of GRα with proteins of the UPS. Co-localization, which refers to co-
compartmentalization or interaction of two molecules (or proteins), can be defined by the 
‘existence of spatial overlap between to molecules’7–9. Each of these molecules are detected 
using different Alexa fluorophores with minimal overlap in their emission spectra, which 
recognize primary antibodies bound to the proteins of interest (Table 3.3), producing a two-
channel image (i.e. red (561 nm) and green (488 nm)). Using the powerful ZENN 2012 
software analysis, which utilizes specialized algorithms the degree of co-localisation between 
two molecules can be detected and visualized. This software displays the co-localisation of 
two proteins, using white pixels containing both red and green intensities, in a 2D-
scattergram, an example of which is also detailed in Costes et al. (2004)
9
. In order to clarify 
random colour overlap between the two fluorophores and confirm co-localization, thresholds 
based on single stains were implemented. Using the visual interpretation of an experienced 
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researcher, Lize Engelbrecht (Central Analytical Facility (CAF), Stellenbosch University), 
the optimal threshold intensities for each channel (or colour), where pixels do not show any 
spatial correlation, were determined and applied.  Thresholds for the channels, red or green, 
and therefore the individual proteins, were determined individually and used as a ‘cut off’ 
between specific staining and non-specific staining. The region where both individual 
channels were above their respective thresholds, was defined as the co-localisation region
9
. 
For the quantification of the co-localisation signal, the weighted co-localization coefficients 
were determined, using the defined thresholds and the ZENN 2012 software analysis to rank 
the pixel intensities in each channel, and plotted. 
3.3.3.4. Interaction of GRα and UPS components using a PLA  
To confirm the interaction of GRα with components of the UPS, a highly sensitive technique 
was used, namely the Duolink proximity ligation assay (Sigma Aldrich, South Africa) (Fig. 
3.1)
10
. A brief description of how this assay works is outlined in Chapter 5, with the details of 
the assay provided in the current section.  
 
Figure 3.1: A simple description of the Duolink PLA taken from Sigma Aldrich
10
 
For this assay, the same protocol detailed in Section 3.3.3 and 3.3.3.1 was followed to just 
after the primary antibody incubation. Unlike with the immunofluorescence, after primary 
antibody incubation cells were washed 3 times with 1.5% PBS-BSA (300 µl/well) for 5 
minutes at a time (at room temperature). Subsequently, Duolink PLA (PLUS and MINUS) 
probes (Sigma Aldrich, South Africa) were diluted at a 1:5 ratio in 5% PBS-BSA just before 
use, vortexed and added to the cells, which were then incubated in a pre-heated humidity 
chamber, for 1 hour at 37⁰C. Following incubation with probes, cells were washed twice with 
1 x Wash Buffer A (Sigma Aldrich, South Africa), for 5 minutes at a time. After washing, the 
Duolink ligation stock (Sigma Aldrich, South Africa) was diluted in high quality distilled 
water, at a ratio of 1:5 and then the ligase (1 U/µl) (Sigma Aldrich, South Africa) was added 
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to the reaction mix at a ratio of 1:40 just before addition to the cells. The cells were 
incubated, in a pre-heated humidity chamber, with the ligation mix for 30 minutes at 37⁰C 
and subsequently washed with 1 x Wash Buffer A twice, for 2 minutes each. Once ligation 
was completed, the Amplification stock (Sigma Aldrich, South Africa) was diluted at a ratio 
of 1:5 in high quality distilled water and the polymerase (Sigma Aldrich, South Africa) added 
to the solution at 1:80. The mix was then immediately applied to the cells and incubated for 
100 minutes at 37⁰C in a pre-heated humidity chamber. Following amplification the cells 
were washed with 1 x Wash Buffer B (Sigma Aldrich, South Africa) twice for 10 minutes 
and then in 0.01% x Wash Buffer B for a further minute. For nuclei visualisation a stock 
solution of 10 mg/ml Hoechst 33258 stain (Sigma Aldrich, South Africa) was diluted 
(1:1000) in distilled water and 300µl/well added to the cells and incubated for 5 minutes at 
room temperature. Finally, cells were washed 3 times with ice-cold PBS (300 µl/well) and 
stored in PBS at 4⁰C for imaging using the LSM780 confocal microscope. The PLA signal is 
visualised, as a fluorescent red ‘spot’, which can then be quantified. 
3.4. Mimicking acquired GC resistance in a cellular model, the MEF cells 
Throughout this study, changes in the expression of the GRα protein are noted across all cell 
lines (COS-1, HepG2 and the MEF cell lines). Additionally, studies have suggested that these 
changes in GRα expression (both at the protein and mRNA level) may have down-stream 
effects on GRα mediated gene expression11,12, which has a number of biological implications, 
such as the development of acquired GC resistance. With this in mind, the current study 
sought to mimic acquired GC resistance using a cellular model (MEF cells) as detailed in 
Section 6.2.2 to investigate down-stream GR mediated gene expression. 
3.4.1. Establishing a working model 
The experimental procedure that was followed is neatly illustrated in a diagram (Figure 6.3), 
which provides details on compound treatments (short-term versus long-term) employed in 
order to mimic acquired GC resistance. 
3.4.2. RNA isolation  
Following specific treatments, cells were washed 3 times with ice-cold PBS and harvested for 
RNA. RNA isolation, cells were lysed with 400 µl Tri Reagent (Sigma, South Africa) and 
stored at -80°C to undergo freeze/thaw cycle. Once samples had thawed and been transferred 
to microcentrifuge tubes, to which 80 µl of chloroform (Sigma Aldrich, South Africa) was 
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added. Samples were then vortexed vigorously for 20 seconds and kept at room temperature 
for 5 minutes. Lysates were centrifuged at 4°C for 20 minutes at 14 000 rpm and 160 µl of 
the clear supernatant was added to chilled microcentrifuge tubes. Next, 200 µl of isopropanol 
(Merck, South Africa) was added to each clear sample, vortexed, incubated at room 
temperature for 10 minutes and then stored at -20°C. The next day samples were centrifuged 
at 4°C for 20 minutes at 14 000rpm. The supernatant was then discarded and the pellet 
washed 3 x with 75% ethanol-Diethyl pyrocarbonate (DEPC) water and then allowed to air-
dry for ten minutes before dissolving it in 10 µl of DEPC treated water. RNA concentrations 
and quality (260/280 ratio) was measured using the NanoDrop 1000 (Thermo Scientific, 
USA). The integrity of the RNA isolated was checked by running 0.5 ug of RNA on a 1% 
agarose formaldehyde gel (for 50 ml: 0.5 g agarose in 36 ml DEPC-treated water, 5 ml 10 x 
3-(N-morpholino) propanesulfonic acid (MOPS) buffer and 9 ml formaldehyde) in 1x MOPS 
buffer, 10 x dilution of 10 x MOPS buffer (0.4 M MOPS, pH 7, 0.1 M sodium acetate and 
0.01 M EDTA, pH 8).  
3.4.3. cDNA synthesis 
cDNA was synthesised from 1ug of RNA using the ImProm-II reverse transcription system 
(Promega, USA) according to the manufacture’s protocol.  
3.4.4. Real-time PCR (RT-PCR)  
Specific primers (Table 3.6) were designed using National Center for Biotechnology 
Information (NCBI) and then purchased from Integrated DNA Technologies (USA). Primers 
were dissolved in 1 x Tris-EDTA (TE) buffer to produce a primer stock solution (100 µM) 
from which the working solution (10 μM) of each primer was made. RT-PCR was conducted 
to measure the expression of various genes using the cDNA prepared. A final reaction 
volume of 10 μl consisting of 1 µg cDNA, 0.3 µl FWD primer and 0.3 µl REV primer (final 
primer concentration of 0.333 nM), 3.4 µl of DEPC water and 5 µl of SYBR green ABI 
PRISM (Kappa Biosystems, South Africa). 
The annealing temperatures for the primer sets were optimized and the primer efficiencies 
where determined (Table 3.6) by preparing a standard curve from a 5 x dilution series of 
prepared cDNA. Primer efficiencies obtained were between 1.87-2.18 (Table 3.6) and were 
calculated using Equation (1)
13
. The expression of the genes of interest was normalized to 
18S (reference gene) amplification and calculated according to  Equation (2)
13
 and expressed 
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as a fold induction or reduction relative to solvent (without tumor necrosis factor alpha 
(TNFα)), unless otherwise stated (see figure legends).  
                     
 
  
     
 
 (5) 
 
                          
                                                                
                                                                  
 (6) 
 
3.5. Statistical analysis 
Statistical analysis throughout this study was conducted using the GraphPad Prism software, 
Version 5. Specifics of the statistical analyses used, including post-tests, are detailed in the 
figure legends. The extent of the statistical significance is indicated using numerical symbols 
(e.g. *, # and $), with the approximate value of these symbols also indicated in the figure 
legends. Non-significant results are indicated by ‘ns’. 
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Table 3.1: Plasmids used throughout this study 
  Plasmid Description Kind gift from Reference 
H
u
m
a
n
 
pRS-hGRα (hGRwt) Human wild type GRα 
Prof. R. Evans, Salk Institute for Biological Studies, 
California, USA 
14  
pHisGRA458T (hGRdim) 
GRα dimerization deficient mutant with single mutation of alanine to a threonine (at amino acid 
458) in D-loop 
Prof. K. De Bosscher, University of Ghent, Belgium.  2 
hGR(N454D/A458T) 
GRα mutant with two mutations, within the D-loop at amino acid 458 and flanking the D-loop at 
454 Prof. A. Cato, Institute of Toxicology and Genetics 
(ITG), Germany. 
15  
hGR(D4X) 
GRα mutant containing the A458T mutation and 3 other mutations, nearby, thought to be important 
for GRα dimerization 
15  
hGRα(R477H) A naturally occurring GRα mutant known to cause generalized GC resistance 
Prof. R. Kofler, Innsbruck Medical University, 
Austria. 
16  
pEGFP-C2-GR 
(GFP-hGRwt) 
Green Fluorescent-tagged (GFP) human wild type GRα Prof. S Okret, Karolinska Institute, Sweden 17 
pEGFP-C2-GRA477T 
(GFP-hGRdim) 
Green Fluorescent-tagged (GFP) GRα dimerization deficient mutant with single mutation of alanine 
to a threonine (at amino acid 458) in D-loop 
Prof. S Okret, Karolinska Institute, Sweden 17 
M
o
u
se
 
pcDNA-mGRwt Mouse wild type GRα 
Prof. S. Bodine, University of California, Davis, USA. 18  pcDNA-mGR(A458T) 
(mGRdim) 
GRα dimerization deficient mutant with single mutation of alanine to a threonine (at amino acid 
458); homologous to hGRdim 
O
th
e
r HA-tagged Ubiquitin Ubiquitin plasmid for overexpression ubiquitin  
Prof. D Bohmann, AAB Institute of Biomedical 
Sciences, New York, USA. 
19  
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Table 3.2: Details of transfection conditions  
 
Type of 
dish
Cell type
Cell number 
(cells/well)
Transient 
transfection
Transfection agent 
Amount of pDNA 
(ng/well)
Plasmid transfected Experiment Chapter Figure O ther 
COS-1 5 x 10
4 
Yes XTremeGENE HP 200 hGRwt WCB 4 4.3 -
COS-1 5 x 10
4 
Yes Fugene 6 200 hGRwt WCB 4 4.4  and 4.5A -
COS-1 5 x 10
4 
Yes XTremeGENE HP 200
hGRwt, hGR(R477H), 
hGRdim(N454D/A458T), 
hGRdim (D4X), mGRwt and 
mGRdim
WB 5 5.18A and B -
COS-1 5 x 10
4 
Yes XTremeGENE HP 400 hGRdim WB 5 5.18A -
MEF-mGRwt and 
MEF- mGRdim
5 x 10
4 
No - - - WCB 6 6.1 and 6.2 -
COS-1 5 x 10
4 
Yes Fugene 6 400 hGRdim WCB 4 4.5C -
COS-1 5 x 10
4 
Yes Fugene 6 400 hGRwt WB 4
4.5B, 4.7A and B, 
4.8A and B
-
COS-1 5 x 10
4 
Yes Fugene 6 800 hGRdim WB 4
4.5D, 4.7A and C, 
4.8A and C
-
COS-1 5 x 10
4 
No - - - WB 4 4.9A -
HepG2 5 x 10
4 
No - - - WB 4
4.5D, 4.7D, 4.8D 
and 4.9B
-
COS-1 1 x 10
5 
Yes Fugene 6 400 hGRwt WB 5 5.4A -
COS-1 1 x 10
5 
Yes Fugene 6 800 hGRdim WB 5 5.4B -
HepG2 1 x 10
5 
No - - - WB 5 5.4C and D -
COS-1 1 x 10
5 
Yes XTremeGENE HP 400 hGRwt WB 5 5.5B -
MEF-mGRwt and 
MEF- mGRdim
1 x 10
5 
No - - - WB, cDNA synthesis and RT-PCR 6
6.4, 6.5, 6.6, 6.7, 
6.8, 6.9 and 6.10
-
COS-1 1 x 10
6 
Yes XTremeGENE HP 3000 hGRwt Co-IP and WB 5
5.5C, 5.5D, 5.5E 
and 5.5F
-
COS-1 1 x 10
6 
Yes XTremeGENE HP 300 HA-tagged ubiquitin Co-IP and WB 5  5.5F -
COS-1 1 x 10
6 
Yes XTremeGENE HP 3000 hGRwt Immunofluoresence and PLA 5
5.6A and B, 5.8A 
and B, 5.9A and 
B, 5.10A and B, 
5.12A and B, 
5.13A and B
COS-1 cells were 
replated into 8 well 
chambers (3 x 10
4 
cells/well), 24 hours after 
transfection and before 
compound treatment.
COS-1 1 x 10
6 
Yes XTremeGENE HP 3000 GFP-hGRwt and GFP-hGRdim  PLA 5
5.14, 5.15, 5.16 
and 5.17
COS-1 cells were 
replated into 8 well 
chambers (3 x 10
4 
cells/well), 24 hours after 
transfection and before 
compound treatment.
8 well 
chamber
COS-1 3 x 10
4 
Yes XTremeGENE HP 200 hGRdim Immunofluoresence and PLA 5
5.7A and B, 5.8A 
and C,, 5.9A and 
C, 5.11A and B, 
5.12A and C, 
5.13A and C
COS-1 cells were directly 
transiently transfected 
into 8-well chamber and 
not re-plated.
24 well
12 well
10 cm
* Whole cell Grαbinding (WCB), Western blotting (WB), co-immunoprecipitation (Co-IP) and Proximity-Ligase Assay (PLA)
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Table 3.3: Antibodies used throughout this study 
Target protein Size (kDa) 
Target 
species 
Primary antibody (1⁰) 1⁰ antibody dilution Secondary antibody (2⁰) 
2⁰ antibody 
dilution 
Application 
GRα 
97 All human sc-8992a 1:1000 Goat anti-rabbit IgG-HRP, sc-2030a 1:10 000 Western blotting 
94 All mouse sc-8992a 1:1000 Goat anti-rabbit IgG-HRP, sc-2030a 1:10 000 Western blotting 
97 Human Ab2768b 1:500 
Goat Anti-Mouse IgG H&L (Alexa Fluor® 
594) (ab150116) b 
1:500 Immunofluorescence  
97 Human Ab2768b 1:500 Duolink kita - PLA  
GAPDH  37 
Human and 
mouse 
sc-47724a 1:500 Goat anti-mouse IgG-HRP, sc-2005a 1:5000 Western blotting 
pSer404-GRα 97 Human Gift from J.Cidlowskic 1:500 Goat anti-rabbit IgG-HRP, sc-2030a 1:10 000 Western blotting 
p53 53 Monkey #2524d 1:1000 Goat anti-mouse IgG-HRP, sc-2005a 1:5000 Western blotting 
TSG101 55 Monkey ab83b 1:500 Goat anti-mouse IgG-HRP, sc-2005a 1:5000 
Co-immunoprecipitation and 
Western blotting 
CHIP/STUB1 35 Monkey ab168768b 1:500 Goat anti-mouse IgG-HRP, sc-2005a 1:5000 
Co-immunoprecipitation and 
Western blotting 
Anti-HA tag 
(ChIP grade) 
- - ab9110b 1:1000 Goat anti-rabbit IgG-HRP, sc-2030a 1:10 000 
Co-immunoprecipitation and 
Western blotting 
Ubiquitin 
8 Monkey ab7780b 1:200 
Goat Anti-Rabbit IgG H&L (Alexa Fluor® 
488) (ab150077) b 
1:500 Immunofluorescence  
8 Monkey ab7780b 1:200 Duolink kita 1:500 PLA  
FBXW7α 
79 Monkey ab109617b 1:500 Goat anti-rabbit IgG-HRP, sc-2030a 1:5000 
Co-immunoprecipitation and 
Western blotting 
79 Monkey ab109617b 1:500 
Goat Anti-Rabbit IgG H&L (Alexa Fluor® 
488) (ab150077) b 
1:500 Immunofluorescence  
79 Monkey ab109617b 1:500 Duolink kita - PLA  
a Santa Cruz, USA. b Abcam, USA. c National Institute of Environmental Health Sciences, USA. d Cell Signalling, USA. 
  
  
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 94 
 
Table 3.4: Other reagents used throughout this study 
Reagent  Application Catalogue number 
Final 
concentration 
MG132 Proteasome inhibitor M7449 a 1 μM 
CHX Translation inhibitor C4859 a 1 μM 
BIO GSK3β inhibitor 361550 b 5 μM 
TNFα Pro-inflammatory cytokine T7539 0.02 μg/ml 
a Sigma Aldrich, South Africa. b Merck, Germany. 
  
 
Table 3.5: Target sequences of siRNA ‘cocktail’ for TSG101 knockdown 
Product name Catalogue number Target sequence 
TSG101_6 a SI02664529 ACCCGTTTAGATCAAGAAGTA 
TSG101_7 a SI02664522 CAGCTGAGGGCACTAATGCAA 
TSG101_8 a SI02655184 CAGTTTATCATTCAAGTGTAA 
TSG101_12 a SI04437398 ATGGTTACCCGTTTAGATCAA 
a Qiagen, Germany. 
  
Table 3.6: Primers used throughout this study 
Species Gene Protein 5'-3' Forward primer sequence 5'-3' Reverse primer sequence 
Optimized annealing 
Temperature (ᵒC) 
Product 
size 
Primer 
efficiency 
Mouse Nr3c1 GRα AAA GAG CTA GGA AAA GCC ATT TCA GCT AAC ATG TCT GGG AAT TCA 55 182 2.18 
Mouse Tsc22d3 GILZ AAT GCG GCC ACG GAT G GGA CTT CAC GTT TCA GTG GAC A 56 166 1.87 
Mouse Tat TAT TCG GCT CTG CTG GAG GCA CT TCT ACC GCA GGG CGT GAG GT 55 289 1.91 
Mouse Fkbp5 FKP51 GCTGGCAAACAACACGAGAG GAGGAGGGCCGAGTTCATT 58 107 1.91 
Mouse Il6 IL-6 ATGCTGGTGACAACCACGGCC AGCCTCCGACTTGTGAAGTGGA 55 189 1.94 
Mouse Rn18s 18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 55 151 1.9 
*All primers were designed using NCBI and then purchased from Integrated DNA Technologies (USA) 
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Chapter 4:   
Receptor dimerization is a requirement for 
ligand-induced down-regulation of GRα 
4.1 Introduction  
Synthetic GCs continue to be the preferred therapeutics for the treatment of diseases associated with 
chronic inflammation, however, these prolonged GC treatment regimens are continuously 
confronted by two major limitations, namely, the generation of undesirable side-effects and the 
development of an acquired resistance to GC treatment
1–5
. 
Considering that 1 – 2% of the global population is currently receiving long-term, high dose GC 
treatment, and that a 34% increase in the incidence of GC treatment was noted between 1989 and 
2008, these limitations (i.e. undesirable side-effects and acquired GC resistance) have major 
implications for the pharmaceutical industry
6–8
. These implications include: increased morbidity 
rates, an increase in financial costs and concomitant economic impact (treating adverse side-effects 
and providing higher GC doses to overcome resistance) and overall, a poorer quality of life for the 
patients
6,8–10
.  
Over recent years, research has focused on investigating and developing SGRMs, which in essence 
aim to maintain a potent anti-inflammatory potential whilst having an improved side effect profile, 
and a number have been used in clinical trials
11,12
. Whilst SGRMs are proving somewhat successful 
in curbing the generation of undesirable side-effects
13–16
, there is still the lingering issue of 
developing acquired resistance to GC treatment following prolonged GC use.  
Perturbations in the ‘functional pool’ of GRα protein may result in resistance, both inherited and 
acquired. Many studies have demonstrated a direct correlation between the ability of a patient to 
respond to GC treatment and the amount of functional GRα protein17–19. The amount of functional 
GRα protein (‘functional pool’) may be altered at a functional level (i.e. GRα gene mutations) or at 
an expression level (i.e. the level of the ‘pool’ or how much is available in the ‘pool’)20–24. 
Fundamental to the current study, is the latter, changes in the level of the ‘pool’, which broadly 
refers to an increase or decrease in GRα protein expression. A reduction in GRα protein expression 
may lead to acquired GC resistance, a major limitation encountered in treating chronic 
inflammation, and thus it is necessary to understand the factors affecting GRα protein down-
regulation.  
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Regulation of protein expression may be described by a simple ‘push’ vs. ‘pull’ mechanism, which 
refers to the dynamic state of protein synthesis and degradation, respectively, working together to 
regulate cellular protein levels, such as those of the GRα protein (Fig. 4.1). The ‘push’ is governed 
by two processes, namely, transcription and translation, whilst the ‘pull’ is defined by protein 
degradation pathways, such as lysosomal and ubiquitin-proteasome mediated degradation (Fig. 4.1).  
 
Figure 4.1: General regulation of protein ‘pool’ described by a simple ‘push’ vs. ‘pull’ mechanism. 
Honing in on GRα, the focus of the current study, one can assume that disturbing this dynamic state 
of regulation (i.e. the ‘push’ vs. ‘pull’ mechanism), will most likely result in altered GRα mRNA 
and/or GRα protein expression (Fig. 4.2). One of the ways in which the dynamic state of regulation 
may be perturbed is through binding of certain cognate GRα ligands to GRα and several studies 
have indeed shown that treatment with GCs, particularly Dex, results in altered, predominantly 
reduced, GRα expression at both the mRNA and protein level25–33.  
 
Figure 4.2: Specific regulation of the GRα protein ‘functional pool’, described by a simple ‘push’ vs. ‘pull’ 
mechanism. 
Firstly, at the mRNA level, Dex treatment has been shown to reduce both nascent and mature GRα 
mRNA expression, by altering GRα gene transcription and affecting mRNA stability, 
respectively
30,34–38
. Interestingly, the effect of Dex treatment on GRα mRNA expression is 
somewhat conflicting and a number of studies have reported GRα mRNA up-regulation, following 
Dex treatment
39,40
. Secondly, at the protein level, it is well accepted that Dex treatment results in 
down-regulation of the GRα protein22,28–30,32,41,42. Dex treatment results in a robust reduction in GRα 
protein expression, directly reducing the ‘functional pool’ of GRα available to perform its 
biological function. Although it is well accepted that the rate of GRα protein down-regulation is 
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increased following Dex treatment, basal GRα protein down-regulation of the unliganded receptor, 
which occurs at a significantly slower rate, should not be disregarded
41
. 
Consistently, and in stark contrast to Dex treatment, a number of studies have shown that CpdA, a 
SGRM, does not result in GRα down-regulation at either the mRNA or protein level30,32. 
Furthermore, following treatment with CpdA, the GRα protein is reported to have a half-life similar 
to that of the unliganded GRα protein30,41. Interestingly, CpdA does not result in GRα dimerization, 
in contrast to Dex treatment
33,43
, which hints at a possible role for ligand-induced GRα dimerization 
in ligand-induced GRα protein down-regulation. 
These thought provoking effects of CpdA treatment on GRα dimerization and GRα down-regulation 
provided a concrete platform for the current study, which investigated the effect of ‘gain’ or ‘loss’ 
of GRα dimerization on ligand-induced GRα protein down-regulation. It was hypothesised that 
‘gain’ of GRα dimerization following Dex treatment of the human wild type GRα (hGRwt) would 
lead to GRα protein down-regulation. In contrast, ‘loss’ of dimerization, either as a result of CpdA 
treatment of hGRwt or through the use of a dimerization deficient mutant (hGRdim), would not 
result in ligand-induced GRα protein down-regulation. 
Broadly speaking, the current study started off by analysing how the ‘functional pool’ of GRα is 
altered by GC treatment by focussing on the type of ligand, concentration of ligand, treatment time 
and the relevance of GRα dimerization in ligand-induced receptor down-regulation. CpdA treatment 
was used as a molecular tool to abrogate dimerization of the wild-type GRα. In addition, the role of 
GRα dimerization in ligand-induced GRα protein down-regulation was confirmed using the 
dimerization deficient mutant, hGRdim
44
.  
Furthermore, process specific inhibitors were used to establish which process, the ‘push’ 
(transcription and translation) or the ‘pull’ (proteasomal degradation), is primarily responsible for 
regulating ligand-induced receptor turn over. Lastly, to rule out a possible direct and general effect 
of CpdA treatment on cellular protein turnover, the degradation of a short-lived tumour suppressor 
protein, p53, was investigated and compared in the absence and presence of CpdA
45
.  
A deeper understanding of the possible association between dimerization and down-regulation of 
GRα may provide more insight into GC resistance. Whilst ligand-induced GRα protein down-
regulation is thought to be an essential cellular function
17,30,33
, it may have pathological 
consequences in patients receiving high dose GC treatment for prolonged periods of time. 
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4.2 Results  
4.2.1 GRα protein down-regulation is ligand and dose-dependent 
It is fairly well documented that the synthetic GRα ligand, Dex, induces GRα protein down-
regulation in a number of cellular systems
22,27–32,42
, however, only a handful of studies have 
investigated the effect of prolonged treatment of F, the endogenous ligand for GRα32,46. 
Furthermore, most previous studies have evaluated effects at a single ligand concentration, which 
may drastically limit the interpretation of results. 
To explore differences between two GRα dimerization promoting ligands, Dex and F, and to 
substantiate previously reported effects on ligand-induced GRα protein down-regulation, COS-1 
cells transiently transfected with hGRwt were treated with Dex or F. Furthermore, to obtain 
additional information, like potency and efficacy, a dose-response (10
-11
M – 10-5M) experiment, at 
a single treatment time of 24 hours, was conducted. Potency (IC50) refers to the concentration (nM) 
of ligand required to reduce hGRwt protein expression by 50%, while the efficacy describes the 
percentage of maximal reduction of hGRwt expression. 
Both Dex (Fig. 4.3A; red) and F (Fig. 4.3A: green) treatment led to ligand-induced GRα protein 
down-regulation. Specifically, the efficacies for Dex and F were 41.3% and 45.5% (Fig. 4.3B), 
respectively, which translated into a 58.7% reduction in hGRwt expression after Dex treatment that 
was not significantly different from the 54.5% reduction induced by F treatment (Fig. 4.3D). A 
clear shift to the right was observed for the F graph, which was reflected in a significantly (p < 
0.01) 50-fold lower potency for F (20nM) when compared Dex (0.4nM) (Fig. 4.3C and D).  
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Figure 4.3: hGRwt protein down-regulation is ligand and dose-dependent. COS-1 cells were seeded into a 24 well 
plate (5 x 10
4
 cells/well) and transfected the next day with hGRwt using a transfection agent. Following 24 hours 
incubation, cells were treated with either solvent (EtOH) or varying concentrations (10
-11
 M to 10
-5
M) of Dex and F for 
24 hours. Thereafter, hGRwt protein expression was assessed by Western blotting where GAPDH was probed to ensure 
equal protein loading. The Western blot shown (A, inset) is representative of three independent experiments. For 
quantification (A), the intensity of the hGRwt and GAPDH bands was determined using UNSCANIT, the hGRwt 
expression was then normalised to GAPDH expression and expressed as a percentage (average ± SEM) of hGRwt 
expression in the presence of solvent (EtOH), which was set at 100% (dotted line). Physiological concentrations of Dex 
(red; 1-20 nM) and F (green; 10-50 nM) are indicated by shaded areas. Efficacy (B and D) and potency (C and D) of 
GCs for hGRwt down-regulation were determined. For statistical analysis, an unpaired t-test was used to evaluate the 
effects of ligands on the efficacy (ns, p > 0.05) and the potency (**, p < 0.01).  
A dose response curve also allowed for the evaluation of effects at a range of concentrations, such 
as the physiological concentrations of Dex (Fig 4.3A: red shaded area) or F (Fig 4.3A: green shaded 
area). In a physiological setting, it is clear that hGRwt protein down-regulation will occur. 
Specifically, free plasma F levels range from 10nM to 50nM during the circadian cycle in non-
stressed individuals
31,47,48
, which would correspond to a 15 – 39% reduction, while the free plasma 
Dex levels range from 1– 20 nM following a low dose administration49, which correlates with a 43 
– 60 % reduction in hGRwt expression. 
In order to eliminate the effect of ligand concentration in subsequent experiments, fractional 
occupancy (F.O) of hGRwt by Dex and F was calculated using Kd values (8nM and 91nM) from He 
et al.
50
 (Table 4.1). F.O refers to the fraction of ligand-bound receptors relative to the total receptor 
‘pool’, bound and unbound, and may be calculated using the following equation: 
                      
        
             
 
Table 4.1: Calculating the fractional occupancy of Dex and F for hGRwt 
Concentration 
(logM) 
Ligand 
concentration 
(nM) 
% F.O 
b
 of Dex for 
hGRwt 
% F.O 
b
 of F for 
hGRwt 
Fold 
difference 
c
 
-9 1 11 1 10 
 
8
a
 50 8 6 
-8 10 56 10 6 
 
91
a
 92 50 2 
-7 100 93 52 2 
-6 1000 99 92 1 
-5
d
 10000 >99 99 1 
a  Kd values for Dex (8 nM) and F (91 nM) provided by He et al.50. b  Fractional occupancy was calculated using highlighted Kd values50 and equation 
above table and is expressed as a percentage. c The fold difference was calculated by dividing the percentage fractional occupancy for Dex by the 
percentage fractional occupancy for F. d The ligand concentration used in subsequent experiments to ensure > 99% fractional occupancy for both GRα 
ligands. 
 
To ensure comparable F.O of the hGRwt, saturating concentrations of Dex and F (10 μM), which 
corresponded to a F.O of ≥ 99% for both ligands, was used in subsequent experiments. 
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In summary, hGRwt protein expression was markedly down-regulated by the dimerization 
promoting GCs, Dex and F, which resulted in a decrease in the level of the ‘functional pool’ of 
GRα. Results represented in Fig. 4.3 highlight that GRα protein down-regulation is ligand- and 
dose-dependent, occurring over a wide range of GC concentrations, including the physiological 
ranges of the GCs tested. Additionally, in both cases (cells treated with Dex and F) GRα down-
regulation is observe when the F.O is around 10%. 
4.2.2 Rate of GRα protein degradation is altered in a ligand-selective manner  
The extent of GRα protein down-regulation is ligand and dose-dependent (Fig. 4.3), however, 
previous studies have suggested that the unliganded GRα protein also undergoes degradation, and 
that GC treatment, especially with dimerization promoting GCs, such as Dex and F, accelerates the 
rate of GRα protein turnover26,28,34,51. In contrast, treatment with CpdA, which abrogates 
dimerization
33,43
, induces minimal receptor turnover, with a degradation rate comparable to 
unliganded GRα32.  
To analyse and compare unliganded and liganded GRα protein down-regulation over time (2 – 72 
hours), COS-1 cells transiently transfected with hGRwt, were treated with solvent (EtOH), Dex, F 
or CpdA (10 μM). To determine, differences in hGRwt protein down-regulation induced by ligands 
over time, half-life (t½) and rate constant (K) values were calculated. The rate constant, K 
(cpm/hour), a measure of the reduction in hGRwt protein per hour, was used to calculate the half-
life (hours), which refers to the time required for a 50% reduction in hGRwt protein expression 
following treatment and was calculated using the following equation: 
     
      
 
 
From the results, it is clear that the unliganded hGRwt protein was degraded in a time-dependent 
manner (Fig. 4.4A) and has a half-life of 70 hours (Fig. 4.4B). Furthermore, the dimerization 
promoting GCs, Dex and F, significantly (p < 0.01) increased receptor turnover (Fig. 4.4A), 
resulting in a decreased half-life of hGRwt of 21 and 22 hours, respectively (Fig. 4.4B). For both 
GCs, maximal hGRwt protein down-regulation was reached following 48 hours of treatment. 
Unlike Dex and F treatment, hGRwt protein down-regulation seemed to be virtually absent 
following treatment with the dimerization abrogating SGRM, CpdA (Fig 4.4A). 
The K values indicated a significant (p < 0.001) increase in the rate of hGRwt protein degradation, 
from 0.01 cpm/hour
 
for the unliganded receptor, to 0.03 cpm/hour following Dex and F treatment 
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(Fig. 4.4C). On the other hand, a decrease in the rate of hGRwt protein down-regulation was 
observed following CpdA treatment (0.004 cpm/hour) (Fig. 4.4A). 
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Figure 4.4: Rate of hGRwt protein degradation is altered in a ligand-selective manner. COS-1 cells were seeded 
into a 24 well plate (5 x 10
4
 cells/well) and transfected the next day with hGRwt using a transfection agent. Following 
24 hours incubation, cells were treated with solvent (EtOH) or the GCs, Dex or F, or CpdA (10
-5
M) for 2 to 72 hours. 
Thereafter, whole cell GRα-binding (A) was conducted using 20nM [3H]-Dex. Once lysed, hGRwt expression was 
detected via a scintillation counter and specific binding values (cpm) were plotted against time. Whole cell GRα-
binding results shown are representative of four independent experiments (average ±SEM), conducted in triplicate. 
Statistical analysis was conducted using a two-way analysis of variance (ANOVA) followed by a Bonferroni post-test 
comparing each time point to solvent (EtOH) (ns, p > 0.05, *, p < 0.05, **, p < 0.01, ***, p < 0.001). Half-lives (B) and 
rate constants (C) were calculated using non-linear regression one-phase dissociation decay analysis. For statistical 
analysis of rate constants, one-way ANOVA followed by a Bonferroni’s post-test was conducted comparing K 
(cpm/hour) values to solvent (EtOH) (ns, p > 0.05, ***, p < 0.001). 
To summarize, the unliganded hGRwt protein underwent basal down-regulation. Moreover, the rate 
of receptor turnover increased and the half-life of the hGRwt protein decreased, relative to the 
unliganded hGRwt, following treatment with the dimerization promoting GCs, Dex and F, but not 
the dimerization abrogating SGRM, CpdA. 
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4.2.3 GRα dimerization is required for down-regulation of the GRα protein  
So far, the current study has established that the extent (Fig. 4.3) and rate (Fig. 4.4) of hGRwt 
protein down-regulation is ligand-selective. Of note was the ability of CpdA treatment to abrogate 
basal hGRwt degradation (Fig. 4.4), in agreement with its previously published ability to preserve 
receptor expression relative to the unliganded GRα30–32. This characteristic of CpdA treatment, 
combined with its capacity to prevent or even abrogate
33,43
 GRα dimerization, sparked interest in a 
possible role for GRα dimerization in ligand-induced receptor down-regulation. 
To determine the effects of ‘gain’ or ‘loss’ of GRα dimerization on GRα protein down-regulation, 
both hGRwt (capable of forming dimers following treatment with GR agonists) and hGRdim, a 
dimerization deficient mutant
44
, were evaluated in COS-1 cells, in the presence of dimerization 
promoting (Dex or F) or abrogating (CpdA)
33,43
 GRα ligands. In addition, the effect of ‘loss’ 
(CpdA) or ‘gain’ (Dex and F) of GRα dimerization on hGRwt protein down-regulation was 
confirmed in HepG2 cells, containing endogenous human GRα (hGRα). In each figure, whole cell 
GRα-binding (Fig.4.5A and C) and Western blotting (Fig.4.5E), the values for unliganded GRα at 
each time point was set at 100% and represented by a dotted line (i.e. liganded GRα expression was 
normalised to unliganded GRα at each time point). This explains why the unliganded receptor 
degradation observed in Fig.4.4A is not apparent in these figures. 
‘Gain’ of hGRwt dimerization via dimerization promoting GCs, Dex and F (10 μM), induced a 
significant (p < 0.001) reduction in hGRwt protein expression over time (Fig. 4.5A and B). To 
validate the findings obtained with transiently transfected hGRwt, the effect of Dex and F treatment 
on endogenous hGRα protein expression was evaluated in HepG2 cells, which also showed 
significant (p < 0.05) reduction in receptor expression (Fig. 4.5E). Specifically at 24 hours, Dex and 
F treatment reduced the ‘pool’ of transiently transfected hGRwt to a mere 38 and 46% of the 
unliganded GRα (100%), respectively (Fig. 4.5A and B), while similarly, but slightly less robustly, 
endogenous hGRα protein expression in HepG2 cells was reduced to 52% and 69%, respectively 
(Fig. 4.5E). Furthermore, transiently transfected hGRwt protein expression was further reduced to 
18% and 23% with Dex and F, respectively, reaching a maximum reduction in receptor expression 
after 48 hours (Fig. 4.5A and B). 
In stark contrast, ‘loss’ of GRα dimerization through the use of hGRdim resulted in no significant 
reduction of hGRdim protein expression, following Dex and F (10
 μM)  treatment (Fig. 4.5C and 
D). In support of the hGRdim result, CpdA treatment, known to abrogate GRα dimerization33,43, of 
the hGRwt did not result in a reduction in hGRwt protein expression (Fig.4.5A and B). In addition, 
due to the lack of an endogenous dimerization deficient mutant in the HepG2 cells, CpdA treatment 
was used as a molecular tool to mimic the effect of ‘loss’ of dimerization33,43 (Fig. 4.5E). As with 
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the transiently transfected hGRwt, CpdA treatment did not lead to down-regulation of the 
endogenous hGRα protein (Fig. 4.5E).  
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Figure 4.5: GRα dimerization is required for ligand-induced GRα protein down-regulation. COS-1 cells were 
seeded into a 24 well plate (5 x 10
4
 cells/well) and transfected the next day with hGRwt (A and B) and hGRdim (C and 
D), using a transfection agent. Following 24 hours incubation, cells were treated with Dex, F or CpdA (10
-5
M) for 2-72 
hours. Thereafter hGRwt (A) and hGRdim (C) expression was monitored via whole cell GRα-binding, using 20nM 
[
3
H]-Dex. Whole cell GRα-binding results shown are representative of five independent experiments (average ± SEM), 
conducted in triplicate. In the graphs, the dotted line represents GRα (hGRwt or hGRdim) expression in presence of 
solvent (EtOH) and is set at 100%. Statistical analysis for (A) and (C) was conducted using a two-way ANOVA 
followed by a Bonferroni post-test comparing experimental values to solvent (EtOH) (ns, p > 0.05, **, p < 0.01, ***, p 
< 0.001) or to Dex (
##
, p < 0.01, 
###
 p < 0.001). GRα protein expression, hGRwt (B) and hGRdim (D) were confirmed by 
Western blotting. The 24 hour treatment time point was repeated, with all ligands, in the HepG2 cells (containing 
endogenous hGRα) (E, inset), which were seeded into a 12 well plate (5 x 104 cell/well). GRα expression was assessed 
using Western blotting where GAPDH was probed to ensure equal protein loading. Western blots shown are 
representative of three independent experiments. For quantification (E), the intensity of the hGRα and GAPDH bands 
was determined using UNSCANIT and hGRα levels were then normalised to GAPDH expression and expressed as a 
percentage (average ± SEM) of hGRα expression in presence of the solvent (EtOH), which was set at 100% (dotted 
line). Statistical analysis for (E) was conducted using a one-way ANOVA with a Dunnet post-test comparing 
experimental values to solvent (EtOH) (*, p < 0.05, ***, p< 0.001).  
To our knowledge, this is the first time that the ability of the hGRdim to undergo ligand-induced 
down-regulation has been investigated and collectively, the results obtained in the current study 
strongly suggest that the dimerization state of the GRα protein is important for its efficient ligand-
induced turnover. Thus ‘loss’ of GRα dimerization through monomer favouring GRα (i.e. hGRdim 
and CpdA treated hGRwt), in contrast to ‘gain’ of GRα dimerization (i.e. Dex or F treated hGRwt), 
may be evading molecular mechanisms involved in regulating ligand-induced receptor turnover. 
Despite the fact that it was clear that the conformation of the receptor (dimer versus monomer) 
affected the sensitivity to the ligand- induced reduction of the ‘functional pool’ of GRα protein, it 
was not yet clear from these results at which level: ‘push’ or replenishment (protein synthesis) 
versus ‘pull’ or depletion (protein degradation), respectively, ‘loss’ of GRα dimerization exerted its 
effects. 
4.2.4 ‘Push’ versus ‘pull’ mechanism 
Cellular protein expression is maintained through a dynamic state of synthesis and degradation, 
which may be described by a simple ‘push’ versus ‘pull’ mechanism (Fig.4.1). Specifically for the 
GRα, the ‘push’ involves transcription of the GRα gene (NR3C1)52,53 to produce GRα mRNA and 
the subsequent translation of this GRα mRNA to form the GRα protein (Fig.4.2). The GRα protein 
may then be subjected to degradation (‘pull’), which a number of studies have suggested occurs via 
the proteasome
22,28,29,54
 (Fig.4.2).  
Having established a role for GRα dimerization in ligand-induced GRα protein down-regulation, it 
seemed necessary to delve deeper, in an attempt to elucidate at what level, transcription, translation 
or degradation, ‘loss’ of GRα dimerization was preventing down-regulation and maintaining the 
‘functional pool’ of GRα. To do this, two inhibitors, CHX and MG132 (1 μM), were used to inhibit 
translation and proteasomal degradation, respectively (Fig.4.6). Following treatment with the 
inhibitors, cells were treated with Dex, F or CpdA (10
 μM) and the effect of translational inhibition 
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by CHX (Fig.4.7) or proteasomal inhibition by MG132 (Fig.4.8) on ligand-induced GRα 
degradation determined. 
 
Figure 4.6: Specific regulation of GRα described by a simple ‘push’ vs. ‘pull’ mechanism, including the 
inhibitors used, CHX
55
 and MG132, to inhibit translation and proteasome degradation, respectively. 
4.2.4.1. Ligand-induced down-regulation of the GRα protein is unaffected by inhibiting new 
protein synthesis  
Previous studies have noted ligand-induced transcriptional and translational regulation of the 
GRα30,34,36–38,56,57, indicating that the ligand-bound GRα is able to down-regulate its own production 
by altering the expression of its gene, NR3C1. In addition, ligand-bound GRα may alter the stability 
of its mRNA
37
. Both of these scenarios result in a decrease in GRα mRNA, which may be reflected 
at the GRα protein level as a reduction in the GRα protein ‘pool’. When investigating the 
translational regulation of the GRα mRNA, one may look at the effects on the GRα mRNA or on 
the GRα protein ‘pool’ (Fig. 4.6). In the current study, it was decided to firstly investigate the 
effects of inhibiting translation, with CHX
55
, on the extent of ligand-induced GRα protein down-
regulation.  
To investigate the effects of inhibiting translation on ligand-induced GRα protein down-regulation, 
COS-1 cells, transfected with either hGRwt (Fig.4.7A and B) or hGRdim (Fig.4.7A and C), and 
HepG2 cells, containing endogenous hGRα (Fig.4.7D), were treated with solvent (EtOH), Dex, F or 
CpdA (10 μM) in the absence or presence of CHX. 
If there was significant regulation of the GRα ‘pool’ at the level of the ‘push’ (transcription or 
translation) one would expect less ligand-induced GRα protein down-regulation when translation 
was inhibited. On the other hand, if regulation at this level did not contribute significantly to the 
overall ligand-induced reduction in the ‘pool’ of receptor, the extent of ligand-induced GRα protein 
down-regulation would remain the same in the presence of CHX.  
As Figure 4.4 suggests, unliganded hGRwt underwent basal receptor turnover in the absence of 
CHX, thereby reducing the hGRwt protein ‘pool’. This effect was absent in Fig.4.7A and B because 
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the normalised hGRwt protein expression for the solvent (EtOH) in the absence of CHX (-CHX) 
was set at 100% and represented by a dotted line. To determine whether the GRα protein undergoes 
further down-regulation in the presence of CHX, unliganded hGRwt and hGRdim protein 
expression was assessed in the absence and presence of CHX. As Fig. 4.7A demonstrates, inhibiting 
translation with CHX, led to a further non-significant 15.8% reduction in hGRwt, but not hGRdim, 
protein expression. 
Having addressed the effect of translational inhibition on unliganded hGRwt and hGRdim protein 
down-regulation, the effect of CHX on ligand-induced GRα protein down-regulation was 
investigated. Important to note, however, GRα protein expression was normalised relative to 
unliganded GRα ‘pool’ in absence or presence of CHX, which was set at 100%. 
Firstly, the ability of dimerization promoting GCs Dex and F, to induce hGRwt or endogenous 
hGRα protein down-regulation was confirmed in the absence of CHX (Fig. 4.7B and D). Secondly, 
inhibiting translation with CHX had no significant effect on the level of Dex or F mediated hGRwt 
or endogenous hGRα protein down-regulation (Fig.4.7B and D). Specifically, Dex treatment 
reduced transiently transfected hGRwt protein expression to 62% and 64%, in the absence and 
presence of CHX, respectively (Fig. 4.7B). Likewise, following Dex treatment, endogenous hGRα 
protein expression was reduced to 51% and 60%, in the absence and presence of CHX, respectively 
(Fig. 4.7D). Almost identical results in the absence or presence of CHX were also observed for F 
via hGRwt and endogenous hGRα (Fig. 4.7B and D). 
In the case of a ‘loss’ of receptor dimerization, using transiently transfected hGRdim in the COS-1 
cells (Fig. 4.7C), or the molecular tool, CpdA treatment, for hGRwt and endogenous hGRα (Fig. 
4.7B and D), inhibiting translation, with CHX, had no significant (p > 0.05) effect on receptor 
protein expression. 
In conclusion, inhibiting translation had no significant effect on the extent of ligand-induced GRα 
protein down-regulation for hGRwt, hGRdim or the endogenous hGRα. Thus, these results provided 
reliable evidence that regulation of GRα protein expression via transcriptional and post-
transcriptional processes was negligible in the test systems, COS-1 and HepG2 cells, used in this 
study. At this point it was postulated that the majority of ligand-induced GRα protein down-
regulation was mediated via the ‘pull’ or post-translational processes (e.g. proteasomal 
degradation). 
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Figure 4.7: Ligand-induced GRα protein down-regulation is unaffected by new protein synthesis. COS-1 cells 
were seeded in a 12 well plate (5 x 10
4
 cells/well) and transfected the next day with either hGRwt (A and B) or hGRdim 
(A and C) using a transfection agent. Following 24 hours incubation, cells were treated with solvent (EtOH) or 1µM 
CHX for 1 hour and, in the absence (- CHX) or presence of CHX (+ CHX), with solvent (EtOH) or the compounds, 
Dex, F and CpdA (10
-5M), for a further 16 hours. GRα protein expression was assessed by Western blotting, where 
GAPDH was probed to ensure equal protein loading. The Western blots shown (B, C and D inset) are representative of 
three independent experiments. For quantification (A, B, C and D), the intensity of the GRα and GAPDH bands was 
determined using UNSCANIT and the GRα expression was then normalised to GAPDH expression expressed as a 
percentage (average ± SEM). Firstly, in the presence of solvent (EtOH), the effect of CHX (+ CHX) on unliganded GRα 
protein expression was investigated (A) and compared to GRα of expression in the absence of CHX (- CHX). 
Thereafter, the effect of CHX (+ CHX) on the extent of hGRwt (B), hGRdim (C) and endogenous hGRα (D) ligand-
induced down-regulation was investigated. The dotted line, in all graphs, represents GRα expression in the absence (- 
CHX) and/or presence of CHX (+ CHX) and in the presence of solvent (EtOH) and is set at 100%. To analyse the 
effects of the ligands on GRα expression in the absence (- CHX) and presence (+ CHX) of CHX, statistical analysis was 
conducted using a one-way analysis of variance (ANOVA) with a Bonferroni post-test comparing GRα expression post 
Dex, F and CpdA-treatment to the solvent (EtOH) (
#
, p < 0.05, 
###
, p< 0.001) (B, C and D). To evaluate the significance 
of adding CHX (+ CHX) on the extent of ligand-induced GRα protein down-regulation, a two-way ANOVA was used 
followed by a Bonferroni post-test (ns, p > 0.05) (B, C and D). 
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4.2.4.2. Ligand-induced down-regulation of the GRα protein occurs predominantly via the 
proteasome 
Ligand-induced GRα protein down-regulation was unaffected by inhibiting protein synthesis 
(‘push’). Worded differently, the effect of the ligand bound GRα on down-regulation of the GRα 
gene (NR3C1) and GRα mRNA stability appeared to be negligible in the test systems, COS-1 and 
HepG2 cells (Fig.4.7B, C and D), used. This result suggested that ligand-induced regulation of the 
‘functional pool’ of GRα most likely occurs predominantly at the level of the ‘push’ or proteasomal 
degradation. 
Indeed, there is strong evidence demonstrating that unliganded and ligand-induced GRα protein 
down-regulation occurs via a proteasome-dependent protein degradation pathway
22,28,29,54,58,59
. 
Thus, a possible role for the proteasome in mediating ligand-induced receptor turnover, in the test 
systems used in the current study, was investigated. 
To explore the role of the proteasome, the effects of inhibiting proteasomal degradation, with the 
proteasome inhibitor MG132, on ligand-induced GRα protein down-regulation was investigated. 
COS-1 cells, transfected with either hGRwt (Fig.4.8A and B) or hGRdim (Fig.4.8A and C), and 
HepG2 cells, containing endogenous hGRα (Fig.4.8D), were treated with solvent (EtOH), Dex, F or 
CpdA (10 μM) in the absence or presence of MG132.  
If GRα protein down-regulation occurs predominantly via the proteasome, one would expect that 
inhibiting proteasomal degradation with MG132 would prevent receptor turnover.  
Figure 4.4 suggests that unliganded hGRwt underwent basal receptor turnover in the absence of 
MG132, thereby reducing the protein ‘pool’ of hGRwt. To determine whether basal GRα protein 
down-regulation was mediated via the proteasome, unliganded hGRwt and hGRdim protein 
expression was assessed in the absence and presence of MG132 (Fig. 4.8A). Clearly, inhibiting 
proteasomal degradation, with MG132, resulted in a significant (p < 0.01) 5.6-fold increase in basal 
hGRwt expression and a non-significant 2.3-fold increase in basal hGRdim protein expression (Fig. 
4.8A), compared to in the absence of MG132. 
Having addressed the effect of proteasomal inhibition on unliganded hGRwt and hGRdim protein 
down-regulation, the effect on ligand-induced GRα protein down-regulation in the presence of 
MG132 was investigated. Important to note, GRα protein expression was normalised relative to 
unliganded GRα ‘pool’ in absence or presence of MG132, which was set to 100%.  
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Figure 4.8: Ligand-induced GRα protein down-regulation occurs predominantly via the proteasome. COS-1 cells 
were seeded in a 12 well plate (5 x 10
4
 cell/well) and transfected the next day with either hGRwt (A and B) or hGRdim 
(A and C) using a transfection agent. Following 24 hours incubation, cells were treated with solvent (DMSO) or 1µM 
proteasome inhibitor (MG132) for 1 hour and then, in the absence (- MG132) or presence of MG132 (+ MG132), 
treated with solvent (EtOH) or the compounds Dex, F and CpdA (10
-5
M) for 16 hours. GRα protein expression was 
assessed by Western blotting, where GAPDH was probed to ensure equal protein loading. The Western blots shown (B, 
C and D inset) are representative of three independent experiments. For quantification (A, B, C and D), the intensity of 
the GRα and GAPDH bands was determined using UNSCANIT and then the GRα expression was normalised to 
GAPDH expression and expressed as a percentage (average ± SEM). Firstly, the effect of MG132 (+ MG132) on 
unliganded GRα protein expression was investigated (A) and compared to GRα of expression in the absence of MG132 
(- MG132). Thereafter, the effect of MG132 (+ MG132) on the extent of hGRwt (B), hGRdim (C) and endogenous 
hGRα (D) down-regulation was investigated. The dotted line, on all graphs, represents the fold increase in GRα 
expression in the presence of solvent (EtOH) and/or absence of MG132 (- MG132) and is set at 1-fold or 100%. To 
demonstrate that the effects of ligands on GRα expression in the absence (- MG132) and presence (+ MG132) of 
MG132, statistical analysis was conducted using a one-way analysis of variance (ANOVA) with a Bonferroni post-test 
comparing to control (- MG132, EtOH) (n.s, p > 0.05; 
#
, p < 0.05; 
##
, p< 0.001). To analyse the significance of adding 
MG132 on the extent of ligand-induced GRα protein down-regulation, a two-way ANOVA was used followed by a 
Bonferroni post-test (ns, p > 0.05, **, p < 0.01, ***, p < 0.001).  
Firstly, the ability of dimerization promoting GCs, Dex and F, to induce hGRwt and endogenous 
hGRα protein down-regulation was confirmed in absence of MG132 (Fig. 4.8B and D). Secondly, 
inhibiting proteasomal degradation (i.e. in the presence of MG132) completely abolished Dex and F 
mediated hGRwt and endogenous hGRα protein down-regulation (Fig. 4.8B and D). Specifically, 
Dex treatment significantly (p < 0.01) reduced transiently transfected hGRwt protein expression to 
55% of the solvent (EtOH) treated hGRwt expression in the absence of MG132 but was unable to 
reduce hGRwt expression (97%) in the presence of MG132 (Fig. 4.8B). Likewise, following Dex 
treatment, endogenous hGRα expression was significantly (p < 0.01) reduced to 61% of the solvent 
(EtOH) in the absence of MG132 but in the presence of MG132, hGRα protein expression was 
similar (113%) to that of the solvent (EtOH) (Fig. 4.8D). An almost identical result was also 
observed for F via hGRwt and the endogenous hGRα (Fig. 4.8B and D).  
‘Loss’ of GRα dimerization using transiently transfected hGRdim in the COS-1 cells (Fig. 4.8C), or 
the molecular tool, CpdA treatment, for the transiently transfected hGRwt and endogenous hGRα 
(Fig. 4.8B and D), prevented ligand-induced receptor down-regulation in the absence MG132. 
Furthermore, blocking proteasomal degradation by MG132 did not significantly affect hGRdim 
expression (Fig. 4.8C) and following Dex treatment, hGRdim expression was maintained at 93% 
and 98%, in the absence and presence of the inhibitor, MG132, respectively (Fig. 4.8C). An almost 
identical result was observed following F treatment (Fig. 4.8C). In addition, transiently transfected 
hGRwt and endogenous hGRα expression was not significantly altered following CpdA treatment, 
whether in the absence or presence of MG132 (Fig. 4.8B and D).   
Lastly, it is important to note the absolute and significant (p < 0.05) difference between transiently 
transfected hGRwt expression following CpdA treatment in the absence (1.15-fold) and presence 
(6-fold) of MG132 (Fig. 4.8B inset), which was masked in Figure 4.8B. Furthermore, a slight but 
significant (p < 0.05) increase (5.6-fold versus 6-fold) was observed when comparing unliganded 
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and CpdA-treated hGRwt in the presence of MG132 (Fig. 4.8B inset). In contrast, when 
investigating the absolute difference between hGRdim protein expression following CpdA 
treatment in the absence (1.2-fold) and presence of MG132 (2.4-fold) (Fig. 4.8C inset) a 
considerably lower fold increase in receptor expression was noted. In addition no significant 
increase (2.3-fold versus 2.4-fold), relative to unliganded hGRdim (- MG132), was observed when 
comparing unliganded and CpdA-treated hGRdim in the presence of MG132 (Fig. 4.8C inset).  
In summary, the unliganded hGRwt, but not hGRdim, underwent significant basal protein down-
regulation, which was mediated by the proteasome. Furthermore, the ligand-induced (Dex and F) 
down-regulation of transiently transfected hGRwt and endogenous hGRα protein was abolished by 
the proteasome inhibitor, MG132. Additionally, inhibiting proteasomal degradation did not alter 
CpdA-treated hGRwt (Fig. 4.8B) or endogenous hGRα (Fig. 4.8D) protein expression nor did it 
affect Dex and F treated hGRdim (Fig. 4.8C) protein expression.  
Taken together, the last two figures (Fig.4.7 and 4.8) provide substantial evidence that the 
proteasomal degradation pathway plays a predominant role in orchestrating the turnover of the GRα 
protein. At this point, it was assumed that it was at this level of proteasome degradation that 
hGRdim and CpdA-treated hGRwt were evading degradation due to their monomeric-favouring 
GRα conformations. 
4.2.5 CpdA treatment does not affect proteasome function 
To rule out the possibility of a direct effect of CpdA treatment on proteasomal function, the 
degradation of the p53 protein was investigated in the absence and presence of CpdA. The p53 
protein is known to have a short half-life
56
, which has been reported to be between 3 and 22 hours 
in different cells
57
, and is degraded via the proteasome. If CpdA treatment was directly disrupting 
the proteasome function, one could assume that the p53 protein expression would not be reduced in 
the presence of CHX.  
COS-1 cells (Fig. 4.9A) and HepG2 cells (Fig. 4.9B), were treated with solvent (EtOH) or the 
translation inhibitor, CHX, to prevent new protein synthesis of p53. Subsequently, cells were 
treated with solvent (EtOH) or CpdA (10
 μM) and p53 expression analysed using Western blotting 
Inhibiting p53 protein synthesis, by blocking translation with CHX, resulted in a significant (p < 
0.05) reduction in p53 protein to 49% of expression in the absence of inhibitor, suggesting 
successful p53 protein turnover (Fig.4.9A). Similar results were seen in HepG2 cells (Fig. 4.9B). 
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Figure 4.9: CpdA treatment does not affect proteasome function. COS-1 (A) and HepG2 cells (B) were seeded in a 
12 well plate (5 x 10
4
 cells/well). Following 24 hours incubation, cells were treated with EtOH (solvent) or 1µM CHX 
for 1 hour and, in the absence (- CHX) or presence of CHX (+ CHX), with EtOH (solvent) or CpdA (10
-5
M) for 16 
hours. The p53 protein expression was assessed using Western blotting, where GAPDH was probed to ensure equal 
protein loading. The Western blots shown below the graphs (A and B inset) are representative of three independent 
experiments. For quantification, the intensity of the p53 and GAPDH bands was determined using UNSCANIT and 
subsequently the p53 expression was normalised to GAPDH expression and expressed as a percentage (average ± SEM) 
of p53 expression in the presence of solvent (EtOH), which is set at 100% (dotted line). To demonstrate the effects of 
CHX and CpdA on p53 expression, statistical analysis comparing all treated p53 protein expression to –CHX/EtOH 
(control) was conducted using a one-way analysis of variance (ANOVA) with a Bonferroni Multiple comparisons post-
test (ns, p > 0.05, *, p < 0.05, **, p< 0.01).  
 In the absence of CHX but in the presence of CpdA, p53 protein expression (107%) was 
comparable to solvent (EtOH) treated expression (100%), in the absence of CHX. Moreover, and 
most importantly, in the presence of CHX and CpdA, p53 protein expression was reduced to 36%, a 
reduction not significantly different from that of the solvent (EtOH) in the presence of the inhibitor. 
Similar results were seen in HepG2 cells (Fig. 4.9B). 
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Together, these results suggest that p53 was as efficiently degraded following CpdA treatment as in 
its absence, and confirmed that CpdA does not directly inhibit proteasome function but rather 
prevents GRα degradation by inducing a preferential monomeric conformation of the GRα. 
4.3 Discussion 
Overcoming inflammation, specifically in a number of autoimmune diseases, is gradually becoming 
more and more difficult. Currently, a number of challenges exist in managing chronic inflammation, 
but central to the current study is the development of GC acquired resistance.  
GC sensitivity is directly proportional to the “functional pool” of GRα available within a cell, tissue 
or individual
5,17–19,55. This GRα ‘functional pool’ may be affected by various factors, the focus of 
this study, however, is ligand-induced down-regulation of the GRα protein26,27,29,38,41–43,58.  
Although, the ability of certain ligands to alter the GRα ‘functional pool’ via autologous down-
regulation is well documented
26,27,29,38,41–43,58
, the factors (such as receptor conformation induced by 
cognate GRα ligands) that influence the extent of this ligand-induced receptor down-regulation are 
not entirely understood. 
In essence, the current chapter established a novel and fundamental role for ligand-induced receptor 
conformation (i.e. dimer vs. monomer) in determining the extent of receptor turnover. Using two 
simple concepts, namely ‘gain’ or ‘loss’ of GRα dimerization, this study cements a link between 
receptor dimerization and GRα protein down-regulation. 
The premise of a ‘loss’ of receptor dimerization preventing GRα protein turnover originated from 
two interesting, previously published, characteristics of the SGRM, CpdA. Specifically, that CpdA 
treatment does not lead to receptor turnover
30,32
 or dimerization
33,43
. In fact, CpdA had been shown 
to abrogate ligand-independent dimers
43
 resulting in a severe ‘loss’ of GRα dimers. These findings 
provided a platform from which this study was launched, which confirmed a role for GRα 
dimerization in receptor turnover. Throughout, the effects of a ‘loss’ of GRα dimerization, either 
ligand-induced (CpdA) or through use of a mutant (hGRdim), were compared to the effects of a 
‘gain’ of receptor dimerization on GRα protein turnover. 
Results comparing the ability of dimerization promoting (Dex and F) and dimerization abrogating 
(CpdA) ligands to mediate ligand-induced GRα protein down-regulation of the wild type receptor, 
hGRwt, yielded some interesting details with regards to the efficacy and potency of these ligands to 
induce receptor turnover but also provided results on the rate of degradation and consequent half-
life of the GRα protein, following prolonged GC treatment.  
Stellenbosch University  https://scholar.sun.ac.za
 116 
 
In agreement with previous published results
30,41,60
, ligand-induced ‘loss’ of receptor dimerization 
through dimerization abrogating CpdA treatment, did not lead to the same extent of GRα protein 
down-regulation as dimerization promoting, Dex and F treatment did in COS-1 cells transiently 
transfected with hGRwt (Fig. 4.4A, Fig. 4.5A and B) or in HepG2 cells (Fig. 4.5E) containing 
endogenous GRα. In fact the extent of down-regulation of the unliganded receptor was significantly 
greater than that of the CpdA treated hGRwt after 48 and 72 hours, respectively (Fig. 4.4A). This 
was reflected in the difference of the half-life values obtained for the unliganded and CpdA treated 
hGRwt where the current study reported a half-life for hGRwt of over 72 hours following CpdA 
treatment, which was slightly higher than that of the unliganded hGRwt (70 hours) (Fig. 4.4B). In 
contrast, Avenant et al.
41
 notes a slightly lower GRα half-life (42 hours) following CpdA treatment, 
relative to the unliganded receptor (44 hours).  
The half-life (70 hours) of the unliganded hGRwt determined in the current study (Fig. 4.4B) was 
higher than the unliganded GRα half-life reported by Avenant et al.41. It was also higher than the 
reported half-lives of unliganded GRα (between 16 - 22 hours) in studies using other cell lines, 
namely rat HTC cells
34
, U2OS osteosarcoma cells and A459 cells
61, and other GRα species (i.e. 
mouse/rat constructs or endogenous human GRα)27,28. This discrepancy may be attributed to the use 
of translation inhibitors such as doxycycline or CHX
27,28,34,61
, which were not used in this 
experiment in the current study.  
In stark contrast to CpdA, ligand-induced ‘gain’ of dimerization by dimerization promoting GCs, 
Dex and F, accelerated GRα protein down-regulation and led to an increase in the rate of receptor 
turnover and a reduction in the receptor half-life (Fig. 4.4B and C). Specifically, Dex and F 
treatment significantly increased the rate of hGRwt protein down-regulation by 3-fold, relative to 
the unliganded receptor turnover. In terms of half-lives, the absolute values of GRα half-lives (Fig. 
4.4B), following treatment with Dex (21 hours) and F (22 hours), in the current study, were 
considerably higher than previously reported values, which range from between 3 and 12 hours, 
post ligand treatment
26,27,34,42,61
. However, the 3.3- (Dex) and 3.5-fold (F) reduction, relative to the 
unliganded receptor, in the hGRwt protein half-lives obtained, corresponded well to the 4.4- (Dex) 
and 3.5-fold (F) reduction reported by Avenant et al.
41
. Furthermore, the 3.3-fold decrease noted in 
the hGRwt half-life after Dex treatment is comparable to additional studies, which suggested fold 
decreases of 2 to 3-fold. 
At saturating concentrations of the dimerization promoting GCs, Dex and F, no notable differences 
in their ability to induce maximal ligand-induced GRα protein down-regulation were observed (Fig. 
4.3B). However, a 50-fold difference in the potencies of Dex (0.4 nM) and F (20 nM) (Fig. 4.3C) to 
facilitate ligand-induced GRα protein down-regulation was revealed using a dose-response curve 
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(Fig. 4.3A). One could argue that this may be due to differences in the ligand binding affinities of 
these two GCs. Indeed Dex has been reported to have a considerably higher affinity than F for 
GRα50. Specifically in a study by He et al.50 Dex had an 11-fold higher affinity for the GRα than F, 
with Kd values for these GCs, determined as 8 and 91 nM, respectively (Table 4.2). This difference 
in the reported ligand binding affinities of Dex and F was not unforeseen as synthetic ligands have 
been designed to mimic and augment the biological action of endogenous GCs. However, this 
difference in affinity cannot be directly correlated to the difference in the potencies of these GCs to 
induce down-regulation because of a non-linear increase in the receptor F.O with increasing ligand 
concentrations (Table 4.1). Therefore to address this, the F.Os of hGRwt by Dex and F were 
calculated at a single ligand concentration (1 nM) and the difference observed in the F.Os was 
directly compared to the difference in the percentage of down-regulation observed at the same 
concentration of ligand (Table 4.2). Thus, treatment with ligands (1 nM) resulted in 11 and 1% of 
hGRwt occupied by Dex and F, respectively, which suggested an 11-fold higher occupancy of 
hGRwt by Dex at this single ligand concentration (Table 4.2). One would expect a consequent 11-
fold increase in the ability of Dex to induce hGRwt receptor turnover, however this was not the 
case. Treatment with Dex and F (1 nM) resulted in an 86 and 2% reduction in hGRwt protein 
expression, respectively (Table 4.2). Thus, a considerably larger 43-fold difference in the ability of 
Dex (1 nM) to induce receptor turnover, after treatment for 24 hours, was noted (Table 4.2).  
Table 4.2: Correlation of the extent of hGRwt protein down-regulation with fractional occupancy of Dex and F 
 
Dex F Fold difference
e
 
Kd (ligand binding nM)
a
 8 91 11 
IC50 (down-regulation nM)
b
 0.4 20 50 
% F.O at 1nM ligand concentration
c
 11 1 11 
hGRwt down-regulation at 1 nM (%)
d
 83 2 43 
a  Kd values for Dex (8 nM) and F (91 nM) provided by He et al.50. b The potency (IC50) values for hGRwt protein down-regulation mediated by either 
Dex or F from Figure 4.3. c Fractional occupancy at 1nM ligand concentration using Kd values50. d Percentage hGRwt protein down-regulation, 
relative to maximal down-regulation 100%, following ligand treatment (1 nM), for 24 hours. e The fold difference was calculated by dividing the 
values for Dex (first column) by the values for F (second column). 
One could postulate that at lower, non-saturating ligand (1 nM) concentrations Dex treatment 
resulted in a slightly different receptor conformation, when compared to that of F treatment, which 
resulted in a higher degree (‘gain’) of GRα dimerization that promoted in GRα protein down-
regulation thus explaining the augmented extent of down-regulation. This postulation is supported 
by findings that suggests that the GRα antagonist, RU486, is less capable of inducing GRα dimers62 
and also not as efficient as Dex at mediating receptor turnover
41
. In contrast, at saturating ligand 
concentrations (10 µM), one could assume that maximal Dex and F-induced receptor dimerization 
and consequent receptor turnover occurred, which is supported by the similar reported efficacies for 
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these GCs, in the current study. These findings seem to support a role for the extent of GRα 
dimerization in mediating receptor turnover, however, the current study did not directly compare 
the degree of GRα dimerization induced by Dex or F and correlate this to the extent of receptor 
turnover, but rather through the investigation of ligand-induced receptor turnover of a dimerization 
deficient mutant, hGRdim, elegantly confirmed a role for GRα dimerization in receptor turnover.  
‘Loss’ of dimerization, through the use of hGRdim (Fig. 4.5C and D), prevented the dimerization 
promoting ligands (Dex and F) from inducing receptor turnover, unlike with hGRwt (Fig. 4.5A and 
B) and the endogenous wild type hGRα (Fig. 4.5E). This novel finding reinforces the link between 
GRα dimerization and ligand-induced GRα protein down-regulation.  
With acquired resistance to GC treatment gaining traction and in many cases posing major clinical 
challenges in treating chronic inflammation, the elucidation, by the current study, of this role of 
receptor dimerization in receptor turnover provides novel molecular insights into areas (i.e. receptor 
conformation) which may be targeted in an attempt to reverse or counteract resistance. One could 
postulate, in the case of a ligand-induced ‘loss’ of GRα dimerization, that GC sensitivity may be 
restored through maintaining the receptor ‘functional pool’, as the ability of patients to respond to 
GC treatment has been associated with higher GRα protein expression1,17,19, however, extensive 
studies investigating responsiveness, in terms of GC responsive gene expression, would need to be 
conducted with dimerization abrogating GRα ligands. 
Throughout this study a high degree of reproducibility, as illustrated in Table 4.3, was maintained. 
In independent experiments, the percentage of hGRwt protein expression following ligand treatment 
for 24 hours, at saturating concentrations, ranged from 39 to 41% for Dex, 46 to 48% for F and 123 
to 124% for CpdA (Table 4.3). Specifically, the notable average reduction in hGRwt protein 
expression to 40% and 47%, following Dex and F treatment, respectively, was not unlike the 55% 
(Dex) and 60% (F) reduction in receptor expression observed by Avenant et al.
41
, using almost 
identical experimental conditions. These highly reproducible findings in the COS-1 cells were 
mirrored in the endogenous system, the HepG2 cells, where hGRα protein expression was reduced 
to 52% (Dex) and 69% (F) post-treatment with ligands (10 µM) (Table 4.3). In agreement with 
these findings, although marginally different, a study using LβT2 cells, containing endogenous GRα 
showed a similar ligand-induced decrease in endogenous GRα protein expression to 60% (Dex) and 
50% (F)
41
. Similar Dex and F mediated down-regulation of GRα has also been confirmed in a 
number of other test systems, under different treatment conditions
28,29
. This ability to produce such 
reproducible results with the wild type receptor, suggested a robust system in which the role for 
GRα dimerization in receptor turnover was established.  
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When investigating at what level, namely the ‘push’ or the ‘pull,  abrogation of receptor 
dimerization prevented GRα down-regulation, results in the current study, strongly implicated the 
proteasome in orchestrating reductions in the GRα ‘functional pool’ through ligand-induced 
(specifically dimerization promoting Dex and F) receptor degradation of transiently transfected 
hGRwt (Fig. 4.8B) and endogenous hGRα (Fig. 4.8D). With the use of a proteasome degradation 
inhibitor, MG132, Dex and F-induced receptor turnover (driven by a ‘gain’ of GRα dimerization) of 
hGRwt and endogenous hGRα was completely abolished, and receptor expression was maintained 
(Fig. 4.8B and D). These findings are in accordance with previous studies, which have suggested 
the GRα is degraded via a proteasome-dependent pathway22,28,29,54. Specifically, in COS-1 cells, 
transfected with wild type mouse or human GRα constructs28,29, as well as in GrH2 cells22, a rat 
hepatoma cell line,  and CHIP6B cells
63
, derived from mouse hippocampal cells. In the case of a 
‘loss’ of receptor dimerization via CpdA treatment of hGRwt (Fig. 4.8B) and endogenous hGRα 
(Fig. 4.8D) or use of hGRdim (Fig. 4.8C), receptor expression remained unaffected in the presence 
of the proteasome inhibitor. In addition, the possibility that CpdA had a direct inhibitory effect on 
the function of the proteasome was ruled out by investigating, for the first time, the effect of CpdA 
treatment on p53 turnover. 
Table 4.3: The percentage of GRα protein expression remaining after ligand treatment in different independent 
experiments 
Interestingly, down-regulation of unliganded hGRwt was also impeded in the presence of MG132, 
which suggested that basal receptor turnover is also mediated in a proteasome-dependent manner as 
is demonstrated by a 5.6-fold increase observed in the unliganded hGRwt protein expression in the 
presence of MG132 (Fig. 4.8A). These results are substantiated by a study from Yemelyanov et 
al.
64
 in which another proteasome inhibitor, bortezomib (BZ), was used with GRα transfected 
LNCaP cells, PC3 cells, D4541, PCa cells, CMET-T lymphoblastic leukaemia cells and NCEB 
mantle cell lymphoma cells
59,64
. Although a slight increase (2.3-fold) in unliganded hGRdim protein 
expression (Fig. 4.8A) was noted in the presence of MG132, this increase was significantly (p < 
  
% GRα expression remaining following ligand treatment 
  
COS-1 HepG2 COS-1 HepG2 COS-1 HepG2 
  
hGRwt hGRdim hGRα hGRwt hGRdim hGRα hGRwt hGRdim hGRα 
Fig. 
Time 
(hrs) 
Dex (10 μM) F (10 μM) CpdA (10 μM) 
4.3 24 41 - - 46 - - - - - 
4.4 24 39 - - 47 - - 123 - - 
4.5 24 39 118 52 48 107 69 124 133 122 
4.7 16 62 89 51 64 94 57 114 116 95 
4.8 16 55 93 61 56 107 69 115 124 102 
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0.05) less than that observed for unliganded hGRwt, which suggests that although basal turnover of 
hGRdim via the proteasome occurs, it is not as drastic as unliganded hGRwt protein turnover and is 
likely due to hGRdim’s impaired ability to form GRα dimers33,43. 
The fact that unliganded and ligand-induced GRα down-regulation relies on a dimeric form of the 
GRα and occurs predominantly via the proteasome, was supported by results obtained in the current 
study following translational inhibition, by CHX, which indicated that protein synthesis (i.e. ‘push’) 
did not affect the extent of receptor turnover. Moreover, any ligand-induced GRα protein down-
regulation occurring at the level of the ‘push’ was insufficient to significantly alter the extent of the 
receptor ‘functional pool’, in the current test systems, COS-1 and HepG2 cells. In terms of basal 
receptor turnover, a decrease in hGRwt protein expression but not hGRdim expression was noted in 
the presence of CHX (Fig. 4.7A). This was to be expected, as the ‘pool’ of hGRwt was no longer in 
a dynamic state of synthesis (‘push’) and degradation (‘pull’) but rather being subjected only to 
degradation and in addition highlighted the inability of the ‘pull’ or degradation process to act on 
the ‘pool’ of, predominantly monomeric, hGRdim protein.  
Taken together, the results in the current chapter propose that efficient degradation of the GRα 
protein relies on a dimeric conformation of the GRα (Fig. 4.10). Furthermore, results implicated the 
proteasome in regulating GRα protein expression, which suggests that the majority of ligand-
induced GRα down-regulation occurs at the level of the ‘pull’ with minimal regulation occurring at 
the ‘push’ level. Understanding at what level the ‘loss’ of GRα dimerization prevents receptor 
turnover, provides insight for future therapeutic drug development to combat chronic inflammation. 
Whilst dimerization promoting GCs may be efficient for short-term treatment, they gradually 
become ineffective during long-term treatment regimes, with a loss in responsiveness through a 
reduction in the receptor ‘functional pool’. Thus, one way to prevent the development of acquired 
GC resistance may be to design ligands, which fully or partially disrupt GRα dimerization and thus 
ultimately maintain receptor expression. These novel ligands could potentially be used alone or in 
combination with current potent anti-inflammatories, such as Dex, to reach and sustain desired 
therapeutic outcomes. In addition, understanding the role of receptor dimerization in ligand induced 
down-regulation could provide additional information when assessing congenital resistance to GC 
treatment, in patients with naturally occurring GRα mutations. 
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Figure 4.10: Ligand-induced ‘gain’ of GRα dimerization is a pre-requisite for efficient receptor turnover, which 
occurs predominantly via the proteasome. 
4.4 Conclusion 
Collectively, the initial results of the current study led to the discovery of a novel requirement for 
‘gain’ of GRα dimerization for effective ligand-induced GRα protein down-regulation. In addition, 
ligand-induced receptor turnover was found to occur predominantly via the proteasomal 
degradation pathway, while translational regulation by GRα ligands in the test systems used in the 
current study is negligible. Lastly, evidence was provided that rules out the possibility of a direct 
effect of CpdA on proteasome function. 
Taken together, results from the current chapter established an important factor for ensuring 
successful ligand-induced receptor turnover, namely GRα dimerization. These findings contribute 
to the understanding of one of the ways in which acquired GC resistance develops. This is 
particularly important as acquired GC resistance is gaining traction and hampering the battle against 
chronic inflammation. The level of GRα dimerization could potentially be exploited 
pharmacologically to overcome acquired GC resistance, however, a deeper understanding of the 
molecular mechanisms involved in the link between GRα dimerization and ligand-induced GRα 
protein down-regulation, is required. The next chapter delves deeper into these molecular 
mechanisms associated with proteasomal degradation.   
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Chapter 5:   
‘Loss’ of receptor dimerization modulates 
post-translational processing of the GRα and 
its turnover. 
5.1. Introduction  
The degradation of many intracellular proteins is mediated by the proteasome degradation pathway 
or UPS
1
. This system consists of a large number of components, which function collectively to 
ensure the highly specific nature of the UPS
1
. In general, proteins are tagged through covalent 
PTMs), which provide the signal for recognition by the catalytic proteasome that subsequently 
mediates the degradation of the protein substrates
1
 (Fig. 5.1).  
Figure 5.1: The GRα protein is post-translationally modified by PTMs such as phosphorylation (P) and ubiquitin 
(Ubq), leading to subsequent recognition and degradation by the proteasome, into inactive protein fragments. 
Like many other cellular proteins, both unliganded and liganded GRα undergoes a number of PTMs 
including acetylation, sumoylation, and particularly important for this study, phosphorylation (P) 
and ubiquitination (Ubq)
2–4
. These PTMs are known to modulate GRα activity and function at a 
number of levels, and essentially contribute to the extensive heterogeneity observed in GRα 
signalling
5
.  
Specifically, phosphorylation, the first identified
6
 and most common
7
 PTM, involves the covalent 
attachment of a phospho group to specific residues (i.e. serine and threonine) on a protein (i.e. GRα) 
by enzymes referred to as kinases
8. The GRα undergoes intense phospho-regulation, predominantly 
at several identified serine residues but it can also occur at other residues, such as threonine
9
 (Fig. 
5.2). One of the more recently discovered sites of GRα phosphorylation is of a serine residue at 
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amino acid position 404 (Ser404) in humans, which is mediated by a kinase known as glycogen 
synthase kinase 3β (GSK3β)8. It is thought that basal GRα phosphorylation at Ser404 occurs, but 
that treatment with certain ligands (e.g. Dex) induces hyper-phosphorylation of the receptor at this 
site
8
. Additionally, this ligand-induced hyper-phosphorylation at Ser404 has been shown to 
decrease overall GRα stability through priming the receptor for recognition by other UPS 
components, followed by additional tagging and subsequent proteasome degradation
8
. 
Figure 5.2: The domain structure of the human GRα and sites of post-translational modifications. A figure from 
Oakley et al.
10
 shows the N-terminal Domain (NTD, blue), the DNA-binding domain (DBD, green), the hinge region 
(H, yellow) and the ligand-binding domain (LBD, yellow). Represented (in red) are specific regions for activation 
domains (AF1 and AF2), the dimerization domain, the nuclear localization domain and the domain that regulates the 
interaction of GRα with Hsp90. Additionally, sites of PTMs are indicated for phosphorylation (P), sumoylation (S), 
ubiquitination (U) and acetylation (A). 
Often, PTMs occur in a sequential manner. It is thought that the PTM, ubiquitination, is dependent 
on preceding protein phosphorylation
1
. Unlike phosphorylation, ubiquitination of a protein requires 
a number of enzymes, with a hierarchy of specificity for the protein substrate, and occurs in a multi-
step manner
11
. Briefly, ubiquitin, a small (8kDa) regulatory protein, is activated in an energy 
dependent two-step process by constitutively active E1 activating enzymes
11
 (Fig. 5.3). Following 
activation of the ubiquitin molecule, a member of the second group of enzymes, termed E2 
conjugating enzymes, then bind the activated ubiquitin molecule and E1 activating enzyme complex 
(or intermediate) and mediate the transfer of the active ubiquitin to the E2 conjugating enzyme, 
forming a second intermediate
11
 (Fig. 5.3). Subsequently, the ubiquitination of a protein substrate is 
completed by E3 ligases, which are highly substrate specific. This step involves the binding of a 
specific E3 ligase to the protein substrate, which then mediates the transfer of the activated 
ubiquitin molecule from the E2 conjugating enzyme to a specific residue, often a lysine, on the 
substrate
11
. The binding of the highly specific E3 ligase to the target protein is thought to be 
mediated in both a ligand-independent and ligand-dependent manner
12
. This process is then 
repeated and once multiple rounds of ubiquitin conjugation have occurred and a poly-ubiquitin 
chain is generated, the substrate is recognised by the large catalytically active proteasome, which 
mediates the subsequent degradation of the substrate into inactive protein fragments (Fig. 5.3). 
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Figure 5.3: The ubiquitination of a substrate is a multi-step process (left) and results in proteasome degradation 
(right). A figure from Lee et al.
12
 shows the steps and enzymes involved during substrate ubiquitination. Ubiquitin 
(Ubq) is activated by an activating enzyme (E1), the activated ubiquitin molecule is then transferred to E2, a 
conjugating enzyme. E3 binds the substrate and the transfer of the activated ubiquitin molecule from E2 to the substrate 
occurs. This is repeated, until a poly-ubiquitinated chain is formed and then recognised and degraded by the 
catalytically active proteasome to produce inactive protein fragments. In some cases, proteins are de-ubiquitinated by 
de-ubiquitinating enzymes (DUB). 
In regards to GRα, a number of these enzymes related to the ubiquitination process, have been 
identified
13–18
. In the current study, three of these enzymes known to interact with unliganded and 
liganded GRα were investigated; namely the E2 conjugating enzyme tumour susceptibility gene 101 
(TSG101)
18
,  and the E3 ligases, namely the carboxy terminus of heat shock protein 70-interacting 
protein (CHIP) (also referred to as STIP1 homology and U-Box containing protein 1 (STUB1))
19
 
and, F-box/WD repeat-containing protein 7 (FBXW7α)20.  
TSG101: 
TSG101 belongs to a group of catalytically inactive enzymes, termed the ubiquitin E2 variants 
(UEV), which resemble classical E2 conjugating enzymes, with high sequence specificity, but are 
incapable of catalysing ubiquitin transfer
15,21
. Interestingly, although catalytically inactive, TSG101 
is still able to bind ubiquitin but this is thought to occur at a different site to classical E2 
conjugating enzymes
21.  As mentioned, phosphorylation in general modulates GRα function at a 
transcriptional level but more importantly at the level of GRα protein stability15. TSG101 is known 
to interact with the non- or hypo-phosphorylated GRα, ultimately stabilizing the receptor and 
preventing its degradation
15
.  
CHIP:  
CHIP is known to be a proteasome-targeting factor or, more specifically, an E3 ligase and is 
considered an important regulatory enzyme functioning to assist the degradation of mis-folded or 
damaged cellular proteins, via the proteasome
19,22,23
. Interestingly, in addition to its ability to 
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mediate the addition of ubiquitin to various client proteins, CHIP is also known to be able to 
ubiquitinate itself
22
. As an E3 ligase, this enzyme has a high specificity for its substrates, which are 
heat shock protein 70 (Hsp70) and heat shock protein 90 (Hsp90) client proteins, one of which is 
the GRα13,22,23. Furthermore, a confirmed role for CHIP in regulating GRα protein turnover via the 
proteasome, has been confirmed, both in the absence and presence of GCs
13
. 
FBXW7α: 
FBXW7α, an F-box protein is, like CHIP, an E3 ligase, which mediates the degradation of 
substrates in an ubiquitin-dependent manner
14
. Moreover, this E3 ligase is thought to specifically 
require prior GSK3β-dependent phosphorylation of the substrate, at a site referred to as a CDC4 
phosphodegron consensus motif
14
. Phosphorylation, at this specific motif, allows for FBXW7α to 
bind its substrate with a high specificity
14
.  
Recently, GRα was found to be a novel client of FBXW7α14. As previously mentioned, GRα 
undergoes GSK3β- dependent phosphorylation at Ser404 and this influences receptor stability8. 
Interestingly, the amino acid sequence that borders this serine residue is known to bear a 
resemblance to the highly conserved phosphodegron consensus motif and it is here that the E3 
ligase, FBXW7α, is known to bind14. Subsequently,  a ligand-dependent increase in the binding of 
FBXW7α to GRα mediates ubiquitination and proteasomal degradation14. Whilst it is clear that in 
the presence of a potent dimerization promoting GC, Dex, this interaction between GRα and 
FBXW7 is well established
14
, it remains to be understood whether dimerization abrogating CpdA, 
can induce an interaction between FBWW7α and GRα. 
Ubiquitin: 
Following interaction with the E3 ligases, ubiquitin, a small 76 amino acid protein is covalently 
attached to its substrates. This process of ubiquitin-tagging is repeated until a poly-ubiquitin chain 
is formed on the substrate, which is then recognized by the proteasome, which then mediates the 
degradation of the substrate into inactive protein fragments
1,11,12,24–28
. 
Ubiquitination of the GRα occurs at a single site, a conserved lysine residue at amino acid position 
419 in humans, which falls within the PEST (a peptide sequence that is rich in proline (P), glutamic 
acid (E), serine (S), and threonine (T) degradation) motif
29
(Figure 5.2). Interestingly, this site K419 
occurs slightly upstream from the phosphorylation site S404, known to regulate binding of 
FBXW7α14. Wallace et al.29,30, elegantly demonstrated that mutation of the lysine found within this 
PEST element resulted in the abrogation of ligand-induced GRα protein down-regulation via the 
proteasome. These findings provide evidence for ubiquitination as a requirement to prime the 
protein for subsequent recognition and degradation by the proteasome, the ultimate site of 
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proteolysis in the UPS. Whilst extensive evidence is available for ubiquitination of other steroid 
receptors (e.g. the AR)
31–34, it would seem the literature available on GRα ubiquitination is 
restricted to a handful of papers
29,30,35
. 
It is well understood that the UPS serves as a vital ‘switch-off’ mechanism to prevent continual 
signalling by prolonged hormone treatment, and to fine-tune the magnitude and duration of its 
response, through degradation of its cognate receptor, such as GRα12. From Chapter 4, it was 
established, that the dimerization state of GRα is an important factor for ligand-induced receptor 
turnover via the proteasome but a description of how a ‘loss’ of dimerization prevented receptor 
turnover at a molecular level was absent. It is this, which the current chapter will focus on. 
Thus, generally speaking, the current chapter investigates how ‘gain’ or ‘loss’ of GRα dimerization 
modulates the post-translational processing of the receptor, more specifically, by investigating the 
PTMs, phosphorylation and ubiquitination, as well as the interaction of GRα with other components 
of the UPS (e.g. E2 and E3 enzymes). Also within this chapter, the ligand-induced turnover of a 
number of other GRα mutants is investigated, as well as the ability of the dimerization abrogating 
ligand, CpdA, to rescue Dex-mediated GRα protein down-regulation. 
Elucidating the exact molecular mechanisms, in terms of the post-translational processing of the 
receptor, of how a ‘loss’ of GRα dimerization prevents ligand-induced receptor turnover, may 
highlight steps in the UPS pathway, which could be exploited pharmacologically for the 
development of novel dimerization abrogating GRα ligands that do not induce receptor turnover and 
maintain receptor levels, even following prolonged GC treatment. This has major implications in 
terms of acquired GC resistance and the battle against counteracting chronic inflammation and 
curbing the progression of auto-immune diseases. 
5.2. Results 
5.2.1. Ligand-induced GRα protein down-regulation is prevented in a mutation specific 
manner 
In Chapter 4, a novel requirement for GRα dimerization in ligand-induced GRα protein down-
regulation was established. More specifically, this link between receptor dimerization and GRα 
protein turnover was investigated by comparing the human wild type GRα to one dimerization 
deficient mutant namely hGRdim, with a single point mutation at amino acid position 458 (Fig. 
5.4A). At this point, it seemed necessary to determine whether this requirement for GRα 
dimerization in receptor turnover is dependent on mutations at a specific site and/or whether it is 
species specific. 
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To do this, a number of other GRα mutant plasmids thought to be impaired in their dimerization 
capabilities, including a natural occurring mutant and a mouse wild type and dimerization deficient 
mutant GRα plasmid (Table 3.1 and Fig. 5.4A), were used36–39. Western blotting was conducted 
following treatment of transiently transfected GRα plasmids, in COS-1 cells, with Dex (10 μM) for 
24 hours, to detect changes in GRα expression. 
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Figure 5.4: Ligand-induced GRα protein down-regulation is prevented in a mutation specific manner. COS-1 
cells were seeded into a 24 well plate (5 x 10
4
 cells/well) and transfected the next day with one of the GRα plasmids in 
(A) namely; hGRwt, hGRdim(A485T), hGR(R477H), hGR(N545D/A458T), hGR(D4X), mGRwt or mGRdim (A465T) 
using a transfection agent. Following 24 hours incubation, cells were treated with solvent (EtOH) or Dex (10
-5
M) for 24 
hours and GRα protein expression determined by Western blotting where GAPDH was probed to ensure equal protein 
loading. Western blots shown below, the quantification graphs for human (B) and mouse (C) are representative of three 
independent experiments. For quantification, the intensity of the GRα and GAPDH bands were determined using 
UNSCANIT and GRα levels were then normalised to GAPDH expression. For each plasmid, GRα expression following 
Dex treatment was expressed as a percentage (average ± SEM) of GRα expression in presence of the solvent (EtOH), 
which was set at 100% (dotted line). For simplicity, only a single bar representing GRα expression in the presence of 
the solvent (EtOH) is depicted in (B and C). Statistical analysis for was conducted using a one-way ANOVA with a 
Dunnet post-test comparing experimental values to solvent (EtOH) (ns, p> 0.05, *, p < 0.05, ***, p< 0.001) or a t-test to 
compare the mutants to hGRwt in the presence of Dex (B) (
#
, p < 0.05 and 
###
, p< 0.001). 
Consistent with previous results from Chapter 4 (Table 3), hGRwt protein expression was 
significantly (p < 0.001) reduced to 40%, relative to solvent (EtOH), following treatment with Dex, 
whilst hGRdim expression was not significantly (p > 0.05) affected (Fig. 5.4B). Interestingly, the 
natural human mutant GRα, hGR(R477H), did not undergo ligand-induced GRα protein down-
regulation similarly to the classical dimerization deficient mutant, hGRdim (Fig. 5.4B). In contrast 
to these two mutants, two additional GRα mutants, hGRdim(N545D/A458T) and hGRdimD4X, 
underwent significant (p < 0.01) Dex-induced GRα protein down-regulation (Fig. 5.4B). Whilst 
hGR(N545D/A458T) and hGR(D4X) expression was reduced to 65 and 63%, respectively, relative 
to the solvent (EtOH), following treatment with Dex for 24 hours, the extent of receptor turnover 
with these two mutants was significantly (p < 0.05) less than that observed with hGRwt (Fig. 5.4B). 
One could postulate that this is due to the mutation at A458T present in both 
hGRdim(N545D/A458T) and hGRdimD4X.  
Additionally, results obtained with the transiently transfected mouse wild type, mGRwt, and 
classical mouse dimerization deficient mutant, mGRdim(A465T) (Fig. 5.4C), were similar to that 
obtained with the hGRwt and hGRdim plasmids, in COS-1 cells (Fig. 5.4B). Following 24 hours 
Dex treatment, mGRwt levels were significantly (p < 0.01) reduced to 42%, whilst 
mGRdim(A458T) levels were not significantly down-regulated (Fig. 5.4C). 
In summary, Dex-induced human GRα protein down-regulation is prevented in a dimerization 
deficient, mutation specific manner. Furthermore, it seems as though, with the human GRα, the 
mutation of an alanine residue to a threonine at position 458, which has been shown to result in a 
‘loss’ of receptor dimerization40, contributes to a loss of receptor degradation in the case of 
hGRdim(N545D/A458T) and hGRdimD4X, but that the additional mutations in these GRα mutants 
(Fig.5.4A) may be unable to restrict Dex-mediated receptor degradation. Interestingly, the mutation 
of the natural mutant, hGR(R477H), occurs outside the D-loop and does not contain the mutation of 
an alanine residue to a threonine at position 458. Although it has been shown that this mutant has a 
reduced ability to bind DNA, which is generally mediated via a GRα dimer, the ability of this 
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mutant to dimerize has not yet been demonstrated and requires further investigation. Lastly, Figure 
5.4C confirms that the novel requirement for GRα dimerization in ligand-induced receptor turnover, 
established in the previous chapter, is not restricted to a single species. 
5.2.2. GRα and FBXW7α  
Having provided further evidence for a link between GRα dimerization and ligand-induced GRα 
protein degradation, the next step was to further investigate the molecular mechanisms involved in 
mediating receptor turnover and how these molecular mechanisms are modulated by different GRα 
conformations (i.e. dimer versus monomer). 
Recently, GRα has been identified as a novel substrate for FBXW7α, which forms part of a larger 
complex, termed the SCF (Skp1/Cul1/F-box) E3 ubiquitin ligase complex, whose primary function 
is to carry out substrate ubiquitination and delivery of this ubiquitin-tagged substrate to the 
proteasome for subsequent degradation
14
. With the degradation of GRα being demonstrated as 
proteasome dependent, it seemed necessary to determine how the dimerization state of GRα 
influences the interaction of the receptor with FBXW7α.  
In addition, many recent studies have highlighted the importance of not only investigating protein 
expression and protein-protein interactions but also determining the subcellular localisation of these 
interactions, to provide further insight into molecular mechanisms occurring within the cell
41,42
. 
Thus, the current study, before determining the effect of GRα conformation (i.e. dimer versus 
monomer) on the nature of the interaction of the receptor with the E3 ligase, FBXW7α, investigated 
how the subcellular localisation and co-localisation of this interaction, was affected by a ‘loss’ or 
‘gain’ of GRα dimerization.  
COS-1 cells were seeded in a 10cm dish (1 x 10
6
 cells/well) and the next day transfected with GRα 
plasmids (i.e. hGRwt, hGRdim, GFP-hGRwt or GFP-hGRdim) (Table 3.1 and 3.2). Cells were then 
treated with solvent (EtOH), Dex, F or CpdA (10 μM) for 3 hours and then lysed, following which a 
co-IP was conducted, or after 24 hours, cells were then re-plated into an 8-well chamber (3 x 10
4
 
cells/well) in preparation for immunofluorescence or PLA. It must be noted, that for hGRdim, COS-
1 were plated into an 8-well chamber (4 x 10
4
 cells/well) and hGRdim directly transfected into the 
chambers (i.e. without the re-plating step) (Table 3.2). Once the cells had settled in the 8-well 
chambers (48 hours post-transfection) they were treated with solvent (EtOH), Dex, F or CpdA (10 
μM) for 3 hours. Following treatment, COS-1 cells were fixed, permeabilized and 
immunofluorescence, or PLA was performed using antibodies specific to GRα and FBXW7α (Table 
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3.3), to determine the subcellular localisation and co-localisation of GRα and FBXW7α, as well as 
the interaction of these two proteins.  
5.2.2.1. Ligand-dependent subcellular localisation of hGRwt modulates its co-localisation 
with endogenous FBXW7α. 
From the results, notable differences in the subcellular localisation of hGRwt, are noted (Fig. 5.5) 
following treatment with compounds, for 3 hours. Firstly, in terms of GRα, no GRα expression was 
detected in untransfected COS-1 cells (Fig. 5.5A). In contrast, in COS-1 cells that had been 
transiently transfected with hGRwt, obvious red fluorescence was observed, suggesting successful 
transfection of hGRwt plasmid (Fig. 5.5A).  
From the quantification (Fig. 5.5B), it is clear that the unliganded hGRwt receptor (i.e. solvent 
(EtOH)) is evenly distributed throughout the cytoplasm and the nucleus (p > 0.05). In contrast, 
treatment with the dimerization promoting synthetic GC, Dex, and endogenous GC, F, resulted in 
total nuclear translocation of hGRwt, with little to no receptor expression detected in the cytoplasm 
(p < 0.001) (Fig. 5.5B). A significant (b, p < 0.001) decrease in cytoplasmic hGRwt and a 
significant increase  (c, p < 0.001) in nuclear hGRwt expression were noted following Dex and F 
treatment, relative to the unliganded hGRwt (Fig. 5.5B).  
  
A 
hGRwt 
FBXW7α 
EtOH Dex F CpdA Untransfected 
DAPI 
Merge 
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Figure 5.5: Ligand-dependent subcellular localisation of hGRwt modulates its co-localisation with endogenous 
FBXW7α. COS-1 cells were seeded into a 10 cm dish (1 x 106 cells) and transiently transfected the next day with 
hGRwt using a transfection reagent. Following 24 hours incubation, cells were re-plated into 8 well chambers (3 x 10
4
 
cells/well) (Table 3.2) and the next day treated with solvent (EtOH), Dex, F or CpdA (10
-5
M) for 3 hours. Thereafter, 
cells were fixed, permeabilized, and immunofluorescence conducted, with antibodies specific for GRα and FBXW7α. 
Cells were then imaged using a confocal microscope. A representative image (A) illustrates the individual subcellular 
localisation of hGRwt (red, first row) and FBXW7α (green, second row), as well as the position of the cell’s nucleus 
(blue DAPI stain, third row) with the merge representing an overlay of all three channels (red, green and blue). For the 
quantification of the subcellular localisation of hGRwt and FBXW7α the relative fluorescence intensity (RFI) of the red 
(hGRwt) (B) or green (FBXW7α) (C) pixels was calculated for individual cells and plotted. In addition, the co-
localisation of these two proteins, in terms of hGRwt (D), was determined using the weighted co-localisation co-
efficients, where the horizontal dotted line represents 100% co-localisation of hGRwt with FBXW7α. Statistical 
analysis was conducted using a two-way ANOVA followed by a Bonferoni’s post-test comparing experimental values 
to solvent’s (EtOH) cytoplasm for hGRwt (B) or FBXW7α (C) (for a,b,c,d and e letters that are the same represent no 
significant difference between values whilst letters, which are different are significantly different from each other p < 
0.05) or comparing the cytoplasmic and nuclear expression of hGRwt (B) or FBXW7α (C) within a treatment group (ns, 
p > 0.05 and ***, p < 0.001).  For co-localisation (D), a one-way ANOVA with a Tukey’s post-test was used, 
comparing experimental values to the solvent (EtOH) (***, p < 0.001). 
Similarly, treatment with the dimerization abrogating GC, CpdA resulted in significant (p < 0.001) 
translocation of hGRwt from the cytoplasm to the nucleus (Fig. 5.5B). However, unlike with Dex 
and F treatment, a substantial amount of hGRwt still resided in the cytoplasm following treatment 
with CpdA (Fig. 5.5B). With that said, the amount of hGRwt present in the cytoplasm following 
CpdA treatment was significantly less (d, p < 0.001) than that observed following treatment with 
solvent (EtOH). 
From the quantification (Fig. 5.5B), it is clear that the unliganded hGRwt receptor (i.e. solvent 
(EtOH)) is evenly distributed throughout the cytoplasm and the nucleus (p > 0.05). In contrast, 
treatment with the dimerization promoting synthetic GC, Dex, and endogenous GC, F, resulted in 
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total nuclear translocation of hGRwt, with little to no receptor expression detected in the cytoplasm 
(p < 0.001) (Fig. 5.5B). A significant (b, p < 0.001) decrease in cytoplasmic hGRwt and a 
significant increase  (c, p < 0.001) in nuclear hGRwt expression were noted following Dex and F 
treatment, relative to the unliganded hGRwt (Fig. 5.5B). Similarly, treatment with the dimerization 
abrogating GC, CpdA resulted in significant (p < 0.001) translocation of hGRwt from the cytoplasm 
to the nucleus (Fig. 5.5B). However, unlike with Dex and F treatment, a substantial amount of 
hGRwt still resided in the cytoplasm following treatment with CpdA (Fig. 5.5B). With that said, the 
amount of hGRwt present in the cytoplasm following CpdA treatment was significantly less (d, p < 
0.001) than that observed following treatment with solvent (EtOH) 
When investigating the subcellular localisation of FBXW7α, little to no FBXW7α expression was 
detected in the cytoplasm, with significant (p < 0.001) nuclear localisation of FBXW7α occurring 
across the different treatment conditions (Fig. 5.5C). Interestingly, a notable decrease (c, p < 0.001) 
in the nuclear FBXW7α expression is observed following treatment with Dex. Furthermore, a slight 
yet, significant (d, p < 0.05), decrease in the nuclear expression of this protein is also detected after 
treatment with F relative to the solvent (EtOH) (Fig. 5.5C). This F-induced decrease in nuclear 
FBXW7α expression was not as severe as that of the Dex-induced decrease in nuclear FBXW7α 
expression, and was comparable to that after treatment with CpdA (Fig. 5.5C). 
Lastly, Figure 5.5D demonstrates the co-localisation of hGRwt and FBXW7α, importantly with 
reference to hGRwt. In other words, the quantification graph (Fig. 5.5D) depicts the percentage (%) 
of the total hGRwt protein expression, which co-localizes with FBXW7α. From this graph, it is 
clear that, in the case of unliganded hGRwt, only 30% of the total hGRwt protein expression co-
localizes with FBXW7α (Fig. 5.5D). This suggests that a large portion of the hGRwt expression 
(approximately 70%) does not occupy the same space as FBXW7α, likely due to the cytoplasmic 
nature of unliganded hGRwt and the predominantly nuclear localisation of FBXW7α. However, 
promoting hGRwt dimerization and its nuclear translocation, through Dex and F treatment, results 
in a significant (p < 0.001) increase in the co-localisation of hGRwt and FBXW7α, with almost all 
(just less than 100%) of hGRwt occupying the same space as FBXW7α (Fig. 5.5D). Similarly, 
treatment with dimerization abrogating CpdA, resulted in a significant (p < 0.001) increase (47%) 
in the amount of hGRwt expression co-localised with FBXW7α, relative to the unliganded receptor 
(30%). However, the percentage co-localisation of these two proteins, following CpdA treatment, 
was half of that noted following Dex and F treatment but significantly greater (p < 0.001) than that 
of the solvent (EtOH) and directly reflects CpdA’s diminished ability to induce nuclear 
translocation of hGRwt to where the predominantly nuclear FBXW7α resides.  
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5.2.2.2. Ligand-dependent subcellular localisation of hGRdim modulates its co-localisation 
with endogenous FBXW7α. 
Having demonstrated that a ‘loss’ of GRα dimerization, through CpdA treatment, did not drastically 
inhibit nuclear translocation of the receptor, the ability of the dimerization deficient mutant, 
hGRdim, to translocate to the nucleus following GC treatment, was  investigated, in order to 
confirm that the mutation did not significantly alter the nuclear translocation of GRα. The 
subcellular localisation and co-localisation of hGRdim and FBXW7α was determined and 
quantified as in Section 5.2.2.1, of the current chapter, but instead of hGRwt, hGRdim was used for 
this section. 
Similarly to the hGRwt experiment (Fig. 5.5) no GRα expression was detected in untransfected 
COS-1 cells, but in cells that had been transiently transfected with hGRdim obvious red 
fluorescence was observed, suggesting that successful transfection of the hGRdim plasmid was 
achieved (Fig. 5.6A). In addition, as with hGRwt (Fig. 5.5B), the unliganded hGRdim is evenly 
distributed throughout the cytoplasm and the nucleus (p > 0.05) (Fig. 5.6B). Moreover, like hGRwt 
(Fig. 5.5B), treatment with Dex and F, resulted in total nuclear translocation of hGRdim with little 
receptor expression detected in the cytoplasm (p < 0.001) (Fig. 5.6B). Likewise, relative to the 
unliganded hGRdim, Dex and F treatment induced a significant (b, p < 0.001) decrease in 
cytoplasmic hGRdim and a corresponding increase (c, p < 0.001) in the nuclear localization of 
hGRdim (Fig. 5.6B). Interestingly, and in contrast to hGRwt (Fig.5.5B), treatment with 
dimerization abrogating GC, CpdA, did not induce significant (p > 0.05) translocation of hGRdim 
from the cytoplasm to the nucleus (Fig. 5.6B) and hGRdim remained evenly distributed throughout 
the cytoplasm and nucleus, similarly to the unliganded receptor (a, p > 0.05) (Fig. 5.6B).  
In terms of FBXW7α, FBXW7α expression was found to be predominantly nuclear (p < 0.001) as 
in Figure 5.5C (Fig. 5.6C). However, the significant decrease in the nuclear FBXW7 expression, 
relative to the unliganded hGRwt, observed following Dex and F treatment of hGRwt (Figure 5.5C) 
was absent in COS-1 cells transfected with hGRdim (Fig, 5.6C). Lastly, CpdA treatment also did 
not significantly (p > 0.05) alter the nuclear localization of FBXW7α in cells where hGRdim was 
present (Fig. 5.6C). 
With regards to co-localisation of hGRdim and FBXW7α, a similar co-localisation pattern to that of 
hGRwt and FBXW7α (Fig. 5.5D), was observed for hGRdim and FBXW7α (Fig.5.6D), however, 
with some notable differences. Specifically, Figure 5.6D suggests that in the absence of ligand, 
approximately 44% of the total hGRdim protein expression co-localizes with FBXW7α, which is 
slightly more than the 30% reported in the previous result for hGRwt (Fig. 5.5D). As with hGRwt 
(Fig. 5.5) Dex and F treatment resulted in a significant (p < 0.001) increase in the co-localisation of 
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the mutant GRα and the predominantly nuclear FBXW7α, relative to the unliganded hGRdim (Fig. 
5.6D). Specifically, about almost all (just less than 100%) of hGRdim is found co-localised with 
FBXW7α, in the nucleus (Fig. 5.6D). In contrast to the results obtained for hGRwt (Fig. 5.5D), 
treatment with CpdA, did not significantly affect the co-localisation of FBXW7α with hGRdim, 
relative to unliganded hGRdim (Fig. 5.6D) and reflects the inability of CpdA treatment to induce 
nuclear translocation of hGRdim, also observed in Figure 5.6B.  
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Figure 5.6: Ligand-dependent subcellular localisation of hGRdim modulates its co-localisation with endogenous 
FBXW7α. COS-1 cells were seeded into a 10 cm dish (1 x 106 cells) and transiently transfected the next day with 
hGRdim using a transfection reagent. Following 24 hours incubation, cells were re-plated into 8 well chambers (3 x 10
4
 
cells/well) (Table 3.2) and the next day treated with solvent (EtOH), Dex or CpdA (10
-5
M) for 3 hours. Thereafter, cells 
were fixed, permeabilized, and immunofluorescence conducted, with antibodies specific for GRα and FBXW7α. Cells 
were then imaged using a confocal microscope. A representative image (A) illustrates the individual subcellular 
localisation of hGRdim (red, first row) and FBXW7α (green, second row), as well as the position of the cell’s nucleus 
(blue DAPI stain, third row) with the merge representing an overlay of all three channels (red, green and blue). For the 
quantification of the subcellular localisation of hGRdim and FBXW7α the relative fluorescence intensity (RFI) of the 
red (hGRdim) (B) or green (FBXW7α) (C) pixels was calculated for individual cells and plotted. In addition, the co-
localisation of these two proteins, in terms of hGRdim (D), was determined using the weighted co-localisation co-
efficients, where the horizontal dotted line represents 100% co-localisation of hGRdim with and FBXW7α. Statistical 
analysis was conducted using a two-way ANOVA followed by a Bonferoni’s post-test comparing experimental values 
to solvent’s (EtOH) cytoplasm for hGRdim (B) or FBXW7α (C) (for a,b,c,d and e letters that are the same represent no 
significant difference between values whilst letters, which are different are significantly different from each other p < 
0.05) or comparing the cytoplasmic and nuclear expression of hGRdim (B) or FBXW7α (C) within a treatment group 
(ns, p > 0.05 and ***, p < 0.001).  For co-localisation (D), a one-way ANOVA with a Tukey’s post-test was used, 
comparing experimental values to the solvent (EtOH) (***, p < 0.001). 
5.2.2.3. ‘Loss’ of GRα dimerization modulates its interaction with FBXW7α. 
Having demonstrated ligand-induced changes in the subcellular localisation and co-localisation of 
GRα (hGRwt and hGRdim) with the E3 ligase, FBXW7α, the current study determined whether a 
‘loss’ of receptor dimerization influenced the ability of FBXWα to interact with GRα using a co-
immunoprecipitation assay and PLA. 
Results from the co-immunoprecipitation assay demonstrated that a ‘gain’ of hGRwt dimerization 
via the potent, synthetic dimerization promoting GC, Dex, leads to a significant (p < 0.05) increase 
in the association of hGRwt and E3 ligase, FBXW7α (Fig. 5.7A). Furthermore, a slight increase in 
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this interaction is noted following treatment with F, however, this increase was not significant (p > 
0.05) (Fig. 5.7A). In stark contrast to the dimerization promoting GCs, ‘loss’ of GRα dimerization, 
following treatment with dimerization abrogating GC, CpdA, did not induce interaction of the 
receptor with FBXW7α, relative to the basal interaction (i.e. solvent (EtOH)) (Fig. 5.7A). 
Moreover, in one of the two experiments conducted, no interaction between FBXW7α and hGRwt 
was noted following CpdA treatment, as seen in the representative Western blot (Fig. 5.7A, inset 
and Fig. S2), which suggests CpdA treatment, may abrogate the basal interaction between these two 
proteins. 
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Figure 5.7: ‘Loss’ of GRα dimerization modulates its interaction with FBXW7α. COS-1 cells were seeded, 
transfected and in some cases re-plated in 8 well chambers. Following 24 hours incubation, cells were treated with 
solvent (EtOH), Dex, F or CpdA (10
-5
M) for 3 hours. For the co-IP (A) experiment, cells were lysed after compound 
treatment and FBXW7α was immuno-precipitated with hGRwt. Western blotting was conducted to determine protein 
expression and GAPDH was probed to ensure equal protein loading. A representative blot of three independent 
experiments is shown. For quantification, the intensity of, hGRwt, FBXW7α and GAPDH were determined using the 
MyECL Image Software Analysis. Moreover, the hGRwt/FBXW7α interaction was normalised to hGRwt input 
expression and dotted line on the graph representative of hGRwt/FBXW7α interaction in the presence of solvent 
(EtOH), and is set at 100%. For the PLA (B and C), following treatment cells were fixed, permeabilized and PLA 
conducted using specific antibodies for GRα and FBXW7α, after which cells were imaged. A representative image of 
individual cells from the hGRwt and FBXW7α (B) and GFP-tagged GRα and FBXW7α (C, below graph) experiment, is 
shown. In these representative images the PLA signal is observed as distinct red ‘spots’ and the cell’s nucleus is 
depicted by the blue DAPI stain (B and C, inset below graph). For quantification of the GFP-tagged GRα and FBXW7α 
interaction (C), the PLA signal (dots/cell) was quantified using the IMAGEJ Software and normalized to the GRα 
concentration (i.e. GFP-signal (RFI)), which was determined using the ZENN 2012 Software Analysis, and plotted. 
Statistical analysis was conducted using a one-way ANOVA followed by a Bonferoni’s post-test (A) comparing 
experimental values to solvent (EtOH) and the same statistical analysis was used with a Tukey’s post-test (C) 
comparing experiment values to GFP-hGRwt solvent (EtOH, (ns, p > 0.05 and *, p < 0.05). Additionally, t-tests were 
used in (C) to compare effects of Dex and CpdA via GFP-hGRwt and the effects of Dex via GFP-hGRdim, relative to 
GFP-hGRwt and lastly, the effects of Dex via GFP-hGRdim, relative to the unliganded GFP-hGRdim (ns, p > 0.05 and 
***. p  < 0.001). 
At this point it was postulated that the GRα monomer (CpdA-bound hGRwt) and FBXW7α 
interaction may be weaker or more transient than the interaction of FBXW7 with a GRα dimer 
(Dex-bound or F-bound hGRwt) due to the fact that ‘loss’ of dimerization did not severely alter the 
co-localisation of GRα with FBXW7α (Fig. 5.5D and 5.6D), relative to a ‘gain’ of GRα 
dimerization, and the lack of interaction between these two proteins demonstrated in Figure. 5.7A, 
following CpdA treatment. Thus, to further explore the interesting result in Figure 5.7A, a PLA was 
conducted.  
Unexpectedly, results from the initial PLA experiment, using hGRwt (Fig. 5.7B), contradicted the 
results from the co-immunoprecipitation assay (Fig. 5.7A). Specifically, the greatest interaction of 
hGRwt and FBXW7α was noted following treatment with solvent (EtOH) and, in contrast to Figure. 
5.7A, treatment with Dex, F or CpdA appeared to reduce the interaction of hGRwt and FBXW7α 
(Fig. 5.7B). This is evident from the fewer fluorescent red spots observed following treatment with 
compounds (Fig. 5.7B). Worth noting is that this experiment was repeated using the dimerization 
deficient mutant and little to no PLA signal was detected (data not shown).  
Essentially, the major limitation of the PLA experiment with hGRwt in Figure 5.7B was the 
inability to account for cells that had been successfully transiently transfected with the hGRwt 
plasmid. Thus, to overcome this challenge, it was decided to repeat the PLA experiment making use 
of green fluorescently tagged (GFP) GRα plasmids, namely GFP-hGRwt and GFP-hGRdim. This 
allowed for simultaneous visualisation of GRα (green) expression and the PLA signal 
(GRα/FBXW7 interaction, red) (Fig. 5.7C). For quantification, the PLA signal for each cell was 
normalised to the GRα content in the same cell and it is this normalized PLA signal (Dots/cell/RFI) 
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which was then plotted (Fig. 5.7C), thus accounting for possible changes in GRα concentration, due 
to potential differences in the transfection efficiency. 
From the results, and in support of the co-immunoprecipitation result (Fig. 5.7A) and co-
localisation results (Fig. 5.5D), promoting dimerization of GFP-hGRwt through treatment with Dex, 
resulted in an increase in the association of the wild-type receptor with FBXW7α, although this was 
not significant (p > 0.05) (Fig. 5.7C). Moreover, ‘loss’ of dimerization of GFP-hGRwt, following 
CpdA treatment, restricted the interaction of the receptor with the E3 ligase (Fig. 5.7C), as in Figure 
5.7A. Interestingly, no significant (p > 0.05) ligand-induced changes in the interaction of the 
dimerization deficient GRα mutant, GFP-hGRdim with FBXW7α, were observed relative to the 
unliganded GFP-hGRwt (i.e. solvent (EtOH)) (Fig. 5.7C). In addition, the ability of dimerization 
promoting Dex to induce an interaction between GRα and FBXW7α was significantly (p < 0.001) 
restricted with the use of GFP-hGRdim, relative to GFP-hGRwt (Fig. 5.7C) and is not a result of a 
lack of Dex-induced co-localisation between GFP-hGRdim and FBXW7α as shown in Fig. 5.6D. 
5.2.2.4. GRα concentration modulates the interaction of GFP-hGRwt with FBXW7α 
During imaging of cells, it was apparent that transient transfection of the untagged GRα plasmids 
did not produce a homogenous population of COS-1 cells with regards to GRα concentration (Fig. 
S3), but rather a population of cells that ranged from low to medium/high GRα concentration. As 
the cellular concentration of GRα is known to modulate GC action, such as nuclear mobility and 
GRα-mediated transcription43,44, the current study set out to determine whether the cellular receptor 
concentration altered the ability of GFP-hGRwt to interact with FBXW7α. 
To do this, the cell population (cell number 1-79) was plotted from lowest to highest GFP-hGRwt 
concentration (RFI) with their correlating PLA signal (dots/cell), which represents the GFP-hGRwt 
and FBXW7α interaction (Fig. S5). This graph demonstrated that increasing cellular GFP-hGRwt 
concentration results in a concurrent decrease in PLA signal, suggesting a role for GRα 
concentration in modulating the interaction of the receptor with the E3 ligase, FBXW7α. To further 
investigate this notion, cells transiently transfected with GFP-hGRwt, were grouped into two 
categories, based on the total cellular GFP intensity (RFI), low GRα (RFI < 25) and medium/high 
GRα (RFI > 25) concentration, which was calibrated using FITC beads and the confocal 
microscope  by a member of our research group lab (unpublished) (Fig. S6). 
From the results, it is evident that at low cellular concentrations of GFP-hGRwt, dimerization 
promoting Dex significantly (p < 0.001) induces GFP-hGRwt/FBXW7α interaction, whilst 
dimerization abrogating CpdA does not (p > 0.05) (Fig. 5.8A). Moreover, the amount of GFP-
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hGRwt/FBXW7α interaction induced by Dex is significantly (p < 0.01) different to that of CpdA 
(Fig. 5.8A).  
At medium/high cellular GFP-hGRwt concentrations, no increase (p > 0.05) in the interaction of 
the receptor with FBXW7 is noted across the treatment conditions (Fig. 5.8D). Additionally, no 
significant difference (p > 0.05) between the ability of Dex and CpdA to induce this interaction is 
noted, in cells with medium/high GFP-hGRwt concentrations (Fig. 5.8D). Interestingly, notable 
differences were observed when comparing the ability of dimerization promoting Dex to induce 
GFP-hGRwt/FBXW7 interaction in cells containing low GFP-hGRwt, to those which contain 
medium/high levels of GFP-hGRwt (Fig. 5.8B and D). Specifically, Dex does not seem capable (p 
< 0.001) of inducing GFP-hGRwt/FBXW7 interaction in cells with medium/high GFP-hGRwt 
expression (Fig. 5.8D).  
Taken together, results from this section on the subcellular localisation, co-localisation and 
interaction of GRα with the E3 ligase, FBXW7α suggest the following:  
Firstly, the unliganded GRα occurs both in the cytoplasm and the nucleus and that ‘loss’ of receptor 
dimerization, through the use of the mutant (hGRdim) does not affect the subcellular localisation of 
the unliganded receptor. Secondly, ‘gain’ of hGRwt dimerization through treatment with 
dimerization promoting GCs, Dex and F, resulted in complete nuclear translocation of hGRwt and 
almost (slightly less than hGRwt) complete nuclear translocation of hGRdim, where FBXW7α 
resides, confirming that the mutation does not drastically affect the subcellular localisation of this  
monomeric GRα or its co-localisation with FBXW7α. Thirdly, in this study, treatment with the 
dimerization abrogating compound, CpdA, induced nuclear translocation of hGRwt but failed to do 
the same for the dimerization deficient mutant. Thus, a significant portion of the hGRwt monomers 
(as a result of CpdA treatment), but not hGRdim monomers following CpdA treatment, were found 
in the nucleus co-localised with FBXW7α. 
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Figure 5.8: GRα concentration modulates the interaction of the receptor with FBXW7α. COS-1 cells were seeded 
into a 10 cm dish (1 x 10
6
 cells) and transiently transfected the next day with GFP-hGRwt (A and B) using a 
transfection reagent. Following 24 hours incubation, cells were re-plated into 8 well chambers (3 x 10
4
 cells/well) and 
the next day treated with solvent (EtOH), Dex or CpdA (10
-5
M) for 3 hours. Following treatment cells were fixed, 
permeabilized and PLA conducted using specific antibodies for GRα and FBXW7α. For the characterisation of cells 
based on GRα content, COS-1 cells transiently transfected with GFP-hGRwt were grouped, based on the total cellular 
GFP intensity (RFI) with their corresponding PLA signal (dots/cell), into two categories; low GRα (RFI < 25) and 
medium/high GRα (RFI > 25) content, which was calibrated using FITC beads and the confocal microscope (Fig. S6). 
For the quantification of the GFP-tagged GRα and FBXW7α interaction (A), the PLA signal (dots/cell) was quantified 
using the IMAGEJ Software and normalized to the GRα concentration (i.e. GFP-signal (RFI)), which was determined 
using the ZENN 2012 Software Analysis, and plotted. Statistical analysis was conducted using a one-way ANOVA 
followed by a Tukey’s post-test comparing all experimental values (ns, p > 0.05, **, p < 0.01 and ***, p < 0.001). A 
representative image (B) depicting the effect of GFP-hGRwt concentration on the interaction of GFP-hGRwt and 
FBXW7α, following treatment with Dex, where the PLA signal is observed as distinct red ‘spots’, GFP-hGRwt 
concentration by the green GFP signal and the cell’s nucleus is depicted by the blue DAPI stain. Lastly, the merge is an 
overlay of all three channels (red, green and blue). 
In terms of the interaction of GRα and FBXW7α, ‘loss’ of GRα dimerization, either following 
CpdA treatment or by the use of the dimerization deficient GRα, restricts an increase in the 
interaction of the receptor with the E3 ligase, relative to the basal interaction. Together, results from 
two different experiments, namely co-IP and PLA, solidify a role for GRα dimerization in 
mediating interaction with the E3 ligase, FBXW7α. Moreover, apart from GRα conformation (i.e. 
monomer versus dimer), the cellular concentration of the receptor itself seems to modulate its 
interaction with FBXW7α. 
To our knowledge, this is the first time the ability of receptor conformation, and cellular 
concentration, to modulate the GRα interaction with the E3 ligase, FBXW7α, has been investigated. 
These findings highlight the importance of receptor conformation in mediating interactions with 
certain UPS components and furthermore, identify a novel cellular effect regulated by changes in 
GRα concentration. This finding may have implications for the rate of ligand-induced GRα 
degradation.  
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5.2.3. Loss of GRα dimerization restricts hyper-phosphorylation at Serine 404. 
The highly specific interaction of FBXW7α with its substrates requires prior substrate 
phosphorylation of a CDC4 phosphodegron motif, at serine or threonine residues, generally 
mediated by a class of enzymes, termed GSK
45,46. Specifically, in terms of GRα, Malyukova et al.14 
demonstrated that the interaction of FBXW7 with GRα is dependent on GSK-mediated hyper-
phosphorylation at Ser404. Interestingly, hyper-phosphorylation of GRα at this site has also been 
directly linked to a decrease in protein stability and increased degradation of GRα via the 
proteasome
8
. With this in mind, it seemed necessary to investigate whether the novel requirement 
for GRα dimerization in mediating the interaction of GRα with FBXW7α, established in the current 
study, would be effectuated at the level of hyper-phosphorylation at Ser404. 
To investigate whether a ‘loss’ of GRα dimerization restricted phosphorylation of GRα at Ser404, 
in turn preventing receptor turnover and maintaining GRα stability, COS-1 cells were transiently 
transfected with hGRwt or hGRdim and treated with solvent (EtOH), Dex, F or CpdA (10 μM). 
Phospho-Ser404 GRα levels were then determined by Western blotting using a phospho-Ser404 
specific anti-body (Table 3.3). This was repeated in HepG2 cells containing endogenous GRα. In 
addition, using a GSK3β inhibitor (BIO), we inhibited the Dex-induced hyper-phosphorylation at 
Ser404, in the HepG2 cells, and determined whether this inhibition would restrict receptor turnover 
and partially restore endogenous GRα protein levels. 
‘Gain’ of hGRwt dimerization via dimerization promoting GRα ligands, Dex and F (10 μM) 
resulted in a significant (p < 0.001) hyper-phosphorylation, at Serine404, of transiently transfected 
hGRwt to 153 and 140%, respectively (Fig. 5.9A). A similar, significant (p < 0.001) increase in 
pSer404-hGRα (145%) expression was observed with endogenous hGRα, in the HepG2 cells, 
following Dex treatment (Fig. 5.9C). Although not significant, hyper-phosphorylation (125%), at 
Ser404, of endogenous hGRα was also noted, after treatment with F (Fig. 5.9C). 
In stark contrast, ‘loss’ of GRα dimerization through the use of the mutant, hGRdim, did not result 
in any hyper-phosphorylation of hGRdim at Ser404, following Dex and F treatment (Fig. 5.9B). In 
fact, pSer404-hGRdim seemed to be completely absent and even basal phosphorylation of 
transiently transfected hGRdim at this site was undetectable (Fig. 5.9B), unlike with the hGRwt 
(Fig. 5.9A). In support of the hGRdim result, CpdA treatment, known to abrogate GRα 
dimerization
47,48
, reduced hyper-phosphorylation of transiently transfected hGRwt (Fig. 5.9A) and 
endogenous hGRα at Ser404 (Fig. 5.9C). More specifically, pSer404-hGRwt expression following 
CpdA treatment was not significantly different from basal pSer404-hGRwt expression, in the 
presence of solvent (EtOH), but significantly different from the hyper-phosphorylation of hGRwt at 
this site, following Dex (p < 0.001) and F treatment (p < 0.001) (Fig. 5.9A). This result was 
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consistent for endogenous hGRα in the HepG2 cells (Fig. 5.9C). In addition, inhibition of the Dex 
mediated hyper-phosphorylation at Ser404 (on the endogenous hGRα), using the GSK3β inhibitor, 
BIO, resulted in significant (p < 0.05) restoration of GRα protein levels (Fig. 5.9D). A slight, yet 
insignificant, increase is also noted in receptor levels following treatment with F and BIO (Fig. 
5.9D). Lastly, no significant change was noted in hGRα protein levels following treatment with 
dimerization abrogating, CpdA, and the kinase inhibitor, BIO (Fig. 5.9D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Monomeric GRα, due to CpdA binding or use of hGRdim mutant, does not undergo hyper 
phosphorylation at pSer404. COS-1 cells were seeded in a 12 well plate (1 x 10
5
 cell/well) and the next day 
transfected with either hGRwt (400ng/well) (A) or hGRdim (800ng/well) (B) using FuGENE 6 transfection agent (see 
materials and methods).  Following 24 hours incubation, cells were treated with compounds Dex, F and CpdA (10
-5
M) 
for 2 hours and subsequently lysed in 80µls/well RIPA buffer (see materials and methods). This experiment was 
repeated in HepG2 cells seeded in a 12 well plate (1 x 10
5
 cell/well), containing endogenous GRα (C). Additionally, 
HepG2 cells were treated with 5μM BIO for 1 hour and then with compounds (D). All pSer404-GR levels were detected 
using Western blotting, blots were quantified (graph) using UNSCANIT and a representative figure from a single 
experiment (positioned below graph, except in the case of hGRdim) is shown. Blots were then stripped, using a 
stripping buffer (see materials and methods), and re-probed for total GRα protein content for normalization. In in the 
case of (D), total hGRα was detected and normalized to loading control GAPDH. For statistical analysis, of hGRwt (A) 
and endogenous hGRα (C), a one-way analysis of variance (ANOVA) followed by a Bonferoni’s Multiple comparison 
post-test (ns, p > 0.05, *, p < 0.05, **, p < 0.01 and ***, p < 0.001) was conducted. Statistical analysis of hGRdim 
could not be conducted due to the absence of any visible pSer404-GRα levels. A t-test was conducted comparing hGRα 
protein levels in the absence or presence of BIO, following Dex, F or CpdA treatment in the last figure. The dotted line 
represents values in presence of control (EtOH) and is set at 100% for each experiment. 
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To summarize, restricting phosphorylation at Ser404 of dimeric GRα, through the use of a kinase 
specific inhibitor, partially stabilizes the receptor levels thereby confirming the role of 
phosphorylation at this site in mediating receptor turnover. In addition, these findings suggest that a 
lack of phosphorylation at Ser404, due to a ‘loss’ of receptor dimerization, through CpdA treatment 
or use of hGRdim, likely restricts the interaction of hypo-phosphorylated GRα with the E3 ligase, 
FBXW7α, as this interaction is dependent on phosphorylation at Ser40414. This, to our knowledge, 
is the first time the link between GRα conformation (i.e. monomer versus dimer) and hyper/hypo-
phosphorylation at Ser404 and interaction with FBXW7α, has been investigated. This finding, in 
combination with the findings in Section 5.2.2, demonstrate how a ‘loss’ of receptor dimerization 
modulates the post-translational processing of the GRα and explains, in part, one of the ways in 
which ligand-induced down-regulation of predominantly monomeric GRα is prevented. 
Furthermore, confirming a role for receptor dimerization in ligand-induced GRα down-regulation, 
initially described in Chapter 4. 
5.2.4.  ‘Loss’ of hGRwt dimerization stabilizes the interaction of the receptor with TSG101, 
increasing receptor stability. 
In addition to FBXW7α, there are other enzymes involved in the UPS, which are known to affect 
GRα stability, namely CHIP and TSG101. Like FBXW7α, CHIP is an E3 ligase known to interact 
with GRα, targeting it for proteasome degradation, however, unlike FBXWα, CHIP has been shown 
to interact with both the unliganded and liganded receptor
13,22,23
. In contrast, TSG101 resembles an 
E2 conjugating enzyme, however it is catalytically inactive and unable to catalyse the transfer of 
ubiquitin to an E3 ligase for the tagging of the substrate
15,21
. Moreover this enzyme, TSG101, is 
thought to stabilize the non- or hypo-phosphorylated form of GRα15. Thus, having demonstrated 
that a GRα monomer is less capable than a GRα dimer of interacting with FBXW7α (Fig. 5.7), it 
was decided to investigate whether a ‘loss’ of receptor dimerization, following treatment of hGRwt 
with CpdA, influenced the interaction of GRα with either CHIP or TSG101, relative to a ‘gain’ of 
hGRwt dimerization, following Dex and F treatment.  
Firstly, to investigate the interaction of hGRwt with CHIP or TSG101 following treatment with 
dimerization promoting, Dex and F, or dimerization abrogating, CpdA, COS-1 cells were 
transiently transfected with hGRwt and treated with solvent (EtOH), Dex, F or CpdA (10 μM). 
Subsequently, a co-IP followed by Western blotting was conducted. 
In terms of the co-immunoprecipitation results, ‘gain’ of hGRwt dimerization (via Dex treatment) 
slightly, but not significantly (p > 0.05), altered the association of the receptor with the E3 ligase, 
CHIP, however F and CpdA treatment did not (p > 0.05) (Fig. 5.10A). One could postulate that this 
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E3 ligase is exchanged for FBXW7α, following Dex treatment. Similarly, an increase in hGRwt 
dimerization, following Dex treatment, resulted in a slight decrease (p > 0.05) in the association of 
the receptor with the catalytically inactive, TSG101 (Fig. 5.10B). Moreover, ‘loss’ of hGRwt 
dimerization, as a result of CpdA treatment, appeared to stabilize the interaction of the receptor with 
TSG101 relative to unliganded hGRwt in one of the two experiments (Fig. 5.10B, see blot) but no 
conclusive deductions can be made and this interaction requires further investigation (Fig. 5.10B). 
Although the quantification of the effect of CpdA on the hGRwt/TSG101 interaction was not 
significantly (p > 0.05) different to that of the unliganded receptor, the Western blot (Fig. 5.10B, 
inset) seemed to show a potential increase in the interaction of these two proteins.  
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Figure 5.10: ‘Loss’ of hGRwt dimerization stabilizes the interaction of the receptor with TSG101, increasing 
receptor stability. COS-1 cells were seeded and the next day transfected with hGRwt (Table 3.2). For the co-IP (A and 
B) experiment, following 24 hours incubation, cells were treated with solvent (EtOH), Dex, F or CpdA (10
-5
M) for 3 
hours and then lysed. CHIP (A) or TSG101 (B) was immuno-precipitated with hGRwt using specific antibodies (Table 
3.3). In the knockdown experiment (C), cells were transfected with either a non-silencing control (NSC) or siRNA 
targeting TSG101 (siTSG101) a day after hGRwt transfection, and then treated with solvent (EtOH) or CpdA (10 μM), 
for 24 hours. Additionally, to block proteasome degradation, pre-treatment for 1 hour with MG132 (1 μM) was 
conducted, followed by CpdA (10 μM) treatment for 24 hours. Following co-IP and knockdown, Western blotting was 
conducted to determine protein expression and GAPDH was probed to ensure equal protein loading. A representative 
blot of two or three independent experiments is shown. For quantification (A and B), the interaction of hGRwt and 
CHIP or TSG101 was calculated by determining the intensity, using the MyECL Image Software Analysis, of CHIP or 
TSG101 (after IP), which was normalized to total hGRwt (i.e. intensity of hGRwt input).  The dotted line on the graph 
represents the interaction of hGRwt with CHIP or TSG101 in the presence of solvent (EtOH), and is set at 100%. 
Statistical analysis was conducted using a one-way ANOVA or t-test (A and B) and a two-way ANOVA (C) with a 
Bonferoni’s post-test comparing all experimental values (ns, p > 0.05 and *, p < 0.05) or an unpaired t-test (C, inset) 
(***, p < 0.001). 
‘Loss’ of GRα dimerization, following CpdA treatment, prevented hyper-phosphorylation of GRα 
at Ser404 (Fig. 5.9), in part stabilizing hGRwt. Furthermore, TSG101 is known to associate with 
non- or hypo-phosphorylated GRα, protecting it from degradation via the proteasome15. Taken 
together, one would expect that TSG101 is important in CpdA’s ability to maintain GRα protein 
levels. Thus, to further investigate a possible role of TSG101 in CpdA-induced stability of the GRα, 
a TSG101 knockdown experiment was conducted (Fig. 5.10C). 
COS-1 cells were transiently transfected with hGRwt and a non-silencing control (NSC) or siRNA 
targeting TSG101 (Fig. 5.10C). Cells were then treated with solvent (EtOH) or CpdA (10 μM) for 
24 hours, or MG132 (1 μM) for 1 hour followed by CpdA (10 μM) for 24 hours (Fig. 5.10C). 
Results from the knockdown experiment, using siRNA targeting TSG101, demonstrate that 
endogenous TSG101 was significantly (p < 0.001) eliminated from the COS-1 cells (Fig. 5.10C, 
inset). Importantly, in the presence of endogenous TSG101 (i.e. NSC samples) and consistent with 
previous results in the current study, 24 hours of CpdA treatment leads to an increase (p < 0.05) in 
GRα protein levels, relative to solvent (EtOH) (Fig. 5.10C). Furthermore, pre-treatment with 
MG132, had no effect on CpdA’s ability to maintain receptor levels, when TSG101 was present in 
the cells (Fig. 5.10C). In contrast, in COS-1 cells where TSG101 had been depleted, CpdA did not 
result in a significant increase in GRα protein levels, relative to the solvent (EtOH), suggesting a 
level of receptor turnover in the presence of CpdA and absence of TSG101 (siTSG101) (Fig. 
5.10C). This was confirmed by the addition of MG132, the proteasome inhibitor, which 
significantly (p < 0.05) prevented GRα protein turnover even in the absence of the stabilizing 
TSG101 protein (siTSG101) (Fig. 5.10C). 
In summary, consistent with literature, results suggest the association of CHIP with GRα occurs in 
the presence and absence of GCs
13. Furthermore, although not significant, ‘gain’ of GRα 
dimerization, through treatment with Dex, may reduce the association of the receptor with the 
stabilizing TSG101 protein, whilst ‘loss’ of dimerization, via CpdA treatment, may stabilize this 
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interaction, however, this requires further investigation. Results do suggest, however, that TSG101 
is in some way required for CpdA’s ability to prevent receptor turnover, which is evident from the 
TSG101 knockdown experiment. 
5.2.5. GRα ubiquitination 
Results from the current study, and others
29,30,49,50
, have demonstrated that the GRα is degraded 
primarily via the proteasome. Furthermore, in order for the proteasome to successfully mediate the 
degradation of protein substrates, in this case GRα, the substrate must be tagged by a poly-ubiquitin 
chain to allow for substrate recognition by the proteasome
1,11,12,24–28
. This formation of the poly-
ubiquitin chain via the covalent attachment of numerous ubiquitin molecules to the substrate is 
mediated by a hierarchy of enzymes, one of them being FBXW7α11,14.  
The current study has shown that a ‘loss’ of receptor dimerization influences the interaction of the 
receptor with components of the UPS (i.e. FBXW7α), in turn affecting GRα stability.   
To determine whether a ‘loss’ of GRα dimerization modulated the ubiquitination status of the 
receptor, the current study investigated whether a ‘loss’ of GRα dimerization modulated the 
subcellular and co-localisation of GRα and ubiquitin, using immunofluorescence. Additionally, the 
effect of GRα conformation (i.e. monomer versus dimer) on the ubiquitination status of the receptor 
was investigated using co-immunoprecipitation and PLA. 
5.2.5.1. Ligand-dependent subcellular localisation of hGRwt modulates its co-localisation 
with endogenous ubiquitin. 5.2.5.1 
The subcellular and co-localisation of hGRwt and ubiquitin was determined as in Section 5.2.2.1 
(for hGRwt and FBXW7α).  
From the results, it is clear successful transient transfection of the hGRwt plasmid was achieved 
(Fig. 5.11A). This is evident when comparing the immunofluorescence for hGRwt (red) between 
the untransfected COS-1 cells and the cells transiently transfected with hGRwt (Fig. 5.11A). From 
the quantification, results from cells containing the hGRwt plasmid showed that the unliganded 
hGRwt is more nuclear than cytoplasmic, following 6 hours treatment with solvent (EtOH) 
(importantly, 3 hours longer than in FBXW7α experiment in Figure 5.5) (p < 0.001) (Fig. 5.11B). 
As expected, treatment with dimerization promoting synthetic GC, Dex, and endogenous GC, F, 
resulted in total nuclear translocation of hGRwt, with little to no receptor detected in the cytoplasm 
(p < 0.001) (Fig. 5.11B). A significant (c, p < 0.001) decrease in cytoplasmic hGRwt but, unlike 
Figure 5.5B which noted an increase, no change (b, p > 0.05)  in the nuclear hGRwt localization is 
observed following Dex and F treatment, relative to the unliganded hGRwt (Fig. 5.11B). A possible 
Stellenbosch University  https://scholar.sun.ac.za
 153 
 
explanation for this is the difference in the periods of compound treatment between the two 
experiments (i.e. 3 versus 6 hours). In addition, treatment with dimerization abrogating GC, CpdA, 
resulted in significant (p < 0.001) translocation of hGRwt from the cytoplasm to the nucleus, 
however, a portion (approximately 30%) of hGRwt remained in the cytoplasm (Fig. 5.11B). 
Although, following CpdA treatment, the hGRwt cytoplasmic localization was similar to that of the 
unliganded hGRwt, the nuclear localization of hGRwt was in fact greater (d, p < 0.05) than that of 
the unliganded receptor (Fig. 5.11B).  In terms of ubiquitin, ubiquitin expression was found to be 
predominantly nuclear (p < 0.001) (Fig. 5.11C) across all treatments.  
Cyt. Nuc. Cyt. Nuc. Cyt. Nuc. Cyt. Nuc.
0
20
40
60
80
hGRwt
EtOH Dex F CpdA
***
***
***
***
B
a
b
c c
b b,d
a
e
R
el
a
ti
v
e 
F
lu
o
re
sc
en
t 
In
te
n
si
ty
 (
R
F
I)
h
G
R
w
t 
ex
p
re
ss
io
n

 S
E
M
; 
4
0
- 
5
0
 c
el
ls
Cyt. Nuc. Cyt. Nuc. Cyt. Nuc. Cyt. Nuc.
0
10
20
30
40
C
*** *** *** ***
a
b
a,c
b
a,c
b
c
b
hGRwt
EtOH Dex F CpdA
R
el
a
ti
v
e 
F
lu
ro
sc
en
t 
In
te
n
si
ty
 (
R
F
I)
U
b
iq
u
it
in
 e
x
p
re
ss
io
n

 S
E
M
; 
4
0
-5
0
 c
el
ls
EtOH Dex F CpdA 
0
50
100
150
hGRwt
***
ns
D
***
%
 o
f 
p
ix
el
s 
re
p
re
se
n
ti
n
g
 t
o
ta
l 
h
G
R
w
t
th
a
t 
a
re
 c
o
-l
o
ca
li
ze
d
 w
it
h
 u
b
iq
u
it
in

 S
E
M
; 
n
 =
 2
0
-3
0
 c
el
ls
 
  
A 
hGRwt 
Ubiquitin 
EtOH Dex F CpdA Untransfected 
DAPI 
Merge 
Stellenbosch University  https://scholar.sun.ac.za
 154 
 
Figure 5.11: Ligand-dependent subcellular localisation of hGRwt modulates its co-localisation with endogenous 
ubiquitin. COS-1 cells were seeded into a 10 cm dish (1 x 10
6
 cells) and transiently transfected the next day with 
hGRwt using a transfection reagent. Following 24 hours incubation, cells were re-plated into 8 well chambers (3 x 10
4
 
cells/well) (Table 3.2) and the next day treated with solvent (EtOH), Dex or CpdA (10
-5
M) for 6 hours. Thereafter, cells 
were fixed, permeabilized, and immunofluorescence conducted, with antibodies specific for GRα and ubiquitin. Cells 
were then imaged using a confocal microscope. A representative image (A) illustrates the individual subcellular 
localisation of hGRwt (red, first row) and ubiquitin (green, second row), as well as the position of the cell’s nucleus 
(blue DAPI stain, third row) with the merge representing an overlay of all three channels (red, green and blue). For the 
quantification of the subcellular localisation of hGRwt and ubiquitin the relative fluorescence intensity (RFI) of the red 
(hGRwt) (B) or green (ubiquitin) (C) pixels was calculated for individual cells and plotted. In addition, the co-
localisation of these two proteins, in terms of hGRwt (D), was determined using the weighted co-localisation co-
efficients, where the horizontal dotted line represents 100% co-localisation of hGRwt with ubiquitin. Statistical analysis 
was conducted using a two-way ANOVA followed by a Bonferroni’s post-test comparing experimental values to 
solvent’s (EtOH) cytoplasm for hGRwt (B) or ubiquitin (C) (for a,b,c,d and e letters that are the same represent no 
significant difference between values whilst letters, which are different are significantly different from each other p < 
0.05) or comparing the cytoplasmic and nuclear expression of hGRwt (B) or ubiquitin (C) within a treatment group (ns, 
p > 0.05 and ***, p < 0.001).  For co-localisation (D), a one-way ANOVA with a Tukey’s post-test was used, 
comparing experimental values to the solvent (EtOH) (***, p < 0.001). 
Lastly, Figure 5.11D demonstrates the co-localisation (i.e. where these proteins occupy the same 
space) of these two proteins, hGRwt and ubiquitin, importantly with reference to hGRwt. In other 
words, the quantification graph (Fig. 5.11D) depicts the percentage (%) of the total hGRwt protein, 
which co-localizes with ubiquitin. From this graph, it is clear that, a large proportion 
(approximately 89%) of the unliganded hGRwt protein co-localizes with ubiquitin (Fig. 5.11D). 
This is due to the ubiquitous, but more nuclear, expression of ubiquitin throughout the cell (i.e. 
cytoplasm and nucleus). With that said, promoting hGRwt dimerization and its nuclear 
translocation, through Dex and F treatment, results in a significant (p < 0.001) increase in the co-
localisation of hGRwt and ubiquitin, with almost all (just less than 100%) of hGRwt now occupying 
the same space as ubiquitin (Fig. 5.11D). In contrast, treatment with dimerization abrogating CpdA 
(85%) did not significantly (p > 0.05) modulate the co-localisation of hGRwt and ubiquitin, relative 
to the unliganded receptor (89%). This is likely due to CpdA’s diminished ability to induce nuclear 
translocation of hGRwt to where the majority of the cellular ubiquitin expression occurs (i.e. the 
nucleus).  
5.2.5.2. Ligand-dependent subcellular localisation of hGRdim does not modulate its co-
localisation with endogenous ubiquitin. 
The subcellular and co-localisation of hGRdim and ubiquitin was determined as in Section 5.2.2.2 
(for hGRdim and FBXW7α).  
As with hGRwt in Figure 5.11, successful transient transfection of the hGRdim plasmid was 
achieved (Fig. 5.12A). Moreover, in cells containing the hGRdim plasmid and treated with solvent 
(EtOH) for 6 hours, an even subcellular distribution of the unliganded hGRdim, across the 
cytoplasm and nucleus, was noted (Fig. 5.12A and B). As expected, treatment with Dex and F 
resulted in total nuclear translocation of hGRdim, with negligible receptor levels detected in the 
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cytoplasm (p < 0.001) (Fig. 5.12A and B). In addition, and unlike hGRwt (Fig. 5.11A and B), 
treatment with the dimerization abrogating ligand, CpdA did not induce (p > 0.05) translocation of 
hGRdim from the cytoplasm to the nucleus (Fig. 5.12A and B) consistent with results in Figure 5.6.  
Interestingly, and in stark contrast to results obtained with hGRwt (Fig. 5.11C), ubiquitin 
expression in COS-1 cells transfected with hGRdim and treated with solvent (EtOH) or compounds 
(Dex, F or CpdA) appeared to vary considerably (Fig. 5.12C). From the image it appears that there 
is less endogenous ubiquitin expression in these COS-1 cells (Fig. 5.12A) in comparison to the 
endogenous ubiquitin expression in Figure 5.11A, however, this is not the case. Rather microscope 
settings were altered in this figure (Fig. 5.12A) to take into account, what appears to be, an increase 
in ubiquitin expression in cells transfected with hGRdim. Moreover, the quantification of the 
subcellular localisation of ubiquitin in these cells generally mimicked the subcellular localisation of 
hGRdim in Figure 5.12B. Specifically, in cells containing unliganded hGRdim, ubiquitin expression 
was prominent in both the cytoplasm and the nucleus, with significantly (p < 0.01) more so in the 
nucleus (Fig. 5.12C). Additionally, treatment with Dex and F, appeared to induce an unexpected 
increase in nuclear and decrease in cytoplasmic expression of ubiquitin, relative to cells containing 
unliganded hGRdim (Fig. 5.12C), suggesting that these GCs are modulating the subcellular 
localisation and potentially the expression of ubiquitin in what seems to be an hGRdim dependent 
manner. Conversely, CpdA treatment did not (p > 0.05) modulate the subcellular localisation or 
expression of ubiquitin, relative to cells treated with solvent (EtOH) (Fig. 5.12C).   
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Figure 5.12: Ligand-dependent subcellular localisation of hGRdim does not modulate its co-localisation with 
endogenous ubiquitin. COS-1 cells were seeded into a 10 cm dish (1 x 10
6
 cells) and transiently transfected the next 
day with hGRdim using a transfection reagent. Following 24 hours incubation, cells were re-plated into 8 well chambers 
(3 x 10
4
 cells/well) (Table 3.2) and the next day treated with solvent (EtOH), Dex or CpdA (10
-5
M) for 3 hours. 
Thereafter, cells were fixed, permeabilized, and immunofluorescence conducted, with antibodies specific for GRα and 
ubiquitin. Cells were then imaged using a confocal microscope. A representative image (A) illustrates the individual 
subcellular localisation of hGRdim (red, first row) and ubiquitin (green, second row), as well as the position of the 
cell’s nucleus (blue DAPI stain, third row) with the merge representing an overlay of all three channels (red, green and 
blue). For the quantification of the subcellular localisation of hGRdim and ubiquitin the relative fluorescence intensity 
(RFI) of the red (hGRdim) (B) or green (ubiquitin) (C) pixels was calculated for individual cells and plotted. In 
addition, the co-localisation of these two proteins, in terms of hGRdim (D), was determined using the weighted co-
localisation co-efficients, where the horizontal dotted line represents 100% co-localisation of hGRdim with and 
ubiquitin. Statistical analysis was conducted using a two-way ANOVA followed by a Bonferoni’s post-test comparing 
experimental values to solvent’s (EtOH) cytoplasm for hGRdim (B) or ubiquitin (C) (for a,b,c,d and e letters that are the 
same represent no significant difference between values whilst letters, which are different are significantly different 
from each other p < 0.05) or comparing the cytoplasmic and nuclear expression of hGRdim (B) or ubiquitin (C) within 
a treatment group (ns, p > 0.05 and ***, p < 0.001).  For co-localisation (D), a one-way ANOVA with a Tukey’s post-
test was used, comparing experimental values to the solvent (EtOH) (***, p < 0.001). 
Lastly, Figure 5.12D demonstrates the co-localisation of hGRdim and ubiquitin, with reference to 
hGRdim. From the graph, it is clear that no ligand-induced changes in the co-localisation of 
hGRdim and ubiquitin occur, with almost all (just less than 100%) of the receptor co-localised with 
ubiquitin, across treatments (Fig. 5.12D). This is in contrast to the result obtained for hGRwt and 
ubiquitin in Figure 5.11. 
5.2.5.3. Decreased GRα ubiquitination is observed following treatment with dimerization 
promoting GCs. 
Previously, a ‘loss’ of receptor dimerization influenced the ability of FBXW7α to interact with 
GRα. Moreover, the current study demonstrates that this is due to a difference in the 
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phosphorylation status between a GRα dimer a monomer. As ubiquitin, is considered the 
‘recognition signal’ for the degradation of the receptor, via the proteasome, it was decided to 
determine whether a ligand-induced ‘loss’ of receptor dimerization alters the ubiquitination status of 
GRα. 
To do this, an initial co-immunoprecipitation assay was conducted followed by PLA. For the co-IP, 
due to a lack of a high quality ubiquitin antibody at the time of this experiment, COS-1 cells were 
transiently co-transfected with HA-tagged ubiquitin and hGRwt, and treated with solvent (EtOH) 
and Dex (10 μM) and the pull-down conducted with a highly specific HA antibody, to determine 
ubiquitinated GRα (Fig. 5.13A). Unlike the co-IP, the PLA was done using a highly specific 
ubiquitin anti-body, which became commercially available to investigate the interaction of 
endogenous ubiquitin with hGRwt (Fig. 5.13B). 
In terms of the co-IP results, an unexpected decrease in hGRwt ubiquitination was observed, 
following treatment with dimerization promoting Dex, relative to unliganded hGRwt (solvent 
(EtOH)) (Fig. 5.13A). Moreover, results from the PLA, supported the co-IP result (Fig. 5.13B). 
Specifically, that promoting hGRwt dimerization through Dex and F treatment appeared to reduce 
the amount of ‘fluorescent red spots’, suggesting a decrease in GRα ubiquitination (Fig. 5.13B). 
One could postulate that this decrease in hGRwt ubiquitination is due to dimeric GRα already being 
degraded, by the proteasome, following 6 hours of Dex and F treatment and is supported by the 
reduction in hGRwt expression, noted in the hGRwt input of the co-IP in Figure 5.13A. 
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Figure 5.13: Decreased GRα ubiquitination is observed following treatment with dimerization promoting GCs. 
COS-1 cells were seeded, transfected and in some cases re-plated in 8 well chambers. Following 24 hours incubation, 
cells were treated with solvent or compounds for 6 hours. For the co-IP (A) experiment, after treatment with solvent 
(EtOH) or Dex (10
-5
M) cells were lysed and ubiquitinated hGRwt was immuno-precipitated with using an HA-
antibody. Western blotting was conducted to determine protein levels and GAPDH was probed to ensure equal protein 
loading. For the PLA (B), following treatment with solvent (EtOH), Dex, F or CpdA (10
-5
M), cells were fixed, 
permeabilized and PLA conducted using specific antibodies for GRα and ubiquitin. A representative image of 
individual cells demonstrating hGRwt ubiquitination, is shown, where the PLA signal is observed as distinct red ‘spots’ 
and the cell’s nucleus is depicted by the blue DAPI stain.  
Interestingly, and in contrast to Dex and F treatment, ‘loss’ of hGRwt dimerization, though CpdA 
treatment, seemed to induce ubiquitination of the receptor, however, the fluorescent spots appeared 
lighter, relative to the unliganded hGRwt (Fig. 5.13B). This suggests that monomeric GRα is in fact 
ubiquitinated, regardless of its lack of hyper-phosphorylation at Ser404 and interaction with the E3 
ligase, FBXW7α. 
Taken together, these results suggest that both unliganded and liganded hGRwt are able to undergo 
ubiquitination. With that said, less hGRwt ubiquitination is observed following treatment with Dex 
and F, which is likely due to significant degradation occurring at this time point. Of interest, is 
whether blocking degradation through the use of the proteasome inhibitor, MG132, would alter the 
observed receptor ubiquitination, following Dex and F treatment for 6 hours? The use of MG132 
should be considered in further investigations of GRα but is beyond the scope of the current study. 
Lastly, the ubiquitination of hGRdim should be investigated to gain further insight on the link 
between receptor dimerization and ubiquitination. Unfortunately, due to time and financial 
constraints, the PLA experiment could not be repeated using the GFP-tagged GRα plasmids as in 
Figure 5.7C. 
5.2.6. Co-treatment with CpdA lessens the extent of ligand-induced GRα protein down-
regulation, thereby partially restoring GRα levels.  
It is clear that the conformation of GRα is vital for ligand-induced receptor turnover at the protein 
level. More specifically, that dimeric GRα, formed following treatment with dimerization 
promoting, Dex and F, is more susceptible to down-regulation and undergoes significant ligand-
induced protein down-regulation. In contrast, monomeric GRα generated following CpdA treatment 
(or the use of hGRdim) evades degradation by modulating post-translational modifications of the 
GRα and altering interactions of GRα with components of the proteasome system, thus maintaining 
receptor levels. 
Up to now, the ligand-selective effects of Dex (dimerization promoting) and CpdA (dimerization 
abrogating) on hGRwt protein down–regulation have been investigated by treating COS-1 cells, 
transiently transfected with hGRwt, with either Dex (10 μM) or CpdA (10 μM) alone. To 
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investigate whether CpdA treatment, in combination with Dex, could minimize the extent of the 
Dex-induced down-regulation of the transiently transfected hGRwt protein, Western blotting was 
conducted following two co-treatments, namely Dex (1 nM) and CpdA (10 μM) or Dex (10 μM) 
and CpdA (10 μM) for 24 hours.  
Consistent with previous results (Chapter 4, Table 3), Figure 5.14 suggests that hGRwt protein 
expression is significantly (p < 0.001) reduced to 34%, relative to the solvent (EtOH), following 24 
hours treatment with a high Dex concentration (10 μM). As one would expect, based on previous 
findings in the current study, treatment with a lower concentration of Dex (1 nM) led to a slightly 
less, yet significant (p < 0.01) reduction in hGRwt protein expression to 52%, relative to solvent 
(EtOH) (Fig. 5.14), suggesting a dose-dependent effect. Moreover, CpdA (10 μM) treatment for 24 
hours lead to a slight (p > 0.05) increase in receptor expression relative to the solvent (EtOH), a 
result that is comparable to previous results in the current study (Chapter 4, Table 3).  
Interestingly, treatment of transiently transfected hGRwt with CpdA (10 μM) in combination with 
Dex (1 nM) significantly (p < 0.05) diminished receptor turnover, relative to Dex-induced hGRwt 
down-regulation, by maintaining hGRwt protein levels at 90% of solvent (EtOH) (Fig. 5.14). A 
similar but more significant (p < 0.01) effect was observed following treatment with CpdA (10 μM) 
in combination with the higher concentration of Dex (10 μM) (Fig. 5.14). 
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Figure 5.14: Treatment of Dex with CpdA partially restores hGRwt protein levels. COS-1 cells were seeded into a 
24 well plate (5 x 10
4
 cells/well) and transfected the next day with hGRwt using a transfection agent. Following 24 
hours incubation, cells were treated individually with solvent (EtOH), Dex (1 μM), Dex (10 μM) or CpdA (10 μM) or 
with CpdA (10 μM) in combination with either Dex (1 μM) or Dex (10 μM) for 24 hours. hGRwt protein expression 
was confirmed by Western blotting where GAPDH was probed to ensure equal protein loading. Western blot shown 
(inset) is representative of four independent experiments. For quantification, the intensity of the hGRwt and GAPDH 
bands were determined using My ECL Image Analysis software and hGRwt levels were then normalised to GAPDH 
expression. For each treatment condition, hGRwt expression as expressed as a percentage (average ± SEM) of hGRwt 
expression in presence of the solvent (EtOH), which was set at 100% (dotted line). To determine the effect of each 
treatment condition on hGRwt protein expression relative to the solvent (EtOH), statistical analysis for was conducted 
using a one-way ANOVA with a Bonferroni post-test (ns, p> 0.05, *, p < 0.05, **, p < 0.001 and ***, p< 0.001). To 
assess the ability of CpdA to preserve hGRwt expression in the presence of Dex a t-test was conducted comparing 
hGRwt expression following Dex treatment (either 1 μM or 10 μM) alone  to Dex treatment in combination with CpdA 
(10 μM) (#, p < 0.05, ##, p< 0.01). 
Taken together, results in Figure 5.14 suggest that CpdA, when combined with Dex, has the ability 
to restrict Dex-induced hGRwt protein down-regulation to a certain extent. One could postulate that 
this is due to CpdA’s ability to abrogate Dex-induced hGRwt dimers. More specifically, that CpdA 
in combination with Dex, results in a lower degree of hGRwt dimerization than Dex alone does, 
which partially prevents hyper-phosphorylation at Ser404 and interaction with FBWX7α, two 
processes, results in the current chapter have highlighted as fundamental for receptor turnover, 
however, this requires investigation. 
5.3. Discussion  
The GC/GRα signalling pathway is subjected to layers of regulation, which function to co-ordinate 
the localization, activity and ultimately expression of various proteins. Central to this pathway is the 
GRα, whose concentration is an important determinant in GC sensitivity5,51–54. 
It is well documented that ligand-induced down-regulation of this receptor occurs
29,30,47,55–60
. 
Moreover, in Chapter 4, a novel requirement for GRα dimerization in mediating ligand-induced 
receptor turnover, specifically via the proteasome degradation pathway, was described. This finding 
provided further insight into the GC/GRα signalling pathway and encouraged further investigation 
into the molecular mechanisms (i.e. post-translational processing of the receptor) involved in 
preventing ligand-induced GRα down-regulation of predominantly monomeric GRα, which was 
explored in the current chapter.  
Essentially, the current chapter begins by determining whether the requirement for GRα 
dimerization in receptor turnover is dependent on a mutation at a specific site and whether it is 
species specific. Having provided further evidence for this link between receptor dimerization and 
protein turnover, this study demonstrates the ability of GRα conformation (i.e. monomer versus 
dimer) to modulate the post-translational processing of the receptor, as well as the interaction of the 
GRα with enzymes associated with the UPS, which ultimately, in part, affected the extent of 
receptor turnover mediated via the proteasome. 
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A factor common to all GRα mutants, with the exception of the natural mutant, is the single amino 
acid exchange of an alanine to a threonine within the D-loop of the DNA-binding loop (Fig. 5.4A). 
All GRα mutants, regardless of species and the presence of additional single point mutations, 
displayed a reduced receptor protein turnover, following treatment with Dex. Specifically, the 
mutation of an alanine residue to a threonine at position 458 (human) and 465 (mouse) is 
fundamentally important in restricting ligand-induced GRα degradation (Fig. 5.4). Moreover, 
additional mutations, such as an asparagine to an aspartate at position 454, in some of these GRα 
mutants (i.e. hGR (N545D/A458T) and hGR(D4X)) partially restores Dex-mediated receptor 
turnover. Additionally, unlike some of the other GRα mutants, the natural mutant hGRα(R477H), 
whose mutation occurs outside of the D-loop, did not undergo significant Dex-induced GRα protein 
down-regulation. Generally speaking, these mutants display a reduced ability to bind DNA and thus 
a reduced ability to induce transactivation of GC-responsive genes
36,37,40,61,62
. These characteristics 
suggest these mutants are likely to be monomeric, however, apart from the classical dimerization 
deficient mutants (hGRdim and mGRdim), little evidence for the ability of these mutants to form 
dimers exists. Recently a study by Presman et a.l
63
 produced a mouse GRα mutant, which contains 
the classical dimerization deficient mutant (A465T) as well as an additional mutation, an isoleucine 
to an alanine substitution at position 634 (I634A), in the ligand-binding domain of the receptor, 
which is severely compromised in its ability to form receptor dimers and mediate the transactivation 
of GC responsive genes. With the current study having demonstrated a novel link between GRα 
dimerization and receptor turnover, it remains to be elucidated, and is of significant interest, 
whether this mutant, termed GRmon
63
, is capable of undergoing ligand-induced protein turnover. 
Recently, GRα was identified as a novel substrate for a highly specific E3 ligase, FBXW7α. This 
protein is an f-box protein, which functions as part of an SCF (Skp1/Cul1/f-box) type of E3 
ubiquitin ligase complex, which as a whole, is responsible for targeting various proteins for 
proteasomal degradation
14. Furthermore, the expression of FBXW7α has been shown to be capable 
of regulating the stability of the receptor, in a ligand-dependent manner
14
. Specifically, in cells 
where an FBXW7α deficiency exists, a decrease in the extent of receptor turnover and a 
corresponding increase in GRα stability, in the presence of Dex, are observed14. Moreover, 
silencing FBXW7α in HEK293 and HeLa cells, in the presence of Dex, led to an increase in GRα 
protein levels, similarly to the noted increase in receptor levels following proteasome inhibition 
with MG132, confirming FBXW7α’s role in mediating GRα protein turnover14. Furthermore, in 
CHX-chase experiments where FBXW7α had been silenced, notable increases in the half-lives of 
the GRα protein in Peer (from 3.8 hours to 5.2 hours) and K652 (7.5 hours to 9.8 hours) leukemic 
cell lines, were noted, even following treatment with Dex
14
. Lastly, in HCT116-FBXW7 knockout 
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cells, reconstituting the FBXW7α expression in these cells led to an almost 3-fold ligand-induced 
decrease in the half-life of the GRα protein14.  
Importantly, in order for FBWX7α to mediate successful ligand-induced GRα turnover, a physical 
interaction between the E3 ligase and the receptor is required
14
. In terms of receptor conformation, 
‘gain’ of GRα dimerization, via treatment with dimerization promoting Dex (10 μM for 1 hour) 
induces the interaction of transiently transfected GRα and FBXW7α in HEK293 cells, promoting its 
degradation by the proteasome
14
. In the current study, it was found that the greatest Dex-induced 
interaction between hGRwt and FBXW7α occurred after 3 hours treatment with Dex (Fig. 5.7A). 
Having established the optimal treatment conditions, using dimerization promoting Dex treatment, 
for the formation of the GRα/FBXW7α complex, the effect of a ‘loss’ of GRα dimerization on the 
ability of a GRα monomer to interact with the catalytically active E3 ligase, FBXW7α, which to our 
knowledge had not yet been elucidated, was investigated. 
Broadly speaking, results in which CpdA treatment was used to abrogate receptor dimerization, 
suggested that a ‘loss’ of GRα dimerization restricts interaction of the receptor with FBXW7α 
(Table 1). More specifically, unlike dimerization promoting Dex and F, CpdA did not induce an 
increase in the interaction of GRα and FBXW7α, relative to the unliganded receptor, in either the 
co-immunoprecipitation or the PLA experiment, where COS-1 cells were transiently transfected 
with hGRwt or GFP-hGRwt respectively (Table 1 and Fig. 5.7). Additionally, ‘loss’ of GRα 
dimerization, as a result of CpdA treatment, appeared to partially reduce interaction beyond the 
basal interaction of the unliganded receptor, which is likely explained by CpdA’s ability to abrogate 
existing unliganded GRα dimers48.  
In support of the CpdA results, ‘loss’ of GRα dimerization through the use of mutant (GFP-
hGRdim) restricted Dex’s ability to induce interaction of the receptor and FBXW7α (Table 1 and 
Fig. 5.7), in contrast to GFP-hGRwt. A similar result was obtained for the untagged hGRdim in the 
PLA experiment (data not shown); however, this may simply be due to differences in the expression 
between untagged hGRwt and hGRdim (Fig. S1). In terms of the co-IP results for untagged 
hGRdim (data not shown), no detectable FBXW7α expression was noted following pull-down using 
a GRα anti-body and Western blotting. This may be due to the lack of hGRdim and FBXW7α 
interaction, however, one cannot exclude the lower expression of the hGRdim in the COS-1 cells as 
a possible reason for this lack of interaction.  
The interaction of FBXW7α with its substrates has been shown to require prior phosphorylation at 
serine or threonine residues of the substrate
45,46
. Of particular interest, for the current study, is the 
way in which FBXW7α interacts with GRα, namely via a CDC4 phosphodegron consensus 
sequence
8
. Interestingly, the amino acid sequence which flanks a recently discovered GRα 
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phosphorylation site, Ser404, resembles this highly conserved CDC4 phosphodegron motif and a 
study by Malyukova et al.
14
 demonstrated that the interaction of FBXW7α with GRα, is dependent 
on hyper-phosphorylation at this novel site
14
. Generally, phosphorylation of the GRα, which is 
considered a phospho-protein with phosphorylation occurring at a number of different sites (Fig. 
5.2), is known to affect the transcriptional response, subcellular localization and protein-protein 
interactions of the receptor with co-regulators
9
. Additionally, Galliher-Beckley et al.
8
 demonstrated 
that ligand-induced hyper-phosphorylation at Ser404 modulates GRα stability by encouraging an 
increase in receptor degradation. With this in mind, it seemed necessary to investigate whether the 
novel requirement for GRα dimerization in mediating the ligand-induced interaction of GRα and 
FBXW7α, established in the current study, would be effectuated at the level of Ser404 
phosphorylation, which then in combination modulates the protein stability of the receptor.  
Indeed, a ‘loss’ of GRα dimerization, through treatment with dimerization abrogating CpdA, 
significantly restricted phosphorylation of the receptor (Table 1 and Fig. 5.9).  By setting Dex-
induced hyper-phosphorylation at Ser404 as 100%, the current study reports a substantial reduction 
in Ser404 phosphorylation to 58% in hGRwt transfected COS-1 cells and 54% in the endogenous 
system (i.e. HepG2 cells), following CpdA treatment (Fig. 5.9A and C). Interestingly, this was not 
the first time CpdA’s ability to restrict GRα phosphorylation had been demonstrated. In a study by 
Avenant et al.
64
, treatment of transiently transfected COS-1 cells, with dimerization abrogating 
CpdA restricted phosphorylation of GRα relative to Dex (100%) at two additional sites, namely 
Ser226 (14%) and Ser211 (24%). This was confirmed in LBT2 cells containing endogenous GRα, 
where CpdA treatment restricted phosphorylation at Ser226 and Ser211 (< 25%), relative to Dex
64
. 
Interestingly, both these sites have also been shown to be linked to receptor turnover, albeit to a 
lesser extent.
64
 
Additionally, results using the dimerization deficient mutant, hGRdim, to replicate the ‘loss’ of 
GRα dimerization observed with CpdA treatment, demonstrated phosphorylation at Ser404 was in 
fact undetectable across all treatment conditions (Table 1 and Fig. 5.9B). A study by  Galliher-
Beckley et al.
8
 demonstrated that a mutant (S404A) incapable of being phosphorylated at Ser404, 
much like hGRdim, had an increased half-life, relative to the wild type GRα, following Dex 
treatment. Furthermore, to explain the increased half-life of the Ser404 mutant, Galliher-Beckley et 
al.
8
 speculated that the lack of phosphorylation at Ser404, causes GRα to adopt different 
conformations, relative to the wild-type GRα. Using a trypsin digest experiment, this group 
demonstrated that the mutant (incapable of Dex-induced hyper-phosphorylation at Ser404) did 
indeed adopt a different conformation to that of the wild-type GRα, following Dex treatment8. From 
the results, in the current study, it would seem probable that the conformation of the Ser404 mutant 
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is predominantly monomeric, however, this requires further investigation. Furthermore, although 
we believe that the conformation of GRdim is likely to restrict the Dex-induced phosphorylation at 
Ser404, we cannot exclude that the mutation itself may affect the interaction of the mutant with the 
GSK enzyme responsible for phosphorylation, at this site. 
In contrast to the lack of phosphorylation of the monomeric GRα, ‘gain’ of GRα dimerization 
(induced by the binding of dimerization promoting GC’s, Dex and F) often results in maximal 
hyper-phosphorylation of GRα at a number of phosphorylation sites64, but not all (i.e. Ser203)49. 
Avenant et al.
64
 showed a Dex and F-mediated maximal GRα phosphorylation at Ser226 (100 and 
122%, respectively) and Ser211 (100 and 91%, respectively). This finding is in line with the 91% F-
induced GRα phosphorylation at Ser404, relative to Dex (100%), in the current study (Fig. 5.9A). 
Furthermore, a study which identified the novel site, Ser404
8
, reported a Dex-induced increase, 
between 1.5 to just over 2-fold, in GRα phosphorylation at Ser404, relative to the basal 
phosphorylation of the unliganded GRα (EtOH), in a number of cell lines either with transfected 
GRα (i.e. U2OS cells) or endogenous GRα (i.e. HeLa, MG-63, A549 and HepG2 cells). This result 
is similar to the Dex-induced (1.5-fold) increase observed in the current study in both the COS-1 
(transiently transfected with hGRwt) and HepG2 cells (Fig. 5.9A and C). Lastly, using the GSK3β 
inhibitor (BIO), Galliher-Beckley et al.
8
 demonstrated a 94% inhibition of the Dex-induced 
phosphorylation at Ser404, however, no investigation into the direct effect of this BIO inhibition on 
GRα stability, was made. Results from the current study, demonstrated that inhibition of GRα 
phosphorylation at Ser404 using BIO
8
 could partially block Dex-induced receptor down-regulation, 
confirming the role of ligand-induced hyper-phosphorylation at Ser404 in driving receptor turnover 
(Fig. 5.9D). 
Table 5.1: Summary of results on GRα phosphorylation at Ser404 and receptor interaction with FBXW7α 
 
Taken together, these results, in combination with previous findings
8,64
 confirm that a ‘loss’ of GRα 
dimerization restricts hyper-phosphorylation of GRα at Ser404, which consequently modulates the 
Unliganded
Ligand-induced 'loss' of GRα 
dimerization
PTM or 
interaction
GRα EtOH Dex F CpdA Cell line Technique Figure
hGRα + ++ ++ +/- HepG2 WB 5.9C
hGRwt + ++ ++ +/- COS-1 WB 5.9A
hGRwt + +++ ++ +/- COS-1 Co-IP 5.7A and B
GFP-hGRwt + ++ N.D - COS-1 PLA 5.7C
pSer404 hGRdim U.D U.D N.D U.D COS-1 WB 5.9B
FBXW7α GFP-hGRdim + - N.D + COS-1 PLA 5.7C
*In the table U.D refers to undetected and N.D to not detected (i.e. experiment was not done), '+' suggests and increase and '-' a decrease ( +++ > ++ > + > +/-  > -), 
Western blotting (WB), co-immnoprecipitation (Co-IP) and proximity-ligation assay (PLA).
Ligand-induced 'gain' of GRα 
dimerization 
pSer404
FBXW7α
Mutant-induced 'loss' of GRα dimerization 
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interaction of the receptor with the catalytically active, FBXW7α. This is likely to be one of the 
molecular mechanisms in which monomeric GRα evades proteasomal degradation. 
An essential requirement for the degradation of proteins via the proteasome is substrate 
ubiquitination, which occurs in a multi-step manner, via a number of enzymes
11
. Tagging of a 
protein substrate with ubiquitin is completed by E3 ligases (e.g. FBXW7α), which bind the protein 
substrate and mediate the transfer of the activated ubiquitin molecule from another UPS enzyme 
(i.e. an E2 conjugating enzyme) to the substrate
11. Specifically, in terms of GRα, interaction of the 
receptor with FBXW7α is an essential step linking preceding GRα phosphorylation to subsequent 
GRα ubiquitination, at a single ubiquitin site29,30, and consequent proteasomal degradation8. For this 
reason, the current study investigated whether differences, dependent on GR conformation (i.e. 
dimer versus monomer), in the ubiquitination status of the GRα exist, following ligand treatment for 
6 hours. This length of treatment was based on results from the current studies’ FBXW7α 
experiment, optimization (data not shown) and previous studies, which have investigated GRα 
ubiquitination
13,30,65
.  
Unfortunately, results from our ubiquitination experiments proved to be somewhat inconclusive. 
Whilst a Dex-induced increase in the ubiquitination status of wild type GRα was expected, a 
significant decrease was noted (Fig. 5.13). It must be noted, that in the current study, MG132 was 
not employed to block proteasome degradation before 6 hours compound treatment in the ubiquitin 
experiment and is something which should be considered in future investigations. A likely reason 
for the decrease in GRα ubiquitination, following Dex treatment, is significant ligand-induced GRα 
degradation after 6 hours (approximately 40% reduction in receptor levels according to Figure 
4.5A). Unlike other steroid receptors
16,66
, very little evidence exists for a significant-ligand induced 
increase in GRα ubiquitination, with a number of studies rather showing a decrease in GRα 
ubiquitination, even in the presence of proteasome inhibition using MG132
30,65
. A study by Wallace 
et al.
30
 demonstrated an obvious reduction in the ubiquitination status of GRα following treatment 
with dimerization promoting Dex (100 nM for 16 hours) even in the presence of the proteasome 
inhibitor, MG132, using similar conditions to that of the current study, namely COS-1 cells 
transiently transfected with untagged hGRwt and ubiquitin (Fig. 5.13A). In a study by Wang et 
al.
65, GRα ubiquitination occurred in both the absence and presence of Dex (1 μM) for 18 hours and 
MG132 (5 μM), in HT22 cells with endogenous GRα and transiently transfected ubiquitin. 
Interestingly, and in contrast to Wallace et al.
30
, a lack of receptor turnover is observed in HT22 
cells 
65, even though ubiquitination of both the unliganded and liganded (i.e. Dex treated) GRα 
occurs. A reason provided for this lack of receptor turnover in the HT22 cells, is that GRα has the 
capacity to be ubiquitinated, however, it’s degradation is hampered at the level of delivery of the 
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ubiquitinated receptor to the proteasome, mediated by E3 ligases, or at the level of proteasome 
activity
65. In terms of the current study, this could explain why GRα ubiquitination is observed 
following treatment with dimerization abrogating GC, CpdA (Fig. 5.13B) and suggests monomeric 
GRα is capable of being ubiquitinated, however, it may not efficiently engage with the proteasome 
thus evading degradation. Moreover, taking into account that monomeric GRα restricts the 
interaction of the receptor with E3 ligase, FBXW7α, this demonstration of GRα ubiquitination 
following treatment with CpdA supports the notion of monomeric GRα stabilizing an interaction 
with other UPS enzymes. In support of this idea is the ligand-dependent switching of ubiquitin 
dependent proteasome degradation for the ER, which has been successfully demonstrated
67
. 
Specifically, CHIP binds the ER and mediates its ubiquitination and turnover in the absence of 
ligand, however, binding of estrogen to the ER results in dissociation of CHIP, thus it is postulated 
that ligand-induced ER degradation occurs via another ubiquitin-proteasome mediated pathway and 
likely another E3 ligase
67
. In support of this finding is the fact that unliganded ER degradation is 
inhibited in cells where CHIP is absent, however, ligand-induced ER turnover in these cells still 
occurs
67
. One could postulate that predominantly monomeric GRα47,48 associates with a complex 
involving CHIP and the catalytically inactive E2-conjugating enzyme, TSG101
15
, whereas dimeric 
GRα, following treatment with Dex or F, preferentially associates with FBXW7α, rather than CHIP 
or TSG101. 
GRα’s association with the catalytically inactive E2 conjugating enzyme, TSG101, is known to be 
dependent on the phosphorylation status of the receptor
15
. More specifically, TSG101 has been 
shown to associate with the hypo-phosphorylated (at Ser203 and Ser211) form of GRα where, in the 
absence of ligand it binds to GRα, protecting it from degradation15. Interestingly, although results 
from the current study suggest that CpdA treatment results in predominantly monomeric, hypo-
phosphorylated GRα, it did not induce a significant increase in the association of GRα and TSG101 
(Fig. 5.10B). With that said, knockdown of the stabilizing TSG101 protein resulted in a 1.5-fold 
reduction in CpdA-treated GRα expression (Fig. 5.10C), a slightly lower fold destabilization (2.9-
fold) than that reported for the non-phosphorylatable mutant (GRα S203A/S211A) used in the 
Ismail et al.
15
 study, following TSG101 knockdown, suggesting, that unlike the GRα mutant 
S203A/S211A, CpdA treatment of wild type GRα might allow for a degree of basal 
phosphorylation of the GRα at Ser404 and other sites (i.e. Ser203 and 211) also supported by Figure 
5.9A and C. Furthermore, the ability of proteasome inhibition (MG132) to impede GRα 
destabilization by approximately 1.5-fold, following CpdA treatment in the absence of TSG101 
(Fig. 5.10C), is similar to the 2-fold increase in the stability of the non-phosphorylatable mutant in 
the presence of MG132, but absence of TSG101
15
. These results with TSG101 provide food for 
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thought with regards to how the conformation of hypo-phosphorylated GRα may dictate the 
associations of the receptor with other UPS enzymes (i.e. TSG101).  
Recent evidence has demonstrated a link between the nuclear shuttling of proteins and protein 
turnover
41,68
. Thus in addition to determining the nature of the interaction of GRα with FBXW7α 
(i.e. using PLA), it was necessary to consider the subcellular and co-localization of GRα with 
proteins of the UPS, as well as, elucidate how a ‘loss’ of receptor dimerization may affect the co-
localization of GRα and UPS proteins, in subcellular compartments. This provided further insight 
into the regulatory molecular mechanisms involved in ligand-induced receptor down-regulation.  
In terms of the receptor, the unliganded GRα is largely cytoplasmic69, however, in support of the 
findings in Figure 5.5 and 5.6, some studies report that the unliganded GRα is evenly distributed 
throughout the cytoplasm and the nucleus, with the overall subcellular localization reflecting both 
the rate of active nuclear import as well as passive export of receptor export
43
. Moreover, the 
subcellular localisation of the unliganded GRα is influenced by the receptor concentration within 
the cell
43,44
. In both cases, it is thought that the unliganded GRα is sequestered, to a certain extent, 
in the cytoplasm bound to a multi-protein complex, whose primary function is to mask the 
receptor’s nuclear localization signal (NLS) and maintain the receptor in a favourable conformation 
for ligand-binding
70–72
.  Interestingly, although considered a transcriptional regulator
15
, TSG101, is 
predominantly cytoplasmic
73
. Moreover, it is postulated that the interaction of TSG101 and GRα, 
via the N-terminus of the receptor,  provides a mechanism in which the unliganded GRα is 
protected from degradation
15
. In contrast to TSG101’s cytoplasmic nature, the E3 ligase, FBXW7α, 
is specifically located within the peri-nuclear space of a cell, also referred to as the nucleoplasm
14
. 
This is evident from the subcellular localization results, of the current study, which depict a 
miniscule amount of FBXW7α expression in the cytoplasm with almost all FBXW7α expression 
found in the nucleus (Fig. 5.5 and 5.6). Additionally, in Figure 5.5A and 5.6A, a prominent ‘ring’ of 
FBXW7α expression around the cell’s nucleus, is observed, and although it appears as if FBXW7α 
is found within the nucleus, one must keep in mind that these images represent an overview of a 
range of images taken throughout the cell. Thus what appears to be nuclear expression of this E3 
ligase is likely the expression of FBXW7α found in the peri-nuclear space at the top and bottom of 
the cell. Furthermore, due to the nuclear localization of FBXW7α and the predominantly 
cytoplasmic nature of unliganded GRα, it makes sense that little co-localization of these two 
proteins occurs, in the absence of GC treatment (Fig. 5.5D and 5.6D). In Figure 5.7B fluorescent 
red ‘spots’, indicating association between GRα and FBXW7α, were detected in the cytoplasm, 
which is unexpected due to the nuclear nature of FBXW7α. As the interaction of FBXWα with GRα 
is dependent on dimerization and phosphorylation at Ser404
8
, it is likely a small population of 
Stellenbosch University  https://scholar.sun.ac.za
 168 
 
ligand-independent GRα dimers in the cyoplasm43 and that the signal detected outside the nucleus 
reflects basal interaction of the unliganded receptor with FBXW7α. Moreover, the PLA assay is 
highly sensitive and involves the amplification of a signal (i.e. red ‘spot’) unlike 
immunofluorescence, which is potentially the reason why no FBXW7α was detected in the 
cytoplasm using immunofluorescence. 
Unlike the unliganded GRα, promoting receptor dimerization, with Dex and F treatment, shifts the 
subcellular localization of GRα, to predominantly nuclear (Fig. 5.5A and B). Thus, ‘gain’ of 
receptor dimerization following Dex and F treatment, reflects a point in time (i.e. 3 hours post-
treatment) where the import rate is significantly higher than the export rate. A study by Robertson et 
al.
43, demonstrates that 50% of GRα is localized within the nucleus after just 4 to 5 minutes, 
following treatment with Dex and F (1 μM), although nuclear import is thought to be ligand and 
concentration dependent
43
. Moreover, a maximal nuclear localization of the wild-type GRα of 
approximately 95% was reached, 1 hour post-treatment with Dex
43
. This finding supports those of 
the current study where almost all (98.6%) of the GRα protein expression is found in the nucleus, 
following treatment with Dex and F (Fig. 5.5 A and B). The nuclear localization of GRα is initiated 
via a conformational change in the receptor, induced by ligand-binding, and the consequent 
dissociation of the inhibitory multi-protein complex
70–72
. It may be that TSG101 is found within this 
multi-protein complex, however, the exact positioning of TSG101, requires further investigation. 
Nevertheless the ligand-bound GRα moves away from the cytoplasmic TSG101, toward the 
nucleus, and as a result of this movement of GRα, an increase in the co-localization of the ligand-
induced dimeric GRα with FBXW7α, occurs (Fig. 5.5D), suggesting that this interaction is likely to 
occur in the nucleus/nucleoplasm. As mentioned the interaction of FBXW7α with GRα is dependent 
on hyper-phosphorylation of the receptor at Ser404, and although basal Ser404 phosphorylation of 
GRα appears to be cytoplasmic, hyper-phosphorylation of this site is thought to occur within the 
nucleus
8. The fact that the enzyme, which is responsible for mediating phosphorylation of GRα at 
this site, namely GSK-3β, is a predominantly nuclear kinase, provides further support for this 
suggestion
8
. Taken together, a ligand-induced ‘gain’ of GRα dimerization drives the receptor into 
the nucleus of the cell where it undergoes phosphorylation at Ser404, which subsequently 
encourages the binding of FBXW7α ultimately leading to its degradation. 
GRα’s ability to dimerize (i.e. ‘gain’ of receptor dimerization), although not an absolute 
requirement for nuclear translocation, has been shown to influence the nucleo-cytoplasmic shuttling 
of the receptor, with a ‘loss’ of GRα dimerization influencing the extent of nuclear import of the 
receptor
43
. Interestingly, a study by Robertson et al.
43
 suggests the effect a ‘loss’ of GRα 
dimerization has on the half-life (i.e. time taken for 50% nuclear distribution) and maximal nuclear 
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import of the receptor, is similar when preventing dimerization through CpdA treatment of the wild-
type receptor or Dex treatment of the dimerization deficient mutant. Results from the current study, 
slightly challenge these findings with different maximal nuclear localization values reported for 
monomeric CpdA-treated hGRwt and monomeric Dex-treated hGRdim, approximately 73% and 
98% respectively (Fig. 5.5 and 5.6). A possible reason for this discrepancy is the different treatment 
periods of 1 hour
43
 versus 3 hours. Thus, CpdA treatment may be, in part, hampering GRα protein 
turnover by sequestering a portion of the receptor population in the cytoplasm, away from GSK-3β-
mediated hyper-phosphorylation at Ser404 and preventing interaction withFBXW7α. This notion is 
supported by the finding in the current study, which demonstrates knockdown of the largely non-
nuclear TSG101 (known to associate with the hypo-phosphorylated GRα), which results in a 26% 
reduction in CpdA-hGRwt protein expression (i.e. by proteasomal degradation). This is comparable 
to the small portion of GRα residing in the cytoplasm, following CpdA treatment (Fig. 5.5). 
However, with that said, a much larger proportion of monomeric CpdA-treated GRα and almost all 
monomeric Dex-treated hGRdim are found in the nucleus, which eludes to the fact that the slight 
differential subcellular localisation of GRα monomers and the co-localisation of these monomers 
with UPS components cannot be the sole reason for monomeric GRα’s increased stability. In other 
words, the lack of interaction between monomeric GRα and FBXW7α is not only due to these two 
proteins existing in different subcellular compartments within the cell. Although the ability of the 
GRα phosphorylation mutant (at Ser404)8 to dimerize has not been investigated, the subcellular 
localization of this mutant has been described, with total nuclear import observed, following 1 hour 
of Dex. This finding further confirms that differential subcellular localization of GRα is not the 
primary method of evading receptor turnover, though, its contribution should not be disregarded, 
and that it is rather the modulated post-translational processing of the GRα which protects the 
receptor from ligand-induced down-regulation. 
Finally, the current study demonstrates that the dimerization abrogating GC, CpdA, is able to 
partially restore GRα protein levels, in the presence of the dimerization promoting GC, Dex (Fig. 
5.14). One could postulate that CpdA treatment is in some way modulating the dimerization status 
of GRα by, in part, preventing the formation of total GRα dimers, induced by Dex. This in turn may 
be restricting the post-translational processing of the receptor, ultimately stabilizing it to a degree. 
To fully understand the effect of Dex and CpdA on GRα, it would be necessary to investigate and 
compare the dimerization state of the receptor relative to GRα expression, following Dex and CpdA 
treatment, alone or in combination. A possible method to do this is the Number and Brightness 
Assay, eloquently described by Presman et al.
63
. 
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5.4. Conclusion 
In conclusion, results from this chapter provide further evidence for a novel requirement for GRα 
dimerization in mediating ligand-induced down-regulation of the receptor, which was established in 
Chapter 4. Additionally, the effects of a ‘loss’ of GRα dimerization on the post-translational 
processing of the receptor, as well as the interaction of the receptor with UPS components, was 
highlighted. Essentially, two molecular mechanisms, namely phosphorylation of GRα at Ser404 and 
interaction of the receptor with E3 ligase, FBXW7α, are restricted when a population of GRα 
monomers rather than dimers exists. Moreover, results from the CHIP and TSG101 experiments 
provide food for thought with regards to their association with differential GRα conformations; 
however, these interactions require further investigation. Lastly, to our knowledge, this is the first 
time a link between GRα conformation and the post-translational processing of the receptor has 
been established.  
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5.6. Supplementary Figures 
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Figure S1: ‘Loss’ of GRα dimerization modulates its interaction with FBXW7α (Repeat 2). COS-1 cells were 
seeded, transfected Following 24 hours incubation, cells were treated with solvent (EtOH), Dex, F or CpdA (10
-5
M) for 
3 hours. For the co-IP experiment, cells were lysed after compound treatment and FBXW7α was immune-precipitated 
with hGRwt. Western blotting was conducted to determine protein expression and GAPDH was probed to ensure equal 
protein loading. A representative blot of three independent experiments is shown. 
 
 
 
 
 
Figure S2: COS-1 cells are express different concentrations of hGRwt following transient transfection. COS-1 
cells were seeded into a 10 cm dish (1 x 10
6
 cells) and were transiently transfected the next day with hGRwt using a 
transfection reagent. Following 24 hours incubation, cells were re-plated into 8 well chambers (3 x 10
4 
cells/well) and 
the next day treated with solvent (EtOH) for 3 hours. Thereafter, cells were fixed, permeabilized and 
immunofluorescence conducted using a GRα antibody. Following immunofluorescence, cells were imaged using a 
confocal microscope. 
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Figure S3: Control figure for PLA depicting no cross-reactivity of primary antibodies. COS-1 cells were seeded, 
left untransfected or transfected with hGRwt and re-plated in 8 well chambers. Following 24 hours incubation, cells 
were treated with solvent (EtOH) for 3 hours. For the PLA, following treatment cells were fixed, permeabilized and 
PLA conducted using specific primary antibodies for GRα together with FBXW7α or ubiquitin (first column), with no 
primary antibodies (second column), with only the GRα primary antibody (third column) or with FBXW7α or ubiquitin 
primary antibodies only (fourth column), after which cells were imaged. A representative image of individual cells is 
shown. In this representative image if the PLA signal was positive it would be observed as distinct red ‘spots’ and the 
cell’s nucleus is depicted by the blue DAPI stain. From the images one can see our negative controls were successful. 
 
Figure S4: Increasing GRα concentrations result in a concurrent decrease in its interaction with FBXW7α. COS-
1 cells were seeded into a 10 cm dish (1 x 10
6
 cells), and were transiently transfected the next day with GFP-hGRwt 
using a transfection reagent. Following 24 hours incubation, cells were re-plated into 8 well chambers (3 x 10
4 
cells/well) and the next day treated with solvent (EtOH) for 3 hours. Thereafter, cells were fixed, permeabilized, and 
immunofluorescence (green) and PLA conducted (red) after which cells were imaged using a confocal microscope). For 
the quantification of the interaction of GRα (GFP-hGRwt) and FBXW7 the dots/cell (red) was quantified using 
IMAGEJ software, whilst the GRα (GFP-hGRwt) concentration was calculated in terms of relative fluorescence 
intensity (RFI), using the ZENN software for individual cells. The cell population (1 to 79 individual cells) was plotted 
from low to high GRα concentration (i.e. increasing GFP (RFI) signal) (indicated by green on graph) with each cells 
corresponding GRα/FBXW7α interaction (dots/cell). 
 
Figure S5: Quantifying GFP-hGRwt concentration ranges using FITC beads and FACS (unpublished work by 
member of our research group). COS-1 cells were seeded into a 10 cm dish (1 x 10
6
 cells) and the next day, were 
transiently with 4000ng of mGRwt using the DEAE-dextran method. After 72 hours, cells were re-suspended in 20% 
FCS medium and sorted into low, medium and high GRα concentrations, relative to calibrated FITC beads by means of 
FACS. Cells were then replated in 8 well chambers in individual populations (i.e. low GRα/well, medium GRα/well and 
high GRα/well) and allowed to recover for 3 hours before imaging using a confocal microscope. Approximate GRα 
concentration per population group was then determined (RFI) and plotted. Statistical analysis was conducted using a 
one-way ANOVA followed by a Newman-Keuls Multiple Comparison post-test comparing all experimental values 
(RFI) (calibrated FITC beads, low, medium and high GFP-hGRwt) to each other (ns, p > 0.05, *, p < 0.01 and ***, p < 
0.001) and (ns, p > 0.05, 
#
, p < 0.05 and 
###
, p < 0.001). 
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Chapter 6:   
Preserving GRα expression through ‘loss’ 
of receptor dimerization: relevance in a 
working model for acquired GC resistance. 
6.1. Introduction  
The functionality and amount (i.e. ‘pool’) of GRα available within a cell, is vital for GCs to 
efficiently elicit their biological actions
1–3
. As GCs are instrumental in regulating 
homeostasis, metabolism and inflammation, perturbations in the GC/GRα signalling pathway 
have been shown to have severe implications, which often results in metabolic and 
immunological complications
4–6
. 
One of the ways in which the GC/GRα signalling pathway is disrupted is by prolonged GC 
treatment that may lead to adverse side effects
4–7
 and/or acquired GC resistance
2,8–11
, which 
may be as a result of severe reductions in the ‘functional pool’ of GRα. The development of 
acquired resistance to GC treatment, poses a major threat for the pharmaceutical industry and 
research is focusing on elucidating ways in which improved sensitivity to GCs can be 
achieved in prolonged GC treatment regimes
4–6
.  
Ligand-induced down-regulation of GRα has been shown to occur at the mRNA and protein 
level
12–22. Specifically, reductions in the mRNA expression of GRα is thought to occur as a 
result of ligand-induced GRα mRNA destabilization13,23,24 or  repression of the GR gene 
itself
15,25,26
 (via a nGRE situated in the GRα promoter16,27). Furthermore, ligand-induced GRα 
protein down-regulation is thought to occur at the proteasomal level
18,19,22,28
. As GCs elicit 
their effects via the GRα, which functions as a ligand-dependent transcription factor to 
‘positively’ or ‘negatively’ regulate GC-responsive gene expression, one could speculate that 
changes in GRα mRNA and/or protein expression would directly modulate the mRNA 
expression of GC-responsive genes. 
Positive’ up-regulation (transactivation) of GC-responsive genes, following GC treatment, 
has largely been thought to be mediated via a GRα dimer (via direct DNA-binding to 
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GREs)
29. On the other hand ‘negative’ down-regulation (transrepression) of such genes is 
generally thought to be regulated by a GRα monomer (via an indirect tethering mechanism to 
transcription factors such as NfκB)
29
 (Fig. 6.1). Although this duality does exist, the 
distinction between these modes of GC-mediated gene regulation is thought to be 
considerably more complex than initially described
29
 (e.g. repression can occur via direct 
DNA-binding to a nGRE
28
). Additional models are eloquently described in a recent review by 
Vandevyver et al.
31
. 
 
Figure 6.1: GRα signalling can lead to either transactivation or transrepression of GC-responsive genes. 
Classically, transactivation is mediated via direct binding of a GRα dimer to a glucocorticoid response element 
(GRE), leading to an increase in gene expression. In contrast transrepression is mediated via the tethering of a 
GRα monomer to a transcription factor (e.g. NfκB), which is bound to its respective response element, in turn 
inhibiting gene expression. 
The current study selected genes from these two broad categories, namely transactivation 
(GILZ, TAT and FKBP51) and transrepression (IL-6), based on their functional relevance to 
metabolism, inflammation and acquired GC resistance, to investigate the biological 
implications of altered GRα protein expression, with general information on these genes 
given below. In addition, effects at the GRα gene level were determined by determining GRα 
mRNA expression and changes in the receptor expression at the mRNA level were compared 
to changes in GRα protein expression. 
GRα-mediated transactivation:  
GILZ  
Glucocorticoid–induced leucine zipper (GILZ) is ubiquitously expressed in a wide range of 
tissues and cell types, including a number of cells, which form part of the immune 
system
32,33
. GILZ is a well-known GC-inducible gene and is thought to be highly responsive, 
with its mRNA expression significantly up-regulated following GC treatment
33–35
. Up-
regulation of this gene is thought to occur via classical GRα-mediated gene transactivation, 
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which involves the binding of a GRα dimer to multiple GREs present in the proximal region 
of the GILZ promoter
36–40
. Although up-regulation of GC-responsive genes is commonly 
associated with an increase in metabolic activity and the subsequent development of adverse 
side-effects (e.g. hyperglycaemia), a GC-induced increase in GILZ mRNA expression has 
recently been shown to partially contribute to the anti-inflammatory potential of GCs
33
.  
TAT 
Tyrosine aminotransferase (TAT) is expressed predominantly in the liver and plays a 
prominent role in gluconeogenesis
41
. The expression of this metabolic enzyme is induced via 
GCs
42–44, which leads to activation of the GRα and subsequent binding of GRα dimers to 
multiple GREs in the proximal region of the TAT gene promoter
42,45–47
. GC-induced TAT up-
regulation is required for regulating glucose metabolism under normal conditions
48
. However, 
prolonged GC treatment and severe up-regulation of TAT has been associated with adverse 
side-effects and may result in metabolic disorders such as hyperglycaemia
49
. 
FKBP51 
FK506 binding protein 5 (FKBP51)
50
 is an immunophilin, which is widely expressed in a 
number of cell types. Higher expression of this immunophillin has been detected in 
metabolically active tissues, such as muscle and adipose, with lower levels observed in 
pancreatic, stomach and spleen tissues
51,52
. The ligand-activated GRα is thought to directly 
increase FKBP51 expression, through binding to two putative GRE-containing regions in the 
FKBP51 gene
53,54
. An increase in FKBP51 expression has been associated with cellular 
desensitization to GC treatment (or acquired GC resistance), via a negative-feedback loop. 
Specifically, the FKBP51 protein acts as a molecular chaperone for GRα and is thought to 
sequester GRα in the cytoplasm, hampering its translocation into the nucleus55–58. This 
mechanism may serve as a protective mechanism to protect the cell from overstimulation by 
GCs, through restricting GC/GR signalling, however, elevated FKBP51 expression has also 
been linked to acquired GC resistance in a number of disease states such as asthma
59–62
. 
GRα-dependent transrepression:  
IL-6 
Interleukin 6 (IL-6) is a pro-inflammatory cytokine whose expression is elevated during 
infection by pathogens
63–65
 or through stimulation by the pro-inflammatory cytokine, tumour 
necrosis factor alpha (TNFα)66–69. The IL-6 promoter contains a number of regulatory 
regions, including binding sites for NFκB and AP-169. Binding of transcription factors (NFκB 
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and AP-1) to the IL-6 promoter, which can be triggered by TNFα through a signalling 
cascade, activates the IL-6 promoter and increases IL-6 expression
69. GRα-mediated trans-
repression of IL-6, via tethering of the GRα to pro-inflammatory transcription factors, 
specifically NfκB and AP-1
70
 bound to their respective response elements, inhibits the 
expression of pro-inflammatory genes, such as IL-6 (Fig. 6.1). It is this inhibition that confers 
the potent immunosuppressive effects of GC treatment
8,31,71
.  
In Chapter 4 of the current study, a novel role for receptor dimerization in ligand-induced 
GRα protein down-regulation was established, in COS-1 cells transiently transfected with 
hGRwt and hGRdim and HepG2 cells containing endogenous hGRα (Fig. 4.5). Specifically, a 
‘loss’ of dimerization was achieved through treatment of hGRwt and endogenous hGRα with 
the dimerization abrogating ligand, CpdA, or through the use of the dimerization deficient 
mutant, hGRdim, which prevented receptor turnover. Subsequently Chapter 5, elucidated the 
molecular mechanisms involved in preventing receptor turnover of predominantly 
monomeric GRα and, in addition, found that this novel requirement for GRα dimerization in 
receptor protein turnover was not species specific but was in fact mirrored using a transiently 
transfected dimerization deficient mutant of mouse origin, namely, mGRdim(A465T) (Fig. 
5.4). Although the HepG2 cells allowed for the investigation of the effect of a ‘loss’ of 
dimerization with endogenous hGRα on receptor protein turnover, using CpdA as a molecular 
tool to mimic the transiently transfected hGRdim mutant, this cellular system did not provide 
a means to determine the effects of a ‘loss’ of dimerization using an endogenous dimerization 
deficient mutant. 
For this reason, additional cell lines, namely MEF-mGRwt and MEF-mGRdim, which are 
immortalised mouse embryonic fibroblasts
72
, were introduced. These cell lines were 
originally isolated from wild type GRα (GR+/+) and GRα dimerization deficient (GRdim/dim) 
mice, respectively
72
. Specifically, the GR
dim/dim 
mice were generated by introducing a single 
point mutation in the dimerization loop (D-loop), situated in the DNA-binding domain of the 
GRα gene, at amino acid position 46572. It must be noted for simplicity the MEF-mGRwt and 
MEF-mGRdim cell lines are referred to as mGRwt and mGRdim, respectively, throughout 
this chapter and should not be confused with the transiently transfected mGRwt and 
mGRdim, in Chapter 5. 
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Importantly, these immortalised cell lines allowed for the investigation and comparison of the 
effects of a ‘gain’ or ‘loss’ of GRα dimerization (via an endogenous mutant), respectively, on 
receptor turnover in an endogenous system. Moreover, the MEF-mGRwt and MEF-mGRdim 
cells provided a system in which the effects exerted by changes in the ‘functional pool’ of 
GRα, (observed in Chapter 4) at the level of GC-responsive gene expression could be 
determined. 
Using these cell lines, it was hypothesised that a ‘loss’ of GRα dimerization through the use 
of mGRdim will prevent ligand-induced GRα protein turnover, following treatment with 
dimerization promoting Dex. Furthermore, by preventing receptor turnover through a ‘loss’ 
of dimerization (i.e. via treatment of mGRwt with CpdA or the use of mGRdim), the 
‘functional pool’ of GRα will preserve its ability to efficiently mediate GC-responsive gene 
expression, even following prolonged GC treatment. In contrast, a ‘gain’ of GRα 
dimerization via treatment of mGRwt with Dex will encourage receptor turnover, leading to 
drastic reductions in the GRα ‘functional pool’, ultimately impairing its ability to mediate 
GC-responsive gene-expression, following prolonged GC treatment. The latter lack of a GC 
response or increase in GC insensitivity has major implications for combatting inflammation 
in patients with chronic inflammation. 
In general, the current chapter begins by characterizing the MEF cells in terms of the initial 
GRα content or ‘functional pool’ and binding affinity for Dex of mGRwt and mGRdim. 
Subsequently, the novel requirement for GRα dimerization in mediating receptor turnover 
(established in Chapter 4) was investigated by comparing the effects of dimerization 
promoting Dex on endogenous mGRwt and mGRdim protein expression, using Western 
blotting and whole cell GRα-binding. Having demonstrated that a ‘loss’ of GRα dimerization 
restricts dose-dependent Dex-induced mGRdim protein turnover, further investigation into 
the ligand-dependent effects of Dex and dimerization abrogating, CpdA, alone or in 
combination, on GRα protein and mRNA expression, was conducted. Using an adapted 
experimental protocol from Li et al.
73
 the time-dependent effects of these GCs (i.e. short- 
versus long-term pre-treatment) on the mGRwt and mGRdim protein and mRNA expression, 
was determined. Once the ligand-selective and time-dependent effects of the GCs had been 
established for mGRwt and mGRdim, the responsiveness, in terms of GC-responsive gene 
expression, of the working model or GC-responsive system established to mimic GC 
acquired resistance, was tested. It must be noted that TNFα, was used throughout the 
experimental protocol designed for establishing a working model to mimic acquired GC 
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resistance (Fig. 6.4). The reason for this being that all the genes (i.e. those mediated via 
transactivation and transrepression) could be analysed from the same sample. With that said, 
the effects of TNFα on basal GRα protein and mRNA expression, as well as the effect of 
TNFα on basal gene expression of GC-responsive genes, is addressed.  
Lastly, due to the fact that prolonged GC treatment (as opposed to short-term GC treatment) 
has been associated with the development of GC acquired resistance, the main focus of the 
current chapter is to mimic acquired resistance to GC treatment. Thus, using the established 
working system (Fig. 6.4), we investigated how the ligand-induced changes in the GRα 
‘functional pool’, or lack thereof, re-directed or re-shaped the GC-responsive gene 
expression, at the mRNA level,  following short-term versus long-term GC pre-treatment.  
Integral to this chapter, is the notion that short-term GC pre-treatment reflects normal GC 
signalling, whilst long-term GC pre-treatment represents the development of acquired GC 
resistance (Fig. 6.4), a relevant and significant pharmaceutical challenge. 
To conclude, demonstrating a role for GRα dimerization in ligand-induced receptor turnover, 
using an endogenous mutant, will substantiate results from previous chapters in the current 
study. Furthermore, elucidating how changes in the GRα ‘functional pool’ modulate the 
expression of GC-responsive genes, provides further insight into the potential effects of 
prolonged GC treatment and the development of GC insensitivity. Lastly, establishing that 
the maintenance of the GRα ‘functional pool’ through abrogation or ‘loss’ of GRα 
dimerization, preserves the anti-inflammatory potential of GC/GR signalling, provides novel 
possibilities in which the GC/GRα signalling pathway may be exploited pharmacologically.  
6.2. Results 
6.2.1. Characterizing MEF-mGRwt and MEF-mGRdim cells with regards to GRα 
expression and Dex-induced receptor turnover 
Having introduced two new cellular systems, namely the MEF-mGRwt and MEF-mGRdim 
cells, in the current chapter, it is necessary to characterize these cells based on their GRα 
content and their ligand-binding affinity for Dex. This allows for the ruling out of differences 
in the initial GRα ‘functional pool’ and differences in the Dex-binding affinities as reasons 
for observed differences between the two cells lines.  
In addition, once characterized, the novel requirement for GRα dimerization in mediating 
Dex-induced receptor protein turnover, established in Chapter 4 (i.e. COS-1 cells transiently 
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transfected with hGRwt and hGRdim or HepG2 cells containing endogenous hGRα) and 
Chapter 5 (i.e. COS-1 cells transiently transfected with mGRwt and mGRdim), was 
investigated.  Importantly, unlike in the transiently transfected COS-1 cells, this system (i.e. 
the MEF-mGRwt and MEF-mGRdim cells) allows for the effective regulation at the 
transcriptional (or ‘push’) level to be investigated. Moreover, the effects of a ‘loss’ of GRα 
dimerization on the ligand-induced down-regulation of an endogenous mutant, mGRdim, can 
be determined using the MEF-mGRdim cells. 
6.2.1.1. Determining the level of GRα expression in the MEF-mGRwt and MEF-
mGRdim cells 
Using whole cell GRα-binding the current chapter started with determining the optimal 
incubation time for binding equilibrium to be reached using an association binding time-
course, which was conducted in the MEF-mGRwt cells. Optimal conditions, with regards to 
incubation time, were applied to the MEF-mGRdim cells and whole cell competitive GRα-
binding experiments were then conducted in both cell lines, after which global fitting curves 
were fitted to the homologous competitive binding data. From these curves, the MEF-mGRwt 
and MEF-mGRdim cells were characterised according ligand-binding affinities (Kd) for Dex 
for mGRwt and mGRdim, respectively. Next, in combination with obtained Bmax values, 
from the curves, the GRα concentration (fmol/mg protein), was calculated. 
From the association binding time course, which was conducted at 0, 2, 4, 6 and 8 hours, 
using 20 nM [
3
H]-Dex, the incubation time required to reach binding equilibrium was 
determined to be 2 hours for the MEF-mGRwt cells (Fig.6.2A). Therefore, 2 hours incubation 
was selected for further whole cell competitive GRα-binding experiments in MEF-mGRwt 
and MEF-mGRdim cells. 
Data obtained from the homologous competitive GRα-binding experiments provided Kd and 
Bmax values, which were required to determine the initial GRα ‘function pool’, for mGRwt 
and mGRdim in the MEF-GRwt and MEF-GRdim cells, respectively (Fig. 6.2B and C). No 
significant difference between the Kd values of Dex for mGRwt (5.6 nM) and mGRdim (8.9 
nM) was observed (Fig. 6.2C). Similarly, the Bmax (cpm/mg protein) value, representative of 
maximal GRα binding, of 2959 cpm/mg protein for the mGRwt was not significantly 
different from the 2815 cpm/mg protein noted for the mGRdim (Fig.6.2C). Using these Kd 
and Bmax values the concentration of GRα (fmol/mg protein) in the MEF-mGRwt and MEF-
mGRdim cell lines was calculated (Fig.6.2C). No difference in the initial GRα content or 
Stellenbosch University  https://scholar.sun.ac.za
  187  
 
‘functional pool’ of GRα, was found, between the two cell lines (Fig. 6.2C). Specifically, the 
calculated concentrations of GRα in the MEF-mGRwt and MEF-mGRdim cells, were 40.7 
and 38.7 fmol/mg protein, respectively, which corresponds to the defined low GRα 
expression (67.0 fmol/mg protein) designated by a previous member in our lab
74
.  
Figure 6.2: Determining GRα concentration in MEF-mGRwt and MEF-mGRdim cells. MEF cells (i.e. 
MEF-mGRwt or MEF-mGRdim cells) were seeded into a 24 well plate (5 x 10
4
 cells/well) and 24 hours later, 
cells were steroid starved. To determine the time to binding equilibrium (A), whole cell GRα-binding was 
conducted in the MEF-mGRwt cells, using 20 nM [
3
H]-Dex. Cells were then lysed and cpms were detected via a 
scintillation counter with specific binding values (cpms) calculated and the plotted against time (in hours). 
Whole cell GRα-binding results shown are representative of six independent experiments (average ±SEM), 
conducted in triplicate. The dotted line, on the graph (at 2 hours), represents the incubation time chosen for 
subsequent experiments. Having established the time required for binding equilibrium to be reached, 
competitive whole cell GRα-binding (B) using two concentrations of [3H]-Dex, namely 20 and 40 nM, and 
increasing concentrations of unlabelled Dex (10
-13
 to 10
-5
 nM), was conducted. Once lysed, total binding (cpm) 
values were detected via a scintillation counter, normalised to total protein concentration (cpm/mg protein) and 
plotted. Whole cell GRα-binding results shown are representative of three independent experiments (average 
±SEM), conducted in triplicate. The solid and dotted lines, on the graph at -8.2 and -8.1, represent the logKd 
values for mGRwt and mGRdim, respectively, which were determined and plotted (C) along with the Bmax 
values. For statistical analysis, an unpaired t-test was used to evaluate differences in ligand binding affinities 
(logKd) of Dex for mGRwt and mGRdim and the Bmax values (ns, p > 0.05). In addition, using these values, 
the concentration of GRα in the MEF-mGRwt and MEF-mGRdim cell lines, was calculated (fmol/mg protein). 
To ensure comparable fractional occupancy of Dex for mGRwt and mGRdim, the fractional 
occupancies were calculated at all ligand concentrations (Table 6.1). Comparable fractional 
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occupancy of 99% for Dex via mGRwt and mGRdim was noted following treatment with 1 
μM Dex and thus this Dex concentration was used in subsequent experiments (Table 6.1). 
Table 6.1: Calculating the fractional occupancy of Dex for mGRwt and mGRdim. 
Ligand concentration  
  % F.O
c
 of Dex for 
mGRwt 
% F.O
d
 of Dex for 
mGRdim 
Fold 
difference
e
 
(logM) (nM) 
-9 1 15 10 2 
 
5.6
a
 50 39 1 
 
8.9
b
 62 50 1 
-8 10 64 53 1 
-7 100 95 92 1 
-6
f
 1000 99 99 1 
-5 10000 >99 >99 1 
a Kd value of Dex (5.6 nM) for mGRwt as established in Figure 6.1. b Kd value of Dex (8.9 nM) for mGRdim as established in Figure 6.1. 
c Fractional occupancy of Dex for mGRwt was calculated using Kd valuea and equation in Chapter 4 and expressed as a percentage.d 
Fractional occupancy of Dex for mGRdim was calculated using Kd valueb and equation in Chapter 4 and expressed as a percentage.e The 
fold difference was calculated by dividing the percentage fractional occupancy of Dex for mGRwt by the percentage fractional occupancy of 
Dex for mGRdim. f The ligand concentration used in subsequent experiments to ensure > 99% fractional occupancy for both GRα ligands. 
6.2.1.2. Endogenous mouse GRα protein turnover is dose-dependent and influenced 
by receptor dimerization  
To confirm and substantiate the novel requirement for receptor dimerization in GRα turnover, 
both MEF cell lines were treated with Dex in a dose-dependent manner (10
-13 
M – 10-5 M) for 
24hrs, after which GRα expression was measured, using Western blotting. From these dose-
response curves, the potencies (IC50) and efficacies of Dex-induced GRα protein down-
regulation of mGRwt and mGRdim was determined. In support of the results obtained using 
Western blotting, competitive whole-cell GRα binding following 1 μM (10-6 M) Dex 
treatment for 24 hours was conducted. 
In agreement with results obtained in the COS-1 cells transiently transfected with hGRwt 
(Fig. 4.3 and 4.4), the mGRwt protein, in the MEF-GRwt cells, undergoes protein down-
regulation following 24 hours treatment with the dimerization promoting GC, Dex (Fig. 6.3). 
Moreover, this Dex-induced down-regulation of the mGRwt protein is dose-dependent (Fig. 
6.3A).  
 In contrast to mGRwt, which is capable of forming receptor dimers, ‘loss’ of dimerization 
via the use of mGRdim protein in the MEF-GRdim cells, results in a partial loss of ligand-
induced GRα protein down-regulation (Fig. 6.3). Although, the mGRdim protein does 
undergo protein down-regulation, the extent of this down-regulation was significantly (p < 
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0.01) less than that of the mGRwt. This is reflected by the difference in efficacy values, 
which are 27.4% for mGRwt and 50.9% for mGRdim, following 24 hours of Dex treatment 
(10 μM) (Fig. 6.3B). In addition, no significant difference (p > 0.05) between the potencies of 
Dex to induce receptor turnover of mGRwt and mGRdim, namely 1.1 nM and 1.5 nM 
respectively, was observed (Fig. 6.3C and D). Using Western blotting, the extent of Dex-
induced down-regulation of the endogenous mouse GRα (Fig. 6.3B) was found to be greater 
than that of the transiently transfected mGRwt and mGRdim, where receptor protein levels 
where reduced to 42% and 76%, respectively (Fig. 5.4C). A possible explanation for this 
observed difference between the COS-1 cells (i.e. transiently transfected with mGRdim) and 
the MEF-mGRdim cells is the lack of effective regulation at the transcriptional (or ‘push’) 
level (Fig. 4.2). Unlike the transiently transfected mGRdim, which is controlled via a 
constitutive promoter, the endogenous mGRdim is regulated by the endogenous GRα 
promoter.  
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Figure 6.3: Endogenous mouse GRα protein turnover is dose-dependent and influenced by receptor 
dimerization. MEF-mGRwt and MEF-mGRdim cells were seeded into a 24 well plate (5 x 10
4
 cells/well) and 
24 hours later, cells were steroid starved. Following 24 hours incubation, cells were treated with either solvent 
(EtOH) or varying concentrations (10
-11
 M to 10
-5
M) of Dex for 24 hours. Thereafter, mGRwt and mGRdim 
protein levels were assessed by Western blotting where GAPDH was probed to ensure equal protein loading. 
The Western blot shown (A, inset) is representative of three independent experiments. For quantification (A), 
the intensity of the mGRwt, mGRdim and GAPDH bands were determined using the My ECL Image Analysis 
software, and the mGRwt and mGRdim expression normalised to GAPDH expression and expressed as a 
percentage (average ± SEM) of mGRwt or mGRdim expression in the presence of solvent (EtOH), which was 
set at 100% (dotted line). The physiological concentration range of Dex (1 – 20 nM) is indicated by vertical 
lines (red). Efficacies (B and D) and potencies (C and D) of Dex for mGRwt and mGRdim protein down-
regulation were determined. For statistical analysis, an unpaired t-test was used to evaluate the differences in the 
efficacy (**, p < 0.01) and the potency (logIC50) (ns, p > 0.05) of Dex via mGRwt and mGRdim. Competitive 
whole cell GRα-binding (E) was conducted using 20 nM [3H]-Dex and unlabelled Dex (10 μM) (as in the COS-
1 cells). Cells were lysed and cpms were detected via a scintillation counter and used to calculate specific 
binding values, which were normalised to total protein concentration (cpm/mg protein). In the graph the dotted 
line represents GRα expression (mGRwt and mGRdim) in the presence of the solvent (EtOH) and is set at 
100%, with the mGRwt and mGRdim expression, following treatment with Dex (1 μM) for 24 hours, calculated 
as a percentage relative to the solvent (EtOH). Whole cell GRα-binding results shown are representative of two 
independent experiments (average ±SEM), conducted in triplicate. For statistical analysis, an unpaired t-test was 
used to evaluate differences in receptor expression, following Dex treatment (1 μM) (**, p < 0.01) 
Lastly, the results from the whole cell GRα-binding (i.e. in the MEF cells) suggest mGRwt 
protein levels were more significantly (p < 0.01) reduced to 54.1%, than the mGRdim protein 
levels which were reduced to 74.8% of the EtOH control following 24 hours treatment with 
Dex (1 μM) (Fig. 6.3E). The extent of down-regulation observed here is less than that 
observed in the Western blotting (Fig. 6.3B), however, one must keep in mind these are 
different techniques and whole cell GRα-binding using transiently transfected mGRwt and 
mGRdim, was not conducted in Chapter 5 and thus a comparison cannot be made. 
Collectively, these initial results obtained with the endogenous mouse GRα in the MEF-
mGRwt and MEF-mGRdim cells, substantiates a requirement for GRα dimerization in Dex-
induced receptor protein turnover, initially established in Chapter 4. Whilst a ‘loss’ of GRα 
dimerization in COS-1 cells transiently transfected with hGRdim completely abolished 
receptor turnover, at the protein level, in Chapter 4 (Fig. 4.5), a slight yet non-significant 
Dex-induced reduction in receptor expression was noted in Chapter 5, in COS-1 cells 
transiently transfected with mGRdim. In comparison, ‘loss’ of GRα dimerization, through the 
use of the endogenous mutant mGRdim in the MEF-mGRdim cells, only partially restricted 
Dex-induced GRα protein turnover, in the endogenous system used in the current chapter, 
and is likely due to additional regulation at the transcriptional level.  
GRα concentration has been shown to modulate receptor function74, thus, importantly, due to 
the fact that no significant differences in the GRα concentration between the MEF-mGRwt 
and MEF-mGRdim cells, or in the binding affinities for Dex for mGRwt and mGRdim, were 
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observed, it is likely that that any differences in ligand-induced GRα down-regulation are, 
most likely, to be due to the dimerization state of the receptor.  
Furthermore, to our knowledge this is the first time the MEF-mGRwt and MEF-mGRdim 
cells have been characterised with regards to GRα concentration, affinity of Dex for 
endogenous mGRwt or mGRdim and subsequent ability of these GRα’s to undergo Dex- 
induced protein down-regulation. 
6.2.2. Establishment and validation of a model to mimic acquired GC resistance, 
using an adapted experimental protocol
73
. 
Previous studies have suggested that the ability of a patient to respond to GC treatment is 
often proportional to the magnitude of the GRα ‘functional pool’ within cells and tissues1,3,75. 
The current study, in combination with others
18,19,28
, has demonstrated that GRα protein 
down-regulation occurs predominantly via the proteasome following treatment with 
dimerization promoting GCs (i.e. Dex), resulting in a significant reduction in the size of the 
GRα ‘functional pool’. In addition, the extent of ligand-induced GRα protein down-
regulation is not only dependent on the type and concentration of ligand, but is also 
dependent on the length of time of the GC treatment (Fig. 4.3 and 4.4). Of utmost importance 
is that, amongst other factors
17,76–79
, this ligand-induced reduction in the GRα expression, 
following prolonged treatment with certain GCs, may result in an acquired resistance to GC 
treatment and poses a major threat in the treatment of inflammatory disorders.  
Having characterized the MEF-mGRwt and MEF-mGRdim cells with regards to initial 
receptor expression and Dex-induced receptor turnover, the current chapter aims to further 
elucidate the biological implications of altered GRα expression. Specifically, how ligand-
induced changes in GRα expression, as a result of either ‘gain’ or ‘loss’ of receptor 
dimerization, modulate down-stream GC-responsive gene expression.  A brief reminder that 
the subset of genes chosen for this study were chosen for the following reasons: TAT for its 
potential link to adverse side-effects, GILZ, which is known to have an anti-inflammatory 
potential, FKBP51 for its association with GC resistance and IL-6 for it pro-inflammatory 
potential, which is counteracted by GC signalling. 
To do this an experimental protocol used in a study by Li et al.
73
 was adapted (Fig. 6.4) and 
employed, in the current study. Firstly, MEF-mGRwt or MEF-mGRdim cells were plated in 
12 well plates (1 x 10
5
 cells/well) (Fig. 6.4, Day 1), the next day (Fig. 6.4, Day 2) cells were 
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steroid starved using charcoal-stripped FCS and 24 hours later (Fig. 6.4, day 3) pre-treated 
with GRα ligands alone, Dex (1 μM) or CpdA (10 μM) and in combination, Dex (1 μM) and 
CpdA (10 μM) (Fig. 6.4). Pre-treatment with GRα ligands followed either a short-term 
protocol (i.e. 2 hours) on the fourth day (Fig. 6.4, Day 4) or a long-term protocol (i.e. 24 
hours) beginning the day before (Fig. 6.4, Day 3), to alter the ‘functional pool’ of GRα. At 
this point, a necessary reminder is that the short-term pre-treatment protocol was designed to 
reflect acute GC/GRα signalling, whilst, the long-term pre-treatment protocol was designed 
to reflect prolonged, chronic GC treatment, which has been associated with the development 
of acquired resistance to GC treatment. 
 
 Figure 6.4: The experimental protocol adapted from Li et al.
73
used, in the current study to establish a 
GC-responsive system in order to mimic acquired GC resistance. 
Following pre-treatment with GRα ligands, cells were induced with the pro-inflammatory 
cytokine, TNFα (0.02 μg/ml), for an additional 8 hours (Fig. 6.4). Important to note, is that 
TNFα was added in the presence of the GRα ligands and was used to induce the expression of 
the pro-inflammatory gene (i.e. IL-6). Whilst the presence of TNFα was not required for the 
other genes investigated (GRα, GILZ, TAT and FKBP51), it was included to allow for the 
analysis of all genes from a single sample. However, any potential effects of TNFα on these 
other genes were addressed. Additionally, a second important detail is that the GRα ligands 
were not removed following pre-treatment and thus essentially resided on the cells for 10 and 
32 hours for the short-term and long-term protocols, respectively (Fig. 6.4). Lastly, following 
treatment with GRα ligands and TNFα, the cells were harvested (Fig. 6.4, Day 4) and GRα 
protein levels and GRα, GILZ, TAT, FKBP51 and IL-6 mRNA expression determined using 
Western blotting and real-time PCR, respectively (Fig. 6.4). 
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6.2.2.1. Modulation of endogenous mGRwt and mGRdim expression in model of 
acquired GC resistance 
In order to successfully assess how changes in GRα expression modulate GC-responsive gene 
expression, it was of utmost importance to initially establish differences between the 
expression of the GRα ‘functional pool’ following short-term (i.e. representing acute 
GC/GRα signalling) and long-term GC pre-treatment (i.e. chronic GC treatment, which may 
cause resistance). This allowed for changes at the level of GC-responsive gene expression to 
be correlated to changes in the concentration of the receptor. 
To begin, the current study addressed the effect of TNFα on mGRwt and mGRdim protein 
and mRNA expression (Fig. 6.5). Once the effects of TNFα on GRα expression, had been 
accounted for, the ligand-selective effects of the dimerization promoting GC, Dex, and the 
dimerization abrogating GC, CpdA, alone or in combination, on mGRwt and mGRdim 
protein and mRNA expression, were determined (Fig. 6.6). Following which, the time-
dependent effects of GC treatment (i.e. short-term versus long-term pre-treatment) on 
mGRwt and mGRdim, at both the protein and mRNA level, were detailed (Fig. 6.6).  Lastly, 
the GC-mediated effects on mGRwt protein and mRNA expression were directly compared to 
those exerted on mGRdim to substantiate evidence for GRα dimerization as a requirement for 
ligand-induced protein turnover (Fig. 6.7). 
6.2.2.1.1. The effect of pro-inflammatory cytokine, TNFα, on GRα protein and mRNA 
expression.  
From the results, it is clear that treatment with the pro-inflammatory cytokine, TNFα, 
significantly increased GRα protein expression to 116% (p < 0.001) and 147% (p < 0.001), in 
mGRwt and mGRdim cells, respectively, relative to GRα protein expression in the absence of 
TNFα (100%) (Fig. 6.5A). Furthermore, a significantly (p < 0.01) higher increase in GRα 
protein expression, following TNFα treatment, was observed in the mGRdim cells when 
compared to GRwt (Fig. 6.5A). In contrast, TNFα treatment had no significant (p > 0.05) 
effect on GRα mRNA levels (Fig. 6.5B) in either the MEF-mGRwt or the MEF-mGRdim cell 
line. Interestingly, the fact that the effect of TNFα treatment on GRα protein expression (Fig. 
6.5A) was not reflected at the GRα mRNA level (Fig. 6.5B) suggests that TNFα does not 
influence the expression of the GRα gene but may be, in part, involved in the stabilization of 
the GRα protein.  
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Figure 6.5: The effect of TNFα on GRα protein and mRNA expression in MEF cells. MEF-mGRwt and 
MEF-mGRdim cells were seeded into a 12 well plate (1 x 10
5
 cells/well). Following 24 hours incubation, cells 
were steroid starved. Following steroid starvation, 48 hours later, cells were treated with solvent (EtOH) or 
TNFα (0.02 μg/ml) for 8 hours. Thereafter, mGRwt and mGRdim protein expression was assessed by Western 
blotting where GAPDH was probed to ensure equal protein loading. For quantification of GRα protein (A), the 
intensities of the mGRwt, mGRdim and GAPDH bands were determined using MyECL Image Analysis 
software and subsequently the mGRwt and mGRdim expression was normalised to GAPDH expression and 
expressed as a percentage (average ± SEM) of mGRwt or mGRdim expression in the absence of TNFα, which 
was set at 100% (dotted line). For quantification of GRα mRNA expression (B), RT-PCR was conducted and 
the expression of the GRα gene, normalized to that of the reference gene, 18S, calculated using Equation 2. GRα 
mRNA expression in the presence of TNFα is represented as a fold increase (average ± SEM)  relative to in the 
absence of TNFα, which is represented by the dotted line and set at 1. For statistical analysis, an unpaired t-test 
was used to evaluate the effect of TNFα on mGRwt or mGRdim protein (***, p < 0.001) and mRNA expression 
(ns, p > 0.05), as well as to determine differences between mGRwt and mGRdim protein (
##
, p < 0.01) and 
mRNA expression (ns, p > 0.05), in the presence of TNFα. 
With the effects of TNFα on GRα protein and mRNA expression being accounted for in the 
current figure (Fig. 6.5), the time-dependent and ligand-selective induced changes in GRα 
expression were determined relative to receptor expression in the presence of TNFα in all 
subsequent experiments. Important to note is that for the rest of this chapter the solvent refers 
to EtOH plus TNFα. 
6.2.2.1.2. Modulation of the GRα ‘functional pool’ is ligand-selective and time-
dependent, at both the protein and mRNA level, in MEF-mGRwt and MEF-
mGRdim cells 
In terms of ‘gain’ of dimerization through treatment of endogenous mGRwt with the 
dimerization promoting Dex, a significant (p < 0.001) reduction in mGRwt protein following 
short-term pre-treatment resulted in the retention of only 58% of the initial ‘functional pool’ 
of GRα protein (100%) (Fig. 6.6A). As expected, long-term Dex pre-treatment promoted a 
further significant (p < 0.001) reduction in mGRwt protein expression ending up with a mere 
29% mGRwt protein remaining, which is significantly (p < 0.05) lower than that of the short-
term protocol (Fig. 6.6A). This finding supports the idea that chronic, prolonged GC 
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treatment further reduces the GRα protein ‘functional pool’, also demonstrated in Chapter 4 
with transiently transfected hGRwt. In addition, these results obtained at the level of mGRwt 
protein expression were reflected at the level of mRNA expression, where short-term Dex 
pre-treatment reduced, although not significantly, mGRwt mRNA expression to 0.7, relative 
to the solvent (Fig. 6.6B). Similarly (p > 0.05) to the short-term pre-treatment, long-term pre-
treatment with Dex reduced mGRwt mRNA expression to just under 0.7, specifically 0.66, 
which, unlike the short-term Dex pre-treatment, was found to be significantly different to that 
of the solvent (Fig. 6.6B). Interestingly, unlike the transiently transfected COS-1 cell system 
in Chapter 4, this endogenous system (i.e. the MEF-mGRwt cells) highlights Dex-induced 
regulation of the GRα ‘functional pool’ at the mRNA level (i.e. ‘push’) (Fig. 4.2). 
In contrast to the dimerization promoting GC, Dex, a ‘loss’ of mGRwt dimerization as a 
result of treatment with the dimerization abrogating GC, CpdA, significantly (p > 0.05) 
restricted GRα protein turnover, following both short-term and long-term pre-treatment (Fig. 
6.5A). Specifically, in support of results obtained in the COS-1 cell system transiently 
transfected with hGRwt (in Chapter 4), endogenous mGRwt protein levels were maintained 
at 94% and 89% of initial levels, post short and long-term CpdA pre-treatment, respectively 
(Fig. 6.6A). Interestingly, and in contrast to what was observed at the protein level, mGRwt 
mRNA expression was significantly reduced, relative to the solvent, to 0.6 (p < 0.01) and 0.4 
(p < 0.001), following short and long-term pre-treatment, respectively, with CpdA (Fig. 
6.6B). This result sparks interest in the ability of a GRα monomer, induced by CpdA 
treatment, to regulate its own gene expression, through ligand-induced down-regulation, 
which to our knowledge has not yet been investigated.  
Interestingly, and in contrast to results obtained with transiently transfected hGRwt in the 
COS-1 cells (Fig. 5.14), the presence of CpdA (in the combination pre-treatment) was unable 
to protect mGRwt protein expression from Dex-induced receptor turnover, relative to Dex 
pre-treatment alone (Fig. 6.6A). Although results in Figure 6.6A do suggest a protective 
trend, it is not significant (p > 0.05). Specifically, both short (p < 0.01) and long-term (p < 
0.001) pre-treatment with the Dex and CpdA combination, resulted in significant reductions 
in mGRwt protein levels, to 61% and 48%, respectively which is a smaller reduction than 
seen with Dex alone (58% and 29%, respectively) relative to solvent (Fig. 6.6A). From the 
mGRwt mRNA expression results (Fig. 6.6B), a significant (p < 0.001) reduction, to 0.3 and 
0.4, relative to solvent, was noted following short and long-term pre-treatment, respectively, 
with the Dex and CpdA combination pre-treatment. Furthermore, results suggest that pre-
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treatment with the combination of Dex and CpdA, unexpectedly, further reduced (p < 0.05) 
mGRwt mRNA expression relative to Dex alone, following short and long-term pre-treatment 
(Fig. 6.6B). Taken together, it appears that at the level of GRα protein expression, the 
dimerization abrogating GC, CpdA, opposes the effects of the dimerization promoting GC, 
Dex. 
In contrast, at the level of ligand-induced GRα mRNA regulation, Dex and CpdA work 
cooperatively to reduce receptor mRNA expression. 
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Figure 6.6: Modulation of the GRα ‘functional pool’ is ligand-selective and time-dependent, at both the 
protein and mRNA level. MEF-mGRwt and MEF-mGRdim cells were seeded into a 12 well plate (1 x 10
5
 
cells/well). Following 24 hours incubation, cells were steroid starved. After steroid starvation, 24 hours later, 
cells were pre-treated with solvent (EtOH), Dex (1 μM), CpdA (10 μM) or Dex (1 μM) and CpdA (10 μM) 
combined for either short (2 hours, lighter bars) or longer (24 hours, darker bars) periods of time. Following pre-
treatment with GRα ligands, cells were treated with TNFα (0.02 μg/ml) for an additional 8 hours. Thereafter, 
mGRwt and mGRdim protein expression was assessed by Western blotting where GAPDH was probed to 
ensure equal protein loading.  Western blot shown for mGRwt (A, inset) and mGRdim (C, inset) are 
representative of two to four independent experiments. For quantification of mGRwt (A) and mGRdim (C) 
protein expression, the intensities of the mGRwt, mGRdim and GAPDH bands were determined using MyECL 
Image Analysis software and subsequently the mGRwt and mGRdim expression normalised to GAPDH 
expression and expressed as a percentage (average ± SEM) of GRα expression in the presence of solvent (EtOH  
+ TNFα), which was set at 100% (dotted line). For quantification of mGRwt (B) and mGRdim (D) mRNA 
expression, RT-PCR was conducted and the expression of the GRα gene (mGRwt or mGRdim), normalized to 
that of the reference gene, 18S, and calculated using Equation 2. GRα mRNA expression, following short- or 
long-term pre-treatment with test compounds in the presence of TNFα is represented as a fold increase or 
decrease, relative to the solvent (EtOH + TNFα), which is represented by the dotted line and set at 1. For 
statistical analysis, a one-way ANNOVA followed by a Tukey post-test was used to evaluate the time-dependent 
and ligand-selective effects of the GRα ligands on mGRwt and mGRdim protein (ns, p > 0.05, *, p < 0.05, **, p 
< 0.01, ***, p < 0.001) and mRNA expression (ns, p > 0.05, *, p < 0.05). 
‘Loss’ of dimerization through the use of the endogenous mutant, mGRdim, partially 
restricted the ability of dimerization promoting Dex to induce receptor turnover, following 
short-term pre-treatment (Fig. 6.6C).  Specifically, mGRdim protein expression was reduced 
to 67% of initial (100%) mGRdim ‘functional pool’, following short-term Dex pre-treatment, 
however, this reduction was not significant (p > 0.05). Furthermore, long-term Dex treatment 
led to a significant (p < 0.05) reduction, to 49%, in mGRdim protein expression, relative to 
solvent (Fig. 6.6C). In stark contrast, this modest Dex-induced reduction in the mGRdim 
protein expression was not reflected at the mRNA level (Fig. 6.6D), suggesting that treatment 
with dimerization promoting ligand, Dex, is unable to induce any significant (p < 0.05) 
reduction in mGRdim mRNA expression, following either short or long-term pre-treatment 
(Fig. 6.6D).  
Briefly, taking into account results obtained with mGRwt following Dex and CpdA 
treatment, it appears that at the level of GRα protein expression ligand-induced monomeric 
GRα (i.e. ‘loss’ of GRα dimerization through CpdA treatment of mGRwt) is the most 
efficient at evading proteasomal degradation. Furthermore, monomeric GRα as a result of the 
mutation (i.e. ‘loss’ of GRα dimerization through mGRdim following treatment with Dex) 
can partially restrict Dex-mediated receptor protein turnover, however, not as efficiently as 
the CpdA-induced GRα monomer. Lastly, dimeric GRα (i.e. ‘gain’ of GRα dimerization 
through mGRwt following treatment with Dex) is the most readily degraded via the 
proteasome. Interestingly, at the level of ligand-induced GRα mRNA regulation, a 
differential pattern is observed with the greatest reduction in receptor mRNA observed 
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following treatment of mGRwt with CpdA, followed by treatment of mGRwt with Dex and 
lastly, treatment of mGRdim with Dex, the latter which did not modulate GRα expression at 
all. 
Whilst mGRwt protein levels were maintained following short-term CpdA pre-treatment 
(Fig. 6.6A), a slight increase to 120%, relative to solvent, was noted for the mGRdim when 
treated with CpdA (Fig 6.6B). A further significant (p < 0.01) increase in mGRdim protein 
levels, to 162%, relative to solvent, was observed following long-term pre-treatment with 
CpdA, however, this up-regulation is not significantly different from the increase after short-
term CpdA pre-treatment (Fig. 6.6B). Consistent with results obtained following treatment 
with Dex, neither short nor long-term pre-treatment of mGRdim with CpdA, resulted in 
significant changes of mGRdim at the mRNA level (Fig. 6.6D). 
In the case of the combination pre-treatment, CpdA was able to significantly (p < 0.05) 
safeguard the mGRdim protein from Dex-induced receptor protein turnover (Fig. 6.6C). The 
mGRdim protein expression was significantly (p < 0.05) increased, relative to that of the Dex 
alone pre-treatment, to 108% and 60%, respectively, following short and long-term co- 
treatment with Dex and CpdA (Fig. 6.6C). Similarly to the results obtained with individual 
Dex or CpdA treatments, the combination pre-treatment of Dex and CpdA had no significant 
effect on mGRdim mRNA expression (Fig. 6.6D).  
The results in Figure 6.6 highlight the ligand-selective (i.e. Dex and CpdA alone or in 
combination) and time-dependent effects (i.e. short versus long-term pre-treatment) of 
receptor turnover in the individual MEF-mGRwt and MEF-mGRdim cell lines. Whilst these 
findings hint at a requirement for GRα dimerization in ligand-induced receptor turnover, in 
these cells, they do not confirm this role by directly comparing whether the effects observed 
via mGRwt are significantly different to those observed via mGRdim, which is addressed in 
the next section. 
6.2.2.1.3. Validating the model of acquired resistance to GC treatment, in terms of 
ligand-induced alterations in GRα ‘functional pool’, and investigating a role 
for dimerization by directly comparing mGRwt and mGRdim. 
In order to validate the model of acquired GC resistance, significant differences in mGRwt 
protein expression following short-term and long-term Dex pre-treatment, needed to be 
obtained. Following short-term Dex pre-treatment (i.e. acute GC/GRα signalling) mGRwt 
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protein expression was significantly (p < 0.001) reduced to 58%, relative to solvent, however, 
importantly, a significantly greater (p < 005) reduction in mGRwt protein expression (i.e. to 
29%) was noted, following long-term Dex pre-treatment (i.e. prolonged GC treatment) (Fig. 
6.6A). Thus, these findings validated the model established to mimic acquired GC resistance. 
Moreover, no significant difference between the mGRwt and mGRdim receptor expression 
was observed following short-term Dex pre-treatment, indicative of acute GC/GRα 
signalling. Conversely, ‘loss’ of GRα dimerization, through the use of the mutant, mGRdim, 
partially but significantly (p < 0.01) restricted ligand-induced GRα protein down-regulation, 
relative to ‘gain’ of GRα dimerization via mGRwt, following long-term pre-treatment with 
dimerization promoting Dex (Fig. 6.7A). Specifically, although mGRdim expression was 
reduced (49% of the ‘functional pool’ remaining post-treatment) approximately 20% more 
GRα expression was noted post long-term Dex pre-treatment, relative to the mGRwt (29% of 
the ‘functional pool’ remaining post-treatment) (Fig. 6.7A). These results confirm a 
requirement, be it partial, for GRα dimerization in receptor turnover at the protein level, 
notably, following prolonged GC treatment. 
In support of a role for GRα dimerization in mediating ligand-induced GRα protein turnover, 
demonstrated using mGRdim, were results obtained with mGRwt following treatment with 
dimerization abrogating GC, CpdA
80,81
 (Fig. 6.7A). No significant ligand-induced reduction 
in mGRwt or mGRdim protein levels, relative to solvent, was noted, following treatment with 
CpdA (Fig. 6.7A). Furthermore no significant (p > 0.05) difference between mGRwt and 
mGRdim protein expression following short-term CpdA pre-treatment was observed (Fig. 
6.7A), while in contrast, long-term CpdA pre-treatment of the mutant, mGRdim, resulted in a 
significant (p < 0.01) increase in receptor protein expression (162% of solvent) relative to 
mGRwt (89% of solvent (Fig. 6.7A). A possible explanation for this is that binding of CpdA 
to mGRdim stabilizes a different GRα monomer species than the Dex-bound mGRdim 
monomer, which may be able to form weak and transient dimers
82
, however this requires 
further investigation. 
In terms of ligand-induced regulation at the mRNA level, Dex pre-treatment (i.e. short and 
long-term) was capable of significantly (p < 0.05) reducing mGRwt mRNA expression 
relative to solvent, while ‘loss’ of GRα dimerization, through use of the mGRdim mutant, 
completely abolished Dex’s ability to induce GRα down-regulation of mRNA expression 
(Fig. 6.7B). Unlike with mGRwt, after short- and long-term Dex pre-treatment mGRdim 
expression was maintained (1.0-fold) or slightly increased (1.3-fold), relative to the solvent 
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(Fig. 6.7B). One could postulate, that this lack of Dex-induced GRα down-regulation of 
receptor mRNA expression may be due to the reduced ability of mGRdim to form dimers
72
. 
However, results from monomeric GRα as a result of CpdA treatment argue against the 
requirement of a GRα dimer for ligand-induced reductions in receptor mRNA expression 
(Fig. 6.7B). Specifically, at the level of mRNA expression, no significant (p > 0.05) 
difference was noted between mGRwt and mGRdim, following short-term pre-treatment with 
the dimerization abrogating SGRM, CpdA (Fig, 6.7B). In contrast, long-term pre-treatment 
with CpdA, led to a reduction in mGRwt mRNA expression (0.4-fold), which was 
significantly different (p < 0.001) to the slight increase noted in mGRdim mRNA expression 
(1.4), following the same pre-treatment conditions (Fig. 6.7B). These findings suggest ligand-
induced GRα down-regulation of the GRα gene and/or mRNA destabilization occurs via a 
CpdA-bound mGRwt monomer but not via a Dex or CpdA-bound mGRdim monomer.  
In summary, Figure 6.7B identifies a novel, mandatory requirement for GRα dimerization in 
ligand-induced receptor turnover at the transcriptional and post-translational level by directly 
comparing the effects of Dex via mGRwt (i.e. ‘gain’ of GRα dimerization) to the effects of 
Dex via the mutant, mGRdim (i.e. ‘loss’ of GRα dimerization) at both the protein and mRNA 
level. Additionally, whilst it has previously been postulated that CpdA bound to mGRwt is a 
similar monomeric species to Dex bound to mGRdim
81
, results from the current study 
highlight significant novel differences between the CpdA-bound mGRwt monomer and the 
Dex-bound mGRdim, specifically at the level of ligand-induced GRα mRNA regulation. A 
possible reason for these differences may be due to varying degrees of a ‘loss’ of GRα 
dimerization between monomeric CpdA bound mGRwt and monomeric Dex-bound 
mGRdim, which is further explored in the discussion of this chapter. Specifically, CpdA has 
a potent ability to abrogate existing GRα dimers81, whilst speculation surrounding the ability 
of the dimerization deficient mutant to form GRα dimers, does exist82.  
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Figure 6.7: ‘Loss’ of GRα dimerization influences receptor turnover at the protein and mRNA level. Data 
was used from Figure 6.6 and for statistical analysis, a one-way ANOVA followed by a Tukey post-test was 
used to evaluate and compare the time-dependent and ligand-selective effects of the GRα ligands between 
mGRwt and mGRdim at the protein (ns, p > 0.05, **, p < 0.01), and mRNA level (ns, p > 0.05, *, p < 0.05, ***, 
p < 0.001). 
6.2.2.2. Determining the responsiveness of the system under acute GC/GRα 
signalling conditions, represented by short-term GC pre-treatment 
Having demonstrated that GRα expression is modulated in a ligand-selective, time- and 
dimerization dependent manner at both the protein and mRNA expression level, it was 
necessary to first determine the extent of acute GC/GRα signalling (i.e. following short-term 
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pre-treatment), which occurs by using the experimental protocol (Fig. 6.4), in the MEF cells, 
and is quantified by measuring the ligand-induced changes in the mRNA expression of the 
GC-responsive genes (i.e. GILZ, TAT, FKBP51 and IL-6). Essentially, in this section, the 
responsiveness of the system (or established working model) is determined with focus on the 
ligand-selective effects of GRα ligands, alone or in combination, in the context of ‘gain’ or 
‘loss’ of GRα dimerization. 
Firstly, the effect of the pro-inflammatory cytokine, TNFα, on basal GC-responsive gene 
expression is addressed. Secondly, the previously published effects of Dex on GC-responsive 
gene expression
35,42,53,69
 were confirmed via mGRwt in the MEF-mGRwt cells, to ensure the 
responsiveness of the system and to confirm acute GC/GRα signalling. Subsequently, these 
effects were compared to the effects of Dex on GC-responsive gene expression via mGRdim, 
in the MEF-mGRdim cells, to establish whether genes were regulated via GRα dimers or 
monomers. Next, the effects on GC-responsive gene expression, mediated via monomeric 
CpdA-bound mGRwt, were compared to that of monomeric Dex-bound mGRdim. Lastly, the 
ligand-selective effects, on GC-responsive gene expression, of Dex and CpdA in 
combination, via mGRwt and mGRdim were compared to the effects elicited by these GCs 
individually. 
6.2.2.2.1. The effect of the pro-inflammatory cytokine, TNFα, on basal GC-responsive 
gene expression 
From the results, it is clear that TNFα treatment, on its own, significantly reduced GILZ 
mRNA expression to 0.4 (p < 0.001) and 0.6-fold (p < 0.05), relative to solvent (EtOH) in the 
MEF-mGRwt and MEF-mGRdim cells, respectively (Fig. 6.8A). Moreover, no significant (p 
> 0.05) change in TAT (Fig. 6.8B) or FKBP51 (Fig. 6.8C) mRNA expression is observed in 
either of the cell lines, following treatment with TNFα. Lastly, as expected, TNFα treatment 
leads to a significant (p< 0.001) 4-fold increase in IL-6 mRNA expression in the MEF-
mGRwt cells and a slightly lower fold increase (2.4-fold) in IL-6 mRNA expression in the 
MEF-mGRdim cells (Fig. 6.8D). For all the genes, the effect of TNFα on GC-responsive 
gene expression in the MEF-mGRwt cells was not significantly (p > 0.05) different to the 
effect observed in the MEF-mGRdim cells (Fig. 6.8A, B, C and D).  
It was necessary to address the effects of TNFα on GC-responsive gene expression, in order 
to account for possible TNFα-induced changes in mRNA expression in subsequent 
experiments. Thus, important to note, is that potential ligand-induced GRα effects on GC-
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responsive gene expression, observed in the context of ‘gain’ or ‘loss’ of GRα dimerization, 
are normalised to changes observed in the presence of solvent plus TNFα, in latter sections. 
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Figure 6.8: The effect of the pro-inflammatory cytokine, TNFα, on basal GC-responsive gene expression. 
MEF-mGRwt and MEF-mGRdim cells were seeded into a 12 well plate (1 x 10
5
 cells/well). Following 24 hours 
incubation, cells were steroid starved. After steroid starvation, 48 hours later, cells were treated with EtOH or 
TNFα (0.02 μg/ml) for 8 hours. Thereafter, the mRNA expression of basal GC-responsive genes was determined 
in the MEF-mGRwt and MEF-mGRdim cell lines by performing RT-PCR. The GILZ (A), TAT (B), FKBP51 
(C) and IL-6 (D) basal mRNA expression was calculated using Equation 2 and normalized to that of the 
reference gene, 18S. TNFα induced changes in basal GC-responsive gene expression was expressed as a fold 
increase or decrease (average ± SEM) relative to the gene expression of the genes of interest in the absence of 
TNFα, which was set at 1 (dotted line). For statistical analysis, an unpaired t-test was used to evaluate and 
compare the TNFα–induced effects on basal GC-responsive gene expression in the MEF-mGRwt or MEF-
mGRdim cell lines, relative to gene expression in the absence of TNFα lines (ns, p > 0.05, *, p < 0.05, ***, p < 
0.001), as well as to compare the TNFα–induced effects on basal GC-responsive gene expression between the 
MEF-mGRwt and MEF-mGRdim cells (p < 0.05). 
6.2.2.2.2. GC-responsive gene expression is ligand-selective under acute GC/GRα 
signalling conditions (i.e. short-term pre-treatment) 
Essentially, results from this section demonstrate that the working model established, using 
the experimental protocol in Figure 6.4, is GC-responsive, following short-term Dex pre-
treatment. 
Firstly, Dex induces transactivation of GC-responsive genes, via mGRwt, leading to a 
significant increase in GILZ (p < 0.001), TAT (p < 0.01) and FKBP51 (p < 0.001) mRNA 
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expression to 6.6- (Fig. 6.9A), 13.3- (Fig. 6.9B) and 4.0-fold (Fig. 6.9A), respectively. 
Moreover, IL-6 mRNA expression is down-regulated, to 0.7-fold relative to solvent, 
following short-term pre-treatment with Dex (Fig. 6.9D). These findings confirm that the 
working model reacts as expected and that a GRα dimer, induced following treatment of 
mGRwt with Dex, is capable of both inducing (i.e. via transactivation) and repressing (i.e. via 
transrepression) a number of GC-responsive genes. 
In contrast to a ‘gain’ of receptor dimerization, using the wild type receptor, mGRwt, ‘loss’ 
of GRα dimerization, through the use of the mutant, mGRdim, restricts GC-mediated 
transactivation of GC-responsive genes, whilst maintaining its ability to induce 
transrepression of the pro-inflammatory cytokine, IL-6. Specifically, unlike in the MEF-
mGRwt cells, Dex short-term pre-treatment was unable to significantly (p > 0.05) up-regulate 
GILZ (1.6-fold, Fig. 6.9A) and TAT (2.3-fold, Fig. 6.9B) mRNA expression, in the MEF-
mGRdim cells. Additionally, a significant difference between the Dex-induced GILZ (p < 
0.01) mRNA levels are noted between the two cell lines (Fig. 6.9A). Although not significant 
(p > 0.05) a similar trend is observed for TAT (Fig. 6.9B) when directly comparing MEF-
mGRwt and MEF-mGRdim cells, following short-term Dex pre-treatment. Interestingly, 
FKBP51 is significantly (p < 0.01) increased after Dex treatment in the MEF-mGRdim cells, 
however, this increase is not as prominent as, and significantly (p < 0.01) lower, than that 
observed in the MEF-mGRwt cells (Fig. 6.9C). In terms of the Dex-mediated transrepression 
of IL-6, via mGRdim, a ‘loss’ GRα dimerization did not significantly (p > 0.05) affect the 
ability of Dex-mediated transrepression of the IL-6 gene and resulted in an equal reduction in 
IL-6 mRNA expression in both cell lines (Fig. 6.9E). This finding is not unexpected as, in 
general, GC-mediated transrepression of GC responsive genes is thought to be mediated via a 
GRα monomer80,81.  
Once the requirement for GRα dimerization in regulating the expression of the GC-
responsive genes, (GILZ, TAT, and FKBP51 but not IL-6) had been determined, the effect of 
a ‘loss’ of mGRwt dimerization as a result of CpdA treatment was compared to the effect of a 
‘loss’ of dimerization via the mutant, mGRdim, following Dex treatment. CpdA treatment, 
failed to induce significant up-regulation of the GC-responsive genes GILZ (1.0-fold), TAT 
(1.5-fold) and FKBP51 (1.0-fold) via mGRwt (Fig. 6.9A, B and C). Although CpdA pre-
treatment was unable to induce GRα-mediated transactivation, most likely due to its ability to 
abrogate mGRwt dimerization
80,81
, CpdA was capable of significantly (p < 0.05) reducing IL-
6 mRNA expression to 0.6-fold (Fig. 6.9D). Essentially, these CpdA-mediated effects via 
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mGRwt are comparable and not significantly different (p > 0.05) to the Dex-mediated effects 
via mGRdim for all genes (GILZ, TAT and IL-6), except FKBP51 (Fig. 6.9A, B, C and D). 
Important to note, is that CpdA short-term pre-treatment of mGRdim also did not lead to 
significant (p > 0.05) transactivation of GILZ (Fig. 6.9A), TAT (Fig. 6.9B) or FKBP51 
(Fig.6.9C), however, did result in significant (p < 0.05) transrepression of IL-6 (0.6-fold), 
similar to the effects observed via mGRwt (Fig. 6.9D). 
Now that the effects of the individual GRα ligands, namely Dex or CpdA, on GC-responsive 
gene expression, via mGRwt or mGRdim, have been addressed, these effects were 
investigated following short-term pre-treatment of these ligands in combination, in both 
MEF-mGRwt and MEF-mGRdim cells. Combining the dimerization promoting GC, Dex, 
and the dimerization abrogating GC, CpdA, did not result in a significant (p > 0.05) increase 
in GILZ (1.2-fold) or FKBP51 (1.2-fold) mRNA expression (Fig. 6.6A and C), similar to the 
effects observed for CpdA alone, but unlike the effects observed for Dex short-term pre-
treatment, in the MEF-mGRwt cells. In contrast, significant (p < 0.05) up-regulation of TAT 
(7.5-fold), via mGRwt, was noted following short-term pre-treatment with the combination of 
GRα ligands (Fig. 6.9B). However, although this increase in TAT mRNA expression (7.5-
fold) is significantly (p < 0.05) higher than that induced by CpdA alone (1.5-fold) it appears 
to be not significantly (p > 0.05) different to the increase following Dex short-term pre-
treatment (13.3-fold). Unlike for transactivation, the combination treatment resulted in 
transrepresion of IL-6 that was higher, but not significantly different, to that of CpdA or Dex 
alone via mGRwt (Fig. 6.6E). As with the individual short-term pre-treatments of mGRdim 
with GRα ligands, the combination pre-treatment did not lead to significant (p > 0.05) 
transactivation of GILZ (Fig. 6.9A), TAT (Fig. 6.9B) or FKBP51 (Fig.6.9C), however, did 
result in significant (p < 0.01) transrepression of IL-6 (0.4-fold) in MEF-mGRdim cells (Fig. 
6.9D). 
Taken together, results from this section, confirmed that the working system established 
using the experimental protocol (Fig. 6.4) is GC-responsive, with GC-mediated 
transactivation and transrepression occurring as one would expect under acute GC/GRα 
signalling conditions
71,83,84
. 
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 Figure 6.9: GC-responsive gene expression is ligand-selective under acute GC/GRα signalling conditions 
(i.e. short-term pre-treatment). MEF-mGRwt and MEF-mGRdim cells were seeded into a 12 well plate (1 x 
10
5
 cells/well). Following 24 hours incubation, cells were steroid starved. After steroid starvation, 24 hours 
later, cells were pre-treated with solvent (EtOH), Dex (1 μM), CpdA (10 μM) or Dex (1 μM) and CpdA (10 μM) 
combined, for 2 hours. Following pre-treatment with GRα ligands, cells were treated with TNFα (0.02 μg/ml) 
for an additional 8 hours. Thereafter, the mRNA expression of GC-responsive genes was determined, in the 
MEF-mGRwt and MEF-mGRdim cell lines, by performing RT-PCR. The GILZ (A), TAT (B), FKBP51 (C) and 
IL-6 (D) mRNA expression was calculated using Equation 2 and normalized to that of the reference gene, 18S. 
Ligand-selective changes in GC-responsive gene expression was expressed as a fold increase or decrease 
(average ± SEM) relative to the gene expression of the genes in the presence of the solvent (EtOH + TNFα), 
which was set at 1 (dotted line), for each cell line. For statistical analysis, a one-way ANOVA with a Tukey’s 
post-test was used to evaluate the effects of GRα ligands (following short-term pre-treatment) on GC-responsive 
gene expression in the MEF-mGRwt or the MEF-mGRdim cells, relative to solvent (EtOH + TNFα) (ns, p > 
0.05, *, p < 0.05, **, p < 0.01, ***, p < 0.001). Furthermore, the letters a, b, c are used to indicate significant (p 
< 0.05) differences between bars within the MEF-mGRwt or MEF-mGRdim cells. An unpaired t-test was used 
to determine the differences between Dex pre-treatment via mGRwt or mGRdim (ns, p > 0.05, ##, p < 0.01) on 
GC-responsive gene expression. Lastly, differences between GC-responsive gene expression induced by CpdA 
pre-treatment of mGRwt and Dex pre-treatment of mGRdim were also determined using an unpaired t-test (ns, p 
> 0.05, $, p < 0.05). 
6.2.2.3. Evaluating acquired GC resistance at a molecular level (i.e. GC-responsive 
gene expression) following prolonged GC treatment. 
It is well documented that a number of chronic auto-immune diseases require long-term and 
high-dose GC treatment to combat the severe inflammation associated with these illnesses 
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and that, following prolonged GC treatment, it is likely that acquired resistance to GC 
treatment may develop as a result of, in part, drastic reductions in GRα expression2,8–11.  
Currently, a need exists for the development of new therapeutic strategies to alleviate GC 
resistance either by reducing the treatment time or by developing novel GRα ligands that 
potentiate the anti-inflammatory effects of existing therapeutic GCs, like Dex
85–87
. One of the 
ways in which the development of GC insensitivity may be circumvented, is by preserving 
GRα expression73.  
Up to now the current study has established, tested, and validated a GC-responsive system, 
using an adapted experimental protocol (Fig. 6.4) from Li et al.
73
, in order to investigate the 
down-stream effects (i.e. the modulation of GC-responsive gene expression) of ligand-
induced changes in the GRα expression, however, the down-stream effects of drastic changes 
in receptor expression, which occur following prolonged GC treatment (i.e. long-term pre-
treatment), have not yet been addressed. Thus, in essence, the aim in this section was to 
evaluate the expression of GC-responsive genes under conditions that mimic acquired GC 
resistance (i.e. long-term GC treatment) and to determine whether inducing predominantly 
monomeric GRα could aid in restoring GC sensitivity, by maintaining receptor expression. 
To begin this section, the ligand-selective effects on a cohort of GC-responsive genes chosen 
due to their relevance in resistance, inflammation or the generation of adverse side-effects, 
associated with GC signalling, were investigated (i.e. GILZ, TAT, FKBP51 or IL-6). 
Specifically, the ligand-selective effects, via GRα, on these genes following long-term GC 
pre-treatment were compared to the effects on these genes after short-term GC pre-treatment, 
by measuring the mRNA expression of these genes, in the MEF-mGRwt (Fig. 6.10) or MEF-
mGRdim cells (Fig. 6.11). Once the effects of prolonged GC treatment on GC-responsive 
gene expression had been determined in each individual cell line, the effect of a ‘loss’ of GRα 
dimerization via the mutant in the MEF-mGRdim cells on GC-responsive gene expression, 
was directly compared to that of the wild type in the MEF-mGRwt cells (Fig. 6.12), to assess 
whether prevention of GC acquire resistance can be achieved via predominantly monomeric 
GRα.  
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6.2.2.3.1. Prolonged GC treatment results in GC acquired resistance, at the molecular 
level, for one, but not all the GC-responsive genes. 
Previously, the current study demonstrated that long-term pre-treatment with dimerization 
promoting Dex in the MEF-mGRwt cells, resulted in a significantly (p < 0.05) greater 
reduction (up to 20% more) in receptor expression, relative to short-term treatment (Fig. 
6.6A). Interestingly, results in Figure 6.10A, suggest a concomitant decrease in the mRNA 
expression of GILZ following long-term pre-treatment relative to the mRNA expression of 
GILZ post short-term Dex pre-treatment. Specifically, long-term Dex treatment significantly 
(p< 0.05) reduced GILZ mRNA expression to 4.6-fold, relative to GILZ mRNA expression 
post short-term Dex pre-treatment (6.6-fold) (Fig. 6.10A). Surprisingly, and in contrast to 
GILZ, no significant (p > 0.05) reduction in TAT and FKBP51 mRNA expression was 
observed following long-term Dex pre-treatment (Fig. 6.10B and C). Furthermore, one would 
expect an increase in IL-6 mRNA expression, as a result of a decrease in mGRwt protein, 
following long-term Dex pre-treatment, however this is not the case (Fig. 6.10D). 
In stark contrast to long-term Dex pre-treatment, long-term treatment with dimerization 
abrogating CpdA did not alter the expression of the GRα ‘functional pool’, relative to solvent 
(Fig. 6.6A). Specifically, mGRwt expression was maintained at 94 and 89% relative to 
solvent following short- and long-term pre-treatment, respectively (Fig. 6.6A). Thus, 
approximately 60% more GRα is available to induce down-stream effects (i.e. modulate GC-
responsive gene expression), following long-term CpdA pre-treatment (89%), relative to 
long-term Dex pre-treatment (29%).  
As one would expect, due to the monomeric nature of CpdA-bound mGRwt and its inability 
to transactivate GC-responsive genes
12,56,88
, no significant (p >0.05) changes in GILZ (Fig. 
6.10A), TAT (Fig. 6.10B) or FKBP51 (Fig. 6.10C) mRNA expression were noted following 
long-term CpdA pre-treatment, as also observed for short-term CpdA pre-treatment. 
Additionally, no significant change in the mRNA expression of IL-6 (Fig. 6.10D) was 
observed, between to two different periods of pre-treatments (i.e. short-term versus long-term 
pre-treatment). One could speculate that this is due to similar mGRwt protein levels detected 
between the short- and long-term pre-treatments with CpdA (Fig. 6.6A). On the other hand, 
one would expect, relative to prolonged Dex-mediated transrepression of IL-6 via mGRwt, 
more CpdA-mediated transrepression of IL-6 due to the 60% more mGRwt available (Fig. 
6.6A) to transrepress this gene, following prolonged CpdA treatment, however this is not the 
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case (Fig. 6.10D). 
 
 
Figure 6.10: Prolonged GC treatment modulates the gene expression profile of GC-responsive genes. 
MEF-mGRwt cells were seeded into a 12 well plate (1 x 10
5
 cells/well). Following 24 hours incubation, cells 
were steroid starved. After steroid starvation, 24 hours later, cells were pre-treated with solvent (EtOH), Dex (1 
μM), CpdA (10 μM) or Dex (1 μM) and CpdA (10 μM) in combination, for 2 hours (short-term protocol; light 
bars) or 24 hours (long-term protocol, dark bars). Following pre-treatment with GRα ligands, cells were treated 
with TNFα (0.02 μg/ml) for an additional 8 hours. Thereafter effects of short- or long-term pre-treatment on the 
mRNA expression of GC-responsive genes, was determined in the MEF-mGRwt cell line by performing RT-
PCR. The GILZ (A), TAT (B), FKBP51 (C) and IL-6 (D) mRNA expression was calculated using Equation 2 
and normalized to that of the reference gene, 18S. Ligand-selective and time-dependent changes in GC-
responsive gene expression were expressed as a fold increase or decrease (average ± SEM) relative to the gene 
expression of the genes in the presence of the solvent (EtOH + TNFα), which was set at 1 (dotted line). For 
statistical analysis, a one-way ANOVA with a Tukey’s post-test was used to evaluate the effects of GRα ligands 
on GC-responsive gene expression in the MEF-mGRwt cells, relative to TNFα alone, at both pre-treatment 
times. In addition, an unpaired t-test was used to determine the direct effect of long-term (24 hours) pre-
treatment on ligand-induced GC-responsive gene expression, relative to the effect observed post short-term (2 
hours) pre-treatment (ns, p > 0.05 and *, p < 0.05). 
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Lastly, in terms of the combination pre-treatment, both short- and long-term pre-treatment 
with Dex and CpdA in combination significantly reduced mGRwt protein expression (Fig. 
6.6A). Moreover, no difference in the extent of mGRwt protein turnover between the two 
periods of combination pre-treatment existed, although reductions in mGRwt expression in 
the combination pre-treatment were slightly less than with Dex alone (Fig. 6.6A). This lack 
of difference between the GRα ‘functional pool’s’, following short- and long-term pre-
treatment of GCs in combination, was reflected at the level of GC-responsive gene 
expression, where no significant change in the mRNA expression of GILZ (Fig. 6.10A), TAT 
(Fig. 6.10B), FKBP51 (Fig. 6.10C) or IL-6 (Fig. 6.10D) was observed.  
6.2.2.3.2. Prolonged GC treatment does not modulate the gene expression profile of 
GC-responsive genes via mGRdim 
Previously, the current study demonstrated that long-term pre-treatment with dimerization 
promoting Dex in the MEF-mGRdim cells, led to a significant reduction to 49% in mGRdim 
expression, relative to short-term Dex pre-treatment (Fig. 6.5C), however, this reduction was 
not as drastic as that observed with mGRwt (i.e. 29%, relative to solvent) following 
prolonged Dex pre-treatment (Fig. 6.5A). In terms of GC-responsive gene expression, a very 
slight, but insignificant reduction reflects the change in mGRdim expression at the level of 
GILZ mRNA expression from 2.1- to 1.9-fold, when comparing short-term and long-term 
Dex pre-treatment, respectively, in the MEF-mGRdim cells (Fig. 6.10A). Moreover, unlike 
GILZ, no significant change in the expression of the other genes was observed following 
long-term pre-treatment with Dex, relative to short-term Dex pre-treatment (Fig. 6.10B, C 
and D).  
Interestingly, long-term treatment of mGRdim with dimerization abrogating CpdA resulted in 
a significant (p < 0.01) increase in the protein expression of mGRdim to 162%, relative to 
solvent, however this increase was not significantly (p < 0.05) greater than that mediated by 
short-term CpdA pre-treatment (i.e. 120%) (Fig. 6.6C). Moreover, prolonged treatment of 
mGRdim with CpdA (i.e. long-term pre-treatment) mediated a slight but not significant (p < 
0.05) increase in the mRNA expression of GILZ, TAT and FKBP51 (Fig. 6.11A, B and C), 
relative to short-term pre-treatment. Furthermore, an interesting observation is made with the 
effect of a CpdA-mediated increase in mGRdim expression on IL-6 expression (Fig. 6.11D). 
Specifically, following long-term pre-treatment with CpdA, mGRdim’s ability to transrepress 
IL-6 is, in part, diminished relative to the short-term CpdA pre-treatment. One could 
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postulate that this observed effect is due to a lack of CpdA-mediated mGRdim nuclear 
translocation, which was demonstrated by the current study in Chapter 5 (Fig. 5.6A), 
however, it does not explain the slight CpdA-mediated increase in .in TAT and FKBP51, via 
mGRdim (Fig. 6.11B and C) nor the effects of short-term CpdA pre-treatment on IL-6 (Fig. 
611D).  
Figure 6.11: Prolonged GC treatment does not modulate the gene expression profile of GC-responsive 
genes via mGRdim. MEF-mGRdim cells were seeded into a 12 well plate (1 x 10
5
 cells/well). Following 24 
hours incubation, cells were steroid starved. After steroid starvation, 24 hours later, cells were pre-treated with 
solvent (EtOH), Dex (1 μM), CpdA (10 μM) or Dex (1 μM) and CpdA (10 μM) in combination, for 2 hours 
(short-term protocol; light bars) or 24 hours (long-term protocol, dark bars). Following pre-treatment with GRα 
ligands, cells were treated with TNFα (0.02 μg/ml) for an additional 8 hours. Thereafter effects of short or long-
term pre-treatment on the mRNA expression of basal GC-responsive genes, was determined in the MEF-
mGRdim cell line, by performing RT-PCR. The GILZ (A), TAT (B), FKBP51 (C) and IL-6 (D) mRNA 
expression was calculated using Equation 2 and normalized to that of the reference gene, 18S. Ligand-selective 
and time-dependent changes in GC-responsive gene expression were expressed as a fold increase or decrease 
(average ± SEM) relative to the gene expression of the genes in the presence of the solvent (EtOH + TNFα), 
which was set at 1 (dotted line). For statistical analysis, a one-way ANOVA with a Tukey’s post-test was used 
to evaluate the effects of GRα ligands on basal GC-responsive gene expression in the MEF-mGRdim cells, 
relative to TNFα alone, at both pre-treatment times. In addition, an unpaired t-test was used to determine the 
direct effect of long-term (24 hours) pre-treatment on ligand-induced GC-responsive gene expression (ns, p > 
0.05, *, p < 0.05, ***, p < 0.001), relative to the effect observed post short-term (2 hours) pre-treatment (ns, p > 
0.05). 
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In the case of the combination pre-treatment, a significant (p < 0.05) difference in mGRdim 
protein expression between the short-term (108%) and long-term pre-treatment (60%) was 
observed (Fig. 6.6C). However, this difference in mGRdim protein expression is not reflected 
by a significant difference in GC-responsive gene expression for any of the genes (Fig. 6.11), 
although prolonged pre-treatment of Dex and CpdA in combination appears to potentially 
affect the mRNA expression of TAT (Fig. 6.11B). 
6.2.2.3.3.  ‘Loss’ of GRα dimerization results in reduced GC-mediated transactivation, 
but not transrepression.  
To directly compare the effects of a ‘loss’ of dimerization, and thus preserved GRα 
expression, results were combined from both cell lines (Fig. 6.12). In terms of GC-responsive 
gene expression no significant (p > 0.05) differences, due to the use of mGRdim, across all 
genes (GILZ, TAT, FKBP51 or IL-6) were noted, following short- and long-term pre-
treatment with CpdA alone or in combination with Dex (Fig. 6.12). 
In contrast, significant differences (p < 0.01 and p < 0.001) in the mRNA expression of GILZ 
(Fig. 6.12A), TAT (Fig. 6.12B) and FKBP51 (Fig. 6.12C), but not of IL-6 (Fig. 6.12D), 
following both short-term and long-term pre-treatment with Dex, were noted, when mGRdim 
was utilized. Although, in terms of IL-6 mRNA expression, ‘loss’ of dimerization, through 
the use of mGRdim, did not significantly modulate Dex’s ability to transrepress IL-6 (Fig. 
6.12D), ‘loss’ of dimerization through CpdA treatment of mGRwt appeared to be more 
efficient (0.5- fold) at transrepressing IL-6, relative to mGRdim (1.0- fold), following long-
term CpdA pre-treatment (Fig. 6.12D). This is likely due to the difference in the subcellular 
localisation of CpdA-bound mGRwt and CpdA-bound mGRdim, which was observed in 
Chapter 5 (Fig. 5.6A).  
To briefly summarize this current section, the use of mGRdim significantly modulated the 
Dex-mediated GC-responsive gene expression of genes mediated via GRα transactivation, 
however, did not alter GRα mediated transrepression of the pro-inflammatory cytokine, IL-6, 
relative to mGRwt. Additionally, ‘loss’ of GRα dimerization, following short-term or 
prolonged CpdA treatment or the use of the mutant, mGRdim, rarely re-shaped the GC-
responsive gene expression profile, relative to mGRwt. These findings suggest, ‘loss’ of GRα 
dimerization, through the use of mGRdim, may restrict the development of adverse side-
effects (i.e. from an up-regulation of metabolic genes such as TAT) but retain the beneficial 
anti-inflammatory potential of GCs, via GRα-mediated transrepression. 
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Taken altogether, results from this entire section, where a GC-responsive system was 
established, tested and validated to mimic an acquired resistance to GC treatment, provided 
some interesting findings.  
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Figure 6.12: ‘Loss’ of GRα dimerization results in reduced GC-mediated, transactivation but not 
transrepression, in MEF-mGRdim cells. Data was used from Figure 6.10 and 6.11 and for statistical analysis, 
a two-way ANOVA with a Bonferroni’s post-test was used to evaluate the effects of a ‘loss’ of GRα 
dimerization on basal GC-responsive gene expression by comparing effects via mGRwt and mGRdim (ns, p > 
0.05, **, p < 0.01, ***, p < 0.001). 
Briefly, having provided further evidence for a role for receptor dimerization in mediating 
ligand-induced GRα protein turnover, using an endogenous dimerization deficient mutant, 
mGRdim, and CpdA treatment of mGRwt, a novel mandatory requirement for GRα 
dimerization in ligand-induced receptor turnover at the level of mRNA expression was noted 
for mGRdim, but not for the dimerization abrogating GC, CpdA, in the current section. 
Specifically, significant differences in the ability of the CpdA-bound mGRwt monomer and 
the Dex-bound mGRdim monomer to regulate expression of the GRα gene, NR3C115,16,25,26, 
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and/or affect GRα mRNA stability, resulting in alterations in total GRα mRNA expression, 
were observed.  
The current study, went on  to demonstrate that drastic reductions in receptor expression (as a 
result of prolonged GC treatment) driven by a ‘gain’ of mGRwt dimerization through 
treatment with dimerization promoting Dex, significantly modulated the expression of GILZ, 
but not TAT or FKBP51. Furthermore, contrary to what was expected, this reduction in wild 
type GRα, following long-term pre-treatment with Dex, did not reduce the ability to trans-
repress the pro-inflammatory IL-6 gene. In terms of acquired resistance to GC treatment, 
these results highlight gene-specific effects and, in the case of the current study, suggest that 
acquired GC resistance at the molecular level, is likely to develop due to a decrease in the 
expression of the anti-inflammatory gene GILZ, rather than an increase in the expression of 
the pro-inflammatory gene, IL-6, following long-term Dex pre-treatment. The fact that no 
decrease in the responsiveness of TAT and FKBP51 expression was observed, even after 
prolonged GC treatment has considerably reduced the level of the GRα ‘functional pool’ 
available to regulate gene expression, suggest that these gene do not appear to have 
implications for acquired GC resistance, importantly, at the molecular level. However, 
maintained expression of TAT and FKBP51 even after prolonged GC treatment has 
implications for the generation of adverse side-effects and clinical resistance associated with 
GC signalling, which is further explored in the discussion of this chapter.  
In contrast to reduced GRα protein expression, as a consequence of a ‘gain’ of receptor 
dimerization, preserving GRα expression, even after long-term GC pre-treatment, due to 
‘loss’ of dimerization through CpdA treatment or dimerization deficient mutant GRα, does 
not result in an increase in the transactivation of GC-responsive genes GILZ, TAT or 
FKBP51. This is consistent with previous results, which suggests GC-mediated GRα 
transactivation occurs predominantly via a GRα dimer29 and thus increasing predominantly 
monomeric GRα expression would not affect transactivation of such GC-responsive genes. 
This finding is beneficial in terms of genes such as TAT and FKBP51, which are linked to 
side-effects and resistance, respectively
2,53,58
. However, the restricted increase in the 
expression of the anti-inflammatory gene, GILZ, due to the presence of predominantly 
monomeric GRα is disadvantageous for counteracting inflammation. Surprisingly, 
maintaining GRα expression did not result in greater trans-repression of the pro-inflammatory 
gene, IL-6. 
Stellenbosch University  https://scholar.sun.ac.za
  215  
 
Lastly, gene-specific effects were observed when investigating the effects between pre-
treatment with the individual GCs and the GCs in combination. This may be linked to the 
degree of receptor dimerization when both the dimerization promoting Dex and the 
dimerization abrogating GC, CpdA, were added together. Taken together, the ability of CpdA 
to partially maintain GRα expression (Fig. 6.6), combined with its ability to mediate 
successful transrepression whilst somewhat restricting Dex-mediated transactivation of GC–
responsive genes (Fig. 6.9), all in the presence of Dex, provide evidence for the potential 
ability of CpdA to counteract the adverse effects of Dex, following prolonged GC treatment, 
which may be exploited pharmacologically.  
6.3. Discussion 
GCs continue to remain the preferred drug choice for the treatment of inflammation even 
though prolonged GC treatment results in adverse side effects and, more importantly for the 
current study, acquired resistance to GC treatment
2,8–11
.  
Over the past years, research has focused on identifying GRα ligands, which maintain vital 
immunosuppressive effects but demonstrate an improved side-effect profile
29
, however, 
acquired resistance to GC treatment has often been overlooked when developing novel 
therapeutics. With the incidence of patient insensitivity increasing
4–6
, and many individuals 
requiring higher GC doses in order to combat inflammation associated with various disease-
states, it seems the recent shift in research focus towards understanding and exploiting the 
molecular mechanisms involved in the development of resistance, is essential. 
Ligand-induced GRα down-regulation, following prolonged GC treatment, is one of the many 
factors that contribute to the development of GC insensitivity or an acquired resistance
12,18–
20,25,57,89,90
. Previous chapters, in the current study, identified receptor conformation, 
specifically GRα dimerization, as a novel requirement for mediating this ligand-induced GRα 
protein down-regulation (Chapter 4) and elucidated how receptor conformation affects the 
molecular mechanisms associated with proteasomal degradation (Chapter 5). Whist these 
findings hinted that targeting receptor dimerization and maintaining GRα expression may 
serve as a potential mechanistic approach to reverse or prevent acquired GC resistance, they 
did not directly address the biological implications of altered GRα expression, in terms of 
acquired GC resistance. Specifically, how maintaining the GRα ‘functional pool’ through a 
‘loss’ of receptor dimerization modulates the expression of GC-responsive genes, generally 
associated with acquired GC resistance. In an attempt to evaluate acquired resistance to GC 
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treatment, at the molecular level, the current chapter established and tested a GC-responsive 
system, or working model, using an adapted experimental protocol from Li et al.
73
. 
Firstly, and of utmost importance, the ability of our working model to mimic acquired 
resistance was validated by demonstrating further reductions in mGRwt expression, 
following long-term Dex pre-treatment (i.e. prolonged GC treatment to mimic acquired 
resistance), relative to short-term Dex pre-treatment (i.e. acute GC/GRα signalling). 
Having established and validated the model, the current study went on to demonstrate the 
development of an acquired resistance to GC treatment, at the molecular level (i.e. GILZ), 
following long-term pre-treatment of mGRwt, relative to short-term pre-treatment, with 
dimerization promoting Dex. Moreover, ‘loss’ of GRα dimerization, through treatment of 
mGRwt or the use of mGRdim, did not display the same effects on GILZ mRNA expression 
(i.e. in terms of molecular resistance), due to the fact that GC-mediated transactivation of 
GILZ requires direct binding of a GRα dimer to the promoter of this gene. 
Additionally, an acquired resistance to GC treatment, at the molecular level, was not 
demonstrated for the other genes, namely TAT, FKBP51 and IL-6, via mGRwt. However, 
these results provided evidence for the development of GC acquired resistance, following 
prolonged GC treatment, in terms of clinical GC resistance (FKBP51 and IL-6), as well as the 
generation of adverse side-effects (i.e. TAT). Furthermore, ‘loss’ of GRα dimerization, 
through treatment of mGRwt or the use of mGRdim, restricted up-regulation of TAT and 
FKBP51, whilst maintaining the ability to transrepress IL-6 (with the exception of long-term 
CpdA pre-treatment via mGRdim). Suggesting, ‘loss’ of GRα dimerization may limit the 
development of acquired GC resistance at a clinical level, as well as the development of 
adverse side-effects. Taken together, these findings highlight the importance of considering 
the effects of ligands on GRα conformation when developing novel therapeutics, especially 
for prolonged therapeutic regimens. 
Specifically, ‘gain’ of mGRwt dimerization mediated by long-term Dex pre-treatment 
encouraged a significantly greater reduction in the mGRwt ‘functional pool’, to a mere 29%, 
relative to the short-term Dex pre-treatment (58%), which subsequently resulted in a loss of 
responsiveness of the GRE-drive gene, GILZ (Fig. 6.6A and 6.10A). Specifically, a 
significantly blunted GILZ response (4.6-fold) in GILZ expression, following long-term Dex 
pre-treatment, was noted, relative to the 6.6-fold increase in GILZ mRNA expression induced 
by short-term Dex pre-treatment (Fig. 6.10A). This approximate 1.4-fold reduction in GILZ 
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mRNA expression, in the current study, is supported by the work of Gossye et al.
90
 in which 
an approximate 1.3-fold reduction (a 22-fold to 17-fold increase, relative to solvent) in the 
mRNA expression of another GRE-driven gene, glutamine synthetase (GS), was noted, 
following prolonged exposure to Dex (32 hours). In addition, the responsiveness of the GILZ 
gene (i.e. in the short-term Dex pre-treatment protocol) in the working model, used in the 
current study, is comparable to the responsiveness of this gene in other studies. Following, 
short-term pre-treatment, which was aimed to represent acute GC/GRα signalling, a 6.6-fold 
increase in the expression of GILZ, was obtained (Fig. 6.10A). In line with this finding, a 
study by Ronacher et al.
20
 demonstrated a 6-fold increase, relative to solvent, in endogenous 
GILZ expression in stably transfected U20S osteosarcoma cells after two hours treatment 
with Dex. Moreover, Wang et al.
91
 reported a slightly lower, up to 5-fold, increase in GILZ 
mRNA expression, relative to solvent, following up to 6 hours treatment with a lower 
concentration of Dex (100 nM), in RAW264.7 cells.  
Interestingly, and unlike GILZ, the expression of another GC-responsive gene, investigated in 
this study, namely FKBP51, was not inhibited by the significantly reduced mGRwt 
‘functional pool’, following prolonged pre-treatment with Dex. Rather a slight, yet 
insignificant, increase in FKBP51 expression from 4.0-fold to 4.4-fold, following short- and 
long-term pre-treatment, respectively, was observed (Fig. 6.10C). This finding correlates well 
with previous studies, which demonstrated that a reduction in GRα expression was 
insufficient to affect the ability of GRα to induce ‘positive’ up-regulation (GRα-mediated 
transactivation) of certain GC-responsive genes
73,90. Specifically, when GRα expression was 
low, following 24 hour (long-term) pre-treatment with Dex (1 µM), the mRNA expression of 
the GRE-driven dual specificity phosphatase 1 (DUSP1) was not significantly different from 
the mRNA expression noted when GRα expression was significantly higher after just 2 hours 
pre-treatment with Dex
73
. Moreover, in a study which investigated the relative expression of 
FKBP51 as a function of time in a lymphoblast cell line, no decrease in FKBP51 mRNA 
expression, was noted after 24 hours GC treatment
92
. Lastly, in a study by Gossye et al.
90
, the 
expression of the GC-inducible pro-collagen C-endopeptidase enhancer 2 (POLCE2) was 
found to be significantly higher in conjunction with a reduction in receptor expression. 
In terms of an acquired resistance to GC treatment, results from the GILZ and FKBP51 
mRNA expression experiments, support the fact that prolonged GC treatment encourages the 
development of GC insensitivity. Importantly, GC sensitivity may be described at the 
molecular level (i.e. diminished GILZ mRNA expression, via GRα, following prolonged GC 
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treatment) or at a clinical, more indirect level (i.e. rather than diminished GC-responsive gene 
expression, mRNA levels are maintained, after prolonged treatments (e.g. FKBP51) but this 
maintained mRNA expression has implications in acquired GC resistance). Specifically, due 
to the fact that GILZ is thought to contribute to the anti-inflammatory potential of GCs
33
, a 
reduction in GILZ expression as a direct result of a reduction in GRα (i.e. acquired GC 
resistance at the molecular level), may promote inflammation. On the other hand, an increase 
in the expression of FKBP51, which was noted following long-term Dex pre-treatment in the 
current study, has been shown to encourage cellular desensitization to GC treatment
59–62
, via 
a negative feedback loop in which the resultant protein of the FKBP51 mRNA expression 
sequesters GRα in the cytoplasm55–58. Although the effects of a reduction in the mGRwt 
expression on GC-responsive gene expression appear to be gene-specific, these findings 
provide evidence that prolonged GC treatment (i.e. specifically with Dex) is a significant 
contributor to the development of clinical acquired GC resistance. 
In contrast, acquired resistance to GC treatment was not achieved at the molecular level for 
IL-6, in the established model of the current study (Fig. 6.10D). Unexpectedly, the reduced 
‘functional pool’ of mGRwt (29%) which was driven by long-term Dex pre-treatment, was 
still able to efficiently transrepress the expression of the pro-inflammatory cytokine, IL-6, 
from 1.0-fold in the presence of the solvent to 0.4-fold (Fig. 610D). These findings contradict 
results from Gossye et al.
90
 where reduced GRα expression impeded the GC-mediated 
immunosuppressive effects on the pro-inflammatory mediators, IL-6, interleukin 8 (IL-8) and 
macrophage chemoattractant protein-1 (MCP-1) in FLS cells isolated from patients with 
active RA. Additionally, Li et al.
73
 elegantly demonstrated that reduced GRα protein 
expression impeded the GC-mediated immunosuppressive effects for a number of other genes 
regulated by GRα, namely interleukin 17 (IL-17), MMP and TNFα. A potential reason for 
observed differences between the current study and the literature, is the greater differences 
(i.e. approximately more than 50%) in GRα expression observed between short- and long-
term protocols in the literature
73,90
 whereas, although a significant difference in the mGRwt 
‘functional pool’ between short- and long-term Dex pre-treatment, 58% and 29% 
respectively, were noted in the current study, it is may be that this difference in receptor 
expression was not enough to modulate the GC-responsiveness of IL-6. 
Lastly, in terms of the generation of adverse side-effects (e.g. hyperglycaemia) associated 
with prolonged GC treatment, results from the effect of a reduced mGRwt ‘functional pool’ 
on the expression of the metabolic gene, TAT, demonstrated that the remaining mGRwt 
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expression (29%), post long-term pre-treatment with Dex, was sufficient to drive the 
‘positive’ up-regulation of the metabolic gene, TAT. Moreover, no significant difference 
between the GC-mediated increase in TAT mRNA expression following short- and long-term 
pre-treatment, which was 13.3-fold and 12.6-fold, respectively, was detected (Fig. 6.10B). 
This finding may provide a possible explanation for why some patients have been shown to 
develop resistance, whilst still displaying adverse side-effects
93
. 
Results highlighted gene specific effects in term of acquired GC resistance at the molecular 
level, with a small subset of GC-responsive genes investigated, and collectively, validated the 
growing concerns associated with prolonged GC treatment, namely the generation of 
undesirable side-effects (e.g. hyperglycaemia) and, more importantly for this study, the 
development of an overall clinical acquired resistance to GC treatment as a result of drastic 
reductions in the GRα ‘functional pool’.  
Whilst a ‘gain’ of mGRwt dimerization driven by long-term pre-treatment with dimerization 
promoting Dex resulted in drastic reductions in the mGRwt ‘functional pool’, a ‘loss’ of 
mGRwt dimerization following long-term pre-treatment with dimerization abrogating CpdA 
maintained mGRwt protein expression at 89%, relative to the solvent (Fig. 6.6A). Neither 
short- nor long-term CpdA pre-treatment resulted in the transactivation of the GRE-driven 
genes GILZ, TAT and FKBP51, relative to solvent (Fig. 6.10A, B and C). Due to the fact that 
CpdA treatment does not result in GC-mediated transactivation of genes, via GRα, it is 
difficult to elucidate the role of maintained GRα expression, relative to the reduced GRα 
‘functional pool’ following Dex treatment (Fig. 6.10A, B and C). However, in terms of GC-
mediated transrepression, via GRα, both short- and long-term CpdA pre-treatment reduced 
IL-6 expression to 0.6- and 0.5-fold, respectively, relative to the solvent (Fig. 6.10D). The 
lack of difference in the CpdA-mediated transrepression of IL-6 between the two periods of 
treatment (i.e. short- and long-term pre-treatment), is likely due to the similar level of the 
mGRwt ‘functional pool’, noted in Figure 6.6A. Specifically, following short- and long-term 
CpdA pre-treatment, the mGRwt ‘functional pool’ was reported to be 94% and 89% 
respectively, relative to the solvent, which is set at 100% (Fig. 6.6A). With that said, we 
postulated that, relative to Dex-treatment, greater CpdA-mediated transrepression of IL-6 
would occur due to the maintenance of the GRα ‘functional pool’ (Fig. 6.6A), following 
CpdA treatment; however, this was not the case.  
Taken together, results suggest that treatment with dimerization abrogating CpdA, short- or 
long-term, in terms of the generation of adverse side-effects (e.g. hyperglycaemia), may be 
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more beneficial than treatment with dimerization promoting Dex. Additionally, with regards 
to acquired GC resistance, CpdA’s inability to transactivate the anti-inflammatory gene, 
GILZ, could be unfavourable. However, CpdA’s ability to prevent an increase in FKBP51 
expression, which is associated with the development of patient insensitivity to GCs, in 
combination with its ability to maintain transrepression of the pro-inflammatory cytokine, IL-
6, corroborates CpdA’s powerful immunosuppressive effects even after prolonged treatment. 
Having addressed the effects of a CpdA-induced ‘loss’ of GRα dimerization, the effects of a 
‘loss’ of dimerization, on GC-responsive gene expression, through the use of the endogenous 
mGRdim mutant, are now discussed. 
Previously, Robertson et al.
81
, suggested that the effects  of CpdA on certain aspects of the 
GC/GRα signalling pathway was elicited through a ‘loss’ of receptor dimerization, as CpdA 
treatment of wild type GRα was comparable to those mediated by Dex treatment of the 
dimerization deficient mutant GRα, in a transiently transfected system. This idea was 
confirmed by results from the current study in Chapter 4, with regards to ligand-induced GRα 
protein down-regulation, where results obtained with monomeric CpdA-hGRwt were similar 
to those obtained with monomeric Dex-bound hGRdim. With that said, Figure 4.5 does show 
a CpdA-induced up-regulation of hGRwt, which was not noted for hGRdim, following 
treatment with Dex. Importantly, results from Chapter 5, further sparked interest in 
differences between CpdA-bound hGRwt and Dex-bound hGRdim, in terms of subcellular 
localisation and Ser404 phosphorylation, however, further investigation of these effects at the 
proteasomal level was beyond the scope of this project.  
Interestingly, the current chapter highlighted and confirmed significant differences between 
CpdA-bound mGRwt and Dex-bound mGRdim at the level of GC-mediated GC-responsive 
gene expression, using the endogenous mutant, mGRdim, in the MEF-mGRdim cells. 
Generally speaking, results confirmed that although these GRα species are thought to be 
similar in conformation (i.e. monomeric) they are not identical, and differ at the level of GC-
responsive gene expression and GRα regulation. 
Firstly, in contrast to transiently transfected COS-1 cells (Chapter 4), where hGRwt and 
hGRdim protein expression was maintained, following CpdA and Dex treatment, 
respectively, results, from the current chapter demonstrated that, following treatment with 
Dex, endogenous mGRdim underwent partial receptor protein turnover. Specifically, ‘loss’ of 
GRα dimerization through the use of mGRdim was unable to fully restrict mGRdim protein 
turnover, resulting in 49% remaining of the mGRdim ‘functional pool’ present following 
Stellenbosch University  https://scholar.sun.ac.za
  221  
 
long-term treatment with Dex (Fig. 6.6C). Importantly, although this Dex-induced down-
regulation was significant it was not as potent as the long-term Dex-induced mGRwt protein 
turnover (Fig. 6.7A). 
In contrast, and dissimilar to Dex via mGRdim (Fig. 6.6C), at no point did a CpdA-induced 
‘loss’ of endogenous wild type GRα dimerization (i.e. mGRwt) drive significant receptor 
turnover at the protein level (Fig. 6.6A). Furthermore, prolonged CpdA treatment resulted in 
a significant increase in mGRdim protein expression (162%), relative to the solvent (Fig. 
6.6C). This finding suggests an additive ‘loss’ of receptor dimerization effect on evading 
proteasomal degradation when CpdA treatment is combined with the use of mGRdim, and 
highlights potential differences between the monomeric conformation of CpdA-bound 
mGRwt, Dex-bound mGRdim and CpdA-bound mGRdim, which will be discussed at a later 
point. 
In support of the observed differences between monomeric CpdA-mGRwt and Dex-bound 
mGRdim at the level GRα protein regulation, are differences which were observed at the 
level of ligand-induced alterations in GRα mRNA expression, which may be due to ligand-
induced alteration in the regulation of the GRα gene and/or mRNA destabilization. Whilst 
ligand-induced down-regulation of the GRα gene is fairly well characterized for classical 
GCs, such as Dex
16,94
, the effects of CpdA on GRα gene regulation is not as well 
characterized. In the current study significant down-regulation of 60% and 40% of mGRwt 
mRNA expression was noted, post short- and long-term CpdA pre-treatment, respectively 
(Fig. 6.6B). In support of this finding, Drebet et al.
95
, using a myofibroblast cell line 
(CT5.3hTERT) demonstrated an approximate 50% reduction in GRα mRNA expression, 
following 24 hours (i.e. between the short- and long-term pre-treatment used in the current 
study) treatment with CpdA. Interestingly, in the same study
95
, this CpdA-induced reduction 
in GRα mRNA expression was abolished following 48 hours of CpdA treatment. Moreover, 
in a study by a previous member in our lab
12
, no CpdA-induced down-regulation of 
endogenous GRα mRNA in BWTG3 cells, was observed, following 24 hours treatment. 
Furthermore, the current study demonstrates that, unlike CpdA via mGRwt, neither Dex nor 
CpdA treatment was able to reduce mGRdim mRNA expression (Fig. 6.6D). To our 
knowledge, this is the first time ligand-induced GRα mRNA regulation has been investigated 
in the MEF-mGRdim cells.  
Recently the specific mechanism by which Dex mediates down-regulation of GRα mRNA 
expression has been established and involves the binding of a ligand–activated GRα 
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monomer, to a nGRE in the promoter of the GRα gene (NR3C1)16. One could postulate, from 
results in the current study, that monomeric mGRwt induced by CpdA treatment is able to 
coordinate ligand-induced regulation of GRα mRNA expression by potentially the direct 
DNA-binding of CpdA-bound GRα to the nGRE, present in the GRα gene, in the MEF-
mGRwt but not the MEF-mGRdim cells. In contrast, it would seem that the Dex-bound 
mGRdim monomer is unable to directly interact with this DNA regulatory region (i.e. the 
nGRE) within the GRα gene promoter.  
Lastly, gene expression results, in the current study, supports previous results
12,56,81,88
 that 
demonstrate CpdA’s ability to restrict the transactivation of simple GREs, via GRα, which 
requires a GRα dimer, as a result of CpdA’s potent ability to abrogate receptor 
dimerization
80–82,96
 (Fig. 6.6A, B and C). In most cases (i.e. GILZ and TAT), a ‘loss’ of 
dimerization through the use of mGRdim mirrored CpdA’s effect via mGRwt, by restricting 
Dex’s well-established ability to drive GRα mediated GRE-gene expression (Fig. 6.9A, and 
B). However, in the case of FKBP51, a significant difference was noted between the ability 
of CpdA bound mGRwt and Dex bound mGRdim to regulate the expression of this gene (Fig. 
6.9C). Specifically, a slight, yet significant, 2.0-fold increase in FKBP51 expression, 
following short-term Dex pre-treatment of mGRdim, was noted (Fig. 6.9C). These findings, 
once again, encourage the notion of differences between the monomeric conformation of 
CpdA bound to mGRwt and Dex bound to mGRdim. 
Taken together, a possible explanation for the observed differences between CpdA-bound 
mGRwt and Dex-bound mGRdim, namely at the level of GRα protein and mRNA regulation 
as well as at the level of GC-responsive gene expression, is that CpdA bound to mGRwt 
produces a slightly different monomeric conformation to that of Dex-bound to the mutant 
mGRdim. Through modelling, CpdA has been shown to bind to the conventional site in the 
ligand-binding pocket of GRα, however, speculation exists that it is capable of binding at a 
second site in the GR-LBD
29,97
, which is supported by the unconventional competitive 
binding curves generated from ligand-binding assays with CpdA
20,96
. This possible binding of 
CpdA to a second site, in contrast to the classical binding of Dex to a single, well 
characterised ligand binding site in the LBD, most likely induces a different GRα 
conformation, which is supported by its inability to induce receptor dimerization
80,81
 and may 
encourage the binding of additional coregulators
20
.  
Whilst it is well accepted that CpdA abrogates GRα dimerization and serves as a useful tool 
to study the effects of a ‘loss’ of dimerization, the idea that dimerization deficient mutants 
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cannot undergo homo-dimerization have recently been challenged
82,98,99
. Pioneering work 
with the dimerization deficient mutant, mGRdim, indicated that this GRα variant had a 
significantly impaired ability to mediate transactivation of GC-responsive genes
72,100
, 
however its lack of ability to form GRα dimers was not thoroughly investigated. Moreover, it 
must be noted that although studies have continued to demonstrate the inability of mGRdim 
to mediated GRE-driven gene transcription, studies using recent technology (i.e. the Number 
and Brightness Assay) to study receptor dimerization in live cells, has brought to light the 
ability of the classical dimerization deficient mutant, mGRdim, to form receptor dimers
82,98
. 
Although mGRdim has been shown to form GRα dimers, the extent of dimer formation is 
significantly less pronounced than for the wild-type GRα82,98,101. 
6.4. Conclusion 
In conclusion, the current study postulates that the conformation of the GRα is fundamental 
in influencing the ability of the receptor to mediate GC-induced transactivation and 
transrepression, which is supported by another study by a member from our research group
81
, 
as well as its novel ability to influence receptor turnover both at the mRNA and protein level. 
For this reason, encouraging a ‘loss’ of dimerization via treatment with dimerization 
abrogating GCs, such as CpdA, and elucidating the dimerization capabilities of mutations 
associated with GC resistance
102
 should be primarily considered when developing novel 
therapeutics for the treatment of chronic inflammatory diseases.  
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Chapter 7:  
Discussion 
7.1. Introduction and overview of results 
To briefly summarize, chronic stress or prolonged exogenous GC treatment disrupts the central 
homeostatic nature of GC signalling (Chapter 1) and often results in various peripheral effects, one 
of which is the tissue-specific reductions in the GRα ‘functional pool’. This reduction in the GRα 
‘functional pool’ may ultimately underlie or drive the development of an acquired GC resistance 
and result in the progression of many psychological and pathological conditions (Chapter 2). Using 
various methodologies (Chapter 3), the current study elucidated a novel requirement for GRα 
dimerization in mediating ligand-induced reductions in the GRα ‘functional pool’ (Chapter 4). 
Moreover, the previously postulated notion
1
 that different GRα conformations may be differentially 
modified post-translationally was explored, and, in general, evidence was provided that the GRα 
monomer evades receptor turnover by differential modulation of the post-translational processing of 
the receptor (Chapter 5). Lastly, the biological implications of altered GRα expression were 
investigated in terms of molecular and clinical GC resistance using a validated endogenous model 
to mimic acquired resistance to GC treatment (Chapter 6). To encapsulate the findings of this study 
in their entirety, we have constructed a proposed model, which also incorporates information from 
previous published studies (Fig. 7.1). 
7.1.1. Proposed model 
1. Unliganded hGRwt (Fig. 5.5) and hGRdim (Fig. 5.6) are primarily cytoplasmic bound to an 
inhibitory chaperone complex consisting of, amongst other factors (e.g. Hsp90)
2
, the inactive E2 
conjugating enzyme of the UPS, TSG101. TSG101 associates with the hypo-phosphorylated, 
unliganded receptor in the cytoplasm, protecting it from proteasomal degradation
3
.  
2. Upon ligand binding, dissociation of the inhibitor chaperone complex occurs2,4. It appears, in 
the case of ‘gain’ of hGRwt dimerization, following treatment with Dex and possibly F, 
dissociation of CHIP may occur, while ‘loss’ of dimerization through CpdA treatment of 
hGRwt may preserve the hGRwt/CHIP complex but further investigation is required (Fig. 
5.10A). Nonetheless, from the current study, we believe that TSG101 remains bound to the 
hypo-phosphorylated CpdA-bound hGRwt with evidence to support this idea in the TSG101 
knockdown experiment (Fig. 5.10C). Moreover, it may or may not translocate with the CpdA-
bound hGRwt into the nucleus, however this requires further investigation. Furthermore, the 
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ability of predominantly monomeric hGRdim to associate with TSG101 following ligand 
binding, remains to be elucidated. 
3. In the case of the dimerization promoting GCs, Dex and F, ligand-dependent dimerization of 
hGRwt occurs (i.e. ‘gain’ of GRα dimerization)5. In contrast, binding of the dimerization 
abrogating GC, CpdA, restricts dimerization
5,6
 and preferentially produces GRα monomers (i.e. 
‘loss’ of GRα dimerization). Similarly, treatment of the dimerization deficient mutant, hGRdim, 
with Dex, F or CpdA, reduces GRα dimer formation, and thus hGRdim remains mostly 
monomeric.  
4. Following ligand-binding the GC/GRα complex translocates from the cytoplasm to the nucleus 
(Fig. 5.5, 5.6, 5.11 and 5.12). Important to note is that the unliganded GRα, although 
predominantly cytoplasmic, can translocate to the nucleus, which may be due to  ligand-
independent dimerization
7
. Translocation of the hGRwt dimer, is rapid, occurring within 
minutes
7
, with almost no cytoplasmic hGRwt detected following treatment with Dex or F (Fig. 
5.5). In the same manner, be it to a slightly reduced extent
7
, Dex and F encourage almost total 
nuclear localisation of hGRdim (Fig. 5.6). Interestingly, CpdA treatment is not as efficacious as 
Dex or F at inducing nuclear translocation of hGRwt (Fig. 5.5) and is incapable of facilitating 
significant movement of the hGRdim monomer from the cytoplasm to the nucleus (Fig. 5.6).  
5. Once in the nucleus, the predominantly nuclear kinase GSK3β8,9 induces hyper-phosphorylation 
of the dimerized Dex- and F-bound hGRwt at Ser404 (Fig. 5.9), a site linked to GRα stability10. 
In contrast, ‘loss’ of GRα dimerization, through CpdA treatment of hGRwt or the use of the 
mutant, hGRdim, restricts hyper-phosphorylation at this site (Fig. 5.9). In fact, no Ser404 
phosphorylation of hGRdim was observed across all treatments (Fig. 5.9B). 
6. In the case of ‘gain’ of hGRwt dimerization, phosphorylation at Ser404 (Fig. 5.9), facilitates 
binding of the E3 ligase, FBXW7α (Fig. 5.7), a predominantly nuclear E3 ligase (Fig. 5.5 and 
5.6), which then mediates hGRwt ubiquitination
11. However, before the binding of FBXW7α to 
its substrate (i.e. hGRwt), ubiquitin is activated and transferred to the E3 ligase by additional 
enzymes, namely ubiquitin activating E1’s and conjugating E2’s (see small dotted box Fig.7.1 
and refer to Fig. 5.3 in Chapter 5 for details). Unlike with ‘gain’ of hGRwt dimerization, ‘loss’ 
of GRα dimerization (via CpdA treatment of hGRwt or the use of hGRdim) restricts, be it 
partially, the binding of the E3 ligase, FBXW7α, (Fig. 5.7) thought to be a direct result of the 
absence of hyper-phosphorylation at Ser404 (Fig. 5.9), which is required for binding of 
FBXW7α11. Moreover, we believe that this lack of FBXW7α binding directly impacts 
ubiquitination of the GRα monomer, however, concede that we were unable to convincingly 
establish this and thus it requires further investigation (Fig. 5.13). Interestingly, we expected an 
increase in GRα ubiquitination via ‘gain’ of GRα dimerization (i.e. Dex treatment of hGRwt), 
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however, we observed a decrease in hGRwt ubiquitin following Dex and F (Fig. 5.13) postulate 
this is due to hGRwt that is already being degraded, following 6 hours treatment (Fig. 4.4). 
Furthermore, whether GRα ubiquitination occurs before or after DNA binding remains to be 
elucidated (see next step) as a wealth of evidence is available for the transcriptional role of the 
UPS system and DNA-proteolysis, reviewed by Maneix et al.
12
 
7. GCs then mediate their biological effects through modulating the expression of a wide range of 
GC-responsive genes, either through the direct DNA-binding of a GRα dimer to GREs (e.g. 
Dex-bound hGRwt to GILZ) (Fig. 6.9A) or the tethering of a monomer to another transcription 
factor (i.e. NFκB) bound to its response element (NFκB-RE) (e.g. IL-6) (Fig. 6.9D). 
Importantly, we have only detailed the classic methods of GRα-mediated GC-responsive gene 
expression, in this model, but others (i.e. tethering via an nGRE) (Fig. 6.7B) do exist
13
.  
8. Following the activation or repression of GC-responsive genes, the GRα dissociates from the 
DNA or transcription factor and is recycled for another round of transcription. 
9. Alternatively, GRα is exported to the cytoplasm, where classically it is thought to be degraded 
(not demonstrated in our proposed model), with evidence for this notion available
14
. However, 
evidence for the presence of proteasomes
15–20, as well as FBXW7α (Fig. 5.5 and 5.6) in the 
nucleus has also been provided and thus, we believe that (in our proposed model), following 
gene transcription, liganded hGRwt dimers but not GRα monomers, are targeted for the 
proteasome, within the nucleus. Moreover, that ligand-induced down-regulation of specifically a 
hGRwt dimer, but not a monomer, into inactive protein fragments, likely occurs in the nucleus 
or potentially even at the DNA, termed DNA-proteolysis
12
, providing a means of rapid 
recycling of receptors at the promoters of GC-responsive genes to tightly regulate the duration 
and intensity of the GC response (see Section 7.3).  
10. In terms of unliganded hGRwt degradation (Fig. 4.4) a basal level of phosphorylation at Ser404 
is observed, which is absent with the unliganded hGRdim (Fig. 5.9). Moreover, due to the fact 
that we observed unliganded hGRwt turnover (Fig. 4.4), we postulate that a ‘switch’ between 
TSG101 and CHIP, potentially reliant on ligand-independent dimerization
7
, may occur, and that 
it is the binding of the E3 ligase, CHIP, which targets the unliganded receptor for degradation. 
We concede, however, that additional experiments for TSG101 and CHIP are required. 
Moreover, investigation into whether the unliganded receptor is degraded in the nucleus or the 
cytoplasm remains to be elucidated. 
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Figure 7.1: Proposed model comparing the effects of ‘gain’ and ‘loss’ of GRα dimerization in GC/GRα signalling 
(see text for details and solid box on model, for definitions). 1. Unliganded, hypo-phosphorylated GRα is primarily 
cytoplasmic bound to an inhibitory chaperone complex, which includes the inactive E2 ligase, TSG101. 2. Ligand 
binding causes dissociation of the inhibitor chaperone complex. 3. Upon ligand binding the hGRwt dimerizes (i.e. 
‘gain’ of GRα dimerization); however this is not the case following CpdA binding of the use of hGRdim (i.e. ‘loss’ of 
GRα dimerization). 4. The GC/GRα complex translocates to the nucleus. Important to note is that the unliganded GRα, 
although predominantly cytoplasmic, can translocate to the nucleus and that the thickness of the arrows refers to extent 
of movement. 5. Once in the nucleus, the dimerized hGRwt undergoes hyper-phosphorylation at Ser404. In contrast, 
‘loss’ of GRα dimerization restricts hyper-phosphorylation at this site. 6. In the case of ‘gain’ of hGRwt dimerization, 
phosphorylation at Ser404 facilitates binding of the E3 ligase, FBXW7α, which binds ubiquitin (small dotted box) and 
mediates hGRwt ubiquitination. Unlike ‘gain’ of GRα dimerization, ‘loss’ of GRα dimerization restricts, be it partially, 
the binding of the E3 ligase, FBXW7α. 7. GCs then mediate their biological effects through modulating the expression 
of a wide range of GC-responsive genes, either through the direct DNA-binding of an hGRwt dimer to GREs or the 
tethering of a monomer to a transcription factor (i.e. NFκB) bound to its response element (NFκB-RE). 8. Following the 
activation or repression of GC-responsive genes, the GRα dissociates from the DNA or transcription factor and is 
recycled for another round of transcription, or 9. targeted for degradation by the proteasome, in the case of a ‘gain’ of 
hGRwt dimerization, but not in the case of a ‘loss’ of GRα dimerization (i.e. CpdA treatment of hGRwt or the use of 
hGRdim). 10. Degradation of the unliganded receptor. 
Having described the proposed model, emanating, in part, from results obtained in the current study 
(Fig. 7.1), in essence, this chapter aims to further consolidate results obtained in the current study 
with the existing literature by presenting a ‘bird’s eye view’ of the significance of this research in 
terms of novel therapeutics for combatting acquired GC resistance by highlighting, the somewhat, 
overlooked and undervalued importance of GRα conformation, specifically in terms of the 
dimerization state of the receptor. Additionally, the short-comings of the current study are also 
noted and this thesis is concluded with some enticing future perspectives, which are briefly 
discussed. 
7.2. The importance of GRα conformation with focus pertaining to the 
dimerization state of the receptor 
GC use for the treatment of inflammatory linked- or driven conditions is imperative, but is not 
without failings of significance, namely the generation of adverse side-effects and in some cases the 
development of acquired GC resistance. Generally, it is in long-term GC treatment regimens where 
the harmful effects exerted by GCs begin to exceed their beneficial effects as therapeutics. For this 
reason, many researchers over the years have directed their research efforts into trying to ‘tip the 
scales’ towards favouring the potent immunosuppressant capacity of GCs.  
A number of strategies have been employed to improve the therapeutic use of GCs with focus 
pertaining to ligands displaying an increased efficacy and/or a defined functional selectivity
13,21,22
. 
Recently, a review by Luttrell et al.
23
 has reiterated the complexity of G-protein coupled receptor 
(GPCR) signalling, brought to light by the ‘emerging paradigms of pluridimensional efficacy and 
functional selectivity’, and developed the idea of ‘biased ligands’. The concepts outlined in his 
review can be fruitfully transposed to GC/GRα signalling, providing a fresh perspective from which 
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to approach the development of novel therapeutic GCs, whilst substantiating the current study’s 
reasoning for the importance of considering receptor dimerization. Thus, throughout the following 
discussion, these concepts from Luttrell et al.
23
 provided a platform on which the current study 
builds, through the consolidation of its results.  
7.2.1. ‘Biased ligands’  
Luttrell et al.
23
 makes a strong case that the biological responses which arise from the interaction of 
a ligand with its cognate receptor are all encoded for at that single point of contact (i.e. within the 
receptor’s LBD) with a change in receptor conformation being the initial consequence of ligand-
binding. Analogous to the ‘binding’ of a baton to a conductor’s hand, which sets the stage for a 
symphony of music driven by the ‘conformation’ the baton and conductor adopt together. Recently, 
in GPCR signalling, the simplified idea that ligands act merely as ‘on’ and ‘off’ switches to 
modulate receptor conformations to and from ‘active’ and ‘inactive’ states, has been revised with 
more complex concepts, such as the idea of a ‘conformational ensemble’, being proposed. Luttrell 
et al.
23
 suggests that the binding of a ligand to a receptor differentially affects downstream 
signalling through modulating the ‘conformational ensemble’, then driving the ‘conformational 
equilibrium’ towards a particular state.  
Traditionally ligands have been classified as agonists (partial or full) or antagonists, however, 
recent evidence has challenged this central dogma with concepts of ‘functional selectivity’ or 
‘biased ligands’ suggesting ligand-receptor interactions are not as simple as once considered13,21–23. 
Endogenous ligands are generally considered as full agonists based on the fact that they have 
coevolved with endogenous receptors to stabilize active receptor conformations, most favourable 
for eliciting the desired physiological biological response
23. On the other hand, ‘biased ligands’ as 
eloquently stated by Luttrell et al.
23: ‘are novel pharmacologic entities that possess the unique 
ability to qualitatively change receptor (i.e. GPCR) signalling’, in effect creating ‘new receptors’. In 
other words ‘biased ligands’, which select specific receptor conformations with efficacy distinct 
profiles from that of endogenous ligands, modify biological responses (via various signalling 
pathways such as the GPCR or GC/GRα signalling pathway), in peripheral tissues or cells, towards 
a more beneficial outcome, which ultimately, is the underlying fundamental reason for the 
development of pharmaceutical agents. 
In terms of GC/GRα signalling one could argue that this notion of ‘biased ligands’ has already been 
explored in terms of SGRMs), designed and developed as potentially improved GC-based 
therapeutics, on the basis of being capable of functionally separating GC-mediated transactivation 
Stellenbosch University  https://scholar.sun.ac.za
 240 
 
from transrepression, generally linked to adverse side-effects and the anti-inflammatory potential of 
GCs, respectively
13,21
.  
Recently, De Bosscher et al.
1
 has developed a concept called ‘The SEDIGRAM concept’, which is 
derived from the selective GRα modulation by SGRMs. Rather than focusing specifically on the 
ability of synthetic ligands to transrepress versus transactivate GC-responsive genes, De Bosscher et 
al.
1
 suggests that due to the vast and complex nature of GC/GRα signalling, one should investigate 
and develop novel GC therapeutics based on their ability to resolve acute versus chronic 
inflammation, proposing that these different processes of inflammation demand different 
therapeutic measures. Moreover, based on in vivo models
6,13,24–29
, which utilized the dimerization 
abrogating GC, CpdA, or the dimerization deficient mutant, GRdim, mice, this review goes on to 
postulate that dimeric GRα (i.e. via selective dimerizing GRα agonists/modulators or 
SEDIGRAMs) is essential for the resolution of acute inflammation, whilst encouraging 
predominantly monomeric GRα (i.e. by selective monomerizing GRα agonists/modulators or 
SEMOGRAMs) may be more beneficial for the treatment of chronic inflammation
1
. 
In the next section the in vivo pharmacological evidence for biased ligand behaviour, provided by 
the use of CpdA or the GRdim mice model, that gave rise to the SEDIGRAM concept
1
, is briefly 
summarized, whilst consolidating results from the current study. Additionally, we explore the 
effects of receptor concentration on GRα dimerization and provide an opinion on how this may 
influence the extent or rate of receptor turnover. 
7.2.1.1. Pharmacological evidence for biased ligand behaviour with the dimerization 
abrogating GC, CpdA 
The use of the SGRM or dimerization abrogating GC, CpdA, has proved relatively fruitful in 
combatting inflammation in a number of in vivo inflammatory mouse and rat models
6,13,24–29
, 
discussed here. Specifically, in the zymosan-induced inflammatory paw mouse model, CpdA was 
found to be as effective as Dex at reducing paw swelling with both compounds reducing paw 
swelling by approximately 50%, relative to PBS-treated mice
25. Additionally, CpdA’s ability to 
attenuate collagen-induced arthritis (CIA) in DBA/1 mice
26
, has been demonstrated. In support of 
these findings, Dewint et al.
6
 also showed CpdA’s ability to restrict the development of arthritis, 
relative to control mice, using the CIA model. Specifically, although less efficacious than Dex 
treatment where 100% of the joints presented normal histopathological features, in contrast CpdA 
treatment resulted in 79% of the joints demonstrating normal histopathological features, relative to 
the PBS-treated control mice where a mere 33% had normal histopatholgical features
6
. More 
recently, Rauner et al.
27, using the same CIA model demonstrated CpdA’s ability to suppress 
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inflammation specifically in terms of reduced disease activity, paw swelling and temperature, and 
although not as potent as Dex (100 μg/mouse) at reducing these factors (i.e. 72%, 22% and 10% 
respectively), CpdA (300 μg/mouse) treatment significantly reduced these factors by 43%, 12% and 
7%, respectively. In a rat model of experimental autoimmune neuritis (EAN), CpdA attenuated the 
build-up of macrophages and lymphocytes, demyelination, as well as the increase in the mRNA 
expression of pro-inflammatory molecules in sciatic nerves
28
. Additionally, CpdA treatment was 
able to reduce muscle inflammation in the forelimbs and hind limbs of mdx mice (i.e. a model to 
study muscle dystrophy) by approximately 40%, relative to control, which was comparable to the 
prednisolone-induced reduction in inflammation
29
. Lastly, in C57Bl/6 mice induced with EAE
24,30
, 
treatment of these mice with 5 mg/kg and 1.5 mg/kg CpdA severely hampered disease progression, 
however higher doses of CpdA (> 15mg/kg) proved to be lethal, providing evidence for CpdA’s 
narrow therapeutic window
24
. 
Furthermore, CpdA’s ability to restrict inflammation in these in vivo models has been shown to 
occur without generating adverse side-effects (e.g. hyperglycaemia and hyper-insulemia)
25,26,28,30
. 
More specifically, unlike Dex, which led to a significant increase in glucose concentrations to 150 
mg/dl, CpdA did not trigger a significant increase in blood glucose concentrations (i.e. 
approximately 100 mg/dl), relative to control mice (i.e. 120 mg/dl), which is indicative of a reduced 
risk for the development of hyperglycaemia
25
 and was unable to induce hyper-insulinemia, relative 
to Dex-treated mice
26
. Moreover, the inability of CpdA to induce hyper-insulinemia has also been 
noted in a model of EAE
30
. Whilst Dex treatment induced an increase in insulin to 5 ng/ml, relative 
to the PBS-treated control mice (i.e. 1 ng/ml), CpdA treatment showed no effect on insulin levels
30
. 
Unlike prednisolone, CpdA has also been shown to partially prevent the destruction of bone and 
cartilage in the joints of mice
6
 and demonstrated an ameliorative effect on markers of muscle 
dystrophy
29
. Lastly, in terms of immune-inflammatory diabetes, CpdA was found to exert a 
protective effect by maintaining blood glucose levels around 10 mM, relative to untreated multiple 
low doses of streptozotocin (MLDS)-induced mice where a steady increase in blood glucose from 
10 mM to 25 mM, was noted
31
. 
These in vivo findings are supported by results from the current study in Chapter 6, which 
demonstrate CpdA’s ability to combat inflammation without generating undesirable side-effects, at 
a molecular level in an ex vivo model, namely the MEF cells. Specifically, similarly to Dex, CpdA 
was able to reduce the expression of the pro-inflammatory cytokine, IL-6, via GRα, without 
inducing the expression of the GRE-driven metabolic gene, TAT. It must be noted, however, that 
this is not the first time this dissociated characteristic of CpdA has been demonstrated in an ex vivo 
model, with a number of studies, including one by a member of our research group
32
, having 
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previously shown similar behaviour in both ex vivo and in vitro models, many of which are 
eloquently reviewed by Sundahl et al.
13
 
7.2.1.2. Pharmacological evidence for biased ligand behaviour through the use of the 
dimerization deficient mutant, GRdim 
The ability of SGRMs to differentiate between the transactivation and transrepression of GC-
responsive genes, is thought to be associated with their ability to induce different conformations of 
the receptor (specifically a GRα dimer versus a monomer) to which they bind5,6. Support for this 
concept of ‘biased ligands’ or SGRMs in GC/GRα signalling originated from early transfection 
studies
33
 using the dimerization deficient mutant, GRdim. Specifically, Heck et al.
33
 demonstrated 
that introducing a single-point mutation in the D-loop of the GRα (i.e. to disrupt the dimerization 
capabilities of the receptor) was sufficient to dissociate GC-mediated GRα transrepression from 
transactivation. Based on these findings, in a study by Reichardt et al.
34
, dimerization deficient 
mutant homozygotic GRdim mice were created and found to be viable, however, they were-
defective in the capacity of GRdim to bind DNA and mediate the transactivation of GRE-driven 
genes yet maintained their immunosuppressive abilities via transrepression of pro-inflammatory 
genes.  
Essentially, these GRdim mice from Reichardt et al.
34
 provided the first in vivo evidence for the 
ability of GRα to repress inflammation, both local and systemic, following GC treatment, without 
the requirement for the receptor to directly bind to DNA, which has subsequently been followed up 
by a number of other in vivo studies
35–37
. Treatment of these GRdim mice
34
 with 
lipopolysaccharides (LPS), to mimic bacterial infection and stimulate a systemic response,  initially 
drove increases in TNFα (i.e. 1 hour after LPS treatment), which was subsequently counteracted by 
a significant increase in the endogenous GC, corticosterone, 3 hours after treatment. In this study 
GRdim mice
34
 were as efficient as wild-type mice at counteracting the LPS-induced effects on 
TNFα, once again confirming that DNA-binding is not a requirement for regulating inflammation 
via GRα mediated transrepression. Additionally, in a model of acute inflammation in which 
inflammation (i.e. oedema) was induced by means of the topical administration of a phorbol ester, 
namely phorbol 12-myristate 13-acetate (PMA), GRdim mice were as efficient as wild-type GRα 
mice, following Dex treatment, at inhibiting the influx of inflammatory cells and, additionally, 
completely restricting an increase in IL-6 serum concentrations (0 pg/ml), relative to PMA-induced 
mice without Dex treatment (100 pg/ml)
35
. In support of these findings, are results from the current 
study in Chapter 6, which demonstrate that Dex-mediated transrepression of IL-6 occurs via 
mGRwt and mGRdim in the MEF-mGRwt and MEF-mGRdim cells, respectively.  
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However, in a study by Kleiman et al.
36
, which made use of two different models of sepsis, 
specifically LPS bolus-induced septic shock and cecal ligation and puncture (CLP), unlike GRwt 
mice, GRdim mice were found to be highly susceptible to sepsis, an-inflammatory-linked 
condition
36. Unlike TNFα, down-regulation of IL-6 and IL-1β was severely diminished in GRdim 
mice even though similar increases in endogenous corticosterone, relative to wild-type mice, were 
noted, following stimulation with LPS or CLP
36
. Moreover, GRdim mice demonstrated a reduction 
in survival rate with a mere 30% of these mice surviving, compared to the approximately 80% of 
wild-type mice surviving, 80 hours post stimulation, suggesting that GRα dimerization is a 
requirement for survival in models of sepsis and that the inability to reduce the prolonged 
expression of IL-6 and, more so, IL-1β, likely contributes to the inability of GRdim mice to survive 
under these septic conditions
36
. 
Lastly, in terms of the metabolic side-effects of GC signalling, a study by Frijters et al.
37
 
investigated and compared the GC-responsive gene expression profiles in the liver tissue of wild-
type and GRdim mice, following prednisolone treatment. Overall, results showed that, whilst 
prednisolone-mediated transactivation of a small subset of genes was completely abolished, the 
transactivation of other GC-responsive genes such as TAT and FKBP51, was significantly reduced 
(i.e. on average approximately 33% in GRdim mice relative to wild-type mice), however, 
importantly, not completely abolished in GRdim mice
37
. In support of this finding is a literature 
search reported and summarized by Frijters et al.
37
, which noted that the GC-induced expression of 
TAT was increased by 4.1-fold in wild-type mice and 1.6-fold in GRdim mice. This corroborates 
well with the 4.0-fold and 2.0-fold Dex-mediated increase in TAT expression, in MEF-mGRwt and 
MEF-mGRdim cells, reported by the current study.  
The effects of the dimerization abrogating GC, CpdA, and the use of the dimerization deficient 
mutant, GRdim, in these in vivo models confirm that tipping the scale towards a GRα monomer, as 
opposed to a GRα dimer, appears to be, in general, beneficial for the treatment of inflammation as 
well as providing an improved side-effect profile, supporting the notion that selectively modulating 
receptor conformation through ‘biased ligands’, may be useful. However, there are limitations when 
it comes to the use of CpdA as a dimerization abrogating GC, as well as limitations with the 
dimerization deficient GRα mutant model. Specifically, although CpdA demonstrates a potent anti-
inflammatory potential in these in vivo models, its stability issues
38
 and its high propensity for 
alkylation as well as its narrow therapeutic window, make it an unlikely candidate for therapeutic 
use in a clinical setting
13
. Furthermore, although mice harbouring the dimerization mutation (i.e. 
GRdim) are as viable as GRwt, under most inflammatory conditions, however, they are highly 
sensitive to septic conditions
34
. Additionally, unlike CpdA via GRwt, Dex via GRdim is still able to 
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mediate a level of GC transactivation
7
, which is supported by the FKBP51 results of the current 
study). It may be that the ability of GRdim to mediate the transactivation of certain genes is due to 
the ability of GRdim to form alternative, potentially unstable, receptor dimers via the LBD 
dimerization domain
39
.  
7.2.1.3. The SEDIGRAM concept1  
7.2.1.3.1. Combatting inflammation versus the generation of adverse side-effects 
Collectively, the pharmacological evidence provided by the use of the dimerization abrogating GC, 
CpdA, and the dimerization deficient mutant, GRdim, gave rise to a novel concept, namely the 
SEDIGRAM concept proposed recently in a review by De Bosscher et al.
1
. In support of Luttrell et 
al.
23
 and the idea of ‘biased ligands’, central to the SEDIGRAM concept, is the idea of selectively 
modulating alterations in the conformations of the receptor or changing the ‘conformational 
equilibrium’, through the binding of specific GRα ligands1. The development of these novel 
ligands, able to modulate receptor conformation, expand the ‘pharmacological toolbox’ not only at 
a molecular level, specifically, by GRα ligands that are capable of dissociating between 
transactivation (i.e. generally mediated via a GRα dimer and associated with adverse side-effects) 
and transrepression (i.e. generally mediated via a GRα monomer giving rise to the potent anti-
inflammatory potential of GCs) of GC-responsive genes, but also, as De Bosscher et al.
1
 suggests at 
a clinical level in terms of the treatment of acute versus chronic inflammation.  
Essentially, this idea that different inflammatory processes (i.e. acute versus chronic) may call for 
different measures has been brought to light by the notion that dissociating GC-mediated 
transactivation from transrepression may not be sufficient in acute GC treatment regimes, due to the 
fact that a number of the anti-inflammatory actions of GCs are mediated via GC-mediated GRα 
transactivation
40
. Thus in terms of short-term acute inflammation, it may be better ‘to paint with 
two brushes’ both via GC-mediated transactivation of anti-inflammatory genes and transrepression 
of pro-inflammatory genes, at the risk of certain short-term side-effects (i.e. increases in blood 
glucose). However, in long-term treatment of persistent chronic inflammation the beneficial anti-
inflammatory potential of classical GCs is outweighed by the adverse side-effects (i.e. the 
development of hyperglycaemia), driven by GRE-mediated transactivation, thus posing a major 
threat to the well-being of the patient. 
De Bosscher et al.
1
 suggests that for short-term acute inflammation it may be more beneficial to 
encourage receptor dimerization through the use of SEDGRAs (i.e. GCs which show an increased 
dimerizing potential) or SEDGRMs (i.e. molecules that may act alone or in combination with GCs 
to increase the dimerization potential of GRα). Essentially, encouraging GRα dimer formation, 
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importantly in short-term treatment regimes, will allow for transrepression of pro-inflammatory 
cytokines (i.e. IL-6 and TNFα) but also GRE-driven transactivation of anti-inflammatory genes (i.e. 
GILZ), even if it should concomitantly increase the risk for adverse side-effects (i.e. an increase in 
glucose concentration). This suggestion aligns itself well with results from the current study in 
terms of the dimerization state of the receptor and GC-responsive gene expression. Specifically, in 
the model established in Chapter 6, we successfully demonstrated that short-term treatment with the 
dimerization promoting GC, Dex, induces the expression (6.6-fold) of the anti-inflammatory 
mediator GILZ, relative to the solvent, whilst repressing the expression of the pro-inflammatory 
cytokine, IL-6, 0.7-fold, and in addition induces the expression of the metabolic gene, TAT, 13.3-
fold. Similarly to Dex, restricting GRα dimerization through treatment with the dimerization 
abrogating GC, CpdA, or the use of the dimerization deficient mutant, mGRdim, restricts the 
expression of IL-6, 0.6-fold and 0.7-fold, respectively, however, monomeric GRα is incapable of 
mediating an increase in the expression of the anti-inflammatory gene, GILZ. Thus the potent 
ability to combat acute inflammation, in short-term treatment protocols, from both angles (i.e. ‘to 
paint with two brushes’ via GC-mediated transactivation and transrepression) has somewhat been 
lost with monomeric GRα. 
In contrast, the use of SEMOGRAMs (i.e. GRα agonists or molecules, which act alone or in 
combination with GCs to favour monomeric receptor formation over its dimerized counterpart) may 
prove to be the way forward for the treatment of long-term chronic inflammation, as suggested by 
De Bosscher et al.
1
. Thus in prolonged GC treatments the anti-inflammatory potential of GCs may 
be slightly compromised, through the use of a GRα monomer, to prevent the generation of adverse 
side-effects
1
. In support of this, results from the current study demonstrate that long-term treatment 
of CpdA was as capable as Dex at reducing the expression of IL-6 (i.e. 0.5-fold and 0.4-fold, 
respectively); however, even long-term treatment with CpdA could not stimulate GILZ expression. 
More importantly, and in stark contrast to Dex (12.6-fold), long-term treatment of CpdA (1.1-fold), 
did not result in an increase in the expression of TAT. Similarly, long-term Dex-treatment of the 
dimerization deficient GRα mutant inhibited IL-6 expression (0.7-fold) without significantly 
inducing transactivation of TAT (1.8-fold). 
To briefly summarize, the SEDIGRAM concept provides new insight into the fact that the GRE-
driven anti-inflammatory effects of GCs via a GRα dimer may be more beneficial for the treatment 
of short-lived acute inflammation, even though certain side-effects such as an increase in blood 
glucose, may occur temporarily. However, for the treatment of persistent chronic inflammation, 
which requires pro-longed exogenous GC treatment, the less potent anti-inflammatory potential of 
GCs, via predominantly monomeric GRα transrepression, may be more beneficial, mainly because 
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the increase in metabolic gene expression and thus side-effects are restricted. Whilst De Bosscher et 
al.
1
 addresses selectively modulating the dimerization state of GRα in terms of the indispensable 
anti-inflammatory effects of GC signalling and the possible generation of adverse side-effects, she 
does not discuss the potential benefits of encouraging monomeric GRα in prolonged GC treatment 
regimes in terms of acquired GC resistance, with focus pertaining to maintaining GRα expression. 
7.2.1.3.2. Acquired resistance to GC treatment 
In this section we make use of results from the current study, in combination with a study by the De 
Bosscher research group
26
, to strengthen the idea that in prolonged GC treatment regimens it may 
also be more beneficial to encourage predominantly monomeric GRα through ‘biased ligands’, 
referred to as SEMOGRAMs by the De Bosscher review
1
, to combat acquired GC resistance. 
Specifically, evidence endorsing the advantageous use of monomeric GRα, as opposed to dimeric 
GRα, in terms of acquired resistance to GC treatment is provided and discussed, essentially building 
on the SEDIGRAM concept. 
It is well documented that chronic exogenous GC treatment or chronic stress over a prolonged 
period of time results in the development of an often, tissue-specific acquired resistance to GC 
treatment. Many studies
41–46
, including our own, have demonstrated that one of the ways in which 
this steady increase in GC insensitivity occurs is through ligand-induced down-regulation of GRα 
expression, both at the mRNA and protein level, which throughout the current study has been 
referred to as the GRα ‘functional pool’. 
Chronic treatment with Dex in vitro, ex vivo and even in vivo, has been shown to reduce the GRα 
‘functional pool’ from anywhere between 10 and 90 %, relative to an untreated control (see Chapter 
2, Table 2.2). Moreover, in the current study, using three cellular models, namely the transiently 
transfected COS-1 cells and the HepG2 and MEF-mGRwt cells, which express endogenous GRα, 
24 hours of treatment with the dimerization promoting GC, Dex, led to a 50 to 70% reduction in 
GRα protein expression (Chapter 4 and 6). Additionally, in a model established to mimic acquired 
GC resistance (Chapter 6), we successfully demonstrated that the more significantly reduced GRα 
‘functional pool’, relative to the receptor expression following short-term Dex treatment, drove 
resistance at a molecular level. Specifically, diminished GC sensitivity was noted when comparing 
the expression of the anti-inflammatory gene GILZ, following long-term Dex treatment (i.e. 4.6-
fold) with GILZ expression following short-term treatment (i.e. 6.6-fold). 
In stark contrast, ‘loss’ of GRα dimerization, via CpdA treatment or the use of the dimerization 
deficient mutant (both hGRdim in the transiently transfected COS-1 cells and endogenous mGRdim 
in the MEF-mGRdim cells) restricted receptor turnover. More specifically, prolonged CpdA 
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treatment (24 to 32 hours) resulted in an increase in expression of wild-type GRα to approximately 
130% and 122% in the COS-1 and HepG2 cells, respectively, whilst maintaining mGRwt 
expression in the MEF-mGRwt cells at 89%, relative to the solvent. In terms of the mutant, and 
unlike with wild-type GRα capable of Dex-induced dimerization, prolonged Dex-treatment was 
unable to induce significant down-regulation of hGRdim in the COS-1 cells, over a 72 hour period. 
Moreover, ligand-induced down-regulation of the endogenous mGRdim in the MEF-mGRdim cells 
was partially restricted (49%) relative to the solvent and more importantly, significantly restricted 
relative to mGRwt (29%), following prolonged treatment with Dex. Whilst the ability of CpdA 
treatment to maintain GRα expression has been demonstrated before26,32,46, to our knowledge, this is 
the first time the ability of the dimerization deficient mutant to restrict receptor turnover has been 
noted. These results, as a whole, provide substantial evidence for the ability of ligand-induced GRα 
down-regulation to be influenced by the dimerization state of the receptor 
Taken together, this novel requirement for GRα dimerization in mediating receptor turnover has 
significant implications for the development of an acquired resistance to GC treatment, especially in 
prolonged treatment regimes. Moreover, with the SEDIGRAM concept in mind, we support the 
notion that selectively modulating GRα conformation through ‘biased ligands’ (or. SEMOGRAMs) 
to preferentially induce GRα monomers is likely to be beneficial for combatting persistent chronic 
inflammation, not only by reducing the generation of adverse side-effects, but also, by maintaining 
GRα expression and GC sensitivity in the long run. 
7.2.1.4. Receptor concentration influences the dimerization state of GRα 
Up to now, the influence of receptor dimerization on ligand-induced GRα turnover has been 
addressed, specifically in terms of acquired resistance to GC treatment, however, we have not yet 
discussed how the dimerization state of the receptor may be influenced by factors, other than 
‘biased ligands’. A study by a member of our research group has elucidated the effects of receptor 
concentration on GRα dimerization7,47, which is briefly outlined in this section. This notion that 
GRα concentration can modulate receptor dimerization has interesting implications for the extent 
and rate of receptor turnover, both in the absence and presence of ligands. 
It is well established that inter-individual differences in GRα concentration exist and that various 
disease states have been associated with increased or decreased receptor concentrations, within 
peripheral cells and tissues (for details and specific references we refer you to Table 2.1 in Chapter 
2 of the current study). Additionally, intra-individual tissue-specific differences in GRα 
concentration are noted between the cells and tissues of healthy individuals. To illustrate the range 
of GRα concentration in cells, PBMCs have been reported to have a receptor concentration on the 
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lower end of the scale, of 4.1 fmol/mg protein
48
, while in contrast skin cells have been reported to 
have a much higher GRα concentration of 893 fmol/mg protein49.  
Recently, a study by a member of our research group, noted that changes in GRα concentration may 
have profound effects on a number of aspects of GC/GRα signalling (i.e. ligand binding affinity, 
nuclear localisation and transcriptional response) but of utmost importance and relevance for the 
current study, is the ability of increasing receptor concentrations to modulate the dimerization state 
of GRα, demonstrated through an increase in positive co-operative binding7. Using an established 
physiologically relevant model, with three distinct GRα concentrations (i.e. low, medium and high), 
Robertson et al.
7
 investigated whether receptor dimerization was a pre-requisite for co-operative 
ligand binding, building on the established idea that positive co-operative binding due to increasing 
GRα concentrations is associated with an enhanced capacity to form receptor dimers50–52. Put 
differently, positive co-operative ligand binding represents ligand-independent GRα dimerization.  
Indeed, Robertson et al.
7
 demonstrated that positive co-operative ligand binding occurs at medium 
GRα concentrations (144 – 152 fmol/mg protein), but not low receptor concentrations (i.e. 41 – 67 
fmol/mg protein) for the wild-type, but not the dimerization deficient GRα mutant. Specifically, 
increasing wild-type GRα concentrations from low to medium resulted in an increase in the Hill 
coefficient from 1.08 to 1.57, which was absent with increasing hGRdim concentrations
7
. 
Additionally, an increase in the ligand-binding affinity (Kd) from low (49.1 nM) to medium (23.9 
nM) was observed with increasing wild-type GRα concentrations, however, remained unchanged 
for the dimerization deficient GRα, thus suggesting that ligand-binding was non-co-operative with 
increasing GRα concentrations of the mutant7. Thus, it was concluded that an increase in co-
operative ligand binding to a GRα dimer occurs with increasing receptor concentrations and in 
order for this to occur a concentration-dependent increase in ligand-independent dimerization must 
occur for the wild-type receptor. These findings provide interesting food for thought on the effect of 
GRα concentration on the extent and rate of ligand-induced receptor turnover. 
In Chapter 6, the GRα concentration was reported to be 40 fmol/mg protein and 38.7 fmol/mg 
protein in the MEF-mGRwt and MEF-mGRdim cells, respectively, which corroborates well with 
the reported low range of GRα concentration (i.e. 41 – 67 fmol/mg protein), reported by Robertson 
et al.
7
. Moreover, no difference between the ligand binding affinity of Dex for mGRwt and 
mGRdim, was reported at this receptor concentration in the current study, which is line with the 
similar ligand-binding affinities for the wild-type and mutant at the low concentration of receptor, 
noted by Robertson et al.
7
. With that said, the current study went on to observe differences in the 
extent or efficacy of Dex-induced receptor turnover between mGRwt and mGRdim, confirming a 
requirement for GRα dimerization in mediating receptor turnover. In terms of the effects of 
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increasing GRα concentration on positive co-operative ligand binding (i.e. reflected by an increase 
in the ligand-binding affinity for the wild-type receptor) and ligand-independent dimerization, it 
would be of interest to determine whether an increase in GRα concentration would modulate the 
extent and rate of receptor turnover, both in the absence and presence of ligand. One could postulate 
that, in the absence of ligand, increasing GRα concentration would drive ligand-independent 
receptor dimerization, ultimately encouraging receptor down-regulation. 
Taken together, the results from Robertson et al.
7
 provided a link between GRα concentration and 
ligand-independent dimerization of the wild-type GRα, but not the dimerization deficient mutant, at 
medium receptor concentrations, which the current study builds on by demonstrating a requirement 
for dimerization in mediating receptor turnover. With vast ranges of physiological concentrations of 
GRα reported in vivo in different tissues and cells as well as in different disease states, these 
findings have implications for characterising the extent and rate of receptor turnover, by 
endogenous and exogenous GCs, in these various conditions. Moreover, the ability to characterize 
the extent and rate of ligand-induced turnover, based on GRα concentration and the dimerization 
state of the receptor, in a disease- or tissue-specific manner, may prove fruitful for the development 
of novel GC therapeutics to combat acquired GC resistance. 
7.3. Where does receptor turnover take place? 
In this section, we delve a little deeper into the spatial effects of the subcellular localisation of GRα 
and how this may modulate its turnover. 
Back in the late 1970s and early 1980s the proteasome degradation pathway was thought to 
primarily function as a means to clear cells of mis-folded or damaged proteins through their 
conversion into inactive protein peptides
53
. However, more and more evidence is unveiling the 
highly complex nature of the UPS system. Specifically, that the UPS has been shown to intricately 
be involved in the transcriptional regulation of a number of genes
12
.  
Classically, in terms of GRα signalling, it has been thought that following GC-mediated 
transcriptional regulation, the receptor dissociates from the DNA and is either recycled in the 
nucleus for another round of GC-mediated transcription or is exported to the cytoplasm, where the 
proteasome resides, and degraded, with evidence to support these ideas available
14
. However, recent 
studies have demonstrated a fundamental role for the UPS in finely tuning the expression of this 
ligand-activated transcription factor, within the nucleus and in some cases at the DNA (i.e. termed 
DNA proteolysis), thus regulating the expression of down-stream GC-responsive genes
12
. As 
Maneix et al.
12
 describes, the rapid elimination (i.e. through proteasomal degradation) of ‘spent 
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transcription factors (i.e. GRα) resets the promoter and allows new copies of transcription factors to 
bind’. 
In addition to demonstrating that GRα concentration modulates the binding affinity of a ligand for 
the GRα and the dimerization state of the receptor Robertson et al.47 detailed the effects of receptor 
concentration on the subcellular localisation of GRα and its nuclear mobility, which in light of 
nuclear proteolysis, may also have relevance for the extent and rate of receptor turnover. Unlike 
nuclear import of GRα, export of the receptor following ligand-treatment is considerably slower47. 
Specifically, following Dex-withdrawal, Robertson et al.
47
 demonstrated, using 
immunofluorescence, that it takes approximately 13.3 hours for the wild type GRα to passively be 
exported back to the cytoplasm. Specifically, Robertson et al.
47
 shows 30% of receptor in the 
cytoplasm after 6 hours, however, one must remember that in this experiment ligand-withdrawal 
was conducted and cells washed prior to the nuclear export determination. In contrast, the current 
study reported no wild-type GRα expression in the cytoplasm, following 6 hours of treatment, with 
saturating concentrations of Dex; however a 33 % reduction in total (i.e. nuclear and cytoplasmic) 
GRα protein expression was noted in Chapter 4. Thus, we believe, in the current study, that ‘gain’ 
of GRα dimerization following 6 hours treatment with a high concentration of Dex (10 μM), and 
importantly without withdrawal, encourages receptor turnover, specifically in the nucleus (and 
potentially at the DNA).  
The postulation that ligand-induced down-regulation of dimeric GRα occurs in the nucleus, at 
saturating Dex concentrations, is supported by findings, which suggest that the proteasome is 
predominantly nuclear but is also found in the cytoplasm
15–20. Moreover, the E3 ligase, FBXW7α, 
which is known to regulate GC-mediated GRα turnover is primarily positioned at the nuclear 
membrane
54
, which the current study confirms (Fig. 5.5 and 5.6). On the other hand, it is possible 
that basal degradation of the unliganded GRα, reported in the current study (Fig. 4.4), and by 
others
46
, occurs in the cytoplasm and is regulated by the predominantly cytoplasmic E3 ligase, 
CHIP
55,56. Moreover, that ‘loss’ of dimerization, through the use of CpdA or the dimerization 
deficient GRα mutant, prevents nuclear degradation of GRα, specifically through restricting hyper-
phosphorylation at Ser404 and the interaction of the receptor with FBXW7α, in the nucleus. 
Interestingly, in the current study, CpdA was unable to mediate translocation of hGRdim (Fig. 5.6). 
This lack of nuclear translocation in combination with the fact that this species is predominantly 
monomeric likely preserves GRα levels more than the unliganded GRα. 
This notion that nuclear receptors may be degraded in different subcellular compartments is not a 
novel one with a study demonstrating that the degradation of ERα, occurs both in the cytoplasm and 
the nucleus, depending on the ligand to which it is bound
57
. However, to our knowledge, the spatial 
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identification of exactly where ligand-induced GRα down-regulation and where the physical 
interaction of the GRα with the proteasome occurs, has not been thoroughly investigated. 
Taken together, we believe that going forward careful consideration needs to be given not only to 
the temporal effects, but also the spatial effects, of ligand-induced down-regulation of the GRα and 
suggest that the dimerization state of the receptor could potentially play a role in where receptor 
turnover takes place within the cell.  
7.4. Short-comings of study and avenues to explore  
Although the current study has provided a wealth of evidence for the importance of GRα 
conformation, specifically dimerization, in mediating the extent of ligand-induced receptor 
turnover, upon reflection there are a few short-comings which require mentioning and are outlined 
in this section. Moreover, potential strategies to overcome these drawbacks, in future studies, are 
provided and discussed. 
Essentially, the most topical aspect is the ability of the dimerization deficient GRα mutant (GRdim) 
to form GRα homodimers. The notion that this dimerization deficient mutant has a reduced capacity 
to form GRα dimers originates from a study by Reichardt et al.34 where a point mutation was 
introduced in the D-loop of the GRα gene in mice to create viable GRdim mutant mice, from which 
subsequent cell lines (i.e. MEF-mGRdim cells) have been derived. These mice harbouring the D-
loop mutation, were found to lack the capacity to mediate GRE-driven transactivation of GC-
responsive genes
34
, which at the time was thought to occur via the direct DNA binding of dimeric 
GRα, whilst maintaining the transrepressive function of pro-inflammatory genes, via predominantly 
monomeric GRα. This classical dissociation of transactivation and transrepression and its 
association with the dimerization state of the receptor has since been challenged
40
. Nonetheless, it 
was this primary characteristic of the mutant GRα in combination with the position of the point 
mutation (i.e. in the D-loop), which fortified the idea of the mutant’s reduced ability to dimerize, 
however, to our knowledge; this was never directly investigated experimentally, in these early 
studies
33,34
. For this reason controversy surrounding the dimerization capabilities of GRdim exists, 
with some papers suggesting it has the potential to fully dimerize following treatment with Dex
39,58
. 
With that said, a number of studies have also demonstrated that whilst GRdim may not be 
completely deficient in its ability to dimerize, its affinity to form GRα dimers is, in part, reduced59 
and is postulated to be dependent on receptor concentration
7
. Specifically, Robertson et al.
5
 
demonstrated that wild type GRα bound to dimerization abrogating GC, CpdA, displayed similar 
characteristics to Dex bound to GRdim in terms of their ability to mediate receptor nuclear 
translocation and the expression of GC-responsive genes, suggesting that these similarities were due 
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to a reduced ability to undergo ligand-induced dimerization. Moreover, that with increasing GRα 
concentrations, positive co-operative binding (where receptor dimerization is a pre-requisite) was 
observed for GRwt but not for GRdim
7
. In addition, the current study observes significant 
differences in the ability of GRwt and GRdim to undergo ligand-induced GRα down-regulation. 
Lastly, a recent study by Yamamoto et al.
59
 investigated and compared the affinity (Kd) of receptor 
homodimerization between wild type GRα and the dimerization deficient mutant in living cells, 
using Fluorescence Cross-Correlation Spectroscopy (FCCS). Results from this study
59
, confirmed 
that the tendency of the mutant toward a monomeric conformation in the nucleus following 
treatment with Dex, was higher than that of its wild type counterpart, and concluded that the 
mutation in the D-loop of GRα was sufficient to impair the formation of GRα dimers, in living 
cells, however, these results could not disregard the ability of a part of the mutant to form dimers in 
vitro, as suggested by Presman et al.
39,58
, and thus proposed a model
59
 of differential pathways of 
GRα dimerization, taking into account receptor subcellular localisation, termed the dynamic 
monomer pathway, and the static dimer pathway.  
In addition to the D-loop, a second dimerization site present in the ligand-binding domain (LBD) of 
GRα has been identified and mutation of this site (I634A), in addition to the conventional D-loop 
mutation (A458T), has been conducted to produce a receptor species, termed ‘GRmon’, which has 
been proven to be incapable of forming receptor dimers
39
. One could postulate that it may be via 
this second-site that the dimerization deficient GRα mutant is able to form dimers, following GC 
treatment. Thus, in terms of the current study, it would be of interest to determine the ability of a 
GRmon to undergo ligand-induced receptor turnover. On the basis of results from the current study 
we would postulate a continuum of GRα dimerization states (GRwt > GRdim > GRmon) and would 
expect this to be reflected in a continuum of efficiency of ligand-induced receptor turnover (GRwt > 
GRdim > GRmon).  
The previously proposed idea that the effects elicited by CpdA via the wild type GRα may represent 
those elicited by Dex via the dimerization deficient mutant, GRdim,
5
 appears to be more complex 
than originally assumed, with the current study highlighting differences between these species in 
terms of GRα mRNA regulation and GC-responsive gene expression (i.e. FKBP51). Specifically, 
CpdA via mGRwt was capable of down-regulating GRα mRNA expression, whereas Dex via 
mGRdim could not and, unlike CpdA via mGRwt, Dex via mGRdim could partially induce the 
expression of FKBP51. Keeping in mind that the GRα LBD has also been associated with receptor 
dimerization, and that CpdA is capable of competing with Dex in terms of ligand binding to GRα5,7, 
could it be that binding of CpdA to the LBD of the GRα abrogates receptor dimerization5 at this 
additional site, unlike the GRdim mutant in which the D-loop mutation occurs in the DBD and only 
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is thought to partially impair the ability of GRα to dimerize? Is it possible that CpdA-bound to 
GRwt is a different monomeric species to Dex bound to GRdim? In order to investigate this it 
would be necessary to repeat experiments from the current study with GRmon from Presman et 
al.
39
. 
An additional challenge, in the current study, was the difference in the expression levels of hGRwt 
and hGRdim, specifically in the transiently transfected COS-1 system. As GRα concentration has 
been shown to modulate certain aspects (i.e. nuclear translocation of the receptor) of GC/GR 
signalling pathway
47
, it is necessary to address these differences. Essentially, one cannot disregard 
the potential effect of a higher cellular hGRwt concentration, relative to hGRdim, on the overall 
dimerization state of the receptor and its subsequent ligand-induced receptor turnover, which the 
current study did not account for in Chapter 4. With that said, introducing the use of the GFP- 
tagged GRα in Chapter 5 allowed for the influence of receptor concentration on the post-
translational processing of the receptor, in terms of the interaction with FBXW7α, to be addressed 
in the PLA. Going forward, the use of the MEF cells (i.e. used in Chapter 6) may be a more 
appropriate system to investigate the post-translational processing of GRα and its interaction with 
various co-regulators, involved in the UPS, due to the equimolar expression of the wild type and 
mutant GRα, in the MEF-mGRwt and MEF-mGRdim cells, respectively. 
Lastly, it was difficult to draw concrete conclusions from the ubiquitin experiments in the current 
study, with no notable differences in GRα ubiquitination observed between the unliganded and the 
ligand-bound receptor. It may be that the unliganded and liganded GRα are ubiquitinated to similar 
degrees in preparation for proteasomal degradation, however, associate with different E3 ligases 
(i.e. CHIP or FBXW7α). In support of this, is the fact, illustrated in the current study, that the 
unliganded GRα does undergo receptor turnover but at a slower rate than the liganded GRα (i.e. 
Dex bound GRα)46 and that, to date, there has only been a single ubiquitin site documented for 
GRα60,61. However, to fully elucidate differences in the ubiquitination status of GRα, in the absence 
and presence of ligands, one should consider re-doing the PLA experiments conducted in the 
present study, using proteasome inhibitors (i.e. MG132) and possibly de-ubiquitinating (DUBs) 
enzyme inhibitors, to prevent receptor turnover and to preserve the poly-ubiquitination chains, 
respectively. Additionally, one should not exclude how the dimerization state of the receptor 
influences other PTMs, such as sumolaytion, which has also been implicated in GRα turnover62. To 
end this section, we believe that the involvement of CHIP and TSG101 in receptor turnover and 
their associations with either a GRα dimer or monomer also require further investigation, with 
results from the current study providing the ‘first green shoots’ for how receptor conformation 
regulates interactions of the receptor with enzymes associated with the UPS. 
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7.5. Future perspectives 
As we delve deeper into the depths of GC/GRα signalling so the complexity of this signalling 
pathway is uncovered. Becoming more and more apparent is the importance of GRα conformation 
as a fundamental aspect of GC/GRα signalling, induced by selective or ‘biased ligands’. As Luttrell 
et al.
23
 suggests, it the binding of the ligand to the receptor (i.e. GRα) that dictates ‘the rest of the 
symphony’. Recent studies, in combination with the current study, have started revising and re-
considering the importance of GRα conformation and the possibility of selectively dictating the 
‘conformational equilibrium’ through ‘biased ligands’, to combat chronic inflammation in various 
psychological and pathological conditions, whilst preventing the generation of adverse side-effects 
and the development of acquired resistance to GC treatment
1,21,23,59
.  
In terms of GC resistance, we provide support for the idea that preferentially selecting for GRα 
momoners and maintaining receptor expression may be the way forward for combatting chronic 
inflammation in prolonged GC treatments regimes. We propose the idea of a ‘continuum of 
resistance’ (Fig. 7.2) where encouraging GRα dimerization, not only may have negative 
implications in terms of the generation of adverse side-effects
63,64
, but also drives reductions in the 
GRα ‘functional pool’, which potentially encourages a decrease in GC sensitivity. Furthermore, in 
addition to the use of compounds
45,65–67
 which may stall receptor turnover (i.e. proteasome 
inhibitors or compounds such as Ginsenoside
45
), we believe that disrupting dimerization through 
‘biased ligands’, in a tissue-specific manner, may be a fruitful approach for developing tailored 
treatments to counteract the development of acquired GC resistance in a number of disease states. 
Moreover, an in depth characterization of the dimerization capabilities
68
 of GRα mutants69 may 
provide more insight into generalized GC resistance and assist in the treatment of these rare, 
pathological conditions. 
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GRα dimerization  
GC sensitive GC resistant 
GRα ‘functional pool’ 
‘Continuum of GC resistance’ 
Stellenbosch University  https://scholar.sun.ac.za
 255 
 
Figure 7.2: A ‘continuum of GC resistance’. As GRα dimerization increases, so increased ligand-induced receptor 
turnover of the GRα ‘functional pool’, both at the mRNA and protein level, occurs. These significant reductions in 
receptor turnover, in many cases, drive the development of an acquired resistance to GC treatment and so the ability of 
a patient to respond to GC treatment diminishes, posing a major threat to the pharmaceutical industry, in combatting 
chronic inflammation. 
7.6. Final conclusion 
Bringing it altogether, the current study has identified a novel and fundamental role for GRα 
dimerization in mediating ligand-induced down-regulation of the receptor, through treatment with 
the dimerization abrogating GC, CpdA, and supported by the use the dimerization deficient GRα 
mutant, using a number of cellular models (i.e. the COS-1, HepG2, MEF-mGRwt and MEF-
mGRdim cells). Additionally, we uncovered the molecular mechanisms involved in mediating how 
a ‘loss’ of GRα dimerization prevents receptor turnover, by demonstrating that the post-translational 
processing of GRα (i.e. specifically phosphorylation at Ser404 and the interaction of the receptor 
with the E3 ligase, FBXW7α) is influenced by the dimerization state of the receptor. Lastly, we 
established and tested a model to mimic acquired GC resistance, in which ligand-induced GRα 
turnover is thought to play a significant role, contributing to the idea proposed by De Bosscher et 
al.
1, that selecting for GRα monomers in prolonged GC regimens may be the way forward, however 
unlike De Bosscher et al.
1
, we make this argument in terms of acquired GC resistance.   
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